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Abstract
Introduction: Most cancers show heterogeneity of response to chemotherapy. This may 
be due in part to the differential expression of drug resistance proteins and the molecular 
targets of the drugs concerned.
Methods: An ex vivo ATP-based Tumour Chemosensitivity Assay (ATP-TCA), 
immunohistochemistry and quantitative RT-PCR have been used to assess the 
chemosensitivity and resistance of a variety of solid tumours and cell lines.
Results:
(a) Melanoma cell lines showed higher chemosensitivity than tumour-derived cells, 
partially reversible by lowering the serum concentration, and hence the proliferation rate 
of the cells.
(b) Studies of retinoblastoma samples confirmed that this malignancy is susceptible to 
cytotoxic drugs of all types, though multidrug resistance may occur in some cases.
(c) The ATP-TCA was used to study the activity of high-dose doxorubicin in 
combination with other cytotoxic agents in ovarian adenocarcinoma samples. The 
combination of liposomal doxorubicin + vinorelbine was selected for further 
development.
(d) A number of experimental drugs with varying sensitivity to resistance mechanisms 
were also assessed. One drug, XR5944, has entered phase I/II clinical trials during the 
course of this project, and the data have provided clinical indications.
(e) An inhibitor of multi-drug resistance, tariquidar, has been tested in combination with 
doxorubicin, vinorelbine or paclitaxel, and has been shown to reverse this resistance.
(f) Molecular studies have determined the expression of topoisomerases and drug 
transporters in tumour cells before and after exposure to chemotherapeutic agents. P-gp 
expression has been found to be a determinant of sensitivity to a certain number of 
drugs.
Conclusion: The results suggest that drug resistance contributes to heterogeneity of 
chemosensitivity in many solid tumour types, as well as other mechanisms. Reversal of 
such resistance may benefit a subset of patients undergoing chemotherapy.
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Chapter 1 - INTRODUCTION
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1.1 Chemotherapy
Chemotherapy is the application of selective toxicity. The goal of chemotherapeutic 
treatment is to selectively attenuate or destroy pathogenic microorganisms or cells with 
minimal side effects to the host. These targeted cells or organisms may be bacteria, 
viruses, protozoans, fungi, helminths, or neoplastic cells. In order to achieve selective 
toxicity, the target for chemotherapeutic agents may be unique to the target population, 
may be structurally different in the target population from the form in the host 
population, or may be more essential in the target population than in the host 
population. The latter applies to classical cancer chemotherapeutic agents, which are 
aimed either to kill cancer cells (a cytotoxic effect), or to halt proliferation (a cytostatic 
effect). Tumour cells are highly metabolically active cells, which are continually 
duplicating their DNA, RNA and proteins providing a large number of therapeutic 
targets. Most cancer chemotherapy has selective toxicity based on the premise that 
tumour cells are dividing more rapidly than non-malignant host cells. However, some 
host cell populations also divide rapidly such as those in bone marrow, gut and 
reproductive/germ cells. These cells are damaged by chemotherapeutic agents as well as 
cancer cells, leading to side effects such as neutropaenia, nausea and sterility.
Cytotoxic drugs fall into four broad categories according to their mode of action: 
antimetabolites; topoisomerase inhibitors, microtubule interfering agents (vinca 
alkaloids and taxanes) and DNA damaging agents (which may be further sub-classified 
according to their chemical structure as nitrogen mustards and derivatives; nitrosoureas; 
busulfan and derivatives; dacarbazine and derivatives; platinum-based compounds);
Table 1.1 contains a list of commonly used chemotherapeutic agents, along with a brief 
description of their mechanisms of action.
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Table 1.1 Mechanism of action of common chemotherapeutic agents.
Cytotoxic agent Mechanism of action
Platinum-based
compounds
Bind to individual bases of DNA disrupting its function. 
Protein binding may also occur resulting in toxicity
Carmustine (BCNU) Alkylates DNA via the production of reactive 
intermediates that attack nucleophilic sites
Cytosine arabinoside 
(AraC, Cytarabine)
Inhibits DNA polymerases involved in repairing damaged 
DNA and is also incorporated into DNA (and presumably 
RNA) resulting in chain termination
Dacarbazine (DTIC) Requires bioactivation by C YP 450, acts via direct 
methylation of nucleic acids
Doxorubicin 
(Adriamycin) or 
Caelyx® or Doxil® 
(liposomal doxorubicin) 
Epirubicin
Pleiotropic effects including:
Inhibition of DNA topoisomerase II 
Activation of protein kinase C signal transduction cascades 
Generation of reactive oxygen intermediates 
Stimulation of apoptosis
Etoposide (VP-16) Inhibition of DNA topoisomerase II
5-Fluorouracil (5-FU) Three main mechanisms of action:
Incorporation of fluorouridine triphosphate (a metabolite of 
5-FU) into the RNA interferes with synthesis and function 
of RNA
Inhibition of thymidylate synthase (TS) by 
fluorodeoxyuridine monophosphate (a metabolite of 5-FU) 
leads to depletion of deoxythymidine phosphates 
Incorporation of fluorodeoxyuridine triphosphate and 
deoxyuridine triphosphate into DNA may affect the 
stability of the DNA
Fotemustine Alkylates DNA via the production of reactive 
intermediates that attack nucleophilic sites
Gemcitabine Cytidine analogue: binds to and inhibits DNA polymerases 
involved in repairing damaged DNA and is also 
incorporated into DNA (and presumably RNA) resulting in 
chain termination
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Table 1.1 (continued). Mechanism of action of common chemotherapeutic agents.
Cytotoxic agent Mechanism of action
Cyclophosphamide Alkylates DNA via the production of reactive 
intermediates that attack nucleophilic sites
Interferon a  2b Direct anti-proliferative effects on the tumour cells, via 
reduction in functional capacity and/or induction of 
differentiation
Indirect induction of host anti-tumour mechanisms
Methotrexate (MTX) Folic acid analogue, inhibits dihydrofolate reductase 
leading to the partial depletion of reduced folates, required 
for deoxythymidine monophosphate (dTMP) synthesis
Mitoxantrone Binds with high affinity directly to nucleic acids and 
inhibits DNA and RNA synthesis, also inhibits 
topoisomerase II
Mitomycin C Active after reduction, binds to DNA via mono- or 
bifunctional alkylation and inhibits DNA synthesis
Taxanes Inhibition of microtubule depolymerisation, causing the 
inhibition of mitosis and probably intracellular transport
Temozolomide Undergoes rapid non-enzymatic conversion under 
physiological conditions to give the reactive compound 
MTIC; the cytotoxicity of MTIC is thought to be primarily 
due to methylation of DNA which occurs mainly at the 06 
and N7 positions of guanine.
Topotecan and Irinotecan Potent inhibitors of DNA topoisomerase I
Treosulfan Bifunctional alkylating agent which can cross-link DNA
Vinca alkaloids Inhibit the polymerisation of microtubules therefore 
inhibiting mitosis
Over the last decade there has been a trend in the pharmaceutical industry to design and 
develop new anti-cancer agents, which target molecular abnormalities differentially 
expressed in tumours. These new drugs may provide a more specific and less toxic way 
of treating cancer. One example is the development of chimeric and humanised 
antibodies (Abs) for the treatment of haematological malignancies and directed towards
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antigens present on the surface of lymphocytes, such as CD20, CD33 and CD52. Some 
of these drugs (rituximab, alemtuzumab) act via Ab-dependent cell-mediated 
cytotoxicity and lysis by complement, while others have been conjugated with toxins or 
radionuclides (ibritumomab tiuxetan, tositumomab, gemtuzumab ozogamicin) in an 
attempt to increase their efficacy and exploit their specificity against targeted cells. In 
the field of solid tumours, the monoclonal Ab trastuzumab has been approved for use in 
the treatment of metastatic breast tumours that overexpress HER-2. HER-2 is a receptor 
tyrosine kinase (RTK) with no known natural ligand and is overexpressed in 
approximately 25% of breast tumours (Ross et al., 2003).
Inhibition of the tyrosine kinase activity of RTKs, as opposed to using monoclonal 
antibodies against the extracellular portion of these receptors, provides another target. 
These inhibitors are able to exert their activity in cells that do not over-express the 
receptor or that have mutant, truncated forms of the receptor that are constitutively 
activated (Lai et al., 2002). The first agent in this class to become clinically available 
was imatinib mesylate, which is an inhibitor of the tyrosine kinase activity of BCR- 
ABL (Druker et al., 1996), the fusion protein that results from the translocation between 
chromosome 9 and 22 (also known as the Philadelphia chromosome), seen in over 95% 
of cases of chronic myeloid leukaemia (CML) and in a small percentage of cases of 
acute lymphoblastic and myeloid leukaemias (reviewed in Laurent et al., 2001). 
Another drug in clinical use is gefitinib, an inhibitor of the epithelial growth factor 
receptor (EGFR) tyrosine kinase activity, which gained FDA approval in 2003 as a 
second-line agent forNSCLC.
Another cellular mechanism that may serve as target for therapeutic intervention 
includes the intracellular pathway that hydrolyses proteins marked for destruction by the 
ubiquitin enzyme cascade (proteasome). The clinical development of bortezomib 
followed preclinical observations of its ability to inhibit reversibly the proteolytic 
(chymotryptic) activity of the proteasome complex in mammalian cells. Inhibition of the 
intracellular protein degradation pathway alters the levels of numerous intracellular 
signaling and regulatory proteins as well as other proteins and, in some fashion, then 
alters the regulation of cellular processes that may lead to growth arrest or apoptosis 
(Mitsiades et al., 2002).
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Table 1.2 Some of the targeted anti-cancer agents that were approved by the FDA in the
period January 1997-December 2003 (Source: FDA website at www.fda.gov).
Tradename 
(Generic name)
Molecular Targets Clinical condition Year of 
FDA 
approval
Rituxan® / 
Mabthera® 
(rituximab)
First monoclonal antibody 
(Ab) directed towards CD20 
molecules present on B 
lymphocytes
CD20 positive low-grade 
or follicular B-cell 
lymphomas 1997
Herceptin®
(trastuzumab)
Ab directed towards HER-2, 
RTK present on surface of 
breast cancer cells
HER-2 positive breast 
cancer 1998
Mylotarg®
(gemtuzumab
ozogamicin)
DNA targeted agent 
(calicheamicin derivative) 
conjugated to Ab directed 
towards CD33 antigen 
present on myeloid cells
Acute myeloid leukaemia 
(AML)
2000
Campath®
(alemtuzumab)
Ab directed towards CD52 
antigen present on 
lymphocytes
B-cell chronic 
lymphocytic leukaemia 2001
Gleevec®
(imatinib
mesylate)
Inhibitor of tyrosine kinase 
activity of BCR-ABL (fusion 
protein in CML) and kit
Chronic myeloid 
leukemia (CML), 
advanced GIST 
(gastrointestinal stromal 
tumour)
2001-
2002
Zevalin®
(ibritumomab
tiuxetan)
^Y-labelled Ab directed 
towards CD20 antigen 
present on B cells
CD20 positive low-grade
non-Hodgkin’s
lymphoma
2002
Bexxar®
(tositumomab)
I-labelled Ab directed 
towards CD20 antigen 
present on B cells
CD20 positive low-grade
non-Hodgkin’s
lymphoma
2003
Velcade®
(bortezomib)
Inhibitor of the proteolytic 
activity of the proteasome 
(intracellular protein 
degradation pathway) 
complex in mammalian cells
Multiple myeloma (3rd 
line)
2003
Iressa®
(gefitinib)
Inhibitor of EGFR tyrosine 
kinase activity
NSCLC (2"“ line) 2003
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1.2 Resistance to anti-cancer drugs
1.2.1 Introduction
Although the design of anti-cancer drugs has become increasingly sophisticated, there is 
no treatment that is 100% effective against cancer. Failure of a patient’s cancer to 
respond to a specific therapy can result from one of two general causes: host factors and 
specific genetic or molecular alterations in the cancer cells. Host factors include poor 
absorption or rapid metabolism or excretion of a drug, resulting in low serum levels; 
poor tolerance to effects of a drug, especially in elderly patients, resulting in a need to 
reduce doses below optimal levels; inability to deliver a drug to the site of a tumour, as 
could occur with bulky tumours or with biological agents of high molecular weight and 
low tissue penetration such as monoclonal antibodies and immunotoxins (Pluen et al., 
2001); various alterations in the host-tumour environment that affect response of the 
tumour including local metabolism of a drug by non-tumour cells, unusual features of 
the tumour blood supply that may affect transit time of drugs within tumours and the 
way in which cells in a cancer interact with each other and with interstitial cells from 
the host (Kobayashi et al., 1993; Green et al., 1999).
Resistance is often intrinsic to the cancer, but as therapy becomes more and more 
effective, acquired resistance has also become frequent. According to an early 
hypothesis formulated by Goldie and Coldman (1979), chemotherapy can select drug- 
resistant clones that develop by spontaneous mutation and the probability of a resistant 
phenotype increases with the mutation rate. However, recently, a few studies have 
suggested that drug resistance can develop not only by mutation but also through 
cellular adaptation. It appears that slow-growing tumours can become chemoresistant 
by altering their molecular phenotype in response to a specific cytotoxic agent 
(Matsumoto et al., 1997; see chapter 11). The most common reason for acquisition of 
resistance to a broad range of anti-cancer drugs is probably expression of one or more 
energy-dependent transporters that eject anticancer drugs from cells. However other 
mechanisms of resistance, including insensitivity to drug induced apoptosis and 
induction of drug-detoxifying enzymes, probably play an important role in acquired 
anticancer drug resistance. Cellular mechanisms of drug resistance have been 
intensively studied, as experimental models can be easily generated by in vitro selection 
with cytotoxic agents. Cancer cells in culture can become resistant to a single drug, or a 
class of drugs with a similar mechanism of action, and may also show cross-resistance
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to other structurally and mechanistically unrelated drugs - a phenomenon that is known 
as multidrug resistance (MDR).
1.2.2 Transport-mediated drug resistance
Transport mediated drug resistance is probably the most studied form of MDR in human 
tumours. Resistance to natural-product hydrophobic drugs, sometimes known as 
classical MDR, generally results from expression of ATP-dependent efflux pumps with 
broad drug specificity. These pumps belong to a family of ATP-binding cassette (ABC) 
transporters that share sequence and structural homology. So far, 49 human ABC genes 
have been identified and divided into seven distinct subfamilies (ABCA-ABCG) on the 
basis of their sequence homology and domain organization (Muller, 2003). Resistance 
results because increased drug efflux lowers intracellular drug concentrations. Drugs 
that are affected by classical multidrug resistance include the vinca alkaloids, the 
anthracyclines, the RNA transcription inhibitor actinomycin-D, and the microtubule- 
stabilising drug paclitaxel (Gottesman et a l , 2002).
There are other drug transporters that do not belong to the large family of ABC 
transporters described above: for example, Major Vault Proteins (MVP) are able to 
pump toxins out of the nucleus and other intracellular compartments, and ATP7B has 
recently been shown to transport cisplatin. Nucleoside Transporters (NT), although 
included in this section, represent a different class of membrane proteins, and are 
responsible for the active transport of cytotoxic nucleoside drugs.
Tables 1.3 and 1.4 list the most studied drug transporters, their physiological substrates, 
chemotherapeutic substrates and inhibitors.
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Table 1.3 Tissue localisation, substrates and inhibitors of ABC transporters (Gottesman et al, 2002; Hamada et al, 2003; Kruh & Belinsky, 2003;
Lage, 2003; Thomas & Coley, 2003; Asakura et a l, 2004)
Common
Name
Gene
name
Localisation Non-chemotherapeutic 
and physiological 
substrates
Chemotherapeutic substrates 
(known and suspected)
Inhibitors
P-gp/MDRl ABCB1
Intestine, liver, 
kidney,placenta, 
blood-brain barrier
Cortisol, aldosterone, 
sphingolipids, IL-2, IL-4, 
interferon-^ neutral and 
cationic organic 
compounds, many 
commonly used drugs
Doxorubicin, daunorubicin, 
epirubicin, vincristine, 
vinblastine, actinomycin-D, 
paclitaxel, docetaxel, etoposide, 
teniposide, bisantrene, 
homoharringtonine (STI-5 71), 
imatinib mesylateb, gemtuzumab 
ozogamicin
Verapamil, nifedipin, azodipin, 
quinine, flupentixol, progesterone, 
megestrol acetate, tamoxifen, 
azythromycina, cyclosporin A, 
valspodar (PSC 833), biricodar 
(VX-710), ONT-093, tariquidar 
(XR9576), zosuquidar (LY335979), 
laniquidar (R101933), elacridar 
(GF120918)
TAPI ABCB2 Peptides Mitoxantrone,epipodophyllotoxins
TAP2 ABCB3 Peptides Mitoxantrone,epipodophyllotoxins
MDR2 ABCB4 Liver Phosphatidylcholine Paclitaxel, vinblastine
SPGP
(BSEP) ABCB11 Liver Bile salts Paclitaxel
BCRP
(MXR) ABCG2
Placenta, intestine, 
breast, liver
Sulfated estrogens, 
prazosin
Doxorubicin, daunorubicin, 
mitoxantrone, topotecan, SN-38
Fumitremorgin C, Ko-143, Cl1033, 
elacridar (GF120918/GG918), 
novobiocin
ABCA2 ABCA2 Brain, monocytes Steroids derivatives, lipids Estramustine
MRP1 ABCC1 All tissues
Glutathione and other 
conjugates, organic 
anions, leukotriene C4
Doxorubicin, epirubicin, 
etoposide, vincristine, 
methotrexate
Genistein, probenecid, MK-571, 
PAK-104P, indomethacin, BSO, 
verapamil, cyclosporin A, valspodar 
(PSC 833)
Table 1.3 (continued). Tissue localisation, substrates and inhibitors of ABC transporters (Gottesman et a l , 2002; Hamada et a l,  2003; Kruh &
Belinsky, 2003; Lage, 2003; Thomas & Coley, 2003; Asakura et a l, 2004)
Common
Name
Gene
name
Tissue Non-chemotherapeutic 
and physiological 
substrates
Chemotherapeutic substrates 
(known and suspected)
Inhibitors
MRP2
(cMOAT) ABCC2 Liver, kidney, intestine
Similar to MRP1, non-bile 
salt organic anions
Methotrexate, etoposide, 
doxorubicin, cisplatin, 
vincristine, mitoxantrone, 
platinum
MK-571
MRP3 ABCC3
Pancreas, kidney, liver, 
adrenal glands, 
intestine
Glucuronate and 
glutathione conjugates, 
bile acids
Etoposide, teniposide, 
methotrexate, cisplatin, 
vincristine, doxorubicin
MRP4 ABCC4
Prostate, testis, ovary, 
intestine, pancreas, 
lung
Organic anions, nucleotide 
analogues Methotrexate, thiopurines
MRP5 ABCC5 Most tissues
Cyclic nucleotides, 
nucleotide analogues, 
organic anions
6-Mercaptopurine, 6- 
Thioguanine
MRP6 ABCC6 Kidney, liver, lung, colon
? Anthracyclines, etoposide, 
platinum
MRP8 ABCC11 Testis, prostate, liver Cyclic nucleotides 5-Fluorouracil (5-FdUMP)
Table 1.4 Tissue localisation, substrates and inhibitors of non-ABC transporters (data from Komatsu et al, 2000; Lu et al, 2002; Damaraju et
al, 2003)
Transporter
Name
Tissue Non-chemotherapy and 
physiological substrates
Chemotherapy substrates 
(known and suspected)
Inhibitors
ATP7B
liver, kidney, placenta; breast, 
ovarian and GI tumours copper cisplatin
MVP (LRP)
lung, digestive tract, renal proximal 
tubules, keratinocytes, 
macrophages, adrenal cortex
nucleocytoplasmic
transport
doxorubicin, mitoxantrone, methotrexate, 
etoposide, vincristine, cytarabine, 
cisplatin
PAK-104P
CNT1 Heart, skeletal muscle, placenta, pancreas, lung
Pyrimidine nucleosides, 
adenosine
gemcitabine, cytarabine, cladribrine, 
idoxuridine
CNT2 Heart, placenta, pancreas, lung Purine nucleosides, uridine cladribine
CNT3 Heart, placenta, pancreas, lung Purine and pyrimidine nucleosides
fludarabine, zebularine, cladribine, 
gemcitabine, 5-fluorouridine, floxidine
ENT1 All tissues Purine and pyrimidine nucleosides
gemcitabine, cladribrine, AraA, 
cytarabine, fludarabine, 5-fluorouridine NBMPR
ENT2 All tissues Purine and pyrimidine nucleosides gemcitabine NBMPR
NCBT1 Kidney, intestine, choroidal plexus, placenta
Purine and pyrimidine
nucleobases,
hypoxanthine
5-FU
NCBT2 Kidney, intestine, choroidal plexus, placenta
Purine and pyrimidine 
nucleobases, uracil and 
5-methyluracil
5-FU
7.2.2.1 P-glycoprotein (P-gp)
The first ABC transporter to be identified was P-glycoprotein (P-gp), the product of the 
human MDR1 gene, localised to chromosome 7q21. This ATP-dependent 
transmembrane efflux pump is responsible for detoxifying normal cells as well as 
rendering tumour cells resistant to chemotherapy. Its role as a cellular efflux pump, 
controlling intracellular concentrations of harmful substances, is reflected by its cell and 
organ specific distribution, as well as its ability to recognise and transport a wide range 
of compounds. MDR1 is mainly expressed on the surface of luminal epithelial cells of 
the lower gastrointestinal tract where it influences intestinal drug absorption. Significant 
amounts of P-gp can be found in biliary canalicular membranes of hepatocytes and in 
the membrane of the proximal tubules in the kidney confirming the importance of P-gp 
for the excretion of xenobiotics and endogenous metabolites. P-gp is also expressed at 
the luminal surface of capillary endothelial cells. In the blood brain barrier this 
expression may have a protective function. The expression of P-gp in untreated human 
cancers is highly variable, being almost universal in colon, hepatic, renal and adrenal 
carcinomas; while it is less common in human haematological malignancies, breast, 
ovarian, lung and gastric carcinomas, skin cancers, certain germ cell tumours and 
sarcomas (Cordon-Cardo et al., 1990). At least part of the heterogeneity is attributable 
to different definitions of positivity, even when a common method of detection is used 
(Beck et a l, 1996).
1.2.2.2 Methods o f P-gp detection
Expression of MDR 1/P-gp can be detected in human cancers by reverse transcription- 
polymerase chain reaction (RT-PCR) for mRNA expression and by 
immunohistochemistry (IHC) for protein expression. Imperfections in these methods 
include errors due to normal tissue contamination of tumour tissue (for RNA methods), 
poor sensitivity and specificity, and difficulties in quantitation (for IHC methods). Most 
studies of P-gp have used IHC. A comparison of several studies reveals that there are 
inter-laboratory differences due to differing tissue fixation, processing, and staining 
technique, experience of the observer in selecting hot spots, and the technique of 
counting positive cells (Beck et al., 1996).
As the activity o f P-gp can be affected by different factors, for example the intracellular 
concentration of ATP (Broxterman et a l, 1995), another approach has been to
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determine its activity; based on the fluorescent properties of the dye rhodamine 123 
(Rhl23), which is transported by P-gp, and a functional flow cytometric assay has been 
developed for the detection of multidrug-resistant (MDR) cells (Ludescher et al., 1992).
Functional assays of P-gp based on flow cytometry have been widely employed to study 
cell lines and haematological malignancies, but only occasionally in cells derived from 
solid tumours (Mechetner et a l , 1998). For these, in vivo radioimaging techniques have 
been developed (Del Vecchio et a l , 1997; Ciarmiello et a l , 1998). The use of 99mTc- 
MIBI and analogous 99mTc-labeled agents (which have been shown to be P-gp 
substrates) allows the clinical assessment of P-gp function in cancer patients (Agrawal 
et a l, 2003), but so far no large prospective clinical trials have been performed to 
investigate their potential as predictive tests (Palmedo, 2002). A current prospective 
study in patients with locally advanced breast cancer correlating functional imaging, 
IHC, and clinical response to chemotherapy may determine the role o f functional 
imaging of MDR in chemotherapy response and prognosis (Tan et a l , 2000).
The plurality of methods for diagnosis of P-gp expression reflects the imperfection of 
currently available diagnostic procedures. In particular, the lack of standardisation has 
been a major concern, because conflicting definitions of assay end points, scarcity or 
diversity in control samples, differing assay reagents, and variable methods of sample 
preparation, data acquisition, analysis, and quality control contribute to inconsistencies 
in P-gp detection. To address these problems the St. Jude MDR Workshop on ‘Methods 
to Detect P-Glycoprotein-associated Multidrug Resistance’ in 1996 reached a set of 
consensus recommendations for standardisation of P-gp assays (Beck et a l, 1996). This 
was intended to improve the reliability of the most common P-gp assays in clinical 
samples (immunocytochemistry, flow cytometry, functional test, RT-PCR). The 
recommendations specified sample handling, assay procedures, data analyses, and 
quality control in detail, but no advice was given with respect to choice of diagnostic 
procedure. Whether the assay parameter should be MDR1 mRNA, MDR1 gene product, 
or P-gp substrate transport ability remains unresolved. However, multiparameter assays 
provide an adequate compromise and should be considered whenever possible. Dual 
parameter flow cytometry is a less cumbersome and attractive approach due to the 
combination of protein detection and functional test in one single assay.
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1.2.2.3 Clinical relevance o f  P-gp
Having outlined the difficulties in detecting MDRl/P-gp in cancer cells, it is not 
surprising that our knowledge of its clinical relevance may be at least partially 
incomplete. Despite this, there is little doubt that levels of expression of P-gp in many 
different tumours are high enough to confer significant drug resistance, and the presence 
of P-gp correlates with drug resistance in several different cancers. In feet malignancies 
considered to be primarily chemoresistant, such as renal cell, adrenocortical, colon, and 
hepatocellular cancers, have been shown to consistently demonstrate expression of 
MDR1 (Fojo et al., 1987; Goldstein et al., 1989).
The acquisition of drug resistance after chemotherapy is associated with increased P-gp 
levels in vitro (Goldstein et al., 1989; Chaudhary & Roninson, 1993), and this increased 
expression occurs via specific molecular mechanisms, such as gene rearrangement and 
selection of cells showing these rearrangements (Mickley et al., 1998), suggesting that 
the P-gp-expiessing cells have a selective advantage.
Tumours with low levels of P-gp expression at baseline, such as leukaemia, breast 
cancer, and SCLC, show an increase in expression on relapse, following chemotherapy. 
Whether this represents selection and repopulation of resistant clones or upregulation 
due to cytotoxic therapy exposure is unclear. However, recent studies have shown that 
the expression of P-gp may be rapidly up-regulated in response to chemotherapeutic 
agents in vivo (Abolhoda et al., 1999; Hu et a l, 1999; Stein et a l, 2002; Tada et a l,
2002), and therefore the latest advances favour the second hypothesis.
Several studies have shown an inverse correlation between P-gp expression and 
chemosensitivity or survival in a variety of tumour types, including leukaemia (Marie et 
al., 1991; Campos et a l, 1992; Damiani etal., 1998), lymphomas (Yuen & Sikic,
1994), osteogenic sarcoma (Baldini et a l, 1995; Serra et a l, 2003), small-cell lung 
cancer (Savaraj et a l, 1997; Hsia et al., 2002), breast cancer (Linn et a l, 1995; 
Gregorcyk et al., 1996; BuTger et al., 2003), advanced ovarian cancer (Baekelandt et a l, 
2000; Raspollini et a l, 2002) and paediatric solid tumours (Chan et a l, 1990,1991a-b). 
The most reproducible studies on expression in human cancers involve leukaemic cells. 
P-gp is expressed in acute myelocytic leukaemia (AML) cells in approximately 30% of 
patients at diagnosis, but in over 50% at relapse (Leith et al., 1999). A lower expression
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rate (17%) of P-gp is found in leukaemic cells from patients less than 35 years of age, 
compared with rates of expression in the elderly (39%), and this may partly explain the 
better response to therapy seen in younger patients (Leith et a l , 1999). The suggestion 
that P-gp is a marker of poor prognosis due to its mediation of drug resistance in 
affected cells is supported by studies showing that the prognostic value of P-gp can be 
mitigated if  treatment consists of agents that are not substrates for P-gp-mediated drug 
efflux (Broxterman et a l , 2000).
The results of studies in solid tumours are more heterogeneous. For example a review of 
ten studies carried out in ovarian cancer showed that only four were able to demonstrate 
a correlation between MDR 1/P-gp expression and response/clinical outcome (table 1.5). 
A marked variation in the reported detection rates can be seen, depending on the method 
of detection, previous therapy, the type of tumour, and the tumour grade. A breast 
cancer meta-analysis concluded that P-gp expression could be detected in 41% of 
patients with breast cancer, with increased levels post-treatment (Trock et a l , 1997). 
However, an incidence range of 0%-80% for expression of P-gp was reported in the 
assembled studies.
Table 1.5 Predictive and prognostic role of MDRl/P-gp expression in ovarian cancer, 
where n indicates the number of samples tested.
Study it Test Correlation with 
response to 
chemotherapy
Correlation 
with survival
Holzmayer et a l, 1993 60 RT-PCR Yes ND
Izquierdo et a l, 1995 57 IHC No No
Schneider et al, 1998 95 IHC No Yes
Arts etal., 1999 115 me No No
Yokoyama e ta l, 1999 58 me No No
Baekelandt et a l, 2000 73 me Yes Yes
Kaniazawa et a l, 2002 27 RT-PCR Yes (paclitaxel-based 
regimen)
ND
Nakayama et a l, 2002 82 RT-PCR ND No
Raspollini et a l, 2003 83 me Yes Yes
Ikeda et a l, 2003 93 IHC ND No
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Studies that have shown a change in expression in treated populations relative to 
baseline are more easily interpietable (Chung et a l, 1997). Table 1.6 lists selected 
studies examining tumour expression levels of P-gp; studies were chosen where data 
were available on pre-and-post treatment expression levels of P-gp.
Table 1.6 Studies that investigated the expression of P-gp before and after treatment, 
where n indicates the number of samples tested.
Disease Study n Pre or post treatm ent
MDRl/P-gp
test
Expression 
of P-gp
AML
Van den Heuvel- 
Eibrink et al. (2002)
20
20
De novo
Relapse/refractory
qRT-PCR
qRT-PCR
0.11 (*) 
0.09 (*)
Han et a l (2000) 109
36
De novo
Relapse/refractory
Flow
cytometry 27%
64%
Chauncey et al. 
(2000)
20
10
De novo 
Secondary
Flow
cytometry 65%
80%
Zhou etal. (1995) 5140
De novo
Relapse/refractory
RT-PCR 18%
33%
Myeloma
Dalton et al. (1995) 412
Pretreatment
Posttreatment
IHC 29%
50%
Grogan etal. (1993) 4749
Pretreatment
Posttrealment
me 6%
43%
Breast
cancer
Chevillard et al. 
(1996)
63 Pretreatment
Posttreatment
me 14%
43%
Mechetner et al. 
(1998)
244 Pretreatment
Posttreatment
me 11%
30%
Ovarian
cancer
van der Zee et al. 
(1995)
89
38
Pretreatment
Posttreatment
me 15%
48%
Sarcoma Oda et a l (1997) 55
Pretreatment
Posttreatment
RT-PCR 40%
20%
Bladder
cancer
Park e ta l  (1994) 295
Pretreatment
Posttreatment
me 75%
80%
Nakagawa et al. 
(1997)
33
28
Pretreatment
Posttreatment
IHC 67%
86°/o
Glioma Abe e ta l (1998) 237
Pretreatment
Posttreatment
IHC 18%
57%
Cervical
cancer
Riou et al. (1990) 848
Pretreatment
Posttreatment
Slot blotting 39%
88%
Schneider et al 
(1992)
9
6
Pretreatment
Posttreatment
me 88%
83%
(*) As MDR1 mRNA was found in all 20 samples, results are expressed as arbitrary 
units (2'ACt; see section 2.4)
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1.2.2.4 Reversal o f  P-gp mediated MDR by chemosensitising agents 
Chemosensitisation strategies use the administration of one drug or agent to render 
cancer cells more susceptible to a second agent (Cree et al., 2002a). A broad range of 
compounds that interact with P-gp and block drug efflux have been reported to reverse 
the MDR phenotype. The first generation modulators consisted of calcium channel 
blockers, calmodulin inhibitors, hormonal/steroidal derivatives, antibiotics, 
cardiovascular drugs and the cyclosporins (Ford, 1996). These compounds were 
developed for pharmacological uses other than the reversal of MDR and were relatively 
non-specific and weak inhibitors. The requirement for more selective and potent agents 
as resistance modifiers has led to the development of several “second-generation” 
modulators such as the non immunosuppressive cyclosporin D analogue, PSC 833 
(valdospar), and VX-710 (biricodar). Second-generation P-gp modulators have a better 
pharmacologic profile than the first-generation compounds, but they also retain some 
characteristics that limit their clinical usefulness. In particular, these compounds 
significantly inhibit the metabolism and excretion of cytotoxic agents, thus leading to 
unacceptable toxicity that has necessitated chemotherapy dose reductions in clinical 
trials. In response to cytotoxic agents, cytochrome P450 enzymes are often induced 
along with members of the ABC transporter family, and it is thought that the genes of 
these families share overlapping regulatory elements. In fact, many of the cytotoxic 
agents that are substrates for P-gp are also substrates for the cytochrome P450 
isoenzyme 3A4. It is not surprising, then, that the agents that are affected by the 
development of MDR are also metabolised by cytochrome P450 3A4 (Wandel et al.,
1999). Several of the second-generation P-gp modulators, including valspodar and 
biricodar, are substrates for this enzyme. The competition between cytotoxic agents and 
these P-gp modulators for cytochrome P450 3A4 activity has resulted in unpredictable 
pharmacokinetic interactions. For example, valspodar inhibits the cytochrome P450 
3A4-mediated metabolism of paclitaxel and vinblastine (Fischer et a l , 1998) resulting 
in increased serum concentrations of the cytotoxic agents and potential risk of cytotoxic 
drug overexposure in patients (Bates et al., 2001). Similarly, in a pharmacokinetic study 
in patients with solid tumours, biricodar administered in a 24-hour intravenous infusion 
decreased the clearance of paclitaxel in a dose-dependent manner (Rowinsky et al.,
1998). It has been suggested that this interaction may be due in part to the inhibition of 
cytochrome P450 3A4 by biricodar, thereby interfering with the metabolism of 
paclitaxel. The most common response of clinical researchers to this drug interaction
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has been to reduce the dose of the cytotoxic agent However, it should be noted that 
since the pharmacokinetic interactions between chemosensitisers and cytotoxic agents 
are unpredictable and cannot be determined in advance, reducing the dose o f a cytotoxic 
agent by a set percentage may result in under- or over-dosing in a significant number of 
patients.
In addition to inhibiting P-gp, many second-generation modulators also function as 
substrates for other ABC transporters involved in the elimination of xenobiotics; 
therefore the inhibition of transporters other than P-gp could lessen the ability o f normal 
cells and tissues to protect themselves from cytotoxic agents. For instance, valspodar 
and biricodar are not specific solely to P-gp; both o f these agents affect MRP1 
(Rowinsky et al., 1998; Krishna et aL, 2000). It is possible that this inhibition of non­
target transporters may lead to greater adverse effects of anticancer drugs, including 
neutropenia and other myelotoxic effects. For example, the ABC transporter BCRP is a 
functional regulator of hematopoietic stem cells (Bunting et a l , 2002) and its inhibition 
may contribute to these effects.
Further studies led to the development of third-generation molecules such as XR9576 
(tariquidar), GF-120918 (elacridar), LY335979 (zosuquidar), R101933 (laniquidar) and 
ONT-093 (Thomas & Coley, 2003). These agents have high potency and specificity for 
P-gp and their clinical efficacy is currently under investigation.
Several phase II studies with first and second generation P-gp inhibitors have been 
conducted with encouraging results. However, these have not been confirmed in phase 
III trials. Table 1.7 summarises the randomised clinical trials conducted with P-gp 
inhibitors up to August 2003. It must be noted that in at least 3 studies the negative 
results of phase III trials are not clear-cut. The study with PSC 833 in AML by Baer et 
al. (2002) administered cytarabine, doxorubicin, and etoposide chemotherapy with or 
without the inhibitor to 120 previously untreated patients. The PSC 833 arm was closed 
early due to excessive mortality, but available data demonstrated no difference in 
disease-free or overall survival rates. However, functional studies in the leukaemic cells 
allowed an analysis of subsets based on P-gp expression. In patients with PSC 833- 
inhibitable efflux (indicating P-gp expression), the median disease-free survival was 
greater at 14 versus 5 months (p = 0.07) with the addition of PSC 833. Similarly,
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patients treated with chemotherapy alone had a lower complete remission rate (41% 
versus 91%), a higher non-response rate (41% versus 9%), and a higher death rate (18% 
versus 0%) when in vitro studies exhibited PSC 833-modulated dye efflux, compared 
with those patients whose cells did not demonstrate efflux (p = 0.03). Similarly, another 
randomised study by Solary et al. (2003) found no difference in response rate or 
survival when a multi-sequential regimen of cytarabine, amsacrine, etoposide and 
mitoxantrone was administered with or without the inhibitor, quinine. However, in the 
subset of 160 patients who could be studied, 54 demonstrated rhodamine 123 efflux, and 
in these patients, quinine significantly improved the CR rate from 12/25 (48.0%) to 
24/29 (82.8%) (p = 0.01).
The findings from this subset analyses suggest that careful selection of patients is 
essential in facilitating positive outcomes, as patients deriving benefit from MDR 
inhibitors may be obscured in trials failing to identify the appropriate target population.
Another little explored field is the ability of P-gp modulators to prevent the 
development of MDR mediated resistance. Cocker et a l (2001) failed in several 
attempts to obtain cell lines resistant to vincristine when the cells were grown in the 
presence of the MDR modulators tariquidar, PSC833, and VX710. In early clinical trials 
testing P-gp modulation in acute leukaemia, cells that survived chemotherapy in the 
presence of modulators, resulting in clinical relapse, had reduced expression of P-gp 
(List et al., 1993; Marie et a l, 1993). The hypothesis that the development of MDR 
may be preventable using Pg-p modulators therefore warrants further clinical studies.
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Table 1.7 Randomised trials of P-gp inhibitors, where n indicates the number of
patients.
Disease Study n Chemotherapy
Response
rate
^inhibitor
Median overall 
survival 
± inhibitor
- + - +
Breast
cancer
Wishart et 
a l , 1994 233 Epirubicin/quinidine 44% 43%
59
weeks
47
weeks
Breast
cancer
Belpomme 
e ta l , 2000 99
Vindesine + 5- 
fluorouracil/verapamil 11% 27%
209
days
323
days*
NSCLC Millward et a/.,1993 68
Vindesine + 
ifosfamide/verapamil 18% 41%
22
weeks
41
weeks*
SCLC Milroy,1993 220 CAVE/verapamil 80% 85%
44
weeks
41
weeks
Multiple
myeloma
Dalton 
e ta l , 1995 59 VAD/verapamil 41% 36%
10
months
13
months
Multiple
myeloma
Sonneveld 
e ta l, 2001 75 VAD/cyclosporin A 53% 49%
13
months
14.6
months
MDS
W
Wattel et 
a l , 1998 131
Mitoxantrone + Ara-C/ 
quinine 41% 47%
11
months
13
months
Acute
Leukaemia
Solary 
eta l, 1996 315
Mitoxantrone + Ara-C/ 
quinine 45.5% 52.8%
11.5
months
11.5
months
AML List et a l , 2001 226
Daunorubicin + 
cytarabine/cyclosporinA 33% 39%
12%
(2-year)
22%*
(2-year)
AML
Liu Yin 
et a l, 
2001
213
ADE (cytarabine, 
daunorubicin, etoposide) 
/cyclosporin A
41% 45% 7% 8%
AML
(S)
Baer e ta l, 
2002 120 ADE/PSC 833 46% 39%
7
months
2
months
AML
(S)
Solary 
etal., 2003 425
AraC+Idarubiciri/
amsacrine/ 
mitoxantrone/etoposide 
+/- quinine
80.6% 81.2% 22months
30
months
♦Statistically significant difference in favour of the modulator.
$ These studies found statistically significant differences in favour o f the modulator 
when the subset of P-gp positive tumours was analysed.
Abbreviations
VAD = vincristine, doxorubicin, dexamethasone
CAVE = cyclophosphamide, doxorubicin, vincristine, etoposide
ADE = cytarabine, daunorubicin, etoposide
MDS = myelodysplastic syndromes
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1.2.2.5 Multidrug resistance associated proteins - the MRP family 
After the discovery of P-gp and the demonstration of its widespread expression in many 
human cancers, it was found that many multidrug-resistant cancers, such as lung 
cancers, rarely express P-gp. Using a doxorubicin-selected multidrug-resistant lung 
cancer cell line as a model system, Deeley and Cole and colleagues (1992) cloned 
another ABC family member, known as MRP (for multidrug resistance associated 
protein). Due to the identification of various homologous proteins to MRP (Borst et al., 
2000), it is now designated as MRP1. Together with the cystic fibrosis trans-membrane 
conductance regulator CFTR, the MRPs constitute the 13 transporter containing human 
ABC-transporter subfamily C. MRP1 shares only between 34% and 58% sequence 
identity with the other MRPs (MRP2-MRP6), but the overall membrane topology is 
similar in all members of subfamily C. MRP1 is widely expressed in many human 
tissues and cancers (Borst et al., 2000). MRP1, unlike MDR1, transports negatively 
charged natural-product drugs. Non-anionic compounds may be transported as 
glutathione, glucuronide, or sulfate conjugates. In some cases cotransport o f glutathione 
(without conjugation) with positively charged drugs such as vincristine can occur (Loe 
et a l, 1998). There is generally some overlapping between the drug resistance spectra of 
P-gp and MRP1, although taxanes are a notable exception as they are usually poor 
substrates for MRP1 (Leonard et a l, 2003). The specificity of MRP 1 for organic anions 
has also been found in other MRPs. The second member of the MRP (ABCC) family, 
MRP2, or canalicular multispecific organic anion transporter (cMOAT), has been found 
to be associated with bilirubin glucuronide transport, with defects resulting in theDubin- 
Johnson syndrome. It is also a transporter of MRP1 substrates and cisplatin, with the 
potential to confer resistance to these agents (Kool et a l, 1997). MRP3 is expressed at 
high levels in the liver and may be involved in the efflux of organic anions from the 
liver to the blood in the presence of biliary obstruction (Zeng et a l, 1999). MRP4 and 
MRP5 have been found to transport nucleoside analogues. Both confer resistance to 
thiopurines, and MRP4 has been found to confer resistance to antiretroviral nucleoside 
analogues (Schuetz et a l, 1999; Kruh et a l, 2001). MRP6 appears to be a lipophilic 
anion pump with a wide spectrum of chemotherapy resistance, and mutations in this 
protein are linked to pseudoxanthoma elasticum (Belinsky et al., 2002).
To date, the only evidence of a link between the MRP family and clinical drug 
resistance is for MRP1. As for P-gp the different studies are difficult to compare
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because of heterogeneity of patient populations, techniques, and because of different 
criteria with regard to the definition of overexpression. In several studies of 
haematological malignancies, no or only minor differences have been found in MRP1 
expression before and after treatment; however other studies found higher levels of 
MRP mRNA at time of relapse in AML (reviewed in van den Heuvel-Eibrink et al.,
2000). The clinical role of MRP1 in solid tumours is even less clear, due to the almost 
ubiquitous expression of this protein in normal tissues. For example, whether the MRP1 
expression levels associated with breast cancer are enough to confer drug resistance is 
not yet resolved (Filipits et al., 1996; Dexter et al., 1998). As MRP1 is expressed 
ubiquitously, it is not surprising that using RT-PCR, MRP1 mRNA can be detected in 
all breast cancer samples at levels comparable to that in normal tissues. However, one 
immunohistochemical analysis of a series of resected invasive primary breast 
carcinomas has reported a correlation between relapse-free survival and MRP1 
expression (Nooter et al., 1997). The incidence of MRP 1 expression is much higher 
(about 80%) in small-cell lung cancer (SCLC) samples. MRP1 expression was detected 
in 100% of non-small cell lung cancers (NSCLC), with higher levels noted in 30% of 
the samples, though this is not surprising, given its ubiquitous expression in normal lung 
tissue (Nooter et al., 1996; Young et a l, 1999).
1.2.2.6 Breast cancer resistance protein (BCRP)
Observations of functional adenosine triphosphate (ATP)-dependent drug efflux in 
certain multidrug-resistant cancer cell lines without overexpression of P-glycoprotein or 
multidrug resistance protein (MRP) family members suggested the existence of another 
ATP-binding cassette (ABC) transporter capable of causing cancer drug resistance. 
Overexpression of a novel member o f the G subfamily of ABC transporters was found 
in a subline of the MCF-7 human breast carcinoma cells, and this was therefore termed 
the Breast Cancer Resistance Protein (BCRP) (Doyle et a l, 1998). Owing to tissue 
localisation in the placenta, bile canaliculi, colon, small bowel, and brain microvessel 
endothelium, BCRP may play a role in protecting the organism from potentially harmful 
xenobiotics (Jonker et al., 2000). The spectrum of anticancer drugs pumped by BCRP 
includes mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I 
inhibitors, methotrexate, flavopiridol, and quinazoline ErbBl inhibitors (reviewed in 
Doyle & Ross, 2003). Transport of anthracyclines is variable and appears to depend on 
the presence of a BCRP mutation at codon 482 (Honjo et a l, 2001). Potent inhibitors of
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BCRP are now being developed (Maliepaard et a l , 2001), opening the door to clinical 
applications of BCRP inhibition. Studies are emerging on the role of BCRP expression 
in drug resistance in clinical tumour specimens, although none o f them has so far 
prospectively investigated the contribution of BCRP to drug resistance in human 
cancers.
As for the other transporters, no method of BCRP detection has so far become the ‘gold 
standard9. IHC studies have employed two different mouse monoclonal antibodies 
against BCRP, BXP34 and BXP21, and have reported differing results (Diestra et al.,
2002). A functional assay for the detection of BCRP has recently been described 
(Robey et a l, 2001): flow cytometric measurement of FTC-inhibitable mitoxantrone 
efflux was found to be a sensitive and specific method in both selected and unselected 
cell lines.
BCRP has been studied in tumour samples from patients with acute myeloid leukaemia 
(AML) both at the mRNA level (Ross et al., 2000; van Den Heuvel-Eibrink et a l, 2002) 
and at the protein level by immunocytochemistry (Sargent et a l, 2001) or flow 
cytometry (van der Kolk et a l, 2002). Ross et a l (2000) found relatively high 
expression of BCRP mRNA in 33% AML samples: BCRP expression did not correlate 
with P-gp expression and the authors suggested that BCRP could be responsible for 
resistance to certain antileukaemic drugs in P-gp negative cases. Sargent et a l (2001) 
found that BCRP detected by immunocytochemistry in the cells of AML patients 
correlated with the LC50 of daunorubicin determined by the MTT in vitro 
chemosensitivity assay, but not with the IC50 values of mitoxantrone, topotecan or 
doxorubicin. Steinbach et a l (2002) were able to associate BCRP gene expression 
measured using TaqMan qRT-PCR with a poor response to remission induction therapy 
in 59 children affected with AML. One study (van der Heuvel-Eibrink et a l, 2002) 
found that BCRP mRNA levels (determined by qRT-PCR) in 20 paired AML clinical 
samples were increased after chemotherapy, while another study (van der Kolk et a l,
2002) failed to find an increased expression of the protein (determined by flow 
cytometry) in relapsed/refractory patients.
There is less information about solid tumours. Nakayama et a l (2002) were able to 
detect BCRP expression in ovarian carcinomas using standard RT-PCR, but did not find
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any prognostic relevance. Kanzaki et a l (2001) found that primary breast carcinomas 
had low mRNA levels (determined by semi-quantitative RT-PCR) of several MDR 
related transporters, including BCRP. Scheffer et a l (2000) found that IHC expression 
of BCRP was undetectable or very low in a panel of human solid tumours. However, 
this series included only a few carcinomas for each tumour type, and most were from 
untreated patients. Furthermore IHC was found to be a poorly sensitive method to detect 
BCRP (Faneyte et al., 2002), compared to other techniques, such as real time RT-PCR, 
which allow detection of the target molecule mRNA even from a single cell. More 
recently Faneyte et a l (2002) studied the expression of BCRP in breast cancer 
specimens from 25 primary carcinomas and 27 anthracycline-exposed patients applying 
a variety of methods, including immunostaining with mouse monoclonal antibodies 
against BCRP, BXP34 and BXP21. The authors were not able to observe specific 
tumour cell staining, but were able to detect BCRP mRNA levels by sensitive qRT-PCR 
in both chemotherapy-naive and anthracycline treated patients. Positive 
immunostaining of vascular endothelium and of a part of the normal epithelium in large 
mammary ducts occurred with both antibodies, suggesting that antibody sensitivity was 
not an issue, but it should be noted that RNA was extracted from 20 pm slices of the 
cryopreserved tissue samples and not from a pure isolated cancer cell population. 
Endothelial cells in the tumour may therefore be responsible for the qPCR results. 
Burger et a l (2003) used qRT-PCR to determine the relevance of BCRP mRNA 
expression in breast specimens. It is notable that all three studies conducted on breast 
tumours failed to find any correlation between BCRP expression and response to 
doxorubicin-based chemotherapy (Kanzaki et a l, 2001; Burger et a l , 2003) or patient 
survival (Faneyte et a l , 2002; Burger et a l , 2003).
1.2.2.7ATP 7B
There is evidence to indicate that reduced drug accumulation is a significant mechanism 
of cisplatin resistance (Kelland, 1993; Chau & Stewart 1999). The cause of the reduced 
cisplatin accumulation in resistant cells may be ascribed to either an inhibition of drug 
uptake, an increase of drug efflux, or both. A defect in the uptake process has been 
investigated, but the mechanism for this remains unclear and has been attributed to 
changes in the non-saturable process of passive drug diffusion (Yoshida et a l , 1994; 
Kelland, 2000) or other forms of active transport (Andrews et a l , 1988; Gately and 
Howell, 1993).
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Development of resistance as a result of increased cisplatin efflux was largely 
discounted in earlier studies involving only P-gp (Teicher et al., 1987; Andrews et al., 
1988). More recently, MRP2 has been associated with cisplatin resistance (Kool et al., 
1997; Koike et al., 1998; Cui et al., 1999), although some controversy still exists (Shen 
et a l, 2000; Nakayama et al., 2002).
A second important area of investigation involving cisplatin efflux has centered on 
ATP7B. This protein is a member of a class of heavy metal-transporting, P-type 
ATPases that pump copper, cadmium, zinc, silver or lead (Solioz et al., 1996; Gupta et 
al., 1999). The induction of the ATP7B gene was observed by exposure to cisplatin in 
cell lines, and human tumour cells transfected with ATP7B acquired significant 
resistance to cisplatin (nine-fold), primarily as a consequence of its enhanced efflux 
(Komatsu et al., 2000).
In human tumours the expression of ATP7B has been studied mainly by IHC and has 
been detected with variable frequency in breast (22%; Kanzaki et a l, 2002), ovarian 
(44%; Nakayama et al., 2002), oesophageal (76%; Higashimoto et al., 2003) and gastric 
(41%; Ohbu et a l, 2003) carcinomas and in 55% of primary oral squamous cell 
carcinomas (SCC) (Miyashita et al., 2003). The expression of ATP7B is generally 
higher in poorly differentiated carcinomas than in well-differentiated tumours (Kanzaki 
et al., 2002; Nakayama et al., 2002; Ohbu et a l, 2003). Recently, two studies, the first 
in ovarian cancer (Nakayama et al., 2002), and the second in oral SCC (Miyashita et al., 
2003) have shown that ATP7B positivity in tumour samples at diagnosis is a negative 
prognostic factor in patients who had received cisplatin-containing chemotherapy.
1.2.2.8 Major vault protein - Lung resistance protein
Although frequently included in discussions of transporter-mediated resistance, lung 
resistance protein (LRP) is not an ABC transporter, but is a major vault protein (MVP) 
(Scheffer et a l, 1995) found in the cytoplasm and nuclear membrane. MVP is broadly 
distributed in normal and malignant cells. High MVP expression is seen in bronchus, 
digestive tract, renal proximal tubules, keratinocytes, macrophages and adrenal cortex 
whereas varying levels were observed in other organs (Kedersha et a l, 1990; Izquierdo
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et a l, 1996; Schroeijers et al., 2002). The localisation of MVP suggests a role in the 
defence of these organs and cells against toxic compounds.
The expression of MVP closely reflects the chemoresi stance profile o f many tumour 
cell lines and untreated cancers (Scheper et aL, 1993; Izquierdo et a l , 1996a;
Kickhoefer et a l, 1998; Schroeijers et a l, 2000; Siva et a l, 2001). Elevated MVP levels 
have been observed in cell lines resistant to various classes of cytotoxic agents 
including doxorubicin, mitoxantrone, methotrexate, etoposide, vincristine, cytarabine 
and cisplatin (Scheper et a l, 1993; Versantvoort et al., 1995; Verovski et a l, 1996; 
Lauren9ot et a l , 1997; Moran et a l , 1997; Wyler et a l , 1997; Komarov et a l , 1998). In 
non-small-cell lung cancer cells, MVP expression levels, determined by protein and 
mRNA, correlated with resistance to cisplatin (Berger et al., 2000). However, in this 
study, no correlation was observed with resistance to daunomycin, bleomycin, 
doxorubicin, etoposide and vinblastine. In contrast, in pharyngeal carcinoma KB-3-1 
cells, increased MVP levels were found to correlate with decreased accumulation of 
doxorubicin in the nuclei of these cells (Cheng et a l, 2000). Another recent study 
performed in U-937 leukaemia cells reports that cells selected by doxorubicin exposure 
upregulated vault levels and acquired resistance against doxorubicin, etoposide and 
mitoxantrone. This resistance seemed to be independent of P-gp (MDR1), multidrug- 
resistance-related protein (MRP1), MRP2 and breast cancer resistance protein (BCRP) 
(Hu et al., 2002).
It is thought that MVP drives drugs out of the nucleus. Recently, the group of Akiyama 
reported on experiments supporting a role for vaults of extrusion of anthracyclines from 
the nuclei of resistant cells (Kitazono et al., 1999 & 2001; Ohno et a l,  2001). Treatment 
of the colon carcinoma cell line SW620 with sodium butyrate led to a strong induction 
of MVP and made the cells significantly less sensitive to doxorubicin, etoposide (VP- 
16), vincristine, paclitaxel and the transport antibiotic gramicidin D. The stable 
expression of two unrelated MVP-specific ribozymes reversed the observed resistant 
phenotype. The molecular mechanism of vault-mediated resistance against doxorubicin 
was investigated more closely. The drug, which accumulated in the nuclei of untreated 
cells, was shown to efflux more rapidly from the nuclei o f sodium butyrate-treated cells. 
The efflux of doxorubicin, from the nuclei in intact cells or isolated nuclei, could be 
inhibited by the expression of the anti-MVP ribozymes or the addition of polyclonal
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anti-MVP antibodies (Kitazono et al'., 1999). In a subsequent study, the pyridine analog 
PAK-104P was introduced as specific inhibitor of vault-mediated efflux (Kitazono et 
al., 2001). Taken together, these findings provide evidence for the hypothetical model 
in which vaults function in nuclear drug export and as a consequence may cause drug 
resistance.
The hypothesis that MVP expression may reflect a novel pathway of multidrug 
resistance has prompted several clinical studies to determine the expression of this 
molecule in human tumours. These studies have mainly focused on whether the level of 
MVP expression predicts clinical outcome after chemotherapy. The majority of the 
studies have been performed in haematological malignancies, but some solid tumours 
have been examined. Various detection techniques have been used for MVP, including 
immunohistochemistry and RNA expression as determined by RT-PCR. The results 
obtained with these detection assays are variable, mainly because a functional assay of 
MVP activity has not yet been developed. Thus far, the evidence that MVP expression 
correlates with clinical response is weak, due partly to the small numbers of patients 
investigated. Another limitation is that most studies have been founded on univariate 
analysis without evaluating other prognostic parameters. Therefore compelling evidence 
that MVP expression correlates with the clinical response and prognosis is still lacking 
and no prospective trials using a functional assay and multivariate analysis of risk 
factors have been performed.
The expression of MVP in human cancers is variable; low rates of MVP positivity are 
seen in testicular cancer, neuroblastoma, and AML; intermediate in ovarian cancer; and 
high in colon, renal, and pancreatic carcinomas (Izquierdo et al., 1996a). Several studies 
have investigated the role of MVP in haematological malignancies. Some investigators 
have proposed that MVP expression negatively correlates with either response or 
survival in AML (Goasguen et al., 1996; List et al., 1996; Hart et al., 1997; Borg et al., 
1998; Filipits et al., 1998 & 2000; Xu et al., 1999). In contrast, other studies have not 
pointed towards a predictive or prognostic significance for MVP (Damiani et al., 1998; 
Legrand etal., 1998; Leith etal., 1999; Michieli etal., 1999; Pallis etal., 1999).
Relatively few studies have addressed the role of MVP in solid tumours. The strongest 
expression of MVP is found in colorectal tumours. In this tumour, the expression
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increases from pre-malignant lesions such as colonic adenoma to aggressive colon 
carcinoma, which indicates that MVP may be associated with more aggressive disease 
(Izquierdo et a l , 1996a; Meijer et a l , 1999). Other tumours in which expression of 
MVP has been reported include melanoma, osteosarcoma and neuroblastoma (Ramani 
and Dewchand, 1995). In uveal melanoma, high expression is observed, which seems to 
correlate with aggressive behaviour of the tumour, (Schadendorf et a l , 1995; van der 
Pol et a l , 1997). In osteosarcoma, MVP expression was reported to correlate with 
failure to respond to chemotherapy and poor survival (Uozaki et a l , 1997). Two studies 
from the same group have investigated the expression of MVP in ovarian cancer 
(Izquierdo et a l , 1995; Arts et a l , 1999). In advanced ovarian cancer FIGO stage III/IV, 
77% of the patients express MVP at diagnosis. In localised cancer FIGO stage I/II, a 
similar figure is observed. In advanced ovarian cancer, a correlation was found between 
MVP expression and lack of response and/or shorter OS, but this was not found in 
early-stage ovarian cancer. In contrast, in early-stage ovarian cancer, MVP expression 
was associated with favourable prognostic variables. Two studies were performed in 
breast cancer using immunohistochemistry to investigate MVP expression. In one study, 
the expression ranged from 69 to 75% without significant differences between samples 
obtained at diagnosis or at relapse after chemotherapy (Linn et a l , 1997). The second 
study found 68% of patients with intermediate or high MVP expression (Pohl et al.,
1999). In neither study, was a clear correlation with clinical outcome observed. 
Similarly, Burger et a l (2003) failed to correlate the expression of MVP mRNA with 
response or overall survival in a series of 59 breast tumour specimens. However this 
study found only a very modest correlation between high expression levels o f LRP and 
poor progression-free survival in a sub-group of patients who had received an 
anthracycline-based regimen.
1.2.2.9 Antimetabolite transporters
Drugs that disrupt nucleotide synthesis are important anticancer therapeutics. Synthetic 
nucleoside and nucleobase analogues, such as 5-fluorouracil, 6-mercaptopurine, 6- 
thioguanine, cytarabine, cladribine, fludarabine and gemcitabine (table 1.1) have been 
developed as clinically useful drugs in the chemotherapy of a variety o f human tumours. 
Drugs inhibiting folate metabolism, such as methotrexate, and drugs inhibiting 
ribonucleotide reductase, such as the hydroxyurea and triapine, also target nucleotide 
metabolism by inhibiting nucleotide synthesis. Other antimetabolites inhibit phosphor­
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ylation of nucleotides, such as tiazofurin. The cytotoxicity of all of these drugs may 
depend on metabolic activation and uptake/efflux of the drugs themselves as well as 
their active metabolites and endogenous or exogenous rescue agents.
Under physiologic conditions, nucleosides and nucleobases and their analogues are 
hydrophilic and they do not readily cross the plasma membrane by diffusion. Efficient 
cellular uptake therefore requires the presence of specialised plasma membrane 
proteins, called nucleoside transporters (NTs) (Baldwin et a l , 1999) and nucleobase 
transporters (NCBTs). The NTs consist of two structurally unrelated protein families 
that are designated ENT and CNT, depending on whether they mediate, respectively, 
equilibrative (E) or concentrative (C) NT processes (reviewed in Damaraju et a l , 2003). 
Concentrative nucleoside transporters (CNTs) have been found in heart, skeletal muscle, 
placenta, pancreas and lung, while equilibrative nucleoside transporter (ENTs) 
expression is ubiquitous.
The NCBTs are expressed in kidney, intestine, choroid plexus and placenta and have 
been demonstrated to be the route of entry for nucleobases and nucleobase analogues 
used in cancer chemotherapy (Griffith et a l , 1996; table 1.4).
As mechanisms of uptake, increased expression of these transporters may therefore 
result in increased sensitivity to their respective substrates. Several in vitro studies have 
suggested that there may be a relation between transporter expression and 
antimetabolite drug sensitivity. Transduction of ENT2 into bone marrow cells resulted 
in resistance to anti-folate drugs in murine bone marrow cells (Patel et al. , 2000). 
Decreased or deficient ENT1 activity has been shown to contribute to the in vitro 
resistance to gemcitabine and the active capecitabine metabolite 5’-deoxy-5- 
fluorouridine (Mackey et a l, 1998 & 2002).
The first assays available for the quantitation o f NT proteins in clinical samples relied 
on radiolabeled or fluorescently labeled binding analysis of the nucleoside transport 
inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR; Gati et a l, 1997). Such 
assays, although technically demanding and requiring large numbers o f homogeneous 
viable cells, demonstrated that hENTl deficiency in myeloblasts correlated with clinical 
cytarabine resistance (Gati et a l, 1997). The relevance of hNTs deficiency in clinical
|
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resistance to nucleoside drugs in solid tumours remains speculative. It is hoped that new 
detection methods for NTs recently developed, such as immunohistochemistry (Mackey 
et al., 2002) and real time PCR (Lu et al., 2002), would clarify the role o f these 
transporters in solid malignancies.
On the other hand, increased expression of NTs may also cause increased resistance to 
nucleoside analogues by importing competing substrates that can rescue cells from 
toxicity.
1.23 Increased dexotification
1.2.3.1. Glutathione S-transferases
Glutathione S-transferases (GSTs) are a family of phase II detoxification enzymes that 
catalyse the conjugation of glutathione (GSH) to a wide variety of endogenous and 
exogenous electrophilic compounds. GSH conjugates are then pumped out of the cells 
by the MRP series of ABC transporter molecules (section 1.2.1). GSTs are divided into 
two distinct super-family members: the membrane bound microsomal and cytosolic 
family members. Cytosolic GSTs are subject to significant genetic polymorphisms in 
human populations. They are divided into six classes, which are designated by Greek 
letters a , p, 0 ,7t, \\f, and £ (Barone & Tew 1996).
Recent studies have demonstrated a regulatory role for the 7i and p classes of GSTs in 
the mitogen-activated protein (MAP) kinase pathway that participates in cellular 
survival and death signaling (reviewed in Townsend & Tew, 2003). Specifically, ASK1 
(apoptosis signal-regulating kinase) is a MAP kinase that activates the c-Jun N-terminal 
kinase (JNK) and p38 pathways leading to cytokine- and stress-induced apoptosis 
(Ichijo et al., 1997). The activity of ASK1 is low in non-stressed cells due to its 
sequestration via protein: protein interactions with GSTpl (GSTpl: ASK1 complex), 
and/or thioredoxin (Trx: ASK1 complex) (Cho et al., 2001; Saitoh et al., 1998). 
Dissociation of the GSTpl: ASK1 complex is heat shock dependent (Saitoh et al.,
1998). Forced expression of GSTM1 blocked ASK1 oligomerisation and repressed 
ASK1-dependent apoptotic cell death (Cho et al., 2001). GST-7T was shown to be an 
endogenous inhibitor of JNK1, a kinase involved in stress response, apoptosis, and 
cellular proliferation (Adler et a l, 1999). In non-stressed cells, low JNK activity is
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observed due to the sequestration of the protein in a GST-71: JNK complex (Adler et al.,
1999). However, suppression of JNK activity is reversed by conditions of oxidative 
stress (UV irradiation or hydrogen peroxide treatment), resulting in the dissociation of 
the GST-ic: JNK complex, oligomerisation of GST-71, and induction of apoptosis (Adler 
et al., 1999). This novel, non-enzymalic role for GST-tc has direct relevance to the GST- 
overexpressing phenotypes of many drug-resistant tumors. As an endogenous switch for 
the control of signaling cascade pathways, elevated expression of GST-71 can alter the 
balance of regulation of kinase pathways during drug treatment, thereby conferring a 
potential selective advantage (Townsend & Tew 2003). This process also provides a 
plausible explanation for the numerous examples of drug resistance linking GST 
overexpression with agents that are not substrates for these enzymes (table 1.8).
Several studies have investigated whether the effects of chemotherapy can be 
potentiated by inhibiting GSH detoxification pathway. The main approaches to 
inhibiting the GSH system are either to deplete cellular glutathione or to inhibit the 
GSTs. The commonest way to deplete cellular GSH is to inhibit its synthesis. Inhibition 
of y-glutamylcysteine synthetase, an enzyme required for GSH synthesis, has been 
found to be the most effective method of inhibition (Barone & Tew 1996). Buthionine 
sulfoximine acts by inhibiting y-glutamylcysteine synthetase (Campbell et al., 1991) 
and it has been shown to enhance the activity of a number of varied drugs, including 
treosulfan (Reber et al., 1998) and cisplatin (Pendyala et al., 1997, Perez et al., 1998).
Inhibition of GSTs has also been studied as a method to increase the efficacy of a 
number of chemotherapeutic agents. Ethancrynic acid (Caffrey et al., 1999) and 
glutathione derivatives (Nakanishi et al., 1997) have all been used to inhibit GSTs and 
to enhance the activity of a wide range of chemotherapeutic agents.
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Table 1.8 Compounds associated with GST mediated resistance (Barrone & Tew, 1996; 
Townsend & Tew, 2003)
Substrates of GST Not characterised as substrates
Chlorambucil 
Melphalan 
Nitrogen mustard 
Phosphoramide mustard 
Acrolein 
Carmustine 
Hydroxyalkenals 
Ethacrynic acid 
Steroids
Antimetabolites*
Antimicrotubule drugs*
Topoisomerase I & II inhibitors*
Bleomycin
Hepsulfam
Mitomycin C*
Doxorubicin*
Cisplatin*
Carboplatin
♦Require JNK activation for cytotoxicity
1.2.3.2 Metallothioneins
Metallothioneins (MTs) are a group of low-molecular weight, cysteine rich intracellular 
proteins, which are encoded by a family of genes containing at least 10 functional 
isoforms in human. Although a number of biological functions have been proposed for 
MTs, most of them are related to its metal-binding property (reviewed in Cherian et al
2003). Thus, MTs may protect against certain metal toxicity, and may donate 
zinc/copper to certain metallo-enzymes and transcription factors. MTs may also protect 
against oxidative stress because of its high cysteine content. MTs are mainly 
cytoplasmic proteins in adult tissues, although they are also detected in the nucleus of 
cells in fetal/early neonatal period (Chan & Cherian 1993). A transient localisation of 
MTs into nucleus under certain conditions such as cell proliferation and differentiation 
has been reported (Apostolova & Cherian 2000).
Previous studies have demonstrated that overexpression of MTs can confer resistance to 
radiation and antineoplastic drugs such as cisplatin (Satoh et al., 1994). It has been 
proposed that the sequestration of free radicals, drugs or their metabolites by MTs, may 
inhibit the direct interaction of antineoplastic agents with their intracellular targets, 
thereby decreasing the efficacy of their chemotherapeutic effects. A role in modulation 
of apoptosis has also recently been suggested, as cadmium-induced MT levels were 
negatively correlated with sensitivity to etoposide-induced apoptosis (Shimoda et al.,
2003).
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The role of MT in the development of chemoresistance in the clinical setting is still 
controversial. Studies in human tumours such as ovarian, testicular and colon tumors, 
appear to suggest that overexpression of MT may have a protective effect against 
antineoplastic agents, whereas there are other reports which do not support this 
perception (Chin et a l , 1993; Ioachim et al., 1999).
In breast cancer, two separate studies have concluded that MT overexpression is 
associated with significantly poorer prognosis and increased recurrence in pT2 invasive 
ductal breast carcinomas (Schmid et al., 1993; Goulding et al., 1995). However Ioachim 
et al. (2003) have recently shown that MT expression is a positive prognostic factor in 
primary invasive breast cancer.
In ovarian cancer, previous studies do not point towards a clinical relevant role of MT 
(Murphy et al., 1991), although there is marginal and discordant evidence that platinum- 
based chemotherapy may increase MT expression in paired tumour biopsies (McGown 
e ta l,  1994; Wrigley et al., 2000).
MT gene overexpression has been found in a number of bladder tumours that had failed 
cisplatin chemotherapy (Wood et al., 1993), and MT was found to be a negative 
predictive factor for cisplatin-based chemotherapy in various urological cancers 
(Bahnson et al., 1994; Kotoh et al., 1994; Siu et al., 1998).
The role of MT in gastrointestinal (GI) malignancies is also controversial. Two studies 
failed to correlate MT expression with tumour progression in colorectal adenocarcinoma 
(Ioachim et al., 1999). However, others have demonstrated that GI cancer is 
accompanied by a decrease in MT expression, but that the most malignant phenotypes 
show the highest MT levels (Janssen et al., 2002). In particular, Janssen et al. (2002) 
found that more than 74% of GI carcinomas had a lower MT level than their 
corresponding normal mucosa. In colorectal cancer patients, but not in gastric cancer 
patients, a high MT level in both the carcinomas and normal mucosa was, however, 
significantly associated with a poor overall survival, independently from 
clinicopathological features. In gastric cancer, however, MT expression in the gastric 
mucosa was not of prognostic significance. MT expression was not found to correlate 
with survival also in another series of 61 oesophageal tumours (44 adeno- and 17
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squamous cell carcinomas) treated only with surgical resection, while low-level P-gp 
expression was a prognostic factor (Aloia et a l , 2001). Similarly, another study found 
no association between MT expression and survival in a group of 118 oesophageal 
cancer patients who were treated with a cisplatin-based regimen (Harpole et al., 2001); 
while high-level expression of GST-71, P-gp, and TS were negative prognostic factors. 
However, in two studies, MT-positive oesophageal squamous cell carcinomas had a 
poor response to chemoradiation therapy (Yamamoto et al., 1999; Kishi et al., 2002).
1.2.3.3 Cytochrome P450 enzymes
Several cytochrome P450 (CYP) enzymes are involved in the metabolism of a range of 
anticancer drugs, including dacarbazine, cyclophosphamide, paclitaxel, and docetaxel 
(Kivisto et al., 1995; Marre et al., 1996; Crommentuyn et a l, 1998). CYP-mediated 
metabolism usually results in reduced activity or inactivation of the anticancer drugs, 
but in some cases bioactivation to a more cytotoxic metabolite occurs.
One example of detoxification of anticancer drugs is shown by the taxanes. The major 
pathway of metabolism of paclitaxel is catalysed by C YP2C8 and involves the 
hydroxylation of position 6 on the taxane ring (Rahman et al., 1994). The metabolite 6- 
hydroxytaxol is 30-fold less cytotoxic than the parent compound paclitaxel (Harris et 
al., 1994), and this metabolite is further metabolised by CYP3A4 (Crommentuyn et al.,
1998). Docetaxel is metabolised by CYP3A to apparently less cytotoxic metabolites 
(Marre et a l, 1996; Crommentuyn et al., 1998), and a role for CYP1B1 has also been 
recently demonstrated (Rochat et al., 2001; Me Fadyen et al., 2001).
Other anticancer drugs are metabolically activated by C YPs, such as DTIC and 
cyclophosphamide (Chang et al., 1993; Reid et a l, 1999). In particular, 
cyclophosphamide must first undergo a 4-hydroxylation reaction to 4- 
hydroxycyclophosphamide by CYP enzymes (CYP2B6 and CYP3A4) (Chang et al.,
1993) before becoming cytotoxic (Bohnenstengel et a l, 1996). CYP3A4 has also been 
shown to be involved in the metabolic activation of doxorubicin to the more cytotoxic 
morpholino-doxorubicin (Lewis et al., 1992; Goeptar et al., 1994).
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1.2.4 Topoisomerase-mediated resistance
Topoisomerases are essential enzymes, which play an important role during cell 
division. Topoisomerases I and II unravel DNA during transcription, DNA replication, 
and DNA repair. While topoisomerase I (TOPO I) cleaves single strands of duplex 
DNA, topoisomerases II (TOPO II) introduce double strand breaks that allow 
relaxation, unknotting and decatenation (Champoux 2001).
TOPO I is involved in DNA replication, RNA transcription, as well as in chromosome 
condensation and segregation. Inhibitors of this enzyme, camptothecin and its 
derivatives, topotecan and irinotecan, are currently used to treat solid tumours such as 
ovarian and colorectal cancer (Takimoto et a l, 1998). Mutations, decreased expression 
and/or activity of TOPO I have all been associated with camptothecin resistance in cell 
line experiments (Saleem et al., 2000). Multiple mechanisms contribute to the 
regulation of TOPO I levels in the cell. In tumours demonstrating increased levels of 
enzyme expression, increased levels of mRNA have also been observed (Husain et a l,
1994). This would indicate either increased transcription or increased mRNA stability. 
On the other hand, cell lines with reduced expression were found to have 
hypermethylalion of one allele of the TOPO I gene, leading to decreased transcription 
and thus reduced enzymatic production of TOPO I (Tan et a l, 1989).
Very little is known about the role played by TOPO I levels in determining 
chemotherapy response in human cancers. Preliminary data suggest that gene 
expression levels of TOPO I may be predictive of response to therapy with irinotecan in 
colorectal cancer patients (Iqbal & Lenz 2001), but further dynamic studies evaluating 
the change of TOPO I expression in cancer patients during a treatment period are 
warranted.
Two isoforms of TOPO II exist, a  and p. TOPO Ila is essential for cell growth and is a 
cell proliferation and tumour marker, while TOPO lip is apparently nonessential for 
growth and its function remains unclear (Enington et a l, 1999). The two isoforms are 
expressed at different points in the cell cycle. TOPO Ha reaches its highest level in the 
late S/G2 phase (figure 1.1), whereas the p isoform is expressed at a constant level 
throughout the cell cycle (Kimura et a l, 1994). In addition, the level of TOPO Ila is
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strongly decreased (Larsen & Skladanowski 1998) in growth-arrested cells. Inhibitors of 
TOPO Ila use multiple mechanisms. Early studies demonstrated that certain 
compounds, including AMSA, doxorubicin and mitoxantrone, act primarly by 
intercalating into the DNA between the bases while other drugs, such as etoposide, bind 
to the actual enzyme (Pommier et a l , 1996). All of these drugs poison the enzyme by 
increasing the steady-state concentration of its covalent DNA cleavage complexes. This 
action converts TOPO II into a physiological toxin that creates double-stranded DNA 
breaks in the genome of treated cells and induces mutagenic and lethal events (Burden 
& Osheroff 1998).
TOPO Ila targeted drugs are considerably more lethal to cells that contain high levels of 
the enzyme and are undergoing high rates of DNA replication. Several studies in patient 
specimens have shown a relation between TOPO Ila expression and the proliferative 
state of the tumour, higher TOPO Ila levels being seen in more highly proliferating 
tumour types (Kellner et a l , 2002). Therefore clinically aggressive cancers such as 
acute leukaemia appear to be most responsive to TOPO II inhibitors (Hande 1998).
In vitro resistance to TOPO II inhibitors can be mediated by efflux pumps (section 1.2, 
table 1.3), but is also seen when the activity and sensitivity of the target enzyme 
topoisomerase TOPO Ila itself are decreased by down-regulation or mutation (‘atypical’ 
MDR) (Kellner et a l, 2002). Mutations in TOPO Ila do not seem to have a major role 
in clinical resistance; the few studies conducted so far found no mutations (Kaufmann et 
a l,  1994) or a low frequency (Kubo et a l, 1996). The relevance of TOPO Ila 
expression in predicting response to chemotherapy is uncertain. No relation was 
observed between expression or activity of TOPO Ila and response to chemotherapy in 
a number of studies (Dingemans et al., 1999 & 2001; Jarvinen et a l, 1998); nonetheless 
one group reported a correlation between complete response to anthracycline-based 
chemotherapy and TOPO Ila gene amplification and protein overexpression in breast 
cancer where TOPO Ila  may be co-amplified with HER2 (Cardoso et a l, 2004). 
Moreover, in one study a trend of reduced TOPO Ila levels was seen in samples taken 
after chemotherapy treatment, as compared with specimens prior to treatment 
(Kaufmann et a l, 1994). While the predictive role of TOPO Ila overexpression is 
unclear, its negative prognostic significance is well established in several malignancies
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(Dingemans et al., 1999 & 2001; Jarvinen et a l, 1998; Provencio et a l, 2003; Skotheim 
et al., 2003), though this probably reflects tumour aggressiveness rather than a 
parameter determining response to chemotherapy.
An observation of considerable clinical interest is that the expression of TOPO Ila can 
be stimulated by TOPO I inhibitors. Treatment of patients with camptothecins led to a 
transient increase in the expression of TOPO Ila protein in peripheral blood 
mononuclear cells (Rubin et a l, 1995; Nicklee et a l, 1996; Gupta et al., 1998). 
Similarly, topotecan or irinotecan treatment resulted in an increase in TOPO Ila levels 
and sensitivity to etoposide in human colon cancer xenografts (Whitacre et al., 1997; 
Eder et a l, 1998). These observations led to phase I trials to evaluate the sequential 
administration of topotecan followed by etoposide, but these have been rather 
disappointing and hampered by severe toxicity (Hammond et al., 1998; Crump et al.,
1999). However, a recent phase I study in patients with advanced malignancies found 
acceptable toxicity and significant activity when the combination of cisplatin and 
irinotecan was followed by etoposide (Licitra et a l, 2003).
An alternative approach to sequential administration studies has been to combine in one 
molecule the properties of both TOPO I and TOPO II inhibitors (Denny & Baguley
2003). Given the differing roles and expression of the two types of enzymes within the 
cell cycle, inhibitors of both TOPO I and II (‘dual inhibitors’) would be expected to 
have significant therapeutic advantage over agents targeting one type of topoisomerase 
alone. In addition, dual inhibitors may circumvent mechanisms of drug resistance 
attributable to alteration (e.g. by mutation or down-regulation) of a single target 
enzyme. Dual inhibitors may also be expected to have a broader spectrum of activity, as 
the expression levels of the two enzymes are variable between different types of cancers 
(Me Leod et a l, 1994). Recently several joint inhibitors of TOPO I and TOPO II have 
been described: DACA/XR5000 (Finlay et a l, 1996), TAS-103 (Utsugi et al., 1997), 
intoplicine (Riou et al., 1993), F 11782 (Perrin et al., 2000), XR11576 (Mistry et al.,
2002), and XR5944 (Stewart et al., 2001), although the last of these has recently been 
found to act mainly via a non-TOPO mediated mechanism of action (Sappal et a l,
2004).
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Figure 1.1 Cell cycle and topoisomerase expression.
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1.2.5 Mechanisms involved in resistance to 5-FU
5-FU is an antimetabolite widely used in the treatment of breast, colorectal and upper 
GI malignancies. More than 80% of administered 5-FU is normally catabolised by 
hepatic dihydropyrimidine dehydrogenase (DPD) to dihydrofluorouracil (DHFU)
(figure 1.2). The remaining 5-FU rapidly enters the cell using the same nucleobase 
transport mechanism as uracil (section 1.2.2.9). 5-FU is converted intracellularly to 
several active metabolites (figure 1.2) that disrupt RNA synthesis and the action of 
thymidylate synthase (TS).
TS catalyses the reductive methylation of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP), and this reaction provides the sole de novo 
source of thymidylate, which is necessary for DNA replication and repair. Preclinical 
studies have demonstrated that TS expression is a key determinant of 5-FU sensitivity. 
Gene amplification of TS with consequent increases in TS mRNA and protein has been 
observed in cell lines that are resistant to 5-FU and fluorodeoxyuridine (FUDR) 
(Johnston et al., 1992; Copur et a l, 1995). Treatment with 5-FU has been shown to 
acutely induce TS expression in cell lines, animal models and human tumours (Swain et 
a l, 1989; Chu et al., 1993; Peters et al., 1995; Welsh et al., 2000). This induction seems 
to be due to inhibition of a negative- feedback mechanism in which ligand-free TS 
protein binds to and inhibits the translation of TS mRNA (Chu et al., 1994). When 
stably bound by FdUMP, TS is no longer able to bind to its mRNA and suppress its own 
translation, resulting in increased protein expression (Chu et a l, 1994). This constitutes 
a potential mechanism of resistance, as the acute increase in TS protein levels would 
facilitate recovery of enzymatic activity.
High TS levels generally predict for lack of response to 5-FU based therapy, while 
lower levels are correlated with response in GI cancers (Johnston et al., 1995; Lenz et 
al., 1996; Leichman et al., 1997; Salonga et al., 2000; Ichikawa et a l, 2003; Hu et a l,
2003). A recent systematic review and meta-analysis of TS expression has shown that 
colorectal tumours expressing high levels of TS appeared to have a poorer overall 
survival (OS) compared with tumours expressing low levels (Popat et a l, 2004).
Several groups have reported that TS levels generally predict for OS also in upper GI 
malignancies (Kuniyasu et al., 1998; Suda et al., 1999; Harpole et a l, 2001), although 
some discrepancies exist (Tsujitani et a l, 2000; Hironaka et al., 2002). Generally,
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mRNA levels of TS have proven to be as good predictors of response as well as protein 
levels determined by IHC (Johnston et al., 1995; Lenz et al., 1996; Leichman et a l, 
1997; Lenz et al., 1998; Aschele et al., 1999; Salonga et al., 2000).
Thymidine phosphorylase (TP) is an enzyme that catalyses the reversible 
phosphorolysis of thymidine and its analogues to their respective bases and 2- 
deoxyribose-1 -phosphate. Hence 5-FU is reversibly converted to fluorodeoxyuridine 
(FUDR), which in turn can be converted to the active metabolite FdUMP (figure 1.2). 
Characterisation of the role of TP in modulating 5-FU responsiveness has been 
confusing due to contradictory pie-clinical and clinical data. TP overexpression in cell 
culture and xenograft models has been shown to increase sensitivity to 5-FU and its 
prodrugs, presumably due to enhanced formation of FdUMP (Patterson et a l, 1995; 
Kato et a l, 1997; Evrard et a l,  1999). However, retrospective analysis of TP mRNA 
expression in colorectal tumours indicated that tumours with high TP expression were 
actually less likely to respond to 5-FU (Metzger et a l, 1998; Salonga et a l, 2000). 
These contradictory findings might be explained by the fact that TP is also an 
angiogenic endothelial-cell growth factor and high TP expression in colorectal 
oesophageal tumours has been correlated with worse prognosis (Takebayashi et al., 
1996; Koide et a l, 1999; van Triest et al., 2000). It is possible that high TP expression 
might be a marker for a more invasive and aggressive tumour phenotype that is less 
responsive to chemotherapy. However, as tumour cells do not benefit from increased 
angiogenic potential in tissue culture, TP-mediated activation of 5-FU might 
predominate in this setting.
The rate-limiting enzyme in 5-FU catabolism is DPD and patients who are deficient in 
DPD experience profound systemic toxicity in response to 5-FU due to prolonged drug 
over-exposure (Johnson et a l, 1999). Recent genetic studies have started to define the 
mutations in the DPD gene that are responsible for the DPD-deficient phenotype 
(Johnson et a l, 2002). In vitro studies have also shown that DPD expression in the NCI 
60 cancer cell line panel is correlated with 5-FU chemosensitivity (Scherf et al., 2000). 
Furthermore, high levels of DPD mRNA expression in colorectal tumours have been 
shown to correlate with resistance to 5-FU chemotherapy in patients (Salonga et a l, 
2000; Ichikawa et a l, 2003) and have also been associated with poorer survival
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(Kommann et al., 2003). These findings presumably reflect higher DPD-mediated 
degradation of 5-FU in these tumours.
In general there is strong evidence that the expression of DPD and TS in GI cancers is 
predictive of response to 5-FU. It should be noted that the concomitant measurement of 
both these markers markedly enhanced the ability to predict tumour response to 5-FU- 
based chemotherapy in a number of studies (Salonga et a l , 2000; Ishikawa et al., 2000; 
Ichikawa et al., 2003; Kommann et al., 2003).
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Figure 1.2. Schematic representation o f  5-FU metabolism. Dihydropyrimidine 
dehydrogenase (DPD)-mediated conversion o f  5-FU to dihydrofluorouracil (DHFU) is 
the rate-limiting step o f  5-FU catabolism in normal and tumour cells. Up to 80% o f  
administered 5-FU is broken down by DPD in the liver. 5-FU is converted to three main 
active metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The main mechanism o f  
5-FU activation is conversion to fluorouridine monophosphate (FUM P), either directly 
by orotate phosphoribosyltransferase (OPRT) with phosphoribosyl pyrophosphate 
(PRPP) as the cofactor, or indirectly via fluorouridine (FUR) through the sequential 
action o f  uridine phosphorylase (UP) and uridine kinase (UK). FUMP is then 
phosphorylated to fluorouridine diphosphate (FUDP), which can be either further 
phosphorylated to the active metabolite fluorouridine triphosphate (FUTP), or converted 
to fluorodeoxyuridine diphosphate (FdUDP) by ribonucleotide reductase (RR). In turn, 
FdUDP can either be phosphorylated or dephosphorylated to generate the active 
metabolites FdUTP and FdUMP, respectively. An alternative activation pathway 
involves the thymidine phosphorylase catalysed conversion o f  5-FU to 
fluorodeoxyuridine (FUDR), which is then phosphorylated by thymidine kinase (TK) to 
FdUMP.
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1.2.6 Other mechanisms of resistance: an overview
Most chemotherapeutic agents act by damaging DNA either directly or indirectly (table 
1.1). When the cellular DNA is damaged, the cell has two main options, either to 
growth arrest and repair the damage, or to enter the apoptosis pathway.
The cell possesses several mechanisms to repair damage to its DNA. These DNA repair 
mechanisms either act directly on the damaged bases (direct repair), or they remove a 
section of DNA containing the damaged bases (indirect repair). Mechanisms which 
repair individually damaged bases usually require only a single enzyme. DNA repair 
mechanisms that remove a section of DNA require numerous different classes of 
enzymes, including DNA polymerases and DNA ligase (Barret & Hill 1998).
The best example of direct repair is by 0 6-alky 1 guanine-DN A alkyl transferase (AGAT), 
an enzyme also called 0 6-methylguanine-DN A methyltransferase (MGMT). MGMT 
removes methyl groups from the O6 position on guanine residues of DNA. Many 
alkylating agents act by alkylating DNA at the O6 position on guanine residues, 
including DTIC, temozolomide, and the nitrosoureas (Friedman et al., 1996, Tew et al., 
1996). High MGMT levels have been shown to cause resistance to DTIC (Friedman et 
al., 1996), temozolomide and the nitrosoureas (Wedge et al., 1996), while low 
expression of this gene is a favourable prognostic factor (Gerson 2002). Chen et al., 
(1994) found a positive correlation between high tumour MGMT activity and poor 
initial response to platinum containing chemotherapy. Other studies in patients with 
gliomas confirmed the silencing of MGMT gene caused by hypermethylation correlated 
with response and survival after treatment with BCNU (Esteller et al., 2000) or 
temozolomide (Paz et al., 2004).
Nucleotide excision repair (NER), an example of indirect repair, is a complex process 
that requires the co-ordinated effects of a series of enzymes to firstly cut-out the 
damaged section of DNA, and secondly to fill in the gap left (Araujo & Wood 1999). 
Enzymes involved in NER include, DNA polymerase, DNA ligase, endonucleases, 
topoisomerases, and several replication factors such as PCNA (Araujo & Wood 1999). 
NER, and above all ERCC1 which has a crucial role in the incision process, is thought 
to be partly responsible for resistance to a number of drugs which damage DNA 
including treosulfan, cisplatin, and many of the other alkylating agents (Barret & Hill
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1998; Rosell et al., 2003). ERCC1 mRNA levels have been correlated with clinical 
resistance to platinum based therapy in NSCLC (Lord et al., 2002) in ovarian 
(Dabholkar et al., 1994) and gastric cancer (Metzger et al., 1998), and also with 
oxaliplatin resistance in colorectal cancer patients (Shirota et al., 2001).
In addition to NER, there are two other major types of DNA repair in human cells: base 
excision repair (BER) and mismatch repair (MMR), both of which may also be involved 
in drug resistance. In common with NER these repair mechanisms both require DNA 
polymerases, DNA ligase and endonucleases in order to repair damaged DNA 
(Kolodner 1995, Seeberg et al., 1995).
BER is similar to NER in that it is a group of proteins that remove the damaged DNA 
and then fill in the gap, however BER only removes the damaged base and not a section 
of DNA either side of the damage (Seeberg et al., 1995). The key proteins in BER are 
redox effector factor-1/apurinic/apyrimidinic endonuclease (Ref-1 /Ape) and poly(ADP- 
ribose) polymerase-1 (PARP). In both prostate and ovarian cancer the level of Ref- 
17 Ape is elevated suggesting that BER provides a growth advantage for tumours (Kelley 
et al., 2001; Tanner et al., 2004). PARP is activated immediately in response to DNA 
damage by alkylating agents. It seems that at lower levels of DNA damage, PARP 
protects against apoptosis. When DNA damage is greater, excessive PARP consumes 
NAD+, thereby depleting the cell of ATP, leading to either necrosis or apoptosis 
(Bernstein et al., 2002). As yet there are no human disorders related to BER 
deficiencies, however inactivation of BER core proteins produces embryonic lethality, 
which underlines the importance of the mechanism (Hoeijmakers 2001).
Unlike NER and BER which repair damaged DNA producing drug resistance, loss of 
MMR is thought to confer resistance upon the cell to a number of different 
chemotherapeutic agents, including methylating agents and cisplatin (Lin & Howell 
1999, Colella et al., 1999, Lage & Dietel 1999). The MMR system is used to correct 
bases mispaired by DNA polymerases and insertion/deletion loops (from 1-10 bases) 
that arise from slippage during replication of repetitive sequences during recombination 
(Jacob et al., 2001). The main components involved are the E. coli prototype factors 
MutS and MutL (Harfe & Jinks-Robertson 2000). In humans more enzymes are 
involved (MLH1, MSH2, PMS2, and MSH6), but serve similar functions. The
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consequence of MMR deficiency in tumours is a high frequency of mutation both in 
noncoding and coding regions of the genome. Alterations in coding regions enhance 
genetic diversity and facilitate the rapid evolution of clones with a more malignant or 
drug-resistance phenotype. Cells exhibiting mutations or deficiency in their MMR 
system often show in vitro resistance to DNA damaging agents (Aquilina et a l 1999). 
Loss of MMR expression has also been shown to confer clinical resistance in a number 
of malignancies. Samimi et a l (2000) investigated MLH1 and MSH2 expression in 
paired ovarian tumor sections from 54 ovarian cancer patients before and after 
platinum-based therapy and found that the immunostaining for both proteins decreased 
significantly after platinum-based therapy. In this study staining of either protein did not 
correlate with survival, but MSH2 staining at diagnosis was shown to be an independent 
prognostic indicator in another study (Geisler et al., 2000). The prognostic significance 
of MLH1 staining has been shown also in breast cancer (Mackay et a l 2000). In this 
study loss of MLH1 expression after combination chemotherapy was shown in paired 
biopsies from some patients and proved to be an independent prognostic marker. In 
addition, malignant gliomas with low immunocytochemical expression of MSH2 and 
MLH1 in combination with high expression of MGMT may identify the majority of 
patients resistant to temozolomide (Friedman et a l , 1998).
A cell with damaged DNA may enter apoptosis. Apoptosis or programmed cell death is 
a highly regulated process by which unwanted cells are removed from tissue 
physiology; it is characterised by the following processes: nuclear chromatin 
condensation; cytoplasmic shrinking; dilated endoplasmic reticulum and membrane 
blebbing (Kastan & Skapek 2001). Most of the proteolytic cleavages during apoptosis 
result from the action of a unique family of cysteine dependent proteases called 
caspases (Eamshaw et a l , 1999). Caspases 8 ,9  and 10 are the major initiator caspases 
identified to date. Upon activation, they acquire the ability to cleave and activate 
effector Caspases 3 ,6, and 7, which are the main enzymes capable of cleaving the vast 
majority o f polypeptides that undergo proteolysis in apoptotic cells. Initiation of the 
caspase cascade can be mediated by two different pathways: the extrinsic and the 
intrinsic pathways (Green 2000; Wang 2001). The extrinsic pathway is initiated by 
ligation of transmembrane death receptors (CD95, TNF receptor, and TRAIL receptor) 
to activate membrane-proximal (activator) caspases 8 and 10. This pathway can be 
regulated by c-FLIP, which inhibits upstream activator caspases, and inhibitor of
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apoptosis proteins (IAPs), which affect both activator and effector caspases. The 
intrinsic pathway requires disruption of the mitochondrial membrane and the release of 
mitochondrial proteins including Smac/DIABLO, HtRA2, and cytochrome c. 
Cytochrome c functions with Apaf-1 to induce activation of caspase 9, thereby initiating 
the apoptotic caspase cascade, while Smac/DIABLO and HtrA2 bind to and antagonise 
IAPs (Wang, 2001; Suzuki et al., 2001). Oncoproteins, direct DNA damage, hypoxia, 
and survival factor deprivation, can activate the intrinsic apoptotic pathway. As a sensor 
of cellular stress, p53 is a critical initiator of this pathway (Lowe & Lin 2000). For 
example, proteins that sense DNA damage, such as ATM and Chk2, phosphorylate and 
stabilise p53 directly, and inhibit MDM2-mediated ubiquitination of p53 (Khanna & 
Jackson 2001). p53 can initiate apoptosis by transcriptionally activating proapoptotic 
Bcl-2 family members (e.g. Bax, Bak, PUMA and Noxa) and repressing antiapoptotic 
Bcl-2 proteins (Bcl-2, Bc1-Xl) and IAPs (survivin) (Hanahan and Weinberg 2000; 
Bartke et al., 2001; Hoffman et a l , 2001; Ryan et al., 2001; Wu et al., 2001). p53 was 
the second tumour-suppressor gene to be identified after the retinoblastoma (Rb); both 
copies of the p53 gene are inactivated in over 50% of human cancers (Vogelstein et al., 
2000; Evan & Vousden 2001). The normal state of p53 is the ‘off* position, only 
becoming activated when cells are stressed or damaged; the result of activated p53 is the 
arrest of progression from the Gj to the S phase of the cell cycle and in many cases it 
will induce apoptosis. This process therefore prevents the replication of mutagenic 
DNA, which could otherwise contribute to carcinogenesis (Hickman & Samson 1999).
Drugs of differing structure and specificity induce the characteristic morphological 
changes associated with apoptosis, and it is now believed that apoptotic pathways 
contribute to the cytotoxic action of most chemotherapeutic drugs (Lowe & Lin 2000). 
Anticancer drugs commonly activate the intrinsic apoptotic pathway. Mutations in p53 
or in the p53 pathway can produce multidrug resistance in vitro and in vivo, and 
reintroduction of wild-type p53 into p53 null tumor cells can re-establish 
chemosensitivity (Wallace-Brodeur & Lowe 1999). However, p53 status is not a 
universal predictor of treatment response, in part because not all drugs absolutely 
require p53 for their apoptotic function (Herr & Debatin 2001) and, in some settings, 
p53 loss can enhance drug-induced cell death (Bunz et al., 1999). Still, loss of p53
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function correlates with multi drug resistance in many tumour types (Wallace-Brodeur & 
Lowe 1999).
Mutations or altered expression of Bcl-2-related proteins can drastically alter drug 
sensitivity in experimental models (Reed 1999; Schmitt et a l, 2000; Wei et a l, 2001; 
Zhang et a l, 2000), and are associated with multidrug resistance in human cancers 
(Reed 1999).
The contribution of the death receptor pathway in chemotherapeutic drug-induced cell 
death is controversial (Herr & Debatin 2001). Treatment of tumor cells with drugs can 
induce CD95 and TRAIL receptors, and downregulate c-FLIP and the IAPs (Asselin et 
a l, 2001; Chatteijee et a l, 2001; Herr & Debatin 2001). However, experiments using 
cells derived from mice with functional mutations in the death receptor pathway 
indicate that this pathway is dispensable for the cytotoxic action of chemotherapeutic 
agents (Los et al., 1999). It has been argued that certain cell types require both the death 
receptor and mitochondrial pathways for drug-induced death, while others require only 
the mitochondrial pathway (Fulda et a l, 2001).
Previous studies have demonstrated that a wide range of anticancer agents induce 
apoptosis in malignant cells in vitro (Mesner et a l, 1997). It is important to emphasise 
that treatment-induced apoptosis is not merely a tissue culture phenomenon. Serial 
examination of peripheral blood mononuclear cells from acute leukaemia patients 
undergoing induction therapy has demonstrated that various agents, including 
cytarabine, mitoxantrone, etoposide, paclitaxel, and topotecan, cause a marked increase 
in the number of apoptotic blasts (Li et a l, 1994). Characteristic apoptotic changes have 
also been described in solid tumors after treatment o f mice with various cytotoxic drugs, 
including cytarabine, 5-FU, fludarabine, doxorubicin, cyclophosphamide, cisplatin, 
etoposide, dactinomycin, and camptothecin (reviewed in Mesner et a l, 1997). The 
occurrence of apoptosis after treatment of solid tumors is not as well documented in the 
clinical setting (Borst et a l, 2001).
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13 Tumour chemosensitivity assays
13.1 Introduction
The prediction of tumour sensitivity to anticancer agents has been intensively 
investigated for the purpose of optimising the therapy for each individual patient. There 
have been two approaches to predict the efficacy of drugs against individual tumours: 
drug-sensitivity tests and molecular assessment of marker genes. Although some of 
these tests, such as the determination of Her-2 status as a marker of sensitivity to 
Herceptin (section 1.1), are already widely available in the clinic, the prediction of 
chemosensitivity remains a goal to be achieved. So far cancer treatment has been 
determined predominantly by histological findings and cancer type. However, in the 
vast majority of cases, histology cannot identify drugs to which the cancer will be 
sensitive or resistant Therefore, assessing the chemosensitivity of individual tumours 
could be greatly beneficial to patient survival, as only drugs that are likely to be active 
against the tumour can be identified and administered to the patient. On the other hand, 
drugs to which the tumour is resistant can also be identified, so avoiding the 
administration of any drugs likely to be unsuccessful and their consequent side effects.
The assessment of the chemosensitivity of individual tumours in the laboratory suffers 
from the obvious limitations common to most in vitro tests: it by-passes in vivo 
metabolism; it cannot recapitulate the complex interactions between stromal and tumour 
cells; there is no implication of the immune system; it cannot recreate the conditions of 
oxygen and nutrient supply found in vivo; importantly, also toxicity to normal tissues is 
not assessed.
Tumour chemosensitivity assays are laboratory tests in which fresh biopsy specimens of 
human tumours are cultured in the presence and absence of anticancer drugs. At the end 
of a period cell culture, measurements are made to determine whether or not the drugs 
were effective in either killing or in preventing the growth of the tumour cells. 
Proponents of these tests maintain that this information correlates with drug effects in 
the patient and can therefore be used to assist the clinical oncologist in selecting the 
most appropriate drugs to be used in the treatment of individual patients.
There has been a proliferation of names/terms applying to this testing. It should be 
noted that the terms ‘chemosensitivity assay’, ‘drug response assay’ and ‘tumour
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response assay’ can be used interchangeably to indicate tests aimed at predicting the 
anti-cancer agents that are most likely to be effective for an individual tumour. Similarly 
the terms ‘chemoresistance assay’ and ‘drug resistance assay’ are synonyms that 
indicate tests aimed at identifying inactive drugs. However from this point onwards the 
generic term ‘tumour chemosensitivity assay’ (TCA) will be employed to indicate all 
those cell-based assays that were developed to predict sensitivity and/or resistance to 
anti-cancer drugs; in fact ‘chemosensitivity’ assays give information about the 
ineffective chemotherapy as well as drugs which are likely to be effective, while 
‘chemoresistance’ assays are more restricted and do not give information about 
sensitivity.
Likewise, the terms "in vitro assay" and "ex vivo assay" will be used interchangeably in 
this context, although the latter should only be used for primary cultures, e.g. fresh cells 
isolated from tumour samples and not exposed to longer-term artificial culture, such as 
that as used in the ChemoFx® Assay (Precision Therapeutics, Pittsburgh, PA), in which 
the tissue explants are pre-incubated in culture medium to grow a living population of 
cancer cells.
All chemosensitivity assays have four essential stages (Fruehauf & Bosanquet, 1993). 
Firstly, the cancer cells must be isolated. When a solid tumour specimen arrives in the 
laboratory, it is finely minced and cells extracted by enzymatic or mechanical means. 
Liquid samples are centrifuged to isolate cells. Assay requirements vary regarding the 
size of a specimen, but the specimen should have a sufficient percentage of viable 
cancer cells and an absence of bacterial and yeast contamination.
Secondly, in all of these assays, cancer cells are exposed to the desired 
chemotherapeutic agents. The incubation time varies from one hour to fourteen days, 
depending on the assay. The concentrations of drugs used in the exposure also can vary, 
depending on the assay, from using a combination of sub-clinical, clinical, and 
supraclinical concentrations to using a single supra-clinical concentration. In addition to 
single drugs, some of the assays can test combinations and sequences of 
chemotherapeutic agents. All of the assays use control samples of tumour cells that are 
cultured under identical conditions but are not treated with the chemotherapeutic agents.
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Thirdly, all chemosensitivity assays must determine the effects of the drugs on the 
cancer cells. This is called the assay endpoint, which is either a measurement of cell 
proliferation or cell death, although biosensor chips are currently being developed to 
monitor several cellular metabolic parameters continuously for several days (Henning et 
a l, 2001; Otto et al., 2003; Mestres-Ventura, 2003).
Lastly, a report of the assay results is issued. There is great heterogeneity in this field, as 
different investigators using different assays have defined various indices of 
chemosensitivity/chemoresistance.
There is a clear divide between TCAs based on cell proliferation as an endpoint 
(clonogenic assays) and TCAs based on cell death as an endpoint Historically, the cell 
proliferation endpoint received great attention, as a result of studies by Salmon, Von 
Hoff, and others during the late 1970s and early 1980s (Salmon et al., 1978; Von Hoff 
et al., 1981). At that time cancer was most prominently considered to be a disease of 
disordered cell growth. In contrast, the concept of apoptosis (programmed cell death) 
had yet to become widely recognised. Also unrecognised were the concepts that cancer 
may be a disease of disordered apoptosis/cell death and that the mechanisms of action of 
most if  not all available anticancer drugs may be mediated through apoptosis (Hickman 
et al., 1992; Zunino et a l, 1997; Jaffrezou et al., 1998). When problems with the first 
proliferation-based assays emerged (Selby et al., 1983), there was relatively little 
enthusiasm for studying cell death as an alternative endpoint.
13.2 Cell proliferation assays
1.3.2.1 Clonogenic assays
The first tests to be developed to assess the chemosensitivity of tumour material, the 
clonogenic assays, were based on the assessment of cell proliferation. Also known as 
the human tumour stem cell assay, clonogenic assays were developed from antibiotic 
sensitivity testing in microbiology (Hamburger & Salmon 1977, Selby et al., 1983). The 
test specimen is subjected to a mild digestion to give a single cell suspension. The cell 
suspension is divided into two parts, one for treatment with the test drug and one as 
control. The cells are incubated with or without test drug at 37°C for one hour.
Following incubation, the cells are washed, plated out on a two-layer soft agar system,
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and incubated for up to 14 days at 37°C. In the original assays the cells were only 
exposed to a single concentration of the test drug for one hour. Alternatively the drug is 
incorporated into one of the agar layers, thus keeping the cells in contact with the drug 
for the total time of the assay (Kern & Weisenthal 1990). The number of colonies 
formed after incubation can be counted by an automated image analysis system, or by 
eye. The number of colonies is compared with the control plates of cells that were not 
exposed to test drug and sensitivity or resistance to test agent can then be assessed.
The clonogenic assay has been regarded as something of a “gold standard” since it was 
first used for assessing chemosensitivity of tumour material, but it has a number of 
difficulties that have limited its clinical utility (Selby et a l , 1983). The major problem 
was an inability to grow sufficient cancer cells for the assay. Only 40%-70% of the 
tumor specimens would grow into colonies, and those that did grow took a very long 
time, reducing the clinical utility of the assay (reviewed in Kochli et a l , 1994). On the 
other hand, if  too many cells were cultured in agar, the cells could not proliferate 
sufficiently and visible colonies were not seen. As with other methods, a single cell 
suspension was required; in fact if the enzymatic digestion was not complete and cell 
clumping occurred, the number of cells plated out could not be determined accurately 
leading to a considerable experimental variation. In addition, determination of whether 
the cells being tested were actually neoplastic or normal cells was difficult.
There have been many clinical studies comparing the in vitro and clinical sensitivity of 
tumours using the clonogenic assay. A review of 54 different correlation trials found 
that a 69% true positive rate (samples sensitive in vitro were also sensitive in vivo) and 
a 91% true negative rate (samples were resistant in vitro and in vivo) (Von Hoff 1990). 
The Southwest Oncology Group (SWOG) conducted a study using the tumour 
clonogenic assay to predict responses in ovarian cancer patients and to direct therapy in 
a group of patients (Von Hoff et al., 1991). The patients treated on the basis of their 
sensitivity using the assay had an increased response rate (28% versus 11% for patients 
treated by physician’s choice; p=0.03) but did not have an improved overall survival. 
This study also found a 100% true positive and a 100% true negative rate, although this 
was only in seven evaluable patients. A third study on a range of tumour types, using a 
modified methodology, found that patients treated on the basis of assay results had a
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better response rate, but once again there was no difference in overall survival (Von 
Hoff et a l, 1990).
A new version of the clonogenic assay has been developed using a collagen gel droplet 
embedded culture system (Inaba et a l, 1996). Although the technical feasibility of this 
test had already been demonstrated by Jason et al. in 1979, its clinical relevance has 
only been reported in more recent years (Kobayashi 2003). After enzymatic dissociation 
from solid specimens, tumour-derived cells are incubated in collagen gel coated flask 
for 12-24 hours. Living cells are then collected, placed in collagen gel droplets (3,000 
cells/droplet) and further incubated for other 24 hours. Cytotoxic drugs are then added 
to the droplets at a single clinically relevant concentration. After incubation for 24 
hours, the drugs are removed, and the cells in the droplets are incubated for further 7 
days in a proprietary serum-free medium (Nitta Gelatin Inc., Osaka, Japan) that inhibits 
fibroblast overgrowth. At the end of this assay, the collagen gel droplets are stained 
with neutral red, fixed and quantified by image analysis (Koezuka et al., 1993). Cell 
growth is assessed calculating the ratio of image density measured on day 7 and day 1 
after the addition of drugs. The cloning efficiency of lung, breast, colon and gastric 
tumour cells cultured in collagen gel droplets is overwhelmingly higher than the 
efficiency in soft agar culture (Kobayashi, 2003). Kobayashi (2003) has reported an 
overall 83% evaluability rate of the assay in over 1,000 specimens tested (including 659 
NSCLC, 163 breast, 107 colorectal cancers). The same author has also reported a 
predictive accuracy of 84.1% in 183 varied solid malignancies; in particular the assay 
was able to predict resistance in 79/89 (88.8%) cases, while the predicted sensitivity in 
75/94(79.8%).
l.S. 2.2 Thymidine incorporation assay/Kern assay
For the last decade, the cell proliferation assay which has been most heavily promoted 
and provided as a service to patients in the USA (Oncotech and Impath) is the 
radioactive thymidine incorporation assay, or Kem assay, as it was originally described 
by Tanigawa and Kem in 1982. In this assay, applied only to solid malignancies and not 
to haematological neoplasms, tumour cells are suspended in soft agarose and cultured 
for 3 - 4 days in the continuous presence of single supra-clinical concentrations of 
chemotherapy agents. At the end of the culture period, radiolabelled thymidine 
([ H]thymidine) is added to the medium to label the proliferating cancer cells. It is
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assumed that the [ H]thymidine is incorporated into the dividing cells replicating their 
DNA, whereas non-proliferating cells and dead cells fail to incorporate the label. After 
further 2 days incubation, the radioactivity is measured using a liquid scintillation 
counter and differences in putative thymidine incorporation into DNA are compared 
between control and drug-treated cultures. Cancer cells that can grow and proliferate in 
such extreme conditions are considered resistant to the chemotherapy agent. On the 
basis of this information, it can be deduced that these assays do not provide any 
information about chemosensitivity but excel at predicting chemoresistance.
Indeed, eight years after developing the assay, Kem and Weisenthal correlated the 
thymidine incorporation assay results with clinical data and defined the concept of 
‘extreme drug resistance’ or EDR (1990). This was defined as an assay result that was 
one standard deviation more resistant than the median result calculated from a database 
of assays. Patients treated with single agents showing EDR in the assay virtually never 
had a partial or complete response. Kem and Weisenthal also defined "low drug 
resistance" (LDR) as a result less resistant than the median and "intermediate drug 
resistance" (1DR) as a result more resistant than the median but less resistant than EDR 
(in other words, between the median and one standard deviation more resistant than the 
median).
The principles and clinical correlation data with the thymidine "EDR" assay were 
reviewed over 10 years ago (Weisenthal and Kem, 1992). Based on the publication 
validating the assay (Kem and Weisenthal, 1990), this test has a very high specificity 
(>98%) for the identification of inactive single agents, but a low sensitivity (<40%). In 
other words, a drug with assay-defined "EDR" is predicted to be almost certain to be 
inactive as a single agent (high specificity for identifying inactive drugs), but many 
drugs without "EDR" will also be inactive (low sensitivity for identifying inactive 
drugs).
Only a few follow-up studies have been published since the 1992 review (Weisenthal & 
Kem, 1992). One such study showed that EDR to one or more of the single agents used 
in a two drug combination is not apparently associated with a lower probability of 
response to the two drug combination in the setting of intraperitoneal chemotherapy of 
appendiceal and colon cancers (Femandez-Trigo et al., 1995). It is, however, possible
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that response to the high drug concentrations achievable with intraperitoneal 
chemotherapy may be more closely associated with drug penetration into the tumour 
than to intrinsic drug resistance of the tumour cells. Eltabbakh et al., (1998 & 2000) 
reported that EDR to paclitaxel did not appear to be a prognostic factor in ovarian 
cancer patients or in patients with primary peritoneal carcinoma treated with paclitaxel 
plus platinum. However, it has been recently reported that EDR to platinum alone in 
ovarian cancer may have prognostic implications (Fruehauf et al., 2001). Previously 
untreated breast cancer patients with tumours showing LDR (defined above) had 
superior times to progression and overall survivals than patients with tumours showing 
either IDR or EDR (Mehta et al., 2001).
1.3.2.3 Other cell proliferation assays
In recent studies Bachrach and Wang have proposed a new chemosensitivity assay 
(1999,2003) using ornithine decarboxylase as a marker for cell proliferation. This 
enzyme catalyses the conversion of ornithine into the diamine putrescine, which is the 
precursor for the synthesis of the naturally occurring polyamines. The polyamines 
spermidine and spermine play an essential role in growth and proliferation processes 
(Russell 1985; Cohen 1998). Ornithine decarboxylase is ubiquitous, it is expressed early 
in the cell cycle and has an extremely short half-life (15-20 minutes), so that it decays 
rapidly when cell proliferation is arrested (Bachrach & Wang 2003). Although the 
Bachrach group originally reported chemosensitivity testing of cell lines using the 
enzymatic activity of ornithine decarboxylase (Assaraf et al., 1994), more recently they 
have employed immunocytochemical detection of this enzyme in lymphocytes from 
patients with haematological malignancies (Wang et al., 1999). The lymphocytes are 
grown for 24 hours in culture medium containing 15% autologous plasma and up to five 
different concentrations of each cytotoxic. At the end of the incubation period, the cells 
are harvested by centrifugation and dropped on slides coated with polylysine. Slides are 
incubated with a primary antibody directed towards ornithine decarboxylase and 
examined with a confocal laser microscope after being exposed to a secondary FITC- 
conjugated antibody. Limited data is available on the clinical usefulness of this method; 
drug resistance was detected in five leukaemic patients who subsequently died; while 
the lymphocytes of other 33 chemo-responders affected with mild haematological 
malignancies showed sensitivity to various drugs (Bachrach & Wang 2003).
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Another type of cell proliferation assay currently in clinical use (NuOncolology Labs, 
Houston, TX) is the adhesive tumour cell culture system, based on comparing 
monolayer growth of cells over a proprietary ‘cell adhesive matrix’ (Ajani et dL, 1987). 
Positive clinical correlations were described with this system in 1987 (Ajani et al., 
1987), but confirmatory and follow-up studies have not been reported.
1 3 3  Total cell kill/cell death assays
As opposed to measuring cell proliferation, there is a closely-related family of assays 
based on the concept of total cell kill, or, in other words, cell death occurring in the 
entire population of tumour cells (as opposed to only in a small fraction of the tumour 
cells, such as the proliferating fraction or clonogenic fraction) (Weisenthal et a l, 1984 
& 1985). The concepts underlying cell death assays are relatively simple, even though 
the technical features and data interpretation can be very complex. There has been 
considerable work based on these assays reported during the past fifteen years.
The basic technology concepts are straightforward. After the cells are incubated with 
the drugs for a variable period (3-7 days), a measurement is made of cell injury, which 
correlates directly with cell death. There is evidence that the majority of available 
anticancer drugs work by causing sufficient damage to trigger “programmed cell death”, 
more properly known as apoptosis (Hickman, 1992; Zunino et al., 1997). Although 
there are methods for specifically measuring apoptosis, per se, there are practical 
difficulties in applying these methods to mixed (and clumpy) populations of tumour 
cells and normal cells.
Thus, more general measurements of cell death have been applied. These include:
(1) loss of protein content, as measured in the sulphorhodamine B assay (Skehan et 
al., 1990, Monks et al., 1991);
(2) delayed loss of cell membrane integrity (which has been found to be a useful 
surrogate for apoptosis), as measured by differential staining in the DISC assay 
method (Weisenthal et al., 1992 & 1993);
(3) loss of cell membrane esterase activity and cell membrane integrity, as measured 
by the fluorescein diacetate assay (Rotman et al., 1988; Larsson et al., 1990; 
Nygren et al., 1992);
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(4) loss of mitochondrial Krebs cycle activity, as measured in the M IT  assay 
(Mosmann 1983; Carmichael et al., 1987);
(5) loss of cellular ATP, as measured in the ATP assay (Kangas et al., 1984; 
Garewal et a l 1986; Sevin et a l , 1988; Andreotti et al., 1995).
1.3.3.1 The Sulphorhodamine B assay
The Sulphorhodamine B assay determines the protein content of a sample and uses this 
as an indicator of cell growth and viability. Tumour cells are grown in 96-well plates 
and cultured in the presence of drug for a set period o f time. After the incubation period, 
the cells are fixed in situ and stained using the long lasting stain sulphorhodamine B, 
which is quantified using a spectrophotometer. There are concerns that debris from dead 
cells being stained by the dye may produce false results (Keepers et al., 1991) but these 
seem to be minimised if readings are taken 24 hours after staining in cell line culture.
The sulphorhodamine B assay can be automated and currently forms the basis of the 
NCI drug screening program (Rubinstein et al., 1990, Skehan et a l, 1990, Monks et al., 
1991).
1.3.3.2 Dye Exclusion Methods /  DiSC Assay
Cell viability testing relies on the phenomenon that living cells exclude various dyes 
whilst dead or dying cells do not. An example of this is trypan blue exclusion, which is 
commonly used in cell culture to assess cell number (as detailed in methods section 
2.2.7). A major drawback of this method of assessment is the poor correlation between 
the ability of a cell to divide and its ability to exclude dye.
The differential staining cytotoxicity (DiSC) assay is a modification on earlier dye 
exclusion methods (Weisenthal et al., 1983, Weisenthal & Kem 1991). Biopsies are 
dissociated to obtain a single cell suspension, which are generally cultured for 4 days in 
liquid media with or without the test drug. Typically, three drag concentrations are 
tested, o f which the intermediate concentration represents clinically achievable plasma 
levels, and the remaining two concentrations represent ten-fold higher and ten-fold 
lower plasma levels. After incubation the cells are stained with either a fast green or a 
fast green/nigrosin dye, which stains dead or dying cells bright green, while the live, 
viable cells remain unstained. The cells are counter-stained with haematoxylin and eosin
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to differentiate between tumour and non-tumour cells. The cells can then be assessed as 
either tumour or non-tumour cells by cytology (which is difficult for entire cell 
populations, as in most cases this requires immunocytochemistry) and as either 
live/viable or as dead/dying cells, to determine the sensitivity or resistance to the tested 
agents. As the state and type of cell needs to be determined by eye, the results are 
subject to the bias of the individual assessor and the procedure is labour-intensive. 
Another disadvantage is that for biological reasons 5-FU cannot be tested in the DISC 
assay. One major advantage of this assay is that it is completed in a relatively short 
period of time (maximum 6 days). In clinical studies more than 70% of specimens have 
been tested for sensitivity to at least one drug or combination (Weisenthal et al., 1983).
In 1991, Bosanquet published a relatively large number of correlations between clinical 
response and DiSC assay results, chiefly in CLL (Bosanquet 1991). More recently the 
same group reported the predictive value of this assay to determine sensitivity to 
fludarabine in 243 CLL patients (Bosanquet et al., 1999). Correlations between DiSC 
assay results and patient survival in ANLL were first published by a Swedish group in 
1989 (Tidefelt et al., 1989). These results were recently confirmed and extended by a 
group at the University of Cologne (Staib et a l , 1999).
1.3.3.3 Fluorescein-based assays
The Fluorometric Microculture Cytotoxicity Assay (FMCA) is another cytotoxicity 
assay that relies on the metabolic activity of live cells after incubation with test drug. 
The tumour cells are incubated with or without cytotoxics in 96-well plates for a set 
period of time, normally 72 hours. At the end of this time the media is removed from 
the cells and fluorescein diacetate is added to the cells. Fluorescein diacetate is a lipid 
soluble material that readily penetrates cell membranes. Viable cells contain a 
membrane esterase that cleaves the dye to non-lipid soluble fluorescein, which is 
concentrated in cells containing a functionally intact membrane; the fluorescence 
emitted by free fluorescein is measured by a spectrofluorimeter and is proportional to 
the number of cells present (Larsson & Nygren 1993). The proportion of live cells 
present in relation to untreated controls can be calculated.
The FMCA is conceptually similar to the DiSC assay, which measures the ability of 
cells with functionally intact membranes to exclude non-lipid soluble dyes, and indeed
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the results obtained with these two assays correlate very well with each other (Nygren et 
a l , 1992,1994; Csoka <?/<*/., 1994).
The FMCA has been evaluated in a number of different tumour types including ovarian 
carcinoma (Csoka et al., 1994), AML (Nygren et a l, 1992, Larsson et a l, 1992, 
Kristensen et al., 1999), and kidney and urinary carcinomas (Nygren et a l, 1999). The 
FMCA has also been used to evaluate new agents and combinations such as vinorelbine 
in relation to current drugs (Fridborg et a l, 1996) or topotecan in combination with 
other cytotoxics (Jonsson et a l, 1998).
A related test is the fluorescent cytoprint assay (FCPA or FCA), which measures the 
activity of cytosolic esterases by monitoring the hydrolysis of fluorescein monoacetate 
to fluorescein. In the FCPA tumours are disaggregated into small clumps, or 
‘microorgans’, which are immobilised between sheets of cellulose-collagen; these 
sheets are then placed onto a grid in tissue culture flasks containing medium and a 
baseline ‘fluorescent cytoprint’ is recorded by digital photography. The cells are then 
cultured for 24 hours, exposed to the drugs for 48 hours, rinsed and grown for an 
additional 48 hours in drug-free medium. Fluorescein monoacetate is then added, the 
second ‘cytoprint’ is obtained and the difference in fluorescence between the two 
images is calculated by image analysis software (Leone et a l, 1991). Although the 
‘microorgan’ structure has the advantage of recreating the in vivo tumour environment, 
it requires samples with a large number of cancer cells, as the assay end point does not 
distinguish between the fluorescent signal produced by the malignant cells and the 
stromal component of each organoid.
The FCPA has been shown good predictive efficacy (~70%) in ovarian and breast 
cancers (Blackman et a l, 1994).
1.3.3.4 MTT assay
In the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, 
tumours are either tested as small fragments grown on collagen gel sponges or as 
disaggregated cells cultured in monolayer adherent conditions. Tumour cells or 
organoids are incubated with or without the test drugs for 4 to 5 days. The MTT assay 
detects mitochondrial succinate dehydrogenase (SDH) activity as a determinant of
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mitochondrial function and cell viability (Mosmann 1983). SDH is a component of the 
citric acid cycle, and it generates FADH2 and fumarate from succinate and FAD. SDH 
activity resides on the mitochondrial inner membrane and requires a functioning 
electron transport system. SDH activity is therefore a measure of mitochondrial and 
cellular viability. SDH activity is measured by its capacity to convert the yellow 
compound MTT into a blue crystallized formazan derivative that is dissolved in DMSO 
at the end of the assay. The amount of formazan formation is determined by measuring 
the optical density of the tissue culture well using a spectrophotometer that measures 
absorbance at the wavelength absorbed by the blue solution (Carmichael et a l,  1987).
A variation of the MTT assay is the XTT assay, which uses XTT (2,3-bis (2-methoxy-4- 
nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2//-tetrazolium hydroxide) as the 
tetrazolium reagent The XTT assay has the advantage that the formazan product is 
soluble in aqueous solution and so DMSO extraction is not required before the results 
are obtained. One disadvantage of the XTT assay over the MTT assay is that several cell 
lines do not metabolise XTT as well as they do MTT (Scuderio et a l, 1988), so the 
MTT assay remains the assay of choice in this situation.
The results obtained for cell lines with the MTT assay correlate well with the other 
methods of assessing viability such as protein measurements, clonogenic assays and the 
dye exclusion assays (Pieters et a l, 1989; Kirkpatrick et a l, 1990; Rubinstein et a l, 
1990; Keepers et a l, 1991). However there are several disadvantages of the MTT assay. 
Firstly, the colour of the formazan product fades within a short time of forming so the 
results need to be read immediately after solubilisation of the formazan in DMSO. 
Secondly, the reduction of the MTT is affected by several factors such as the pH of the 
media and chemical interference or chemical reduction of MTT by factors in the growth 
media, including some drugs. For this reason paclitaxel and docetaxel cannot be tested 
in this assay. Thirdly, the metabolic condition of the cells affects the reduction of MTT. 
For example, if the cells are lacking a vital metabolite, such as glucose, they may not be 
able to produce reducing agents capable of reducing the MTT.
Despite these difficulties, the MTT assay has been used to predict the response of 
patients to chemotherapy in solid and haematological malignancies (Yamaue et a l,
1992, 1996; Stute et a l, 1999; Xu et a l, 1999; Taylor et a l, 2001).
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1.3.3.5 ATP assays
As the name suggests, the ATP assays are based on measurement of ATP as an 
endpoint. ATP is the major intracellular source of energy required for metabolism, and 
it is therefore considered a valid indicator of living cells (Lundin et al., 1986). When 
cells die their ATP is rapidly degraded by ATPases. Firefly luciferin-luciferase has been 
used as a means of quantifying amounts of ATP. The hydrolysis o f ATP to AMP by 
luciferase in the presence of the substrate D-luciferin produces light according to the 
reaction described below.
Luciferase (E.C. 1.13.12.7)
ATP + D-Luciferin + O2 _______________________p. AMP + 2Pi + C02 + Light
The light emitted is proportional to the amount of ATP hydrolysed, so the concentration 
of ATP can be determined for comparison between samples.
This phenomenon forms the basis of the ATP bioluminescence assay which has been 
used in various forms by several groups to determine in vitro and ex vivo 
chemosensitivity of different tumours (Kangas et al., 1984; Maehara et al., 1986; 
Kumitz et al., 1986; Crouch et al., 1993; Andreotti et al., 1995; Mollgard et al., 2000).
The method of testing chemosensitivity is similar to that of the MTT assay, although 
considerable technical variations of this method exist between different groups. While 
all of the ATP chemosensitivity assays measure ATP as an endpoint, major differences 
exist in culture media, assay formats, drug concentrations and incubation time. The 
method described here is that of Andreotti et al. (1995), currently sold as a kit (TCA- 
100) by DCS Innovative Diagnostik Systeme, Hamburg, Germany (see ‘Materials and 
Methods’ Chapter 2). The tumour sample is subjected to gentle enzymatic dissociation 
to produce a single cell suspension. The cells are then cultured in liquid media in 96 
well polypropylene plates with or without the test drugs. Two controls are included; a 
maximum inhibitor (MI) is added to kill all the cells present giving a zero ATP count 
and a medium-only control (MO), which equates to the 100% ATP level achievable 
with that sample. The cells are cultured for 6 days at 37°C with 5% CO2.
A commercial extraction reagent is then used to lyse the cells and inhibit the ATPases 
contained within the cells, which prevents ATP degradation. ATP quantification takes
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place by adding luciferin-luciferase to the cell lysate. The amount of light produced is 
measured with a luminometer. By comparing the readings obtained for the controls, 
with the results for the cells cultured with drugs, the effects of the drugs on the tumour 
can be assessed. If the ATP levels for the drug treated cells are lower than the 100% 
ATP control then the drug is showing an inhibitory effect on the growth of the tumour 
cells, i.e. the tumour is sensitive to the drug. The degree of sensitivity to the drugs can 
be quantified by comparing the readings of drug treated cells to the controls. Indices of 
efficacy such as IC50 and IC90 can be calculated from the data.
The ATP assay is more sensitive than any of the other assays described above, requiring 
plating densities of as few as 1000 tumour cells per well to obtain an evaluable reading. 
This compares favourably with the MTT assay, which, for example, requires at least
25,000 cells to give evaluable readings (Petty et al., 1995). The ability of the ATP assay 
to measure the presence of <5 viable cells remaining in one well after the assay means 
that drugs can be compared for their ability to kill all of the tumour cells present 
(Andreotti et al., 1995, Cree & Kurbacher 1997). The sensitivity of the ATP assay 
translates into high evaluability rates, which are usually greater than 90% (table 1.9).
A further advantage of the ATP assay is that interference from non-tumour cells is 
minimised by the use of round-bottomed polypropylene plates, which inhibit cell 
adherence. Fibroblasts, mesothelial cells and other stromal cells can proliferate in 
adherence-based culture systems and therefore add ‘noise’ to most assay types when the 
cancer cell growth/death signals are measured. The growth signal of disaggregated cells 
obtained from tumour biopsies grown in non-adherent culture conditions is therefore 
more cancer-cell specific than growth in adherent culture systems. The use of a serum- 
free medium in another technique employed to suppress non-transformed cell 
proliferation. Andreotti et al. performed immunocytochemical analysis to assess the 
ratio of malignant to non-malignant cells before and after culture in a specialised media 
(Complete Assay Medium; CAM; DCS, Hamburg, Germany). They found that the 
mean proportion of malignant cells increased from the initial 54% to 83% by the end of 
the 6- to 7-day assay period, with a significant expansion of the malignant population in 
98% of the cases evaluated.
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One drawback of the ATP assay in that the observed reduction of ATP in response to 
drug treatment may be due not only to a decrease of the number of cells but also to a 
decrease in the ATP content per cell. As already stated, ATP is essential for cell 
viability and DNA replication. Metabolically active cells will produce more ATP, as 
will cells metabolising glucose through the citric acid cycle linked to aerobic 
mitochondrial function. In vitro drug effects that inhibit glucose metabolism or 
mitochondrial function result in decreased intracellular ATP concentrations.
The ATP tumour chemosensitivity assay (ATP-TCA) has shown good correlation 
between ex vivo sensitivity and clinical response in breast and ovarian carcinomas (table 
1.10). A phase III randomised, multi-institutional, international trial was concluded in 
2003 to compare assay-directed therapy to physician’s choice treatment in patients with 
recurrent platinum-resistant ovarian adenocarcinoma (Kurbacher et al., 1997b). Follow- 
up data are still being collected and no data analysis has been published at the time of 
writing.
The ATP-TCA described above has been employed to predict the e -vivo activity of 
novel drug combinations such as mitoxantrone plus paclitaxel (Kurbacher et a l , 1997a), 
treosulfan plus gemcitabine (Neale et a l , 1999), liposomal doxorubicin plus vinorelbine 
(Di Nicolantonio et a l , 2002; see chapter 8), mitomycin C plus gemcitabine 
(Whitehouse et a l , 2003); the activity of the first two combinations translated well in 
vivo, while the remaining two are currently being assessed in the clinic.
Finally the ATP assay has also shown its potential usefulness in evaluating new 
cytotoxic agents (Neale et a l , 2000; see chapters 8 and 9) and chemosensitizers (see 
chapter 10).
Table 1.9 Evaluability rates of the ATP tumour chemosensitivity assay performed 
according to TCA100 protocol (DCS, Hamburg, Germany).
Tumour site Assay evaluability % Reference
Breast 97% Cree eta/., 1996
94.5% Kurbacher et al., 1996
Colorectal 87% Whitehouse et a l, 2003
Choroidal melanoma 84% Neale et a l , 1999
Cutaneous melanoma 96% Cree et a l, 2000
Oesophageal 73% Mercer et a l, 2003
Ovarian 93% Kurbacher et a l, 1998
89% Konecny et a l, 2000
Retinoblastoma 70% Di Nicolantonio et a l, 2003
Table 1.10 A summary of recent studies with clinical correlation using the ATP tumour 
chemosensitivity assay.
Tumour
site
Number of 
samples
Findings Reference
Breast 29 76% positive predictive value Cree et a l, 1996
Ovarian 114 Greater than 90 % accuracy for 
predicting cisplatin resistance
Andreotti etal., 
1995
Ovarian 25 64% overall response rate compared to 
37% in control group with increased 
progression free survival and overall 
survival
Kurbacher et al., 
1998
Ovarian 38 76% of patients were classed as 
chemosensitive, and had significantly 
longer progression free-survival (28.5 vs 
12.6 months, P  < 0.033) and overall 
survival (46.1 vs 17.6, P < 0.03) than 
patients predicted to be resistant
Konecny et al., 
2000
Ovarian 54 61% overall response rate in patients that 
were treated with assay-selected therapy
Sharma et a l , 
2003
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1.4 Correlation of mRNA expression data from DNA microarrays with drug 
response
Another approach to predict sensitivity in cancer chemotherapy takes advantage of the 
latest genomic technologies, and DNA microarrays in particular (Macgregor & Squire 
2002), which enable the study of the expression levels of several thousand genes 
simultaneously. This is attractive, as resistance to anticancer drugs is multi-factorial (see 
section 1.2) and considering the effect of single factors in isolation may therefore be 
insufficient to predict chemosensitivity.
1.4.1 DNA microarray technology
The two most commonly used DNA microarrays are based on oligonucleotide and 
cDNA probes. Short oligonucleotide probes (~25mers), first introduced by Affymetrix 
(http://www.afifymetrix.com), are synthesised on the array in situ using photolithog­
raphy (Lipshutz et a l , 1999). The newest Affymetrix array (HG-U133) contains 
approximately 45,000 probe sets representing >39,000 transcripts derived from about
33,000 well-substantiated human genes (Macgregor 2003). Alternatively, longer 
oligonucleotide probes (50-80 bases) can be spotted onto solid supports such as glass 
slides using robotic printers. cDNA microarrays are produced by robotically printing 
PCR products or plasmids onto glass slides (DeRisi et a l , 1996).
A commonly used approach to identify genes involved in chemosensitivity is to 
correlate gene expression profiles in multiple cancer tissues with drug response. 
However the accuracy of this approach depends on the selectivity, precision and 
accuracy of the mRNA expression data obtained from microarray experiments. The 
results from microarrays can vary considerably in quality, especially when these rely 
only on single measurements for each gene. Most spotted oligonucleotide and cDNA 
array experiments are performed using two RNA samples (a reference and an 
experimental sample) that are labelled with different fluorescent dyes. Quantitation of 
absolute mRNA levels is problematic and thus only ratios between the two samples can 
be assessed. By contrast, Affymetrix arrays permit the measurement of absolute mRNA 
levels with the use of analysis metrics for multiple probes and controls for each 
transcript (perfect match and mismatch probes). However, accurate measurement of 
expression may vary among genes, and furthermore, comparison between Affymetrix 
arrays and ratio arrays is difficult (Macgregor & Squire 2002). Proper normalisation
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procedures are critical to obtain reliable data. Therefore, links between anticancer drugs 
and important chemosensitivity genes might be difficult to assess. In addition, 
microarrays are inherently less sensitive than other quantitative methods, such as 
quantitative RT-PCR, so less abundant transcripts can be missed.
1.4.2 Chemosensitivity studies using untreated cell lines
Scherf and coworkers have pioneered the use of cDNA microarrays for profiling 
chemosensitivity (Scherf et al., 2000). These researchers analysed the gene expression 
patterns of the NCI60 panel. Gene expression was then correlated with the growth 
inhibitory activity of a subset of -70,000 compounds that had been previously tested 
against the NCI60 panel. Increased expression of a given gene in cell lines sensitive to a 
given drug yields a positive correlation between gene expression and drug activity, 
whereas increased expression in resistant cells results in a negative correlation. The NCI 
study focused on 1376 genes (out of a total of 8000) that showed the strongest patterns 
of variation across the cell lines, and 118 drugs with established mechanisms of action. 
Two previously known drug-gene relationships revealed by the correlation analysis 
served to validate this approach. First, DPD expression was negatively correlated with 
5-FU activity, which is consistent with the finding that high levels of DPD, which is 
involved in the catabolism of pyrimidines and 5-FU, decrease exposure of cells to the 
active phosphorylated forms of 5-FU (see section 1.2.5). Second, the expression of 
ASNS (asparagine synthetase) was negatively correlated with sensitivity to L- 
asparaginase in the NCI60 panel. Because L-asparaginase is used in the treatment of 
leukaemia, this correlation was tested in a sub-panel of leukaemic cells, resulting in an 
even stronger negative correlation. This is consistent with the notion that leukaemia 
cells lacking ASNS are more sensitive to L-asparaginase because it depletes 
extracellular L-asparagine.
Affymetrix oligonucleotide microarrays have also been used to measure expression 
levels of approximately 6800 genes in the NCI60 panel in a second study (Staunton et 
al., 2001). The gene expression data were similarly applied to the NCI database of 
cancer susceptibility to anticancer drugs. Staunton and coworkers generated a panel of 
genes, the expression of which was predictive of sensitivity or resistance to 232 drugs. 
The authors suggested that for some drugs prediction of chemosensitivity in clinical 
samples might become feasible. However, none of the genes in the predictive panel was
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directly associated with known mechanisms of drug resistance, and may represent char­
acteristics of the tumour cell, such as proliferative ability. Moreover, correlation 
between gene expression in the NCI60 panel measured by Affymetrix arrays and that 
measured by cDNA arrays was only moderate (Scherf et al., 2000). Therefore, array 
results must be validated before conclusions can be drawn concerning the mechanism of 
the interaction and the utility for clinical applications.
Owing to the complex nature of the array data, several studies have applied advanced 
computational models for mining the NCI60 databases. One study used relevance 
networks to deduce a stringent correlation coefficient threshold for extracting significant 
gene-drug relationships from the noise associated with mRNA expression data in the 
NCI60 (Butte et al., 2000). Another study developed a refined strategy to identify the 
gene-drug, gene-gene and drug-drug associations that might exist within a cell line 
subset, but not in the complete NCI60 set (Bao et a l , 2002). Wallqvist and coworkers 
assessed the reproducibility of the gene expression data within the different array 
datasets and found statistically significant results for no more than 36% of those cases 
where at least one replicate of a gene appears in each dataset (Wallqvist et al., 2002).
An independent study similar to that of Scherf and coworkers involved the development 
of an integrated chemosensitivity database of 55 anticancer drugs and the gene 
expression profiles of 39 human cancer cell lines (Dan et al., 2002). This study 
identified several genes with expression patterns that showed significant correlation to 
patterns of drug response. Some of these genes were correlated with entire classes of 
drugs. For example, AKR1B1 (aldose reductase) and DDB2 (damage-specific DNA 
binding protein 2) showed positive correlation with multiple drugs, indicating that they 
are common predictive markers of chemosensitivity. They also identified genes that 
were correlated only with specific drugs that had similar mechanisms of action. For 
example, BIRC5 (survivin) and BIRC2 (apoptosis inhibitor 1), genes involved in 
apoptosis, were negatively correlated with the activity of 5-FU derivatives.
Another group evaluated the relationship between chemosensitivity to eight anticancer 
drugs and gene expression profiles in eight human hepatoma cell lines using cDNA 
microarray analysis, and analysed the data by constructing relevance networks 
(Moriyama et a l, 2003). They identified 42 genes that showed significant correlation.
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Nearly 20% of these represented various types of membrane transporters, most of which 
were negatively correlated with chemosensitivity. For example, TAPI (transporter 
associated with antigen processing 1) was associated with resistance to mitoxantrone, 
consistent with previous reports (Lage et al., 2001).
These studies demonstrate the utility of correlating gene expression and drug activity in 
transformed human cell lines. Because gene expression was measured in untreated cells, 
these studies focused on preexisting sensitivity to drug treatment rather than on the 
consequences of treatment.
1.43 Gene expression changes as a result of drug exposure
A number of recent studies have focused on the molecular consequences of exposure to 
anticancer drugs or have addressed differential expression patterns between drug- 
sensitive cell lines and those with acquired resistance. Kudoh and colleagues used 
cDNA microarrays to monitor the expression profiles of MCF-7 cells that were either 
transiently treated with doxorubicin or selected for resistance to doxorubicin (Kudoh et 
al., 2000). These researchers identified a set of genes with altered expression that 
overlap between doxorubicin-induced and -selected cells. The authors suggested that 
these genes represent a profile indicative of putative doxorubicin resistance. 
Furthermore, gene expression profiles of doxorubicin- and cisplatin-resistant cells were 
found to differ -  as one would expect for drugs with different mechanisms of action.
A similar study used cDNA microarrays to search for differentially expressed geneS 
between a human multiple myeloma cell line and doxorubicin-selected sub-clones that 
express ABCB1 (MDR1) and show multi-drug resistance (Watts et al., 2001). This 
study identified many differentially expressed genes, including ABCB1 and genes 
involved in apoptotic signaling.
Wittig et al. (2002) determined the difference in gene expression between a drug- 
sensitive melanoma cell line and three derived sub-lines with acquired resistance to the 
DNA-damaging agents cisplatin, etoposide and fotemustine. They found that 110 genes 
were transiently or permanently deregulated in at least two resistant sublines, and 14 
genes were differentially expressed in all three drug-resistant sub-lines. In addition, 
chromosomal aberrations (such as deletions and duplications) were investigated by
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comparative genomic hybridization and compared with gene expression, which was 
used as a criterion for the selection of promising candidate genes.
Another study (Maxwell et a l, 2003) determined the difference in gene expression 
between the MCF-7 breast cancer cell line and a 5-FU induced sub-clone. Genes that 
were consistently found to be up-regulated were spermine/spermidine acetyl transferase 
(SSAT), annexin II, thymosin-beta-10, chaperonin-10, and MAT-8. However, it must be 
noted that the majority of genes identified in these studies have no known role in 
chemosensitivity.
1.4.4 In vivo chemosensitivity studies
Zembutsu and coworkers extended the method of correlation analysis to in vivo animal 
models (Zembutsu et a l, 2002). They used a cDNA microarray representing 23,040 
genes to analyze expression profiles in a panel of 85 cancer xenografts derived from 
nine human organs. Furthermore, the xenografts were examined for sensitivity to nine 
anticancer drugs and 1578 genes displaying expression levels that were correlated with 
chemosensitivity were identified.
Drug efficacy in mouse models might differ from that in humans. To avoid this 
confounding factor, gene expression profiles of clinical samples were compared with 
drug response. The expression profiles of 20 oesophageal cancer tissues from patients 
who were treated with the same chemotherapy regimen after tumour removal by surgery 
were examined using cDNA microarray analysis of 9216 genes (Kihara et a l, 2001). 
Comparison of these expression profiles with the duration o f survival identified 52 
genes having expression profiles correlated with prognosis, and probably with 
sensitivity and/or resistance to drugs. However, these candidate genes could affect 
tumour aggressiveness rather than chemosensitvity, which cannot be separated in this 
study. Surprisingly, the correlation between ABCB1 expression and response was 
moderate at best, even though the chemotherapy regimen used includes MDR1 
substrates. The controversy over whether MDR1 represents a clinically important 
chemoresistance factor in oesophageal cancer remains unresolved.
Sotiriou et al (2002) used cDNA microarrays to study gene expression profiles 
obtained from fine-needle aspirations of primary breast tumours before and after
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systemic chemotherapy. This study identified candidate genes that might distinguish 
tumours with complete response to chemotherapy from tumours that do not respond. 
However, it remains unclear whether gene expression-based predictors reflect 
sensitivity to treatment or more fundamental aspects of tumour cell biology that are 
important to disease progression (Ramaswamy et a l , 2003).
Although several studies claim that clinical outcome of individual cancer patients can be 
predicted using gene expression profiles of primary tumours at diagnosis (for review see 
Ntzani & Ioannidis 2003), further work needs to be done to confirm the role of these 
genes in chemosensitivity and to validate the microarray technology.
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Table 1.11 Representative studies that correlated gene expression with 
chemosensitivity.
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1.5 Experimental Hypothesis and Aims
1.5.1 Hypothesis
This thesis examines the hypothesis that changes in molecular phenotype, particularly 
with respect to multidrug resistance, underlie resistance and sensitivity of human 
tumour-derived cancer cells to TOPO inhibitors and other anti-cancer agents.
1.5.2 Aims:
1. To develop methods to determine the degree of correlation between the 
molecular phenotype of tumour cells, cell lines and chemosensitivity to 
chemotherapeutic agents.
2. To determine the effect of combined inhibition of TOPO I and II on tumour- 
derived cells.
3. To determine the effect of the combination of TOPO inhibitors with other 
cytotoxic drugs.
4. To determine the importance of known mechanisms of sensitivity and resistance 
to chemotherapeutic agents.
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Chapter 2 - MATERIALS and METHODS
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2.1 Introduction
This chapter describes the various methods that have been used during the course of this 
Ph.D. The main method used was the ATP based chemosensitivity assay (ATP-TCA, 
which is described in section 1.3. The ATP-TCA was used to assess the ex vivo 
chemosensitivity of retinoblastoma, cutaneous melanoma, ovarian, breast and GI 
carcinoma samples, as well as various cell lines. The ATP-TCA was also used to 
evaluate new drug combinations and the use of tariquidar as a chemosensitiser in human 
cancer specimens.
qRT-PCR (section 1.4) has been employed to investigate molecular changes that occur 
after exposure to anticancer agents used in the ATP-TCA and in vivo in oesophageal 
cancer patients.
IHC has been used for several different purposes throughout this study; to determine 
cell type, and to investigate expression levels of different proteins during the course of 
an ATP-TCA and exposure to different drugs. All of the IHC used here was carried out 
by the staff of the Histopathology laboratory, Queen Alexandra Hospital, Portsmouth, 
and of the Histology laboratory, Institute of Ophthalmology. The method used is 
included here for completeness.
2.2 Materials and Methods for the ATP-TCA
The ATP based Tumour Chemosensitivity Assay (ATP-TCA) was performed as 
previously described (Andreotti et al., 1995) and according to the protocol supplied by 
DCS Innovative Diagnostik Systeme, Hamburg Germany for the TCA-100 kit. The 
method is described below.
2.2.1 Cell Culture media
All chemosensitivity assays for human specimens were performed in Complete Assay 
Medium (CAM) (DCS Innovative Diagnostik Systeme, Hamburg, Germany). CAM is 
serum free and does not contain growth factors. This media was supplemented with 100 
IU/ml penicillin and 100 pg/ml streptomycin (Sigma Chemical CO Ltd, Poole, Dorset, 
Cat No. P0781) and 10 mM HEPES (Sigma H9136).
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2.2.2 Transportation of tumour material
Tumour material was transported in sterile polystyrene tubes containing 10ml 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma D5671) to which 100 IU/ml 
penicillin and 100 jig/ml streptomycin (Sigma P0781) and 10 mM HEPES (Sigma 
H9136) had been added. Tumour material from contaminated sources was transported in 
the same medium, with added 2.5|xg/ml amphotericin B (Fungizone, A2942; Sigma) and 
lpg/ml metronidazole (Flagyl®; Rhone Poulenc Roreer Limited, Eastbourne, UK).
Up to 225 ml of ascites and pleural fluid were transported in 250 ml bottles, containing 
25 ml (DMEM) (Sigma D5671) to which 250 IU/ml penicillin and 250 pg/ml 
streptomycin (Sigma P0781) and 250 mM HEPES (Sigma H9136). Heparin sodium 
5000 IU (Monoparin®, CP Pharmaceuticals Ltd, Wales) was added as a precaution to 
prevent blood clots forming whilst in transit. Tumours that required overnight delivery 
were packed in a polystyrene box containing an ice pack, with the specimen separated 
from the ice pack by paper towels to prevent freezing of the specimen, which results in 
cell death and an inadequate sample for assay.
2J23 Source of tumour material
Tissue was sent under sterile conditions to the laboratory, at either the Institute of 
Ophthalmology (before April 2001) or the Translational Oncology Research Centre in 
Portsmouth (after April 2001). Fresh tumour material was obtained with patient consent 
for research use of the tissue from several hospitals and cancer centres. Enucleations 
from retinoblastoma patients were obtained from Moorfield’s Eye Hospital and St 
Bartholomew’s Hospital, London. Cutaneous melanoma biopsies from metastatic 
deposits were sent from Southend General Hospital, Westcliff-on-Sea, Essex and St 
Mary’s Hospital, Portsmouth, Hampshire. Gastro-intestinal and breast carcinomas were 
obtained from Queen Alexandra Hospital, Portsmouth, Hampshire. Ovarian carcinoma 
samples (ascites and solid tumours) were submitted by Southend General Hospital, 
Westcliff-on-Sea, Essex; Royal Preston Hospital, Preston, Lancashire; Airedale General 
Hospital, Keighly, West Yorkshire; Dorset Cancer Centre, Poole Hospital, Dorset; 
Mount Vernon Centre for Cancer treatment, Northwood, Middlesex; New Cross 
Hospital, Wolverhampton, West Midlands; Western General Infirmary, Edinburgh, 
Scotland; St Maiy’s Hospital, Portsmouth, Hampshire.
92
Many of the ovarian adenocarcinoma specimens were obtained from platinum- 
refractory patients requiring second line chemotherapy as part of a randomised trial 
comparing physician’s choice chemotherapy against chemosensitivity assay directed 
therapy (Kurbacher et al., 1997b).
Ethics committee approval was granted from Moorfields Eye Hospital and Portsmouth 
Hospitals NHS Trust Ethics Committees for the use of tissue not required for diagnosis. 
Individual trials received approval from the Local Regional Ethics Committee (LREC) 
for the areas submitting tissue. The TCA Ovarian Cancer trial had Multi-centre 
Regional Ethics Committee (MREC) approval.
2.2.4 Initial preparation of solid tumour specimens
Upon receipt of solid tumour specimens, a small piece of tumour material was cut from 
the biopsy and placed into 10% buffered formaldehyde for histopathological 
examination to ensure that the specimen contained neoplastic cells. The hospital 
sending the sample kept the majority of the sample so that a pathology report could be 
obtained for patient management and only material not required for diagnosis was sent 
for testing. The remaining tumour material was digested as described in section 2.2.6.
When the number of cells allowed, drop-preparations of ascites and pleural effusion 
samples and cytoclots were prepared so that an immunohistochemical diagnosis could 
be made to confirm that neoplastic cells were present.
2.2.5 Enzymatic tumour dissociation
Two different enzymes were used to digest the tumour specimens: collagenase (Sigma 
C8051) or Tumour Dissociation Reagent (TDE) (DCS, Innovative Diagnostik Systeme, 
Hamburg Germany). Depending on tumour type (table 2.1), the appropriate dissociation 
enzyme was reconstituted with 10 ml complete assay medium (CAM, DCS Innovative 
Diagnostik Systeme, Hamburg, Germany) and diluted to the concentrations listed in 
table 2.1. The enzyme solution was then filter sterilised into a 30ml sterile universal 
using a 0.22 pm filter and 10 ml syringe.
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Table 2.1. Enzymes used for the dissociation of tumour samples. Collagenase was made 
up in DMEM containing 100 IU/ml penicillin and 100 pg/ml streptomycin. 
Amphotericin B (2.5 pg/ml) and metronidazole (1 pg/ml) were included if the tumour 
was thought to be contaminated (i.e. GI tumours).
Dissociation enzyme Dissociation time Tumour
Collagenase 0.075 mg/ml 2 hours Retinoblastoma
Collagenase 0.50-0.75 mg/ml 6 hours - O/N Cutaneous melanoma
Collagenase 0.75 -  1.0 mg/ml 6 hours - O/N Ovarian and breast carcinoma
Collagenase 1.0-1.5 mg/ml 6 hours - O/N GI tumours
Tumour Dissociation 
Reagent* 1:4 dilution
6 hours - O/N
Ovarian adenocarcinoma (clinical 
trial specimens only)
*TDE, DCS Innovative Diagnostik Systeme GmbH, Hamburg, Germany
2.2.6 Preparation of solid tumour specimens
The tumour specimen was placed in a 100 x 15 mm Petri dish and dissected within a 
class It safety cabinet Using sterile scalpels, excess fat and connective tissue (and skin 
in the case of some cutaneous melanoma metastases) was excised. The specimens were 
then minced using surgical scalpels into 0.5 - 2.0 mm3 pieces and transferred into the 
universal containing the previously prepared enzyme solution. If the tumour sample was 
large, i.e. greater than 5 x 1 0 x 1 0  mm, then more than one container was set up with 
equal amounts of tumour material going into each digest. The tumour and enzyme 
solution was then incubated for a minimum of 2 hours, but generally overnight (table 
2.1), at 37° C. The mixture was shaken / inverted at intervals to disrupt the specimen 
and encourage the dissociation.
Once a cell suspension was evident, the preparation was centrifuged at 300g for 10 
minutes at room temperature (RT) and the supernatant discarded. The cells were then 
washed twice by resuspending in 10 ml CAM and centrifuging at 300g for 10 minutes. 
The supernatant was kept separate from the sample after each wash until the cells had 
been counted. After the second wash, the cells were resuspended in 10 ml CAM (less if 
the specimen was small) and the universal stood vertically to allow any undigested 
material to sediment out.
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The cell viability and concentration were then assessed using the trypan blue exclusion 
method described in section 2.2.7. If the cell viability was below 50%, if there was a 
large amount of debris, or blood cells were present, the viable cells were separated using 
Ficoll-Hypaque density gradient centrifugation (see section 2.2.9).
In the case of ascitic or pleural fluid samples, the specimen was centrifuged at 300g for 
10 minutes and resuspended in CAM before assessing cell number and viability. The 
majority of ascites specimen contained a large amount of blood cells that were removed 
by Ficoll - Hypaque density gradient centrifugation (see section 2.2.9).
2.2.7 Trypan Blue exclusion method
Cell number and viability were routinely assessed using a haemocytometer and the 
trypan blue exclusion method. Equal volumes of cell suspension and a 0.4% solution of 
trypan blue (Sigma T8154), normally 15 pi, were mixed in a polypropylene Eppendorf 
container and pipetted onto the haemocytometer. Dead or dying cells are unable to 
pump trypan blue out of the cytoplasm and so appear blue under the microscope with 
viable cells remaining clear (Kaltenbach et a i9 1958).
After counting the number of viable cells (N) present in the grid of the haemocytometer, 
the number of cells per millilitre can be calculated using the following formula: N * 
20,000.
This method also allowed the number of red blood cells to be estimated, as these are 
much smaller than other cells. When the number of erythrocytes represented more than 
10% of the total number of cells, excess red blood cells were removed by Ficoll- 
Hypaque density gradient centrifugation (see section 2.2.9). The specialised media 
(CAM) and the culture plates ensured that lymphocytes and other non-malignant cells 
did not survive in culture and therefore did not interfere with the assay results (see 
Chapter 1.3).
2.2.8 Ficoll-Hypaque density gradient separation
Ficoll-Hypaque density gradient (Boyum, 1968) separation was performed following 
manufacturers instructions as described below. 10 ml of Ficoll-Hypaque (Histopaque
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Sigma 1077-1) was transferred into a sterile polystyrene 30 ml universal container. An 
equal volume of the digested specimen was layered on top of the Ficoll-Hypaque using 
a sterile Pasteur pipette, taking care not to mix the two layers. The sample was then 
centrifuged at 400g for 30 minutes at room temperature. After this period the blood cells 
should have formed a pellet, leaving the tumour derived cells forming an interface 
between the Ficoll-Hypaque and CAM. The interface was transferred using a sterile 
Pasteur pipette into another sterile 30 ml universal. The cells were then washed twice 
with 10 ml CAM by centrifugation at 300g for 10 minutes. The cell number and 
viability were then reassessed using the trypan blue exclusion method.
2.2.9 Preparation of chemotherapeutic agents
The cytotoxic drugs used in the assay were obtained as vials for injection either from 
the Pharmacy Departments at Southend General Hospital or at Queen Alexandra 
Hospital in Portsmouth. All of the chemotherapeutic drugs or combinations were tested 
in triplicate at 6 dilutions, corresponding to 200%, 100%, 50%, 25%, 12.5% and 6.25% 
of the estimated Test Drug Concentration (TDC). The TDC is based on the peak plasma 
concentration and the protein binding for the individual drugs (Andreotti et al., 1995), 
and in some cases has been adjusted to provide correlation with clinical response rates. 
In each 96-microwell culture plates four drugs could be tested. The remaining wells in 
the plate were used for maximum inhibitor (MI) and no drug (MO) controls. The 
Maximum Inhibitor (MI) reagent consists of 0.02% v/v Triton X-100 (Sigma T8787) in 
DMEM (Sigma D5671); Triton X-100 is a detergent that kills all the cells, and is used 
as a negative control. The plate design used is shown in Figure 2.1.
All the chemotherapeutic drugs were prepared following manufacturers instructions and 
divided into aliquots which were then stored at room temperature, 4°C, -20°C or -70°C 
(Hunter et ah, 1994). A list of all the drugs used including the stock and test drug 
concentrations and the storage conditions can be found in Table 2.2.
An 800% TDC solution of each drug to be tested was prepared by diluting the stock 
solution into either 5 or 10ml CAM. Table 2.2 shows the volume that needs to be added 
to 5ml CAM to obtain an 800% TDC solution, as well as the TDC for all the drugs 
used. CAM contains Penicillin, Streptomycin and Gentamicin: Amphotericin B and
96
Metronidazole were added if the tumour sample was not sterile, as previously published 
(Whitehouse et a l 2003). This has no effect on the sensitivities observed (Dr Pauline 
Whitehouse, personal communication).
Table 2.2 Storage and TDC for drugs used in the ATP-TCA. Room temperature has 
been abbreviated as room temp.
DRUG TDC
pM
TDC 
Mg/ml
Stock
mM
Stock
mg/ml
pL added to 5 ml 
CAM to give 
800% TDC
Storage
Cisplatin 10 3.0 3.3 1.0 120 room temp
Doxorubicin 0.86 0.50 3.4 2.0 10 -20°C
Liposomal
Doxorubicin 2.6 0.50 10 2.0 30 -20°C
DTIC 110 20 55 10 80 -20°C
Epirubucin 0.86 0.50 3.4 2.0 10 -20°C
Etoposide 81 16 34 20 96 -20°C
5-FU 346 45 192 25 72 room temp
Gemcitabine 40 12 133 40 12 -20°C
Irinotecan 148 100 29 20 200 -20°C
Mitomycin C 2.0 0.70 2.9 1.0 28 -20°C
Mitoxantrone 1.2 0.60 3.9 2.0 12 room temp
Paclitaxel 16 14 7.0 6.0 91 room temp
Temozolomide 52 10 103 20 20 -20°C
Topotecan 1.6 0.75 2.2 1.0 30 -20°C
Treosulfan 72 20 180 50 16 -20°C
Vinblastine 0.55 0.50 1.1 1.0 20 -20°C
Vinorelbine 11 12 9.3 10 48 +4°C
2.2.10 Choice of drugs for ATP-TCA
The panel of drugs used for each assay were chosen by Prof Cree in consultation with 
the referring Oncologist to represent different mechanisms of action and the drugs 
normally used for the particular tumour type. The drugs tested in the ovarian, breast, GI 
and cutaneous melanoma samples formed part of a set drug list due to their inclusion in 
clinical trials. Whenever the number of cells allowed, additional plates were also set up 
with experimental agents. The set drug lists are shown below.
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Breast Cancer
Plate A
1. Epirubicin / doxorubicin
2. 5-fluorouracil (5-FU)
3. Paclitaxel
4. Cisplatin
Colorectal Cancer
Plate A
1. 5-FU
2. Irinotecan
3. Oxaliplatin
4. Oxaliplatin + 5-FU
Plate B
5. Mitomycin C + 5-FU
6. Mitomycin C
7. 5-FU + irinotecan
8. Mitomycin C + gemcitabine
Plate C (from 1st August 2002 only)
9. Celecoxib
10. Celecoxib + 5-FU
11. Celecoxib + irinotecan
12. Celecoxib + 5-FU + irinotecan
Cutaneous melanoma
Plate A
1. Cisplatin
2. Paclitaxel
3. Cisplatin + paclitaxel
4. Vinorelbine
Plate B
5. DTIC
6. Treosulfan
7. Gemcitabine
8. Treosulfan + gemcitabine
Oesophageal Adenocarcinoma 
Plate A
1. ECF (Epirubicin + cisplatin + 5-
2. 5-FU
3. Epirubicin
4. Cisplatin
Plate B
5. Gemcitabine
6. Cisplatin + gemcitabine
7. Mitomycin C (MMC)
8. MMC + 5-FU
Plate C
9. Irinotecan
10. Irinotecan + 5-FU
11. Irinotecan + cisplatin
12. Paclitaxel
Recurrent Ovarian Cancer - Phase III trial (drug list from protocol)
Plate A
1. Cisplatin
2. Gemcitabine
3. Cisplatin + Gemcitabine
4. Doxorubicin x3 (Caelyx)
Plate B
5. Paclitaxel
6. Mitoxantrone
7. Paclitaxel + Mitoxantrone
8. Topotecan
Plate C
9. Treosulfan
10. Treosulfan + Gemcitabine
11. Cisplatin x2 + Etoposide
12. Etoposide
Plate D
13. Vinorelbine
14. Doxorubicin x3 + Vinorelbine 
Retinoblastoma
Plate A
1. Cisplatin
2. Etoposide
3. Vinblastine
4. Doxorubicin
Plate B
5. VAC (cisplatin + doxorubicin + vinblastine)
6. VEC (cisplatin + etoposide + vinblastine)
7. 5-FU
8. Gemcitabine
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Figure 2.1 96-well-plate layout used for the ATP-TCA. Four drugs are tested at six concentrations ranging from 6.25% up to 200% o f  the TDC. 
The plate has 12 no drug controls (MO) and 12 maximum inhibitor wells (MI) to allow for percentage growth inhibition values for each drug at 
each concentration to be calculated at the end o f  the assay.
2.2.11 Preparation of 96-well microculture plates for addition of tumour cells
All ATP-TCAs with tumour-derived cells were performed in round bottomed 
polypropylene culture plates (Coming-Costar, High Wycombe, UK, cat no.3790), 
unless specified in chapter 3. The maximum inhibitor reagent (Ml) was either purchased 
from DCS Innovative Diagnostik Systeme, Hamburg, Germany, or freshly prepared 
using 0.02% v/v Triton X-100 in DMEM. An aliquot (100 pi) of MI solution was added 
to the wells in the top row of the plate as illustrated in Figure 2.1. To the remaining 
wells of the plate, including the MO wells (e.g. positive control, no-drug) in row H, 
lOOpl of CAM was added.
An aliquot (100 pi) of the 800% TDC solution of each drug was added in triplicate to 
row B o f the 96-well plate. Using a multichannel pipette (or a robot, Kemble mod SPI) 
the drugs were serially diluted down the plate from row B to row G, while the excess 
lOOpl remaining after the serial diluting was discarded. The plate was now ready for 
addition of the tumour cells.
2.2.12 Addition of tumour cells to the 96-well plate
The tumour cells were diluted in CAM to give a final concentration o f200,000 cells per 
millilitre. For ovarian ascites and pleural fluid the cells were diluted to 100,000 cells per 
millilitre. Aliquots (100 pi) of cells were then added to each well of the 96 well plate. 
The final cell concentration in each well was 20,000 for solid tumour specimens and
10,000 for the ascites and pleural fluid. The plates were incubated in a 95% air 
humidified, 37°C, 5% CO2 incubator for 5-7 days. The plates were checked periodically 
for overgrowth and infection.
Any cells that were not required for ATP-TCA were cryopreserved in DMEM 
supplemented with 100 IU/ml penicillin and 100 pg/ml streptomycin, 10% foetal calf 
serum (FCS) (Labtech International, East Sussex, UK, cat. 4-101-500) and 10% DMSO 
(Sigma D5879), as detailed in section 2.3.3.
After the incubation period the cells were lysed and the ATP was quantitated.
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2.2.13 ATP extraction
A reagent for the extraction of ATP was either purchased from DCS Innovative 
Diagnostik Systeme (‘ATP extractant’, Hamburg, Germany) or prepared according to 
the recipe herein described. Hepes buffer (101.7 mg/ml; Sigma H-4034) ammonium 
meta-vanadate (1.267 mg/ml; Sigma A-l 183) and Triton X-100 (0.5% v/v; Sigma T- 
8787) were dissolved in sterile water (B.P. Water for Irrigation, Pharmacy, Queen 
Alexandra hospital) and the solution was titrated to pH=7.8 with 5.0 N sodium 
hydroxide. The solution was then let stand overnight in a safety cabinet uncovered until 
the colour of the liquid changed from yellow to clear. The solution was then filter 
sterilised using a 0.22 pm filter and 20ml syringe and aliquoted into 30ml sterile 
universal containers, which were stored in the refrigerator.
The ATP was released from the cells by the addition of 50 pi of ATP extraction reagent 
to each o f the wells of the 96 well plate. The cells were immediately mixed by gentle 
pipetting 4-6 times using a multichannel pipette. Pipette tips were discarded after each 
drug triplicate. Plates were incubated at room temperature for a minimum of 20 minutes 
and a maximum of one hour before the ATP was measured.
2.2.14 Preparation of Luciferin-Luciferase Counting Reagent
The ATP in the wells was quantitated using a luciferin-luciferase ‘counting’ reagent, 
which was obtained from DCS Innovative Diagnostik Systeme (Hamburg, Germany) 
until the first half o f2001. A bottle o f lyophilised luciferin-luciferase counting reagent 
was reconstituted with 21ml of Dilution buffer (DCS Innovative Diagnostik Systeme, 
Hamburg, Germany), which allowed for four 96 well plates to be read as well as an 
ATP standard curve (figure 2.2). The bottle was inverted several times to mix and 
incubated at room temperature for at least 30 minutes before use. The vial containing 
the reconstituted luciferin-luciferase was wrapped in foil to protect the reagent from 
light.
Alternatively (from July 2001 onwards), D-luciferin (Cat 800-LN) and recombinant 
luciferase (Cat. 700-LF) were purchased from R&D systems (Abingdon, UK) and a 
luciferin-luciferase counting reagent was prepared as described below. Firstly, a lOx 
Hepes buffer was prepared mixing 4.766mg/ml HEPES powder (Sigma H-0887) and
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1.221mg/ml magnesium sulphate heptahydrate (Sigma M-9397). The solution was 
adjusted to pH 7.7 with 5.0 N sodium hydroxide, filter sterilised and used to dissolve D- 
luciferin (0.732mg/ml buffer). Secondly, a 0.5 M Tris-succinate buffer containing 1% 
BSA was prepared dissolving 0.226 mg/ml TRIZMA®-succinate (Sigma T-9632) and
25.9 pl/ml bovine albumin 35% solution (Sigma A-7409) and adjusted to pH to 7.5 with 
sodium hydroxide. This buffer was used to reconstitute the recombinant luciferase 
(1 .Omg/ml); the solution was then held on ice for 1.0 hour to let the luciferase dissolve 
completely. The final reagent was then prepared combining 102.5 ml of lOx Hepes 
buffer containing D-Luciferin with 24.75 ml of recombinant luciferase (1.Omg/ml) in 
0.5 M Tris succinate buffer and 41.25 ml of 3% BSA. The solution was stored at -20°C 
in 2.0 ml aliquots. Before use each 2.0 ml aliquot was diluted with 18 ml o f dilution 
buffer, which consisted of a 1 in 10 dilution of the HEPES buffer that was used to 
dissolve the D-luciferin.
The ATP was measured using a Berthold Diagnostic Systems MPLX luminometer 
(Berthold Diagnostic Systems, Pforzheim, Germany). All luminescence measurements 
were performed following the manufacturer's instructions.
2.2.15 ATP standard curve
An ATP standard curve was generated prior to reading any ATP-TCA plates as a 
quality control to ensure that all reagents and equipment were working properly. A vial 
o f lyophilised ATP standard (DCS Innovative Diagnostik Systeme, Hamburg,
Germany) was reconstituted with 2 ml of dilution buffer to give a stock ATP 
concentration o f250 ng/ml. Alternatively, a vial of ATP suitable for luminescence 
application was purchased from Sigma (Cat FLAAS), and a stock solution o f 100 
pg/ml was prepared in dilution buffer (HEPES powder 0.4766mg/ml; magnesium 
sulphate heptahydrate 0.1221 mg/ml; pH 7.7). The ATP solution was then filter 
sterilised using a 0.22 pm sterile disposable filter and a disposable 10 ml plastic syringe, 
and stored in 25 pi aliquots at -20°C for a maximum of six months. For each calibration 
curve 10 pi of the stock solution were added to 4 ml of dilution buffer to give a final 
concentration o f250 ng/ml.
A serial dilution of the ATP standard was performed in the first 9 wells of a white 
polysterene 96 well plate (Dynatech, Cat no 7905), with each well containing 50 pi of a
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1:3 dilution o f  the ATP from the previous well to give ATP concentrations o f  151, 50.4, 
16.8, 5.60, 1.86, 0.620, 0.207, 0.0689 and 0.0218 nM. An aliquot (50 pi) o f  the 
previously prepared luciferin-luciferase counting reagent was added to each well and 
then the luminescence was read using the luminometer. Plotting the log o f  ATP 
concentration against the log o f  luminescence counts produced a straight standard curve 
(figure 2.2).
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Figure 2.2 ATP standard curve produced on a Berthold MPLX plate luminometer. 
Results are shown as mean (±SD) o f  triplicate values. Here and elsewhere in this thesis, 
when error bars are not shown for some data points, this is because they are smaller than 
the markers on the graph.
2.2.16 Evaluability criteria
For an assay to be evaluable the average positive control luminescence had to be at least 
as high as the luminescence produced by 1.86 nM (equivalent to 1.028 ng/ml) ATP in 
the standard curve. The luminescence produced by 1.86 nM ATP varied with the age o f  
the ATP standard, and the luciferin-luciferase counting reagent. This also varies with 
the luminometer used, as all such instruments express their measurements as relative 
light units. The evaluability cut-off for the ATP was chosen according to previous data 
published by Andreotti et al. (1995), as low cell numbers can produce spurious results.
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Also a cut-off at 1.86 nM provides a good discrimination between the luminescence 
measured in the MI and MO wells.
2.2.17 Reading ATP levels from assay plates
To read the ATP levels in the ATP-TCA plates following cell lysis (ATP extraction), 50 
pi from each well of the 96 well culture plate was transferred into a white 96 well plate, 
using fresh pipette tips for each drug. To each well, 50 pi of the previously prepared 
luciferin-luciferase counting reagent was added and then the luminescence was read 
using the luminometer, following the manufacturer's operating instructions. After 
reading, the remaining extracted cells were stored in the 96 well culture plate at -80°C 
until the data had been analysed confirming that the plate did not need to be read again, 
or to permit RNA to be extracted for further experiments.
2.2.18 Alternative procedure of ATP extraction for qRT-PCR studies
The material left over after ATP extraction and reading did not prove suitable for RNA 
studies. The cell lysis buffer (section 2.2.13) was not found able to prevent RNA 
degradation by RNAses. Therefore, an alternative procedure of ATP extraction and 
quantification was set up for tumour-derived cells that were employed in further qRT- 
PCR experiments. Prior to cells lysis with the ATP extracting reagent, 150 pi of cell 
suspension were removed from each well, centrifuged, washed with phosphate buffered 
saline (PBS) and stored at -80°C in 350 pi GTIC-containing solution that prevented 
RNA degradation for at least six months (lysis buffer RA1, Macherey-Nagel, Germany, 
Cat. N.o 740961). The remaining 50 pi cell suspension was then lysed by adding 12.5 pi 
of ATP extracting reagent. After 20 minutes 50 pi of cell lysate were transferred to a 
white plate and the ATP was measured following addition of 50 pi luciferin-luciferase.
2.2.19 Calculation and interpretation of luminometry results
The data produced from each ATP-TCA plate was entered into an Excel (Microsoft) 
spreadsheet that calculated the percentage tumour growth inhibition at each 
concentration, the IC50, IC90 and the area under the concentration versus inhibition 
graph (IndexAuc) for each drug (see Appendix). The data calculated in the Excel 
spreadsheets was then entered into an Access (Microsoft) database. The % inhibition at 
each drug concentration was used to plot % inhibition curves for each drug or
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combination. As the variation between the wells that were averaged to calculate % 
inhibition is small (typical coefficient of variance of less than 10%), error bars 
representing the standard deviation cannot be seen in most graphs shown in this thesis, 
as they are often smaller than the markers on the graphs.
The percentage tumour growth inhibition was calculated as follows:
[ i _ ( p ^ ] ) _ J ^ )  1-100 = Percent tumour inhibition 
1 J
(TEST) = mean counts for test drug wells
(MI) = mean counts for maximum inhibitor wells
(MO) = mean counts for no drug controls
For ease o f comparison between different tumours, a sensitivity index IndexsuM for each 
drug in each tumour was calculated. This involved summing the percentage tumour 
growth inhibition and subtracting this figure from 600 (IndexsuM = 600 -
Sum[Inhibition6 25.....200])- The figure 600 derives from the fact that 6 drug
concentrations are tested in the ATP-TCA and the maximum % inhibition caused by 
each drug dilution is 100. Therefore a hypothetical drug able to kill the totality of the 
cells at all concentrations tested would have an IndexsuM equal to zero. The Excel 
spreadsheet calculated the sensitivity index automatically for each drug or combination.
A second sensitivity index, IndexAuc, was calculated using the trapezoidal rule to 
calculate the area under the % inhibition curve for each drug (see Appendix). The 
effects o f combinations of drugs compared to the constituent single agents are also 
analysed in the Excel spreadsheet using the methods determined by Poch et al (Poch et 
al.9 1990; 1995), which compares the expected (additive) effect with the achieved effect 
at each drug concentration. The results are presented graphically (Chapter 6, figure 6.3). 
As suggested by Neale et al. (1999), the methods of Poch et al. are better suited to the 
data produced by the ATP-TCA than other methods commonly used to evaluate 
combination effects such as those of Chou and Talalay (Chou & Talalay 1984). The 
methods of Poch et al. propose a corrective factor for dose response curves having a 
slope different from 1, such as those commonly shown by vinorelbine in the ATP-TCA
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(see chapters 6 and 8). A Chou and Talalay analysis was also performed when the Poch 
method suggested at least additivity between two agents and the results were compared. 
In detail the combination indices (Cl) were determined at 50% and 90% cell death, and 
were defined as follows:
C I a+ b  =  [ ( D a / a +b ) / D a ]  +  [ ( D b /a +b ) / D b ]  +  [ « ( D a /a +b  x  D b /a +b ) / D a D b ]
where C I a + b  = Cl for a fixed effect (F=50% or 90%) for the combination of cytotoxic A 
and cytotoxic B; D a / a + b  = concentration of cytotoxic A in the combination A + B giving 
an effect F; D b /a + b  = concentration of cytotoxic B in the combination A + B giving an 
effect F; Da = concentration of cytotoxic A alone giving an effect F; Db = concentration 
of cytotoxic B alone giving an effect F. a= parameter with value 0 when A and B are 
mutually exclusive and 1 when A and B are mutually non-exclusive. According to 
Greco et al. (1995), the combination index Cl indicated: synergism <0.8; 0.8< additivity 
<1.2; antagonism >1.2.
2 3  Cell line assays
23.1 Cell lines
The M14, MALME-3M, RPMI-7951, UACC-62 and SK-MEL-2 melanoma cell lines 
and the acute lymphoblastic leukaemia CCRF-CEM cell line were purchased from the 
ATCC (LGC Promochem, Teddington, Middlesex, UK). The SK-MEL-28 melanoma 
cell line was kindly supplied by David Jackson, ICRF, Leeds, England. The SK-MEL- 
28 cell lines were supplied as growing cultures. All the remaining melanoma cell lines 
and CCRF-CEM cell line were supplied as frozen aliquots. All cell lines grew as 
adherent cultures with the exception of the CCRF-CEM cells, which grew in 
suspension.
2 3 3  Cell Culture Media
All melanoma cell lines were grown in standard RPMI-1640 medium (Sigma R7638) 
supplemented with 10% foetal calf serum (FCS) (Labtech International, East Sussex, 
UK, cat. 4-101-500), 100 IU/ml penicillin and 100 pg/ml streptomycin (Sigma P0781), 
and 2 mM glutamine (Sigma G7513). The cells were incubated at 37°C in a humidified 
5% CO2 incubator until they were confluent. Ficoll-Hypaque density gradient 
centrifugation was used to separate pure cell populations from debris or dead cells that
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might adversely affect the ATP-TCA. Following viability estimation and cell counting 
by Trypan blue exclusion, cells were plated (seeding density 2,000 cells/well) in 96 well 
polystyrene microplates (Falcon, BD Biosciences, Oxford, UK, Cat 35 3072) containing 
drugs that had been diluted as previously described above (section 2.2).
For the experiments described in Chapter 4, the cells were seeded in the plates and 
incubated for 24 hours at 37°C in a humidified 5% CO2 atmosphere; before adding the 
drugs, the FCS in the wells was diluted to 2% by replacing 160 pi of the RPMI medium 
containing 10% FCS with 110 pi of serum free standard RPMI medium.
The CCRF-CEM cell line was grown in RPMI-1640 Dutch Modification medium 
(Sigma R7638) containing 2 mM L-glutammine, 100 IU/ml Penicillin, 100 pg/ml 
Streptomycin and 20% FCS.
Cell lines, obtained from the supplier as frozen aliquots, were initially passaged into 25 
cm2 flasks and cultured at 37°C, 5% CO2. Cultures were grown to confluence and 
passaged into either 75 cm or 175 cm (Falcon) flasks. Cultures were passaged 
regularly when between 80-95% confluent Cell lines were regularly screened for 
Mycoplasma by the technicians at the Institute of Ophthalmology using the 
VenorGeM® Mycoplasma-PCR-Detection Kit (Minerva Biolabs, Berlin, Germany).
2 3 3  Storage of cell lines in liquid nitrogen
Early passage number cells were divided into aliquots of about 106 cells per ml growth 
media and stored in a liquid nitrogen dewar. The method used was that suggested by the 
European Collection of Cell Cultures (ECACC, Centre for Applied Microbiology & 
Research, Salisbury, Wiltshire, England). Briefly, the adherent cells were trypsinised 
using a 1:10 dilution of a lOx trypsin-EDTA solution (5.0 g/L trypsin in 0.2% EDTA; 
obtained either from Gibco BRL, Cat. 35400-027, or from Sigma, Cat T4174). After the 
cells were completely detached from the flask, the trypsin activity was inhibited by the 
addition of growth media containing foetal calf serum, and the cells pelleted by 
centrifugation at 300g for 10 minutes. After two washes in growth media, the cells were 
counted using the trypan blue exclusion method and were adjusted to lx l0 6 cells per ml 
in growth media containing 10% v/v dimethylsulphoxide (DMSO) (Sigma D5879). The
108
cells were then divided into aliquots of 1 ml in polypropylene cryovials (Coming Costar 
cat no.430658 or 430659) and placed in a ‘Mr Frosty’ cryo-container (Nalgene cat no. 
5100-0001) and then immediately placed in a -70°C freezer. After 24 hours in a -70°C 
freezer the cryovials containing cells were transferred to a rack in a liquid nitrogen 
dewar.
23.4 Selection of CCRF-CEM cells with XR5944
The bis-mesylate salt of the experimental agent XR5944 was supplied by Xenova Ltd 
(Slough, Berkshire, UK) as powder. It was dissolved in DMSO to give a stock solution 
of 1.28 mM (equivalent to 1.0 mg/ml) and aliquots were stored at -80°C. CCRF-CEM 
lines were grown in RPMI-1640 (Sigma, R7638) supplemented with 2mM L- 
Glutammine (Sigma, G7513) and 10% FCS. A resistant subline was obtained by step­
wise treatment with XR5944 up to 10 nM. In brief, cells were initially exposed to 
O.lnM XR5944 for 7 days, after which the cells were spun, washed and fed with fresh 
medium containing no drug. After resting for 7 days cells were treated again with 
XR5944 at a concentration 0.25 nM for a further week. Rest-treatment cycles were 
repeated for several weeks exposing the cells to the following concentrations of 
XR5944: 0.50 nM, 1.0 nM, 2.0 nM, 4.0 nM, 6.0 nM, 8.0 nM, lOnM. Resting time was 
increased to 14 days when the cells were treated with the top three concentrations. After 
drug selection, the cell response to XR5944 was tested in the ATP-TCA. The IC50 
values for XR5944 were 0.27±0.05 nM and 4.24 ±0.25 nM in the CCRFCEM parental 
and XR5944-iesistant sub-lines, respectively. These values were essentially unchanged 
when the assay was repeated two months after the end of the exposure to XR5944.
23.5 External Quality Assurance (EQA) for ovarian trial
To ensure that intra-laboratory results were comparable, an EQA scheme was started 
between the three laboratories involved in the TCA Ovarian Carcinoma Trial. Two 25 
cm2 flasks of CCRF-CEM cells and 100 ml of culture media were sent out to each of the 
laboratories taking part in the trial. Each laboratory upon receipt of the cells set up an 
ATP chemosensitivity assay with the cells, using the above standard protocol with some 
modifications. Instead of CAM the assays were performed in CCRF-CEM media with 
10% FCS. Cells were plated out at 2,000 cells per well.
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Only one plate was set up for the quality assurance; the cytotoxics needed to be tested at 
lower concentrations (table 2.3) than those employed for clinical samples as the CCRF- 
CEM cells are extremely chemosensitive.
Table 2.3. List of drugs used for the ATP-TCA ovarian cancer trial EQA.
DRUG TDC pM TDCpg/ml StockmM
Stock
mg/ml
pL added to 5 
ml medium to 
give 800% TDC
Cisplatin 1.7 0.50 3.3 1.0 20
Doxorubicin 0.17 0.10 3.4 2.0 2.0
5-FU 38 5.0 192 25 8.0
Vinblastine 0.11 0.10 1.1 1.0 4.0
The results from each laboratory were sent to Prof. Ian Cree for comparison.
2.4 Materials and Methods for the Immunohistochemistry (IHC)
2.4.1 Introduction
All the IHC technical work described in this section has been carried by the biomedical 
scientists working with Prof Cree’s research team in Portsmouth and London, namely 
Mrs Lisa Mills, Mrs Alison Parker and Mrs Penny Johnson.
IHC techniques have been in use for the recognition of cells in tissue sections for at 
least 50 years. The first method reported use of fluorescent labels, while enzymatic 
labels, such as horseradish peroxidase (HRP) and alkaline phosphatase (AP), were 
introduced later. The IHC techniques employed in this thesis are based on a dual 
antibody (Ab) system using the Avidin-Biotin Complex method. The primary Ab binds 
to specific antigens present in the specimen and any excess is removed by washing. 
Next, the secondary Ab-conjugated to biotin is added and reacts with the primary Ab 
present on the tissue. Unbound Ab is removed by washing. The sample is then 
incubated with a solution containing the enzymatic label conjugated to avidin, which 
binds to the biotin-labelled secondary Ab present on the tissue. As avidin has an 
extraordinarily high affinity for biotin, their binding (unlike antibody-antigen 
interactions) is essentially irreversible. Finally, chromogenic substrates are added 
which, in the presence of the enzymatic label, deposit a coloured insoluble precipitate at 
those antigenic sites recognised by the primary Ab.
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Two methods have been used to stain the samples studied in this thesis, the Vectastain® 
Universal Alkaline phosphatase kit (Vector laboratories, LTD, Peterborough. UK, Cat# 
AK-5200) until February 2002 for MDR1, TOPOI and TOPO Ila; while the Chemicon 
IHC Select™ - Immuno Peroxidase secondary detection system (Chemicon 
International, Chandlers Ford, Southampton, UK, Cat# Det-HPlOOO) was employed 
from March 2002 onwards for all Abs. Table 2.4 provides a list of the Abs used, their 
source together with the appropriate antigen retrieval method for each. The 
concentration of each Ab was determined by titration on positive control material and 
was made up to its optimal dilution in Tris buffered saline (TBS) pH 7.6 (table 2.4). A 
positive control section was run with each batch of staining (table 2.4). A duplicate of 
each test section was included as a negative control by omitting the primary Ab and 
replacing it with TBS.
2.4.2 Preparation of cytodots
Cells were centrifuged at 400g and washed with PBS. Pellets were resuspended with an 
equal volume of human plasma using a Pasteur pipette. A few drops of human thrombin 
were added to the cellular suspension and mixed vigorously. The solution was allowed 
to clot for about 1 minute and the clot was transferred into 10% buffered formalin. Clots 
were fixed for 24-48 hours, processed as standard solid specimens and embedded in 
paraffin wax.
2.43 Specimen preparation and pre-treatment
Sections from paraffin-embedded blocks were cut on to Surgipath® positively charged 
slides and dried at 37° C for 24 hours. Wax was removed from the sections prior to 
staining by immersion in several changes of xylene followed by several changes of 
alcohol and rinsed in running tap water.
The appropriate antigen retrieval method for each Ab (pressure cooking, trypsination, 
microwaving; table 2.4) was used to reveal the antigen presenting sites blocked by 
formalin fixation. The sections were rapidly cooled and washed in running tap water.
I l l
2.4.4 Alkaline Phosphatase (AP) method
The sections were stained manually according to the protocol described below. Slides 
were incubated for 20 minutes in normal serum. This was followed by incubation at 
room temperature for 30 minutes with the primary Ab for TOPO I and Ila. To block 
endogenous avidin binding, sections for the MDR-1 Ab were treated with separate 
blocking stages of 20 minutes in avidin and 20 minutes in biotin, prior to overnight 
incubation in the primary Ab at 4°C in a humid incubation chamber.
Following incubation in the primary Ab and rinsing in TBS, the slides were incubated 
for 30 minutes with diluted biotinylated universal secondary solution, rinsed and then 
incubated for 30 minutes with VECTASTAIN® ABC-AP reagent (Vector laboratories, 
AK-5200). To visualise the reaction the slides were incubated for 20 minutes in 
Vector® Red alkaline phosphate substrate kit (Vector laboratories, SK-5100). 
Levamisole was also included to inhibit endogenous AP activity (Vector laboratories, 
SP-5000). AP catalyses the hydrolysis of a variety of phosphate-containing substances 
in the alkaline pH range. The enzymatic activity of AP can be localised by coupling a 
soluble product generated during the hydrolytic reaction with a chromogenic substrate, 
such as Vector® Red, producing a coloured insoluble precipitate.
The slides were counterstained with Gill’s Haematoxylin, dehydrated and cleared using 
the Leica© XL slide staining machine. The sections were mounted in Vector® Mount 
(Vector laboratories, H5000), which produces a permanently mounted section, and has 
an optimal retractive index to retain the colour intensity of Vector® Red substrate 
reaction product.
2.4.5 Horseradish Peroxidase (HRP) method
The slides were placed on a Dako Autostainer instrument (Dako, Ely, UK) and were 
stained according to an automated protocol. Reagents were added in the following order 
and incubation times for each are indicated in brackets: normal goat serum (20 
minutes); primary Ab (30 minutes; overnight; table 2.4); secondary Ab (15 minutes); 
streptavidin HRP (15 minutes); chromogenic reagent (3,3’ diaminobenzidine, DAB, HD
112
Supplies, Aylesbury, UK, Cat. 4170) (5 minutes). DAB produces a brown colour during 
the enzymatic degradation of hydrogen peroxide (H2O2) by HRP.
Rinses (5 minutes) with TBS (pH 7.6) were performed between each step. 50pl 
avidin/ml goat serum and 50jil biotin/ml primary Ab were used to block endogenous 
avidin binding.
The slides were counterstained with Gill’s Haematoxylin, dehydrated and cleared using 
the Leica © XL slide staining machine. The sections were mounted in Styrolite® 
mounting medium (BDH, Cat# 361704Y), which produces a permanently mounted 
section.
2.4.6 Assessment of IHC slides.
Assessment of slides was performed by a histopathologist (either Dr Silvana Di Palma 
or Prof Ian A Cree) using the H-score. Staining intensity (none, 0 points; weak, 1 point; 
moderate, 2 points; strong, 3 points) and percentage of positive tumour cells were 
multiplied to achieve a score between 0 and 300. An H-score of 100 or more was 
chosen as an arbitrary cut-off and regarded as positive by the histopathologist.
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Table 2.4 List of Abs used for immunohistochemical studies. When sections required microwaving a Matsui MIIOM microwave was used at 
800W power. Pressure cooking was performed with a Tefal Clipso Pressure Cooker using 70P power.
Ab Pre-Treatment Dilution Incubation Cat No. Source Control Tissue
COX-2
(Clone CX229)
Pressure Cook 
2 min 
pH 6.0
1:100
30 min; 
room
temperature CAY-160112
Cayman Chemicals 
(Distributor: Alexis -  
Nottingham, UK) Ca Colon
P-glycoprotein 
(MDR-1) 
(Clone JSB-1)
Pressure Cook 
2 min 
pH 6.0
1:100 Overnight; 
4° C NCL-JSB1
Novo Castra
Newcastle-upon-Tyne, UK
Kidney
Topoisomerase I 
TOPO-I 
(Clone 1D6)
Pressure Cook 
2 min 
pH 6.0
1:50 30 min; room
temperature
NCL-TOPOl Novo CastraNewcastle-upon-Tyne, UK
Tonsil
Topoisomerase II Alpha
TOPO-IIa
(Clone 3F6)
Pressure Cook 
2 min 
pH 6.0
1:40
30 min; 
room
temperature
NCL-TOPOIIA
Novo Castra
Newcastle-upon-Tyne, UK Tonsil
2.5 Materials and methods for quantitative reverse-transcriptase polymerase chain 
reaction (qRT-PCR)
2.5.1 Introduction
Total mRNA was extracted from tumour-derived cells, reverse transcribed and the 
resulting c-DNA amplified by qRT-PCR. All the steps were performed using filter- 
barrier sterile tips and plasticware that was certified DNase- and RNase-free by the 
manufacturer (Fisher Scientific, UK).
The polymerase chain reaction (PCR) is an in vitro method for enzymatic synthesis and 
amplification of defined nucleic acid sequences, such as a particular known DNA 
sequence. The cDNA product (amplicon) formed by a thermostable DNA polymerase in 
one cycle can serve as a template in the next cycle so in an ideal, fully optimised PCR 
reaction, the number of amplicons doubles every cycle. Ten cycles will yield 1024 
amplicons; 20 cycles more than a million. After a fixed number of cycles, the amplified 
cDNA can be analysed for size and quantity, usually by electrophoresis on agarose gels, 
and sequenced.
In recent years there has been intensive use of the newly developed technique of qRT- 
PCR for the investigation of gene expression. qPCR enables the monitoring of the 
progress of the PCR as it occurs. This is achieved including SYBR Green in the 
reaction mixture, an intercalating dye that emits a strong fluorescent signal when it 
binds to double-stranded nucleic acid; the fluorescence is proportional to the amount of 
product formed. Alternatively, in addition to the primers, a probe labelled with two dyes 
can be added to the reaction mixture. These molecular probes consist of a short 
oligonucleotide sequence (usually between 20 and 30 bases) which is encompassed in 
the region amplified by the primers. These probes rely on the close proximity of a 
quenching dye to the reporter dye and disruption of this quenching interaction by the 
action o f the polymerase causes an increase in fluorescence that is proportional to the 
product formation. Compared to SYBR Green method such probes are more specific, 
and give lower background fluorescence, but they are more expensive and require 
greater optimisation.
During a real time PCR, data are collected after every cycle, rather than allowing 
completion of a fixed number of cycles before analysis of the products. In the initial
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cycles of PCR there is little change in the fluorescent signal, and this defines the 
baseline for the amplification plot. Detection of an accumulating product is indicated 
by an increase in fluorescence above this baseline. The parameter ‘threshold cycle’ (Ct) 
is defined as the fractional cycle number at which the fluorescence crosses a fixed 
threshold. This method has many advantages over conventional PCR, having a greater 
accuracy and sensitivity, a wider dynamic range, a capacity for high throughput of 
samples, and no requirement for post-FCR manipulations, with their potential for 
contamination of other samples. In qRT-PCR, reactions are characterised by the point 
in time during cycling when amplification of a target is first detected, rather than the 
amount of target accumulated after a fixed number of cycles. The higher the starting 
number of the RNA target, the sooner a significant increase in fluorescence is detected.
qRT-PCR is a relatively new technique, and different research groups have used 
different methods of experimental design and data analysis. For the work in this thesis, 
various techniques and systems were trialled, and eventually a methodology was 
selected that allowed repeated, high-throughput of biological samples with a high 
degree of reliability, reproducibility and robustness. Chapter 3 will describe the 
technical development of the real time methodology used in this thesis, while the 
remaining part of this section will focus more in detail on the single steps performed to 
investigate the changes of gene expression caused by exposure of cancer cells to 
chemotherapeutic agents.
2.5.2 Total RNA extraction
The first step in the measurement of gene expression is the isolation of RNA from the 
sample. This was done using one of a variety of commercially available kits, based on 
the nucleic acid binding properties of silica membranes, the NucleoSpin® RNA II mini 
kit, that was purchased from Macherey-Nagel, Germany (Cat. #740955). The 
instructions provided in the kit manufacturer’s protocol were essentially followed.
Cells that survived after drug exposure in the ATP-TCA were pooled from at least 6 
wells to increase nucleic acid yield and stored as previously described in section 2.2.18. 
Ice-cold 70% ethanol (350 pi) was added to the cell lysate, and the mixture was 
vortexed. For each preparation, one NucleoSpin® RNA II column was placed in a 2ml 
centrifuge tube, and the lysate was added. The column was centrifuged for 1 minute at
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8,000g, after which the eluate was discarded. A Membrane Desalting Buffer (MBD) 
(350 |il) was added, and the column was centrifuged at 1 l,000g for 1 minute to dry the 
silica membrane of the spin column. At this stage the protocol included a DNase 
digestion step to prevent carry-over of genomic DNA in further analysis. A DNase 
reaction mixture was prepared in a microcentrifuge tube; for each sample, 10 pi 
reconstituted DNase I were added to 90 pi DNase reaction buffer and mixed by flicking 
the tube. The DNase reaction mixture (95 pi) was then applied directly onto the centre 
of the membrane of the column, and incubated at room temperature for 15 minutes. At 
the end of this period 200pl buffer RA2 were added to the column to inactivate DNase. 
The sample was then centrifuged for 1 minute at 8,000g, after which the eluate was 
discarded, and the spin column placed in a new 2 ml microcentrifuge tube. 600 pi wash 
buffer RA3 were then added to the column and centrifuged for 1 minute at 8,000g. The 
eluate was discarded and another wash step was performed with 250pl buffer RA3 and 
centrifuging the sample for 2 minutes at 11,000g. The eluate was discarded, and the 
column was centrifuged again for 1 minute at 11,000g to completely dry the membrane. 
Finally, total RNA was eluted in 60pl RNase-ffee water by further centrifugation at 
ll,000g for 1 minute. The eluate was collected in a RNase-ffee Eppendorf tube and 
immediately frozen at -80°C.
2.53 Reverse transcription
Prior to starting the PCR process, target RNA is subjected to reverse transcription, a 
process during which the enzyme reverse transcriptase synthesises a complementary 
strand for each strand of RNA. The resulting single stranded product is known as 
complementary DNA, or cDNA.
Two basic techniques of RT-PCR are described in the literature: one-step and two-step 
RT-PCR. In one-step RT-PCR, all reagents for both reverse transcription and the PCR 
process are added to the same tube, and a thermal cycling protocol is utilised that allows 
these reactions to proceed sequentially. Two-step RT-PCR initially involves a first- 
strand cDNA synthesis reaction that is followed by inactivation of RT-enzyme and 
dilution of the mixture. The second step involves addition of the newly-synthesised 
cDNA to a PCR mix containing DNA polymerase. Each method has its benefits and 
drawbacks. One-step RT-PCR reduces hands-on time and the likelihood of introducing 
contaminants into the reaction, and is quicker. Two-step RT-PCR allows dilution of the
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newly-synthesised cDNA, so that more reactions can be performed, and reduces the 
formation of non-specific PCR products. Throughout the work in this thesis, in which 
limited amounts of RNA were available, the two-step process was employed.
Total RNA was reverse-transcribed using the Promega ‘reverse transcription system’ 
(Promega, Southampton, UK, Cat # A3500) according to the manufacturer’s protocol. 
A master mix solution for the required number of reactions was prepared pipetting all 
the reagents in the sequence listed in table 2.5, except the Avian Myeloblastosis Virus 
(AMV) reverse transcriptase enzyme and RNA. As a negative control, 11.4pl were 
transferred to a thin-wall 0.2 ml PCR tube, to which 0.6pl of water had been previously 
pipetted. After preparing the negative control, the AMV enzyme was added, the master 
mix solution was vortexed and aliquoted into thin-wall 0.2 ml PCR tubes. 8pl RNA 
sample was added to each reaction, and the tubes were incubated for 10 minutes at RT 
to allow extension of the primers.
Table 2.5 List of reagents, volumes and concentrations for each RT reaction
Reagent Volume / sample Master Mix Final 
Concentration
Sterile nuclease-free water 1.9 pi
MgCl2 25mM 4.0 pi 5 mM
Reverse transcription 10X buffer 2.0 pi IX
dNTP Mixture — 10 mM each 2.0 pi 1 mM
Random primers 0.5 pg/pl 1.0 pi 25 ng/pl
Recombinant RNasin® ribonuclease 
inhibitor (50 U/pl)
0.5 pi 25 U
AMV reverse transcriptase (25 U/pl) 0.6 pi 15 U
RNA sample 8.0 pi
TOTAL 20.0 pi
The samples were then transferred to a thermal cycler (ThermoHybaid, Ashford, UK) 
and incubated at 42°C for 60 minutes to improve the efficiency of the reaction, as 
recommended by the manufacturer. At the end of this period, samples were heated at 
95°C for 5 minutes, then incubated at 4°C for 5 minutes to inactivate the AMV Reverse 
Transcriptase and prevent it from binding to the cDNA. The c-DNA samples were then 
stored at -80°C.
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2.5.4 qPCR
The c-DNA was amplified by real-time quantitative PCR in 96 well plates (BioRad Cat 
2239441) on a Biorad iCycler instrument (BioRad Laboratories, Hemel Hampstead, 
UK). All reagents were obtained from Applied Biosystems (Warrington, UK), and used 
in accordance with the manufacturer’s instructions. The final constituents of each PCR 
(25 pi) were 1 pi of cDNA, 200-500 nM of each primer (table 2.6), 200pM each dATP, 
dCTP, dGTP, 400pM dUTP, 3.0-5.0 mM MgCl2, 0.625 units of AmpliTaq Gold DNA 
polymerase, lx SYBR Green PCR buffer (SYBR Green PCR Core Reagents, Applied 
Biosystems, P/N 4304886) and 0.125 units AMPErase® uracil-N-glycosylase (UNG).
UNG was added to the reaction to prevent carry-over contamination (Longo et a l , 
1990). During PCR, abundant amplification products are synthesised. Contamination of 
new PCRs with trace amounts of these previously amplified products (carry-over 
contamination) yields false positive results. Carry-over contamination can be controlled 
by incorporating dUTP in all PCR products and treating all subsequent PCRs with 
UNG. UNG hydrolyses the N-glycosidic bond between the deoxyribose sugar and uracil 
in DNA that contains deoxyuridine in place of thymidine (Lindahl et a l , 1977). UNG is 
thermolabile, being fully active at 50°C, and being inactivated by ten minutes 
incubation at 95°C. UNG is active on both single- and double stranded DNA that 
contains uracil, but has no activity on thymine-containing DNA. The resulting 
apyrimidinic sites block replication by DNA polymerases, and are very labile to 
acid/base hydrolysis. Because UNG does not react with dUTP, and is also inactivated 
by heat denaturation prior to the actual PCR, carry-over contamination of PCRs can be 
controlled effectively if the contaminants contain uracils in place of thymines.
The reagents were prepared in the following order. Firstly, a master mix was made up 
containing the following - SYBR Green dye in a 1 Ox buffer solution, dNTP mixture, 
AMPErase®UNG, DNA polymerase, an appropriate volume of 25mM MgCl2, and 
DNase-ffee water. The final volume of the master mix was enough to aliquot 12.5pl into 
each reaction well. Next, a mixture was made up containing an appropriate 
concentration of the forward and reverse primers, and 7.5 pi was added to each reaction 
well. Finally, 5pl of 1:5 diluted cDNA template was added to each reaction well, taking 
the final volume to 25 pi. Negative control wells were incorporated into the plate design 
(figure 2.1); instead of template, these contained 5 pi water only (no template controls)
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or 5pi of appropriately diluted RNA that had undergone reverse transcription reaction in 
the absence of the AMV enzyme (RT-negative controls). All negative control wells 
contained primers and DNA polymerase.
Product amplification was performed up to 50 PCR cycles, after uracil removal by 
AMPErase®UNG for 2 minutes at 50°C and DNA polymerase activation for 10 minutes 
at 95°C. Each two-step PCR cycle comprised denaturing (15 s at 95°C), annealing, and 
extending (1 min at 60°C). An amplification reaction includes the target complementary 
DNA (cDNA), a thermostable DNA polymerase, two oligonucleotide primers, 
deoxynucleotide triphosphates (dNTPs), and reaction buffer containing magnesium. In 
the initial step of a cycle, heating to 95°C for 15 seconds denatures the target cDNA; 
this separates the two strands from each other, providing a single-stranded cDNA 
template for the thermostable polymerase. In the next step, the temperature is cooled to 
60°C for 1 minute, encouraging annealing of the oligonucleotide primers with the 
separated strands of cDNA. This allows DNA synthesis by the thermostable DNA 
polymerase, extending the oligonucleotide primers to copy the target cDNA. At the end 
of each run a final melt curve cycle (cooling to 50°C and then increasing stepwise 1 °C 
for 10 seconds up to 95 °C) was performed to exclude the presence of non-specific 
products. During amplification cycles, fluorescence measurements were made in each 
cycle during the last 15 seconds of the 60°C phase. During the subsequent melt curve 
analysis, they were made in the last 2 seconds at each new temperature.
At least two housekeeping (HK) genes were used as internal references for each 
experiment chosen among the following: glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1), human 
porphobilinogen deaminase (PBGD), succinate dehydrogenase complex-subunit A 
(SDHA) and TATA box binding protein (TBP). The internal reference genes were 
selected due to their relative low abundance in normal tissue (Vandesompele et al., 
2002). The HK genes were amplified in parallel to the target genes in separate wells.
The target genes were different for each series of experiments and were chosen among a 
number of genes known or suspected to confer resistance to the anti-cancer agent tested, 
or generally associated with cell growth and proliferation. Figure 2.3 shows the layouts 
that were used for each case.
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When possible, primers were chosen to have similar melting temperatures (Tm; this can 
be estimated using the following simplified formula Tm = 2°C x (A+T) + 4°C x (G+C)) 
values and, whenever possible, to span exon-exon boundaries in the target sequences 
(table 2.6). Negative controls with no template and RT-negative as template were added 
in every experiment (figure 2.3). All assays were run in triplicate. Validation 
experiments were run to show that the efficiencies of the target and reference genes 
amplifications were approximately equal, and in the range 95-105% (see chapter 3). The 
PCR cycle number that generated a fluorescence signal above a set threshold (threshold 
cycle, Ct; 10 standard deviations above the mean fluorescence generated during the 
baseline cycles) was determined, and a comparative Ct method was then used to 
measure relative gene expression (ABI PRISM 7700 User Bulletin #2,2001 update). 
The following formula was used to calculate the relative amount of the transcript in the 
sample: 2_AACt, where ACt is the difference in Ct between the gene of interest and the 
mean of at least two reference genes, and AACt = ACt of drug exposed cells minus ACt 
of control cells (exposed to medium only), for the ex vivo experiments, or AACt = ACt 
of post-chemotherapy sample minus ACt of pre-chemotherapy sample, for paired 
tumour biopsies.
Real time RT-PCR is a relatively new technique, and there is not yet a universally 
applicable method of data analysis, nor is there a means by which statistical significance 
can be estimated. Various groups have analysed their data in different ways, with 
differing levels of robustness. The data analysis methods used in this thesis were 
developed within our group, primarily by Surgeon Lt Cmdr SJ Mercer and myself, 
following assessment of methods recommended by real time PCR instruments, such 
Applied Biosystems and BioRad, and assisted by a critical appraisal of the literature. 
The details are described in Chapter 3.
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Table 2.6 Sequence o f  primers (forward and reverse) used for qPCR experiments. GenBank accession numbers for each gene are indicated in brackets. When 
no reference is indicated, the primers were designed using an old version o f  the software Primer 3.0, available at the follow ing website: http://www- 
genome.wi.mit.edu/cgi-bin/primer/primer3.cgi. Tm values were calculated using a demo version o f  the Beacon Designer Software (PREMIER Biosoft
Name
(GenBank
num.)
v  ^ 7*
Sequence 5’-3’ (forward and reverse primer)
Product
size(bp)
Product
Tm(°C)
Primer 
cone nM
Primer
Tm (°C)
MgJ+ 
cone mM Reference
GAPDH
(NM002046)
5’-GAA GGT GAA GGT CGG AGT C-3’ 226 86 200 62.3 4
5’-GAA GAT GGT GAT GGG ATT TC-3’ 200 58.3
HPRT1
(NM000194)
5’-TCA GGC AGT ATA ATC CAA AGA TGG T-3’ 84 84 400 61.3 4 Moniotte et al., 2001
5’-AGT CTG GCT TAT ATC CAA CAC TTC G-3’ 400 62.9
PBGD
(NM000190)
5’-CTG CAC GAT CCC GAG ACT CT-3’ 98 89
400 64.5 4 Van den Heuvel- Eibrink, et a l, 20025’-GCT GTA TGC ACG GCT ACT GG-3’ 400 64.5
SDHA
(NM004168)
5’-TGG GAA CAA GAG GGC ATC TG-3’ 86 81 400
62.4 4
Vandesompele et al., 
20025’-CCA CCA CTG CAT CAA ATT CAT G-3’ 400 60.8
TBP
(X54993)
5’-CAC GAA CCA CGG CAC TGA TT-3’ 89 85 400 62.4 4 Bieche et al., 19995’ Ttt tct tgc tgc cag tct gga c.3’ 400 62.6
BCRP
(AF098951)
5’-CAC AAC CAT TGC ATC TTG GC-3’ 74 82 400 60.4 4 Faneyte et al., 2002
5’-GCT GCA AAG CCG TAA ATC CA-3’ 400 60.4
COX-2
(M90100)
5 ’-CCT TCC TCC TGT GCC TGA TG-3’ 81 83
400 64.5 4 Sales et al., 2002
5’-ACA ATC TCA TTT GAA TCA GGA AGC T-3’ 400 59.7
DPD
(NM 000110)
5’-CCA AAG GCA GTA AAG CAG GAA-3’ 66 84 400
60.6 4 Blanquicett et al., 2002
5’-TCA CGA CTC CCC GTA TCG A -3’ 400 62.3
EGFR
(NM005228)
5’-TGG TCA AGT GCT GGA TGA TAG A-3’ 156 86 400 60.8 4
5’-GGT AGA AGT TGG AGT CTG TAG GA-3’ 400 62.7
ERCC-1
(NM001983)
5’-GGG AAT TTG GCG ACG TAA TTC-3’ 71 87
400 60.6 3 Lord et al., 2002
5’-GCG GAG GCT GAG GAA CAG-3’ 400 64.5
GST-7t
(NM000852)
5’-CGG AGA CCT CAC CCT GTA-3’ 169 90
400 62.2
5
5’-CGC CTC ATA GTT GGT GTA GA-3’ 400 60.4
Table 2.6 (continued). Sequence of primers (forward and reverse) used for qPCR experiments. GenBank accession numbers for each gene are indicated in 
brackets. When no reference is indicated, the primers were designed using an old version of the software Primer 3.0, available at the following website: 
http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi. Tm values were calculated using a demo version of the Beacon Designer Software (PREMIER 
Biosoft International, Palo Alto, USA).
Name
(GenBank
num.)
Sequence 5 ’-3’ (forward and reverse primer) Product
size(bp)
Product
Tm(°C)
Primer 
cone nM
Primer
Tm(°C)
Mg/+ 
cone mM
Reference
MDR1
(AF016535)
5’-TGG TTC AGG TGG CTC TGG AT-3’ 72 83 300 62.5 4 Yague et al., 20035 ’-CTG TAG ACA AAC GAT GAG CTA TCA CA-3’ 300 63.0
MLH-1
(NM000249)
5’-GGC ACA GCA TCA AAC CAA GT-3’
147 84 400 60.4 45’-GCA AGC ATG GCA AGG TCA A -3’ 400 60.2
MRP1
(L05628)
5’-CAA TGC TGT GAT GGC GAT G-3’ 70 83 400 60.2 4 Van den Heuvel- 
Eibrink, et al., 20025’-GAT CCG ATT GTC TTT GCT CTT CA-3’ 400 61.0
MRP2
(NM000392)
5’-TGC AGC CTC CAT AAC CAT GAG-3’ 80 84 400 62.6 3 Taipalensuu et al., 20015’-GAT GCC TGC CAT TGG ACC TA-3’ 400 62.5
MT-II
(NM005953)
5’-GAT CCC AAC TGC TCC TGC-3’ 127 90 400 62.2 45’-ACT TGG CAC AGC CCA CAG-3’ 400 62.2
MVP
(NMO17458)
5’-CAG CTG GCC ATC GAG ATC A -3’ 68 87 400 62.3 4 Van den Heuvel- 
Eibrink, et al., 20025’-TCC AGT CTC TGA GCC TCA TGC-3’ 400 64.5
TP
(NM001953)
5’-CCT TGG ATA AGC TGG AGT CT-3’ 107 87 400 60.4 4
5’-CCT ACT CTG ACC CAC GAT AC-3’ 400 62.4
TS
(NM001071)
5’-CCA GAG ATC GGG AGA CAT GG-3’
66 86 400 64.5 45’-TAC GTG AGC AGG GCG TAG CT-3’ 400 64.5
TOPO I 
(J03250)
5’-CTC CAC AAC GAT TCC CAG AT-3’ 149 86 400 60.4 35’-TTA TGT TCA CTG TTG CTA TGC TT-3’ 400 57.4
TOPO Ila 
(NM001067)
5’-GTA ATT TTG ATG TCC CTC CAC GA-3’ 223 85 400 61.0 35’-TCA AGG TCT GAC ACG ACA CTT-3’ 400 60.6
TOPO up 
(NM001068)
5’-GCA GCC GAA AGA CCT AAA TA-3’ 85 81 400 58.4 35’-AAT CAT TAT TGT CAT CAT CAT CAT C-3’ 400 56.4
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Figure 2.3 (a) Plate layout employed to study changes in gene expression after ex vivo exposure to doxorubicin in breast- and ovarian-tumour 
derived cells.
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Figure 2.3 continued, (b) Plate layout employed to study changes in gene expression after ex vivo exposure to topotecan in ovarian-tumour 
derived cells.
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Figure 2.3 continued, (c) Plate layout employed to study changes in gene expression after ex vivo exposure to irinotecan in colorectal-tumour 
derived cells.
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Figure 2.3 continued, (d) Plate layout employed to study changes in gene expression after ex vivo exposure to 5-FU in breast, upper GI and 
colorectal-tumour derived cells.
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COX-2 DPD GST-71 MDR1 MRP1 MT MVP TP TS
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Figure 2.3 continued, (e) Plate layout employed to study changes in gene expression in paired upper GI biopsies after in vivo administration o f  
Epirubicin+Cisplatin+5-FU (ECF). The same layout was also employed when oesophageal tumour derived cells were exposed to ECF in the 
ATP-TCA.
Chapter 3 - Technical development
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3.1 Introduction
A considerable amount of work has been carried out to establish or improve the 
methodologies described in chapter 2. This chapter summarises these efforts.
3.2 Further development of the ATP-TCA
Despite having great advantages over the other TCA methods, the ATP-TCA still 
suffers from some limitations, including: the number of cells required (a minimum of
10,000 cells/well which means a total of 180,000 cells is required to test each drug in 
triplicate at 6 different concentrations); the cost of reagents; the time to prepare the 
drugs and set up the plates.
A translation of the ATP-TCA from the current 96-well format to a 384-well format 
would have the advantage that it would reduce the amount of tumour material needed 
for the test and also the quantity (and costs) of reagents employed.
This approach was explored during the first part of my studies. The initial experiments 
were performed in 384 well polypropylene plates with flat bottom wells (Coming 
Costar, High Wycombe, UK) or V-shaped wells (Falcon, BD Biosciences, Oxford, UK). 
The first assays were carried out by plating tumour cells (usually spare cells from 
ovarian tumour ascites) without the drugs to establish the ideal number of cells under 
the new conditions. The results showed that the amount of ATP detected after 6 days 
incubation at 37°C and 5% CO2 was dependent on the number of cells originally plated. 
An example can be viewed in figure 3.1.
On the basis of such preliminary data the number of cells for 384 well plates was set up 
at 3,000 cells/well for ascites samples and at 5,000 cells/well for solid samples. This 
represents a quarter of the number of cells needed for the corresponding 96-well plate. 
The final incubation volume in each well of the 384-well plate was set up at 40 pi, 
consisting of 20 pi of cell suspension with the remaining 20 pi with medium only (MO 
or positive control), or medium containing drug(s) at the appropriate dilution, or 
maximum ATP-inhibitor (MI or negative control). The volumes of reagents required 
were therefore only 20% of those required to perform the assay in the 96-well format.
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Figure 3.1 ATP content o f  untreated ovarian tumour derived cells cultured for 6 days in 
polypropylene 96-well and 384-well plates.
To test the system, 4 ovarian adenocarcinoma samples were then tested in parallel in 
both plate formats (96 and 384-well) adding the drugs. These experiments generally 
produced erratic results in the 384-well format (figure 3.2). Furthermore, the percentage 
o f  variation among triplicates was higher in the new format, as shown in table 3.1.
Table 3.1 Difference in the coefficient o f  variation (CV) among triplicates in 96-well 
and 384-well plates (the results are shown in figure 3.2); * p<0.01 t student test
Mean values o f  % CV
96-well plate 384-well plate
Control (12 wells) 5.84% 23.4%
Cisplatin 9.04% 24.4%
Gemcitabine 7.13% 15.5%
Cisplatin + Gemcitabine 5.39% 17.6%
Doxorubicin x 5 7.40% 33.8%
M EAN 6.96% * 23.0% *
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Figure 3.2 ATP-TCA results obtained culturing ovarian tumour derived cells in a 384- 
well plate. Results shown are means (± SD) o f  triplicate values. Erratic results were 
obtained for this sample when the ATP-TCA was performed in a flat-bottomed 3 84-well 
plate compared to a standard 96 well plate.
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A robot suitable for application to 384-well plates was also employed (Kemble 
instruments, mod. SPI) and the cells derived from 3 ovarian adenocarcinoma ascites 
were simultaneously tested both in 96-well and 384-well plates, either by hand or by the 
machine. The use of the robot did not improve the accuracy of the assay in the 384-well 
format, giving CVs even higher than expected (table 3.2).
Table 3.2 Untreated tumour-derived cells were plated both in 96-well and 384-well 
plates, either by hand or by robot. The ATP content was inferred by measurement of 
light output, expressed as Relative light units (RLUs). Data represented are mean values 
of 12 replicates.
Plate format 96 Hand 96 Robot 384 Hand 384 Robot
RLUs mean 17572 13811 12349 15931
CV 4.20% 4.82% 22.7% 39.2%
During the second year of my PhD studies, better data was obtained by growing the 
cells in a new brand of 384-well plates that were introduced on the market (Coming 
Costar, Cat. N. 3656). These plates have rounded bottoms and rounded square-well 
geometry (Costar). The second feature, in particular, was a determining factor that 
improved the accuracy of pipetting. Figure 3.3 shows an example of ATP-TCA results 
obtained in a single 384-well plate for 12 agents or combinations. In this instance, the 
cells were obtained from a solid ovarian tumour by enzymatic digestion and plated at 
5,000 cells/well.
The cross-talk between wells was found to be generally greater than usually observed in 
the 96-well plates. To minimise this effect a new plate layout was designed (Figure 3.4) 
which included three consecutive rows of positive controls (MO), with the first and 
third one adjacent to the wells containing the lowest concentrations of cytotoxics.
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Figure 3.3 ATP-TCA results obtained culturing cells in a 384-well plate. Results shown 
are means o f  triplicate values. Error bars indicate SD, however in some cases these are 
not visible as they were smaller than the symbols on the graph.
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Figure 3.3 (continued). ATP-TCA results obtained after culturing the cells in a 384-well 
plate. Results shown are means o f  triplicate values. Error bars indicate SD, however in 
some cases these are not visible as they were smaller than the symbols on the graph.
The 384-well format has been employed to assess the chemosensitivity o f  12 samples (6 
uveal melanomas, 2 ovarian ascites, 2 ovarian biopsies, 1 unknown primary and 1 
oesophageal) and evaluable results were obtained in 11/12 cases (92%). The only failure 
was attributed to insufficient cell growth o f  the oesophageal biopsy, a specimen type 
which was found to produce evaluable results only in 60% cases when plated in the 
standard 96-well format (Mercer et a l, 2003).
In general, the tumours grown in the successful assays were very well digested, with 
little, i f  any, cell aggregates. A  source o f  variability between the 96- and 384-well plates 
could be the seeding density (Crouch & Slater, 2001). This might have affected my 
results, as well as the choice o f  the plate. Tumour derived cells are often aggregated in 
clumps, and the larger volume o f  cell suspension added to the 96-well plates compared 
to the 384-well plates (100 pi versus 20 pi) is likely to minimise the variation in cell
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number when the cells are plated. This was confirmed by the fact that in our laboratory, 
assays with the leukaemic CCRF-CEM cells produced highly reproducible results. 
Dissociation of tumour to a single cell suspension would involve greater loss of cells 
during their preparation, and would be counter-productive.
Another factor that increases variability of the assay could be the sensitivity of the 
detection system, but this is not likely to have influenced the results, as the ATP 
bioluminescence assay gave a CV of <3% for the replicate experiments using an ATP 
standard of 1 pM (Crouch and Slater 2001), and similar results are consistently seen in 
our laboratory when ATP standard curves are performed (chapter 2).
In conclusion, although partially positive results were obtained, the 384-well format is 
not recommended for routine use in the ATP-TCA with tumour-derived cells.
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Figure 3.4 A diagram representing the 384-wel plate layout.
33  Real time PCR development
33.1 Relative versus absolute quantitation of gene expression
Gene expression can be quantitated on a relative basis or an absolute basis. Absolute 
quantitation yields gene expression in terms of nanograms of mRNA, and requires that 
the absolute quantities of a standard be obtained by some independent means, such as 
the use of plasmid DNA or in vitro transcribed RNA. The concentration of the absolute 
standard is obtained by means of an ultraviolet spectrophotometer, and converted to the 
number of copies using the molecular weight of the RNA. Absolute mRNA quantitation 
is more expensive and more complicated than relative quantitation, and inaccuracy is 
introduced by the instability of RNA in solution.
Relative quantitation compares the expression of a target gene in a sample with the 
expression of a reference gene in that same sample (also known as a housekeeping gene 
or an internal control) and is particularly suited to RT-PCR which allows greater 
sensitivity by amplification of small amounts of mRNA. A reference gene is a gene 
whose expression is constant under all cellular conditions; its expression must not be 
affected by differences in temperature, pH or drug exposure. Use of a reliable reference 
gene allows normalisation of a number of variations that would otherwise introduce 
inaccuracies into the system (for instance, the amount of starting material, and 
differences between cells in overall transcriptional activity). It also avoids the 
requirement for post-PCR analysis of data to determine the exact mass of mRNA in the 
starting material.
In the experiments detailed in this thesis, relative quantitation of mRNA was performed 
using the standard curve method, in which target quantity is calculated from a standard 
curve graph and divided by the target quantity of the calibrator. This method requires 
the preparation and maintenance of an accurately diluted stock RNA solution; also, 
standard curves must be prepared for the reference gene and all target genes, with 
regular revalidation of all standards.
A development of this method for qRT-PCR is the use of the comparative Ct method 
(threshold cycle), in which an arithmetic formula is used to achieve the same result.
This means that, so long as the appropriate validation experiments have been carried 
out, the use of standard curves can be eliminated, and the amount of a target can be
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measured by the use of an equation (chapter 2), which includes the difference in Ct 
between target and housekeeping gene. Before using this method for quantitation of 
gene expression, a validation experiment must be performed to demonstrate that the 
efficiencies of the PCR reaction for target and reference are approximately equal. Once 
this has been proven, relative quantitation can be calculated without the requirement to 
run standard curves on the same plate.
3.3.2 Selection of appropriate reference genes
The selection of appropriate reference genes is critical to the accuracy of qRT-PCR 
when the comparative Ct method described above is used. If varying cellular conditions 
(such as pH or drug exposure) alter the expression of the reference gene, then any 
calculations made using that reference gene are invalid. Also, if the initial starting 
concentration of the reference gene is of a different order of magnitude to the target 
genes, this makes it less precise for the quantitation of those target genes. This is due to 
the mathematics of PCR; indeed, the BioRad iCycler instruction manual include tables 
that show how the different efficiency of the reaction can affect the accurate 
measurement of gene expression. For example, if a reference gene is detected 10 cycles 
earlier than the target gene, then even a 5% difference in efficiency between the 
amplification of the reference gene and the target gene would lead to an inaccuracy of 
0.36 cycles, equating to a 30% apparent difference in expression.
Investigators using qRT-PCR techniques have employed a number of different reference 
genes. One of the most commonly used is GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), an enzyme involved in glycolysis and gluconeogenesis. This gene has 
been used in a large proportion of studies using relative methods of quantitation, and is 
recommended for the optimisation of qRT-PCR techniques by some manufacturers 
(ABI PRISM 7700 User Bulletin #2,2001 update). However, there is increasing 
evidence that the expression of GAPDH is altered by a number of conditions, including 
drug exposure and mitogenic stimulation. GAPDH is also expressed to a relatively high 
level in the majority of cells, which makes it less accurate for the quantitation of genes 
with low expression levels (Vandensompele et ah, 2002).
Other groups have used the gene P-actin as a reference gene. However, this gene is 
expressed at an extremely high level in most cells, with a Ct of between 3 and 10, and
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as already demonstrated, large differences in Ct lead to inaccuracy in quantitation of 
low levels of target gene expression.
A possible solution has been published by Vandesompele et al. (2002). This involves 
the use of multiple reference genes to increase the accuracy and reliability of relative 
quantitation. They studied 10 different reference genes across a range of tissues, and 
assessed the constancy with which each was expressed. As expected, they demonstrated 
that the conventional use of a single gene for normalisation could lead to relatively large 
errors in a significant proportion of samples tested. However, by taking the geometric 
mean of multiple carefully selected reference genes, they were able to calculate an 
accurate normalisation factor. For these reasons, we initially selected three reference 
genes from the panel tested by Vandesompele et al. (2002): HPRT1 (Hypoxanthine 
Phosphoribosyl-Transferase-I); PBGD (Porphobilinogen Deaminase) and TBP (TATA- 
box Binding Protein). These three reference genes were included in every PCR 
performed for the work in this thesis. For some experiments (chapter 2), GAPDH or 
SDHA (succinate dehydrogenase complex, subunit A) were also included.
Primers for each of these reference genes were obtained and optimised (see Primer 
selection and optimisation, section 3.2.3). Further analysis of results from qRT-PCR 
enabled refinement of the selection. PBGD expression sometimes varied markedly from 
sample to sample, particularly following exposure to chemotherapeutic agents. Thus 
PBGD was eventually excluded from the data analysis, and the geometric mean of the 
remaining two reference genes was used as a normalisation factor (see data analysis, 
section 3.2.5).
33 3  Use of SYBR Green vs TaqMan™ probes
In qRT-PCR, target RNA is measured by the fluorescence of a DNA-binding dye or a 
sequence-specific fluorescence-labelled probe. Both methods were considered during 
the early stages of the experiments described in this thesis, and in particular the use of 
the SYBR Green intercalating dye or TaqMan™ fluorogenic labelled probes (chapter 2) 
was evaluated.
Each of these methods has its advantages and disadvantages. The SYBR Green method 
does not require the use of labelled probes, so assay set-up and running costs are
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reduced. Because it is non-specific, it measures the amplification of any double­
stranded DNA sequence. However, a TaqMan™ labelled probe only allows for specific 
hybridisation between the target sequence and the probe, which increases the specificity 
of the reaction and eliminates the requirement for post-PCR analysis and sequencing of 
the product. A further advantage of TaqMan™ methodology is the ability to label 
probes with different, distinguishable dyes, allowing amplification and measurement of 
two or more distinct target sequences in one reaction tube (multiplex PCR). The 
primary disadvantage of TaqMan™ methodology is that a different probe is required for 
the detection of each target sequence. Also, TaqMan™ is less sensitive than SYBR 
Green; this is because multiple DNA binding dyes can bind to a single amplicon in 
direct proportion to its length, whereas with a fluorogenic probe a single reporter dye is 
released from quenching for each amplicon synthesised, whatever its length.
Although the lack of specificity of SYBR Green represents a drawback, at the same 
time it has also the advantage of detecting non-specific amplification products, which 
can seriously affect the accuracy of measurements made using TaqMan probes. At the 
end of a fixed number of cycles of qRT-PCR, the reaction mixture contains a quantity 
of amplified cDNA product. If an intercalating dye such as SYBR Green is the detection 
dye, then a melt curve can be constructed. The thermal cycler is programmed to cool the 
reaction mixture to 50°C, which allows annealing of all complementary cDNA strands 
to each other; SYBR Green binds to double-stranded DNA and fluoresces, so at 50°C 
the SYBR Green fluoresces in proportion to its concentration. The temperature of the 
mixture is then raised by 1°C every 10 seconds, and the fluorescence measured again.
As the temperature increases, there comes a point at which the cDNA strands start to 
separate; strand separation prevents binding of SYBR Green dye, and the fluorescence 
reduces in proportion. The point at which 50% of strands are separated is the melting 
temperature (Tm), and at around this temperature there is a marked reduction in 
fluorescence as there is a high rate of strand separation. The temperature is raised in 
stepwise fashion to 95°C, by which time all strands will have separated, so fluorescence 
will be almost zero. A graph is then plotted of the first differential of fluorescence 
versus temperature; this gives the rate of change in fluorescence. A peak in this curve 
represents a temperature at which marked strand separation is occurring; usually, the 
peak representing the target amplicon will be at the predicted Tm of the PCR product. If 
there are other peaks in the melt curve, then other, non-specific sequences were also
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amplified in the reaction mixture. Thus the melt curve gives useful information about 
the specificity of the qRT-PCR reaction. Melt curves cannot be obtained using 
fluorogenic-labelled probes, because separation of the reporter dye from the TaqMan™ 
probe is an irreversible reaction.
The experiments in this thesis were performed using SYBR Green as the fluorogenic 
probe; TaqMan™ probes were used occasionally due to their specificity, mainly as a 
means of confirming the identity of the product amplified by a primer pair.
33.4 Primer selection and optimisation
Primer design was carried out using one of a number of computerised primer-design 
programs; Beacon designer 2.0 demo version (Primer BioSoft, Ca, USA) and an old 
version of the software Primer 3.0, (available at the following website: http://www- 
genome.wi.mit.edu/cgi-bin/primer/primer3.cgi/) were used for the development of 
primers in this thesis. The peer-reviewed literature was another source of primer 
sequences (Chapter 2, table 2.6). The set parameters for primer design were: length 
between 18-25 bases; similar annealing temperature, usually between 55°C and 60°C; 
content of guanine (G) and cytosine (C) between 40% and 60%. The size of the 
amplified target sequence was usually 70-200 base pairs, although longer amplicons 
have occasionally been used (Chapter 2, table 2.6). Whenever possible, primers were 
designed to cross exon boundaries; this makes the primers specific for cDNA rather 
than also annealing to genomic DNA. This was done by forcing the primer design 
software to find suitable primers in a specified region of the target sequence.
Once primers were designed, they were checked against the entire human DNA 
genome, using the BLAST computer program. If marked homology existed between the 
primers or the target amplicon and more than one site in the genome, this suggested a 
lack of specificity, and new primers were designed.
For each target, at least two primer pairs were designed, obtained and tested against 
pooled cDNA from a variety of human tumours, including breast, ovarian, colorectal 
and oesophageal carcinoma. Analysis of the peer-reviewed literature suggested that 
each of the target genes (table 2.6) might be reasonably expected to appear in each of
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these tissues, and the use of pooled cDNA from different tissue types made this 
assumption even more likely.
Salt-free purified primers were purchased from Qiagen Operon (Cologne, Germany) 
and reconstituted with DNase free water to give a 100 pM solution, which was stored at 
-80°C. Prior to experiments, primers were diluted to 1:10, usually mixing 15 pi of the 
100 pM solution with 135 pi DNase free water. The resulting diluted primers (10 pM) 
were stored at 4°C for a maximum of 2 weeks, after which they were discarded and 
fresh dilutions were prepared from the stock solution.
New primers were initially tested at a final concentration of400nM in the PCR, which 
also contained 4.0mM MgCh, 200pM each of dATP, dCTP, dGTP, 400pM dUTP, 
0.125 units AMPErase® uracil-N-glycosylase (UNG), 0.625 units of AmpliTaq Gold 
DNA polymerase and lx SYBR Green PCR buffer (SYBR Green PCR Core Reagents, 
Applied Biosystems, P/N 4304886). For each new pair of primers four reactions were 
performed, two wells containing respectively 1 pi and 0.25 pi cDNA (previously 
diluted), and two negative control wells containing water or RT-negative as a template. 
Due to the exponential amplification of DNA during the PCR, the tested 1:4 dilution 
should theoretically be detected 2 cycles later than the concentrated sample, while no 
fluorescence indicating the absence of non-specific products should be produced in the 
negative controls.
As an example, four different pairs of primers were designed for TOPO Ila and tested 
as described above.
141
(a)
3500035000
Topo Ila 
primers set 2, 
lp l cDNA
3000030000
25000 25000Topo Ila 
primers set 2, 
0.25pl cDNA 20000£ 20000
in
c  15000 15000
10000m 10000
50005000
Cycle Other primer sets for TOPO Ila
7000
TOPO Ila primers
sets 2, Tm=85.5°C6000
5000
4000
TOPO Ila primers
sets 1,3,4
3000
2000
1000
0
60 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96
Temperature, Celsius
Figure 3.5 (a) Amplification curve o f  new primer pairs for TOPO Ila. The presence o f  
an amplification curve indicates that the primers have detected the target; the slope o f  
the curve is an indication o f  the efficiency o f  amplification, (b) The shape o f  the melt 
curve demonstrates specificity o f  the primer pair, while the peak o f  the melt curve 
indicates the Tm o f  the product, which should correlate with that predicted by the 
design program.
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Table 3.3 Threshold cycle (Ct) values obtained during the evaluation of four different 
primer pairs for TOPO Ila. N/A indicates no amplification.
Primers for 
TOPO Ila c-DNA ljxl c-DNA 0.25pl
Negative
(water) RT-negative
Set 1 22.9 25.0 N/A N/A
Set 2 18.3 20.3 N/A N/A
Set 3 22.1 24.1 N/A N/A
Set 4 25.6 26.1 N/A N/A
Of the four set of primers tested for TOPO Ila, only one pair was selected, set 2, which 
amplified the target sequence earlier and more efficiently than the others (table 3.3; 
figure 3.5). None of the primer pairs designed for TOPO Ila resulted in primer-primer 
interactions as shown by single peaks measured during the melt curve analysis (figure
3.5 (b). However, some of the primers designed for other genes were discarded because 
of the formation of non specific products detected by a typical double-peak in the melt 
curve.
The selected primer pairs for each target were then tested in other experiments to find 
their optimal concentration for the amplification reaction. This was done concurrently
i
with other experiments aimed at determining the optimal Mg concentration.
Mg concentration is a crucial factor affecting the performance of PCR, because DNA
polymerase is inactive in the absence of adequate Mg2+. Many of the reaction
<•%
components can bind free magnesium, reducing the amount of free Mg ; however, 
excess free Mg2+ decreases DNA polymerase fidelity and increases the level of non- 
specific amplification. Thus there is an optimal Mg concentration for each primer pair.
The primer concentrations are also critical for the optimum efficiency of qRT-PCR. 
Inadequate primer concentration leads to low efficiency reactions, and a certain excess 
of primers is required for optimum efficiency. However, too high a concentration 
increases the incidence of non-specific annealing and primer-primer interactions, 
reducing the accuracy of the system.
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For each functioning primer pair, a qRT-PCR experiment was performed to find the 
optimum Mg2+ concentration and the optimum concentration o f  each complementary 
primer. This was done using a checkerboard design, in which 3 different concentrations 
o f  each variable were tested in every possible combination, using the same known 
quantity o f  pooled cDNA in each reaction well (table 3.4).
Table 3.4. Plate layout for the optimisation o f  primers. Each forward (+) and reverse (-) 
primers were tested at lOOnM, 200nM or 400nM with 3 different concentrations o f
Mg2+.
1 2 3 4 5 6 7 8 9 10
3mM Mg5’" 4mM Mg2i 5mM Mg5 r
A lOOnM + 
100 nM -
lOOnM + 
200nM -
1 OOnM + 
400nM -
lOOnM + 
100 nM -
lOOnM + 
200nM -
lOOnM + 
400nM -
lOOnM + 
100 nM -
lOOnM + 
200nM -
lOOnM + 
400nM -
-ve
control
B 200nM + 
100 nM-
200nM + 
200nM -
200nM + 
4OOnM -
200nM + 
100 nM-
200nM + 
200nM -
200nM + 
400nM -
2 OOnM + 
100 nM-
200nM + 
200nM -
200nM + 
400nM -
-ve
control
C 400nM + 
100 nM-
400nM + 
200nM -
4 OOnM + 
400nM -
400nM + 
100 nM-
400nM + 
200nM -
400nM + 
400nM -
400nM + 
100 nM-
400nM + 
200nM -
400nM + 
400nM -
30000
•25000
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■5000
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Figure 3.6 Amplification plot recorded during the optimisation o f  TOPO Ila primers. 
There is considerable variation in Ct for each o f  these options, and the checkerboard 
analysis allows the best to be chosen. The inset shows the corresponding melt curve.
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Figure 3.7 Melt curve recorded during the optimisation o f  TOPO Ila primers.
The PCR amplification plot and the melt curves (figures 3.6 and 3.7) were examined to 
determine which combination o f  primer concentrations and Mg2+ concentration 
demonstrated the highest efficiency. Figures 3.6 and table 3.5 show the amplification 
plot and the Ct results from one o f  such experiments using TOPO Ila primers set 2. It 
was concluded that a Mg2+ concentration o f  3 mM, with 5 ’- and 3 ’-primer 
concentrations o f  400 nM, had the highest efficiency in this system.
Table 3.5 Ct values o f  the TOPO Ila primer optimisation experiment performed 
according the plate layout shown in table 3.4. An optimal concentration o f  3 mM was 
chosen for Mg and both primers were used at a final concentration o f  400 nM in all 
following assays.
1 2 3 4 5 6 7 8 9 10
3mM Mg2+ 4mM Mg2+ 5mM Mg2+
A 29.6 33.0 30.0 27.9 27.1 26.9 28.3 25.8 25.8 N/A
B 32 25.5 24.5 27.8 25.2 23.4 24.7 24.5 22.2 N/A
C 25.9 22.4 21.2 24.2 22.1 21.2 22.8 21.8 21.4
145
3.3.5 Construction of a standard curve for each primer pair
Once the optimum reaction conditions for each amplification have been established, the 
efficiency of the primer pair must be calculated. This is done by making a series of 
dilutions of pooled cDNA, and testing them under the optimised reaction conditions. 
The resulting amplification curves yield a series of Cts that are plotted against the 
logarithm of the pooled cDNA concentration to give a standard curve for that particular 
primer pair. The ideal primer pair, with an efficiency of 100%, would lead to a doubling 
of the amplicon quantity during each PCR cycle; application of a mathematical formula 
to the slope of the standard curve yields a value for the efficiency of the primer pair.
Table 3.6 shows the PCR plate layout for an experiment to determine the efficiency of 
TOPO Ila primers; figure 3.8 (a) shows the resulting amplification plot, and figure 3.8 
(b) is a graph of the resulting standard curve. The slope of the curve is -3.333, which 
equates to an efficiency of 99.6% for this primer pair across a 4,000-fold dilution series.
Table 3.6 PCR plate layout employed when primers calibration curves were performed.
1 2 3 4 5 6 7 8
A lpl 1:4 1:16 1:64 1:256 1:1024 1:4096 -ve
B lp.1 1:4 1:16 1:64 1:256 1:1024 1:4096 -ve
C lpl 1:4 1:16 1:64 1:256 1:1024 1:4096
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Figure 3.8 (a) Amplification curve recorded during the amplification o f  1:4 serial 
dilutions o f  1 pi c-DNA using TOPO Ila primers, (b) A calibration curve in generated by 
a plot o f  the Ct values versus the amount o f  c-DNA (on a logarithmic scale).
Standard curves were generated for all the genes studied in this thesis (table 2.6) and the 
following efficiencies have been calculated: GAPDH 99%; HPRT1 98%; PBGD 101%; 
SDHA 100%; TBP 98%; BCRP 101%; COX-2 97%; DPD 100%; EGFR 100%; ERCC- 
1 101%; GST-pi 102%; MDR1 100%; MLH-1 106%; MRP1 99%; MRP2 95%; MTII 
98%; MVP 97%; TOPO I 100%; TOPO Ila 100%; TOPO Up 102%; TP 96%; TS 95%.
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3.3.6 Intra-assay and inter-assay variability
All qRT-PCR in this thesis were carried out in triplicate. This allows detection of the 
majority of pipetting errors and malfunctions in a single well in the qRT-PCR machine. 
For data analysis, the geometric mean value of the triplicate measurements was taken.
Tests of intra-assay and inter-assay consistency are an essential control to confirm the 
reliability and accuracy of qRT-PCR for the quantitation of mRNA expression. The aim 
of the intra-assay control was to confirm accuracy of pipetting of the microlitre volumes 
involved and to confirm consistency of measurement between wells in the PCR 
machine. The aim of the inter-assay control is to confirm reproducibility from day to 
day. Combined, these controls validate the technique for the reliable, accurate and 
reproducible measurement of mRNA expression on different samples on different days, 
as long as consistent conditions are employed throughout.
The qRT-PCR plate layout used for these experiments is shown in table 3.7. All 96 
wells of a plate were used. Twenty-one replicates of 4 reference genes were used as the 
targets, with equal concentrations of primers in each well. The remaining wells of the 
plate were used as template-negative controls.
Table 3.8 shows the results of these experiments. Exactly the same experiment was 
performed on 3 different days, and statistical estimates of intra-assay and inter-assay 
variability were calculated. There is minimal variation between points within each 
experiment. This indicates that taking the mean value of 3 triplicate measurements in 
experiments using tumour cells is an appropriately precise means of obtaining an 
accurate reading of mRNA expression in this system.
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Table 3 .7  P late layout u sed  for a sse ss in g  intra-assay and inter-assay variab ility
1 2 3 4 5 6 7 8 9 10 11 12
A -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve -ve
B GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRT1 PBGD PBGD PBGD TBP TBP TBP
C GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRT1 PBGD PBGD PBGD TBP TBP TBP
D GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRTi PBGD PBGD PBGD TBP TBP TBP
E GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRT1 PBGD PBGD PBGD TBP TBP TBP
F GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRTI PBGD PBGD PBGD TBP TBP TBP
G GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRTI PBGD PBGD PBGD TBP TBP TBP
H GAPDH GAPDH GAPDH HPRT1 HPRT1 HPRTI PBGD PBGD PBGD TBP TBP TBP
Table 3.8 Intra-assay variability was estimated by measuring the expression levels o f  
each reference gene in 21 reactions. Inter-assay variability was assessed by 3 repeats o f  
each experiment performed on 3 different days. The parameter ACt indicates the 
difference in threshold cycles between the Ct o f  GAPDH and the Ct o f  the other 
reference genes.
GAPDH HPRTI PBGD TBP
Exp 1 Mean 22.7 29.2 31.0 30.9
SD 0.19 0.31 0.44 0.29
CoV 0.85% 1.0% 1.4% 0.94%
ACt 0.00 6.52 8.34 8.19
Exp 2 Mean 22.5 29.0 30.8 30.7
SD 0.13 0.34 0.29 0.33
CoV 0.57% 1.2% 0.96% 1.1%
ACt 0.00 6.59 8.29 8.21
Exp 3 Mean 22.4 29.0 30.9 30.8
SD 0.16 0.32 0.40 0.36
CoV 0.70% 1.12% 1.29% 1.16%
ACt 0.00 6.60 8.53 8.40
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Figure 3.9 Intra- and inter-assay variability o f  qPCR. Each o f  the points represents the 
mean o f  63 reactions performed in 3 different days; the error bars represent 2 standard 
deviations on each side. The parameter on the y  axis represents the difference in Ct 
between HPRT1 and the other reference genes.
3.3.7 Data analysis
The technique o f  qRT-PCR is relatively new, and there are not yet any universally 
recognised methods o f  analysing the data, nor have tests o f  statistical significance been 
appropriately applied in the field. The peer-reviewed literature includes a number o f  
papers that attempt to use qRT-PCR data to compare gene expression between multiple 
samples; some o f  the methods used are questionable, and none include appropriate 
statistical analysis o f  the results. Therefore, in order to use the data generated by the 
experiments in this thesis, an in-house method o f  analysis was developed.
Before any data analysis was performed, the PCR amplification curves were inspected 
to confirm that the traces for the reference and target genes appeared as expected. The 
melt curves were also inspected to ensure that there was no non-specific amplification 
and that the Tm o f  each amplicon corresponded to that predicted by the primer design 
software. Figure 3.10 shows the traces o f  a single experiment that compared gene 
expression in breast tumour derived cells exposed to medium only (control) or 
doxorubicin. The plate layout has been shown previously in chapter 2 (figure 2.3, panel
a). The amplification plot demonstrates non-specific amplification or possible minimal
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contamination in one of the 24 negative control wells, and in particular the RT negative 
control for the MRP1 gene; however this signal appeared about 20 cycles later than the 
corresponding MRP1 traces in the sample wells (figure 3.11); moreover, the second 
negative control for this gene, the PCR negative (containing all the reagents, including 
primers and DNA polymerase, except cDNA) did not produce any trace, and therefore 
the results relative to MRP1 in this instance were still considered evaluable.
The final output of the BioRad iCycler PCR machine is a series of 96 numbers, accurate 
to 1 decimal place, corresponding to the Ct of the sample of each individual well. A 
template worksheet was created in Excel 2000 (Microsoft) to speed up the analysis of 
the qPCR data (figure 3.11). The PCR results can be copied directly from the PCR 
machine analysis software into the Excel template, which calculates the mean, the 
standard deviation and the coefficient of variation for each set of triplicate values.
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Figure 3.10 (a) Amplification plot and (b) melt curve analysis o f  a single 96-well 
experiment that compared gene expression in breast tumour derived cells exposed to 
medium only (control) or doxorubicin.
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TOPO TOPO TOPO
HPRT1 PBGD TBP BCRP COX-2 ERCC1 MDR1 MRP1 MVP I IIA IIB
1 2 3 4 5 6 7 8 9 10 11 12
22.2 26.7 23.8 29.2 19.3 24.3 28.7 22.2 21.9 19.4 22.7 19.8
Control 22.3 26.9 24 28.8 19 24.6 28.5 22.1 21.8 19 22.6 19.7
TCA cells 21.9 26.2 23.9 28.7 18.8 23.9 28.7 22.2 21.6 19 22.2 19.6
primers N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
RT neg N/A N/A N/A N/A N/A N/A N/A 43.1 N/A N/A N/A N/A
24.4 24.8 25.3 30.7 19.7 25 30.9 22.8 21.8 22.1 30.1 22
Doxo 24.5 25.3 25.6 31.9 20 24.7 31.4 22.7 22 22.2 30.6 22.1
TCA cells 24.6 25.5 25.7 30.8 20 25 31.5 22.8 22.1 22.3 30.6 22.3
Control 22.13 26.60 23.90
0.21 0.36 0.10
0.94% 1.36% 0.42%
Mean 24.21 28.90 19.03 24.27 28.63 22.17 21.77 19.13 22.50 19.70
SD 0.26 0.25 0.35 0.12 0.06 0.15 0.23 0.26 0.10
CoV 0.92% 1.32% 1.45% 0.40% 0.26% 0.70% 1.21% 1.18% 0.51%
D oxo 24.50 25.20 25.53
0.10 0.36 0.21
0.41% 1.43% 0.82%
Mean 25.08 31.13 19.90 24.90 31.27 22.77 21.97 22.20 30.43 22.13
SD 0.67 0.17 0.17 0.32 0.06 0.15 0.10 0.29 0.15
CoV 0.87% 0.70% 1.03% 0.25% 0.70% 0.45% 0.95% 0.69%
Calculations
ACt = Ct target - Ct [(HPRTl+PBGD+TBP)/3] 
AACt = ACt [Doxo] - ACt [Control]
Control 0.00 4.69 -5.18 0.06 4.42 -2.04 -2.44 -5.08 -1.71 -4.51
Doxo 0.00 6.06 -5.18 -0.18 6.19 -2.31 -3.11 -2.88 5.36 -2.94
AACt 0.00 1.37 || 0.00 -0.23 1.77 -0.27 -0.67 2.20 7.07 1.57
2A-AACt | ... . J  _ :j 0.39 [ 1.00 ! >■>« !| 0.29 | 1.20 |1 1-59 || 0.22 | 0.01 0.34
Figure 3.11 Template worksheet for qPCR data analysis. The data generated from the 
reaction shown in figure 3.10 were copied into an Excel 2000 spreadsheet which 
calculated the mean, SD and CoV for each set o f  triplicate values.
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The second step in data analysis was the inspection of each triplicate in turn. If the 
coefficient of variation (CoV) of the mean of a triplicate was greater than 1%, the raw 
data were examined for outliers; this allowed either exclusion of an outlier or 
acceptance of a CoV of greater than 1% for that particular triplicate. For instance, in the 
example shown in figure 3.11, one of the replicate wells for BCRP is judged to be an 
outlier and excluded from the final analysis.
Next, the mean Ct of the reference genes was calculated and normalised, and the mean 
Ct of each target gene was subtracted from this to give a ACt for each target gene 
(figure 3.11). This is a measure of the expression of each target gene relative to that of 
the reference gene, and can be represented graphically for each sample. Finally, the 
relative target gene expression in drug treated cells was calculated according to the 
equation 2_AACt, where AACt = ACt of drug exposed cells -ACt of control cells (exposed 
to medium only).
These relative values can then be represented graphically. There is currently no 
established way of representing real time PCR data graphically. While some published 
studies represented simple ACt values (van den Heuvel-Eibrink et al., 2002), others 
used undefined arbitrary units (Burger et a l , 2003) and many preferred a numerical 
description. As the comparative Ct method is used for the determination of relative gene 
expression, no absolute units can be given on the Y axis, and this is probably the reason 
underlying the lack of a conventional graphical representation of real time PCR data.
In figure 3.12 two graphics have been drawn to present the results of the reaction shown 
in figures 3.10 and 3.11. These graphics show the actual 2'AACt values, respectively 
plotted on a linear (a) or a Logl 0 scale (b).
In this thesis the results of the PCR assays that measured gene expression changes 
induced by cytotoxic drug treatment in each individual sample are represented by 
plotting the actual 2’AACt values on a logarithmic scale, as shown in figure 3.12-b.
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Figure 3.12 Graphic representations o f  AACt values calculated in the worksheet shown 
in figure 3.11. Both graphs show the actual 2'AACt values, plotted either on a linear (a) or 
on a logarithmic scale (b).
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When drug-induced changes are studied in more than one sample, the analysis can be 
more complicated. In most published studies, the measurement of gene expression 
levels among different samples is performed within one or few experiments. This is 
because most studies have investigated one or two target genes in reference to a single 
house-keeping gene, and therefore several samples could be processed in a handful of 
reactions. For the work described in this thesis only one sample was tested at any one 
time to obtain a molecular profile for multiple gene changes, rather than a single target. 
This fact, combined with the demonstration that the conventional use of a single gene 
for normalisation in relative real time PCR could lead to relatively large errors in a 
significant proportion of samples tested (Vandesompele et a l , 2002), persuaded us to 
use up to four house-keeping genes in any single reaction. To further increase the 
accuracy and reliability of relative quantitation, we decided to analyse the changes 
induced by anticancer drug exposure on housekeeping gene expression levels. During 
the course of the experiments it was noted that cytotoxic exposure did occasionally 
affect the expression of some reference genes. The reference gene most commonly 
affected by chemotherapeutic agents appeared to be PGBD, but some mathematical 
basis was required to confirm this. The literature contains no such search for the most 
reliable reference genes, the majority of papers simply rely on GAPDH or another gene, 
without validating its constancy in their system. This renders their results questionable.
The procedure employed to validate the use of housekeeping genes in tumour-derived 
cells exposed to doxorubicin is described below.
At the end of the PCR experiments shown in this thesis, all the results were entered into 
an Access 2000 database for further analysis. A list of all the mean Ct values of the 
house-keeping genes was obtained and a plot of these values recorded in 14 breast 
samples was drawn (figure 3.13; a). If the expression levels of each housekeeping gene 
in different tumour samples were constant, this plot would show three parallel lines. In 
the case of the 14 breast tumours analysed the yellow line indicating PBGD was not 
parallel to the other two housekeeping genes in at least two samples. Another graph was 
drawn, this time comparing the Ct values of control cells versus the Ct values of drug 
exposed cells for each individual housekeeping gene (figure 3.13; b). The data was then 
normalised to the control cells and the graph re-plotted (figure 3.13; c). Finally, the
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mean change in reference gene expression was calculated and plotted in a separate 
graph (figure 3.13; d), where the error bars represent 2 standard deviations on each side.
This demonstrates that although the expression of reference genes is sometimes affected 
by exposure to doxorubicin, HPRT1 and TBP exhibit less variation with respect to each 
other. Use of the mean value of HPRT1 and TBP as the normalising factor will 
minimise the errors introduced by inconsistency of the reference genes.
Similar plots of variation in housekeeping gene expression were obtained for the other 
cytotoxics. Table 3.9 lists the reference genes that produced the least variation for each 
drug in each tumour type; mean values (±2 SD) of the differences in the housekeeping 
gene expression between control and drug treated cells are also given.
Table 3.9 Housekeeping genes selected for the analysis of gene expression in 
tumour derived cells from different human cancers.
Drug
Tissue 
(n= number of 
samples)
Selected HK 
genes
Variation 
Mean ±2SD
Discarded
HK
gene(s)
5-FU Breast (n=13) HPRT1 & TBP -0.29 ±1.35 GAPDH,PBGD
5-FU Colorectal (n=10) HPRT1 & PBGD -0.17 ±1.00 TBP
Doxorubicin Breast (n=14) HPRT1 & TBP 0.04 ±0.89 GAPDH
Doxorubicin Ovarian (n=12) HPRT1 & TBP -0.32 ±0.86 PBGD
ECF(*) Oesophageal (n= 12) HPRT1 & TBP 0.53 ±2.94 PBGD
Irinotecan Colorectal (n=7) HPRT1 & TBP -0.31 ±0.58 PBGD
Topotecan Ovarian (n=10) SDHA&TBP -0.18 ±0.98 HPRT1,TBP
(*) ECF chemotherapy was administered in oesophageal cancer patients and 12 
paired biopsies - 6 before and 6 after treatment - were obtained from 6 patients.
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Figure 3.13 Analysis o f  house keeping gene expression levels in breast cancer cells 
exposed to doxorubicin in the ATP-TCA. The combination o f  HPRT1 and TBP was 
more consistently expressed than the other two. Panel d) shows the mean values (±2SD) 
o f  the differences in the housekeeping gene expression between control and doxorubicin 
treated cells.
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Figure 3.13 (continued). Analysis o f  house keeping gene expression levels in breast 
cancer cells exposed to doxorubicin in the ATP-TCA. The combination o f  HPRT1 and 
TBP was more consistently expressed than the other two. Panel d) shows the mean 
values (±2SD) o f  the differences in the housekeeping gene expression between control 
and doxorubicin treated cells.
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Following housekeeping gene analysis, all the ACt and AACt values were recalculated 
by using the mean only of the two reference genes that were shown to be less affected 
by a particular treatment in a determined tumour type. The data was entered into a new 
Access database and analysed on the basis of the variation of each target gene. As 
considerable heterogeneity of expression was found for most targets in all tumour types, 
the results were expressed as median values, rather than using means, which have 
statistical meaning only when the data follow a normal distribution.
As in the case of the individual experiments, a widely recognised way of displaying the 
data does not exist. The most straightforward graphic can be obtained by plotting the 
values of 2_AACt calculated for each tumour for the gene of interest, as shown in figure 
3.14 (a). However, this way of representing the data results in a plot that only shows 
how the levels of a certain gene are affected by a particular treatment. No information is 
given about the differential expression of that gene in the various tumour samples. This 
information can be displayed only when the actual ACt values are plotted (figure 3.14,
b), as any other method that employs AACt values will always show normalized data 
(i.e. the expression of the target gene is always ‘0’ or ‘ 1 ’). To allow a more 
comprehensive visualisation of the results in this thesis the parameter ACt has been 
plotted in those graphs that included more than one tumour sample (figure 3.14, b).
In conclusion, the new technique of qRT-PCR is extremely sensitive, highly specific 
and repeatable, has a wide functional range, and is able to provide robust quantitative 
data. These attributes make it the ideal investigative tool for quantitating low levels of 
expression of putative chemoresistance genes, and for detecting differences in 
expression caused by chemotherapy treatment ex vivo and in vivo. However, it should 
be noted that the sensitivity and quantitative capabilities of this technique can only be 
fully utilised following a considerable effort to optimise reagents, methodology and data 
analysis.
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Figure 3.14 Effect o f  doxorubicin on the levels o f  TOPO Ila in breast cancer cells tested 
in the ATP-TCA (n=14 samples), (a) Actual 2'MC‘ values; (b) 2'AC|, where ACt is the 
difference in Ct between TOPO Ila and the mean o f  two reference genes (HPRT1 and 
TBP, in this instance).
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Chapter 4 - Differential chemosensitivity of 
cutaneous melanoma cell lines and tumour 
derived cells
162
4.1 Introduction
4.1.1 Preclinical screening of anti-cancer drugs
Most anticancer agents that enter clinical trials are never approved for use, and in the 
majority of cases their development is aborted by insufficient anti-tumour activity in 
Phase II clinical studies rather than intolerable or unpredictable toxicity. The current in 
vitro drug screening panels used by the NCI (Monks et al., 1991) and by most 
pharmaceutical companies are composed of human tumour cell lines derived from 
multiple sequential in vitro subcultures of human tumour explants. In the NCI screening 
programme, the candidate drugs are tested for efficacy on 3 cell lines from a panel of 
60, representing all the major human cancers. Active compounds progress to be tested 
against a panel of human tumour xenografts in nude mice. If successful, the drugs enter 
phase I and phase II clinical trials.
The NCI-60 cell line panel is well characterised from a molecular standpoint and can be 
useful in identifying molecular determinants of in vitro sensitivity (Scherf et a l , 2000; 
Staunton et a l , 2001) or confirming putative molecular mechanisms of action of the 
compounds screened. The use of cell lines has also many other advantages. It is 
relatively inexpensive, and gives rapid, reproducible results. However, there are some 
disadvantages. Anticancer drug screening programmes work on the premise that in vitro 
drug sensitivity will correlate with in vivo performance (Phillips et a l 1990).
However, as is the case for all in vitro systems, these assays cannot account for the in 
vivo pharmacological determinants of antitumour activity. In contrast to human solid 
tumours, which often show low growth rates, cell lines consist of rapidly proliferating 
cells that grow reproducibly in culture. The convenience of rapidly growing cells in 
culture may have implications for their sensitivity to chemotherapy, as most anti-cancer 
agents preferentially target dividing cells. Even normal proliferating cells show 
enhanced sensitivity to anti-cancer drugs (Drewinko et a l , 1981; Dewys et a l , 1972). 
This is reflected in the response rates of rapidly proliferating cancers to anti-cancer 
drugs (Valeriote & van Putten 1975), but also applies to cell lines derived from tumours 
by selection for cells which grow rapidly in serum-containing cell culture. In addition to 
this, cell lines consist of a homogenous population, while most human tumours have 
many accumulated genetic and molecular abnormalities and display a high degree of 
phenotypic heterogeneity.
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Before the initiation of clinical trials new anticancer agents which are found to be active 
in vitro are then screened in vivo in human tumour xenografts grown subcutaneously in 
nude mice. However, most of these studies use tumour growth inhibition, not tumour 
shrinkage, as sufficient evidence of antitumour activity. These xenografts are not 
representative of the heterogeneous population of tumour cells of the human tumour 
from which they were derived. Considerable changes in chemosensitivity may occur 
when cells are brought from in vitro to in vivo conditions and vice versa (Tveit et al., 
1981). It is well known that the morphological and cell kinetic characteristics of the 
tumours change with subsequent passages (Kruczynski & Kiss 1993). In many cases, 
xenografts are selected to suit the putative molecular mechanism of the agent tested, the 
approach being one of proof of principle in an in vivo model rather than screening the 
new agent in a panel of clinically relevant and predictive models.
The use of ex vivo chemosensitivity testing of fresh tumour cells derived from clinical 
specimens has recently been suggested as an aid to anticancer drug development (Cree 
2003; Neale et al., 2000; see chapters 6,7,10). Tumour-derived cells have the distinct 
advantage of preserving the heterogeneity observed in human cancers, but this method 
has its drawbacks too. It is technically difficult and costly to obtain large numbers of 
tumour-derived cells. Cells derived from different tumours vary in their 
chemosensitivity (Hunter et a l, 1993; Cree et al., 1999; Neale et a l, 2001) and it is 
therefore difficult to compare experiments between tumours. The approach has some 
merit when considering which tumours may respond to a new drug, but is not suitable 
for screening large numbers of potential anti-cancer agents for activity (Cree & 
Kurbacher 1999).
4.1.2 The chemosensivity of cutaneous melanoma
Advanced malignant melanoma has a very poor prognosis. Systemic therapy, both 
adjuvant and treatment of disseminated (stage IV) disease, remains unsatisfactory, with 
response rates lower than 30% (Helmbach et a l, 2003). Chemotherapy is mainly 
ineffective and unsatisfactory in this tumour type because of the drug resistance that is 
characteristic of this disease and is either intrinsic or develops during chemotherapy 
(Helmbach et a l, 2001). Alternative treatment methods based on immunological 
principles are currently being developed but have shown limited efficacy. Thus 
chemotherapy continues to be the primary treatment method for disseminated melanoma
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and urgently needs to be improved. Regimens including treatment with DT1C are still 
widely used in malignant melanoma, though only a minority of patients achieve a long- 
lasting response and the overall survival is poor (Middleton et al., 2000).
Chemosensitivity testing studies with fresh melanoma samples have been undertaken to 
identify the minority of patients who are most likely to benefit from chemotherapy. The 
first reports Using the clonogenic assay found cutaneous melanoma to be highly 
chemoresistant in vitro, in keeping with the poor chemotherapeutic response observed 
in vivo (Salmon, 1984; Tveit et al., 1988). Some correlation of in vitro data with clinical 
response was also provided by Schadendorf et al. (1994) in a small group of 19 samples 
tested with a clonogenic assay. Another study used an agarose-based cell culture system 
and measured [3H]-thymidine incorporation as an indicator of cell growth (Marshall et 
al., 1992). In this paper the authors did not provide any clinical correlation, but showed 
considerable heterogeneity of chemosensitivity among different melanoma samples.
This heterogeneity of chemosensitivity and general chemoresistance were essentially 
confirmed in later studies performed with the ATP-TCA in both uveal (Myatt et al., 
1997) and cutaneous melanoma (Cree et al., 1999; Ugurel et a l, 2003). Neale et al. 
(1999) employed the ATP-TCA to develop and test the ex vivo activity of a novel drug 
combination, treosulfan plus gemcitabine, in uveal melanoma (Pfohler et al., 2003); this 
regimen is currently being clinically evaluated in cutaneous melanoma and ovarian 
cancer.
More effective chemotherapeutic regimens are needed for the treatment for metastastic 
melanoma. The ex vivo ATP-TCA has already shown the ability to predict the clinical 
activity of new combinations (Kurbacher et a l, 1997), but the availability of fresh 
tumour cells limits the number of drugs and combinations that can be tested. Therefore 
we started a pilot study aimed at investigating the chemosensitivity of a panel of human 
melanoma cell lines in the ATP-TCA, in comparison to that observed in human tumour 
samples. The ultimate goal was to select one or more cell lines, which - cultured under 
growth-limiting conditions - could be used as a model of human melanoma in molecular 
and chemosensitivity studies.
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4.2 Materials and Methods
Cell lines and tumours. Six melanoma cell lines (M l4, MALME-3M, RPMI-7951, 
UACC-62, SK-MEL-2 and SK-MEL-28) were grown in RPMI-1640 medium (Sigma 
R7638) supplemented with 10% FCS (Labtech International, East Sussex, UK, cat. 4- 
101-500), 100 IU/ml penicillin and 100 pg/ml streptomycin (Sigma P0781), and 2 mM 
glutamine (Sigma G7513), as detailed in section 2.3. The chemosensitivity of the cell 
lines was assessed and compared to previous data available from chemosensitivity tests 
performed on 56 skin melanomas (31M:25F, patient median age 54 years, range 30-87).
ATP-TCA. Chemosensitivity testing of cell lines was performed in RPMI-1640 medium 
supplemented with either 10% FCS or 2% FCS (section 2.3.2) according to the standard 
protocol described in section 2. At least three experiments for each cell line were carried 
out in media containing 2% FCS and four cell lines (MALME-3M, RPMI-7951, SK- 
MEL-2 and SK-MEL-28) were also tested in medium containing 10% FCS. Finally, 
three experiments for the cell line SK-MEL-28 were also performed in CAM (DCS). 
Nine single agents were tested for each cell line, CDDP, DTIC, gemcitabine (Gem), 
interferona-2b (IFNa-2b), paclitaxel (Tax), temozolomide (Temo), treosulfan (Treo), 
vinblastine (VinB), vinorelbine (VinR), and one combination, treosulfan plus 
gemcitabine (Treo+Gem) (Neale et al.9 1999). The TDC of IFNa-2b was 1000 IU/ml, 
while all other cytotoxics were tested at the concentrations previously indicated (table 
2.2, chapter 2).
Data analysis. The percentage cell growth inhibition in the presence of various 
concentrations of FCS was calculated as follows:
[ 1 -  fa/oFC S) (Aff) i jqq _ p ercent cejjs grOWth inhibition 
1 (l 0%FCS) -  (Ml) 1
(X % FCS) = mean counts for wells containing cells grown with X % FCS
(MI) = mean counts for maximum inhibitor wells
(10% FCS) = mean counts for wells containing cells grown with 10% FCS
Chemosensitivity results were expressed as IndexsuM (MEAN±SD) calculated by the 
direct addition of the % survival at each concentration (section 2.2.19); this parameter
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was preferred to other values, such as IC90 and IC50, as it was previously found that a 
natural logarithmic sum index provides the best discrimination between drugs and 
tumour samples to show the heterogeneity of the activity observed (Hunter et al., 1993; 
Andreotti et al., 1995; Konecny et al., 2000). For the purposes of comparison between 
drugs and tumours, an IndexsuM of <300 was taken as ex-vivo sensitivity and >350 as 
resistance, as previously published (Hunter et al., 1993; Cree et al., 1999). Values 
between these two points were regarded as equivocal. An arbitrary cumulative 
chemoresistance index was also calculated for each cell line summing the means of the 
IndexsuM values for the twelve agents tested; the higher the index, the more resistant is 
the cell line in question.
4 3  Results
43.1 Measurement of cell line growth in different FCS concentrations
The first series of assays were carried out by growing the cell lines in RPMI-1640 
supplemented with 10% FCS. The cell lines were found to be extremely chemosensitive 
under these conditions, and no typical drug response curves were obtained for most 
agents, the curves having a fiat rather than a sigmoidal shape.
The hypothesis that the high chemosensitivity was due to a rapid growth rate of the cell 
lines In the presence of 10% FCS led me to perform experiments with various FCS 
concentrations without drugs to establish the minimum concentration of serum required 
for the growth of each cell line (figure 4.1).
A second series of experiments was carried out culturing the cells in RPMI-1640 
supplemented with 2% FCS, as at this level cell growth rate was substantially 
diminished, but evaluable readings (luminescence equal to or greater than the 
luminescence produced by 1.86 nM ATP in the standard curve; section 2.2.16) were . 
still obtained.
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Figure 4 .1 Cell growth inhibition was evaluated in the presence o f  various 
concentrations o f  FCS in the (a) MALME-3M, (b) RPMI-7951, (c) SK-MEL-2 and (d) 
SK-MEL-28 cell lines. Data is represented as Mean±SD o f  at least three experiments for 
each cell line.
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43.2 Chemosensitivity of melanoma cell lines
As expected, the cell lines showed heterogeneity o f sensitivity to the agents tested (table 
4.1). One cell line, RPMI-7951, appeared to be particularly sensitive to all the 
cytotoxics and therefore had the lowest cumulative index (table 1.4; figure 4.2). Based 
on this parameter, the most resistant cell line was SK-MEL-2, followed by the 
MALME-3M and the SK-MEL-28 lines (figure 4.2).
The most effective single agents in all cell lines were paclitaxel and gemcitabine, while 
in tumour-derived cells, both these drugs showed a mean IndexsuM in the resistance 
range (>350). The combination of treosulfan with gemcitabine was extremely active in 
all the cell lines and at both concentrations of FCS tested (figure 4.3); it also showed 
good cytotoxicity in the series of melanomas studied. However, while all cell lines 
grown in serum showed an IndexsuM less than 100, the mean IndexsuM value for this 
combination in tumour samples was 226+125, suggesting considerable heterogeneity. It 
is notable that sensitivity indices similar to those found for both gemcitabine and 
Treo+Gem in tumour-derived cells were obtained when the SK-MEL-28 line was grown 
in serum-free CAM (IndexsuM= 312+32 and 219+15, for GEM and TREO+GEM, 
respectively) (figure 4.4).
The vinca alkaloids were extremely active in all cell lines, while tumour samples were 
usually resistant, in particular to vinblastine. It must be noted that considerable 
heterogeneity was found in melanoma biopsies, and a number of tumours were found to 
be sensitive to the microtubule-active agents. The decrease of serum in the culture 
medium did not significantly affect the chemosensitivity to the vinca alkaloids in the 
SK-MEL-28, MALME-3M and RPMI-7951 lines. However, a moderate increase in 
resistance was observed in the SK-MEL-2 cells when the concentration of FCS was 
reduced to 2% (figure 4.3).
The activity shown by the alkylating agents DTIC and temozolomide was rather 
disappointing. DTIC was active only in the UACC-62 cell line (table 4.1); however the 
MALME-3M and RPMI-7951 also exhibited sensitivity to this agent when cultured 
with 10% FCS (figure 4.3). The M l4 were the most resistant cells (table 4.1) with a 
mean sensitivity index a little lower than the corresponding value calculated in the
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tumour series. Temozolomide was consistently the least active drug in both the series o f  
tumour samples and the panel o f  cell lines (table 4.1).
Variable sensitivity was observed with the other two DNA damaging agents tested, 
CDDP and treosulfan. In the group o f  skin melanomas, treosulfan was on average more 
active than CDDP, while in the cell lines the activity o f  CDDP was similar, i f  not 
superior, to that o f  treosulfan. Interestingly, the line SK-MEL-2 was rendered more 
resistant to both agents by lowering the serum concentration (figure 4.3). The SK-MEL- 
28 cells, in contrast, showed little or no change in sensitivity to either CDDP or 
treosulfan when tested in 2% FCS (figure 4.4). However a significant increase in 
resistance to these drugs was found when the SK-MEL-28 cells were grown in serum- 
free CAM (figure 4.4). Thus the IndexsuM for CDDP increased from a mean value o f  
210±23 to 456±20 (p<0.0005, unpaired t test), and the IndexsuM for treosulfan from 
344±23 to 456±38 (p<0.02, unpaired t test).
Cumulative sensitivity IndexSuM 
Tumour samples 4343
SK-MEL-2 3181
MALME-3M 2603
SK-MEL-28 2492
M 14 2295
U ACC-62 2045
RPMI-7951 1627
Resistance
Sensitivity
Figure 4.2. Cumulative sensitivity IndexsuM values that were calculated summing the 
means o f  the IndexsuM for all the agents tested in each cell line in the presence o f  2% 
FCS.
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Table 4.1 Summary of the chemosensitivity IndexsuM values expressed as mean±SD. Cell lines were grown in standard RPMI-1640 containing 
2% FCS; while tumour samples were cultured in serum-free CAM. Abbreviations are listed in section 4.2.
Sample DRUGS
(Number of assays) CDDP DTIC Gem IFNa-2b Tax Temo Treo Treo+Gem VinB VinR
M14 138 499 19 434 34 832 153 11 72 103
(n=3) (±47) (±69) (±12) (±282) (±12) (±146) (±78) (±5) (±31) (±56)
MALME-3M 236 360 99 519 100 598 327 66 144 154
(n=6) (±77) (±99) (±49) (±94) (±41) (±156) (±33) (±27) (±30) (±27)
RPMI-7951 45 313 11 438 6 667 101 5 27 14
(n=4) (±39) (±111) (±3) (±42) (±3) (±140) (±18) (±2) (±28) (±3)
SK-MEL-2 424 384 162 458 50 742 402 72 248 239
(n=5) (±48) (±20) (±23) (±63) (±14) (±107) (±39) (±26) (±66) (±64)
SK-MEL-28 210 318 128 485 100 516 344 91 147 153
(n=3) (±23) (±34) (±22) (±22) (±17) (±10) (±39) (±12) (±41) (±56)
UACC-62 220 266 51 404 15 454 260 47 162 166
(n=3) (±146) (±22) (±46) (±164) (±12) (±66) (±99) (±37) (±165) (±142)
Tumour samples 429 563 403 502 358 614 347 226 527 374
(n=56) (±126) (±96) (±176) (±139) (±131) (±195) (±139) (±125) (±205) (±182)
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Figure 4.3. Chemosensitivity indices calculated from the ATP-TCA performed in 
RPMI-1640 medium containing 10% or 2% FCS. Data is represented as mean±SD o f  at 
least three experiments for each cell line, MALME-3M (a) and RPM I-7951 (b).
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Figure 4.3 (continued). Chemosensitivity indices calculated from the ATP-TCA 
performed in RPMI-1640 medium containing 10% or 2% FCS. Data is represented as 
mean±SD o f  at least three experiments for each cell line, SK-MEL-2 (c) and SK-MEL- 
28 (d).
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Figure 4.4. Concentration-inhibition curves for the SK-MEL-28 cell line grown in 
serum-free CAM (a); 2% FCS -  RPMI-1640 medium (b); 10% FCS -  RPMI-1640 
medium (c). Data are represented as mean±SD o f  at least three experiments.
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4.4 Discussion
The results show that melanoma cell lines tested against cytotoxic drugs at standard 
10% FBS concentrations are much more sensitive to certain classes of anti-cancer agent 
than tumour-derived cells. One cell line, RPMI-7951, appeared to be particularly 
sensitive to all the cytotoxics. This is reflected by the rapid growth rate of these cells 
that required passaging every two days and remained viable even in serum-free culture 
media. Three cell lines, namely SK-MEL-2, SK-MEL-28 and MALME-3M, grown in 
the presence of reduced serum levels, exhibited a lower chemosensitivity that, at least 
for certain drugs, resembled the chemosensitivity of clinical samples. In particular, pilot 
experiments with the SK-MEL-28 in serum-free CAM suggested that this might provide 
even better congruity between cell lines and tumour-derived cells than reduced serum.
A literature search revealed only one previous study on the same subject (Marshall et 
al., 1992), which however used the [3H]-thymidine incorporation method and not a cell- 
death based assay. Although the results are not directly comparable, these investigators 
also found that the chemosensitivity of two established melanoma cell lines (MM-96 
and FME) was comparable to that exhibited by at least some fresh tumour biopsies. The 
results presented in this chapter also partially confirm data that were published over 20 
years ago by Drewinko et al. (1981) using the clonogenic assay. This group found that 
several anticancer drugs, including doxorubicin, 5-FU and vincristine, were more 
cytotoxic to S-phase colon carcinoma cells compared to cells in a phase of stationary 
growth. However, this early study did not use a cell death based assay, and did not 
provide any comparison with the chemosensitivity of fresh tumour derived cells.
As expected, some heterogeneity of chemosensitivity was noted between the cell lines, 
although this was not true for some of the drugs tested.
Among the single agents, the activity of DTIC and temozolomide was rather 
disappointing in all the cell lines. DTIC requires metabolism by cytochrome P450 
(CYP450), primarily by the isoforms 1 Al (extrahepatic) and 1A2 (hepatic) (Reid et al., 
1999), to form the reactive N-hydroxylated metabolite, 5- [3 -hydroxymethy 1-3-methyl- 
triazen-1 -yl]-imidazole-4-carboxamide (HMMTIC), ultimately forming the methylating 
species 5-(3-methyltriazene-1 -yl)imidazole-4-carboxamide (MTIC) which is 
responsible for cytotoxicity. In this process, MTIC itself is decomposed to the major
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plasma and urine metabolite 5(4)-aminoimidazole-4(5)-carboxamide (AIC) and the 
reactive species methane diazohydroxide, which produces molecular nitrogen and a 
methyl cation believed to be the methylating species (Tsang et al., 1991; Long & Dolan 
2001). The cytotoxicity of MTIC is thought to be primarily due to alkylation at the O6 
position of guanine and N position of adenine. An early study (Tsang et al., 1991) that 
investigated the in vitro cytotoxicity of DTIC, MTIC and temozolomide in TLX5 
murine lymphoma cells found that DTIC was only active in the presence of exogenous 
CYP450; whereas MTIC and temozolomide were cytotoxic even in the absence of 
mouse liver microsomes. This raises the possibility that a lack of bioactivation in 
melanoma cells could be responsible for the poor activity observed by DTIC. However, 
over the last decade, most human tumours were found to express several isoforms of 
CYP450, namely 1 A, IB, 2C, 3A, 2D (Patterson & Murray 2002). CYP450 enzyme 
expression patterns were also determined for the NCI cell 60 panel (Yu et al., 2001) 
using a series of enzymatic assays. This study found that the melanoma cell line SK- 
MEL-2 was the most active of the entire NCI60 panel in the assay that determined 
CYP1 Al activity; the SK-MEL-28 and UACC-62 cells were also found to be active; 
while the enzyme activity was below the limits of detection in the M14 cell line, which 
was also the least sensitive line to DTIC in our panel. Therefore it seems likely that 
most tumour cells have enough CYP450 to activate DTIC; in the case of Ml 4 cells, the 
undetectable CYP1 Al activity might be one factor explaining the poor activity of 
DTIC, though this hypothesis needs to be explored in further studies.
Temozolomide has been proposed as an alternative agent to DTIC in the treatment of 
advanced melanoma (Agarwala & Kirkwood 2000) due to its penetration into CNS, and 
therefore its potential activity in treating brain metastases. Temozolomide was the least 
active drug in both the series of tumour samples and the panel of cell lines. No 
heterogeneity of chemosensitivity to temozolomide was noted in the melanoma 
specimens that were all extremely resistant to this drug (INDEXsum>400). 
Temozolomide is an imidazotetrazine alkylating agent which is stable at acid pH, but 
undergoes chemical conversion at physiological pH to the active species 5-(3- 
methyltriazene-l-yl) imidazole-4-carboxamide (MTIC). The instability of 
temozolomide and its active metabolite at physiological pH could account for the poor 
cytotoxicity observed in our samples. Previous studies have shown that MTIC is 
unstable in human plasma at 25°C with a half life less than 30 minutes (Kim et a l,
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1997). In another study the same group found that almost all of the temozolomide was 
converted to AIC after 45 minutes of incubation at 37°C in human plasma (Kim et al.,
2001); while at 4°C the decomposition rate was slower, a substantial 30% of 
temozolomide was converted to AIC after 120 minutes. Although every precaution was 
taken while preparing the solutions of the cytotoxic drugs (diluting temozolomide last in 
ice-cold medium), the time required to set up the plates before the addition of the cells 
often exceeded 30 minutes. Thus it is possible that the cells were only exposed to a 
minimal fraction of the initial drug concentration, and for an extremely short time.
Most importantly, it can be suggested that temozolomide and DTIC showed reduced 
cytotoxicity due to DNA repair mechanisms present in these melanoma cell lines. The 
first cellular line of defense to the cytotoxicity elicited by these two agents is provided 
by the enzyme MGMT (see chapter 1.2.6), that removes 0 6-methylguanine adducts 
caused by DTIC and temozolomide. The level of MGMT varies depending on cell type 
(Irving & Hall, 2001). It is possible that the melanoma cell lines used in this study show 
a particularly high expression of this enzyme able to confer resistance to methylating 
agents. This might be the case of the SK-MEL-28 line, as recently reported by Pepponi 
et al. (2003). However the same study also reported a high sensitivity of M14 cells to 
temozolomide in the MTT assay which correlated with their modest MGMT enzymatic 
activity. This is in contrast with our findings that M l4 cells were the least sensitive to 
both DTIC and temozolomide.
A second possible mechanism of resistance to DTIC and temozolomide is represented 
by loss of MMR (Liu et al., 1999). In fact, after saturation of MGMT, any remaining 
0 6-methylguanine adducts may then be detected by the MMR system, leading to cell 
death. For cells with proficient MMR, high MGMT levels prevent the cytotoxic effect 
of methylating agents by removing all 0 6-methylguanine adducts, and inhibition of 
MGMT sensitizes the cells (Middleton et al., 2000; Pegg, 2000). Loss of a functional 
MMR system and its detector function allows the cell to resist the cytotoxic barrage and 
continue to divide whilst accumulating 0 6-methylguanine residues. These can in turn 
accelerate the rate of accumulation of mutations as they can result in GC->AT 
transitions. Of the cell lines used in this study, data on the MMR status have been found 
only for the SK-MEL-28 and M14 cells, both of which were shown to have a proficient
177
MMR (Pepponi et al., 2003); therefore, at least for these two lines, our results cannot be 
explained by a loss of MMR.
The largest differences between cell lines and tumour-derived cells were seen with 
spindle-active agents (paclitaxel, vinblastine) and with gemcitabine. The apparent high 
activity of gemcitabine was also been noted is some tumour samples, and in these cases 
the dose-response curve appeared as a flat line. Some recent work by Peters’ group in 
Amsterdam (Van Moorsel et al., 2000 & 2003) has shown that gemcitabine could alter 
the ribonucleotide pools in various cell lines; however a similar range of gemcitabine 
concentrations to those used in the ATP-TCA, produced an increase of ATP, rather than 
diminishing its levels. Therefore the decreased amounts of ATP measured in the ATP- 
TCA after gemcitabine exposure are unlikely to be caused by this ribonucleotide 
perturbation effect.
The results show that melanoma cell lines tested against cytotoxic drugs at standard 
10% FCS concentrations are much more sensitive to certain classes of anti-cancer agent 
than tumour-derived cells. To some extent this lack of relevance can be reversed by 
lowering the serum concentration, and hence the proliferation rate of the cells. While 
this produces greater apparent relevance for most of the cell lines examined, some 
appear more suitable than others for chemosensitivity studies. On the basis of the results 
presented in this chapter, the SK-MEL-2, MALME-3M and SK-MEL-28 lines should 
be included in an optimised panel of cell lines used for anti-cancer drug screening.
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Chapter 5 - The ex vivo chemosensitivity profile 
of retinoblastoma
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5.1 Introduction
Retinoblastoma (RB) is the most common primary intraocular tumour in children, with 
an incidence of 1 in 15,000-20,000 live births (Finger et a l , 1999). More than 90% of 
cases are diagnosed before 5 years of age, and presentation of RB in adults is rare 
(Biswas et a l , 2000).
Successful treatment of RB has traditionally depended on surgery and external beam 
radiation therapy, which is associated with significant short and long-term morbidity 
(reviewed in Wilson et at’, 2001). Recently, multiple studies have been published 
reporting initial experiences with an association of systemic chemotherapy and focal 
methods as primary treatments for this type of cancer (Shields & Shields, 1999; 
Friedman et a l , 2000).
Chemotherapy is used in RB as adjuvant therapy to control intra-ocular tumour growth 
with or without radiation, to prevent the growth of metastases and to treat metastatic 
disease once this has become clinically apparent (Gallie et a l , 1996; Kingston et a l, 
1996; Gunduz et a l, 1998). Current regimens are based on empirical drug combinations 
derived from neuroblastoma treatments (Gobie et a l, 1990; Kingston et a l, 1996). Few 
clinical trials have been conducted due to the rarity of this tumour and the difficulty of 
funding such trials. The current regimens in use tend to use carboplatin, vincristine, 
thiotepa, etoposide or doxorubicin.
Metastasis is rare following adjuvant therapy, but potentially devastating. There is a 
need to design less toxic, but equally or more effective regimens with a low risk of 
mutagenesis that might avoid the development of second malignancies (Tucker et a l, 
1987). This is a particular problem for some alkylating agents, such as 
cyclophosphamide, (which has been used in RB) and etoposide, which is associated 
with an increased risk of leukaemia (Felix, 1998). Etoposide is still widely used in RB, 
though at a dose not expected to cause problems (Shields et a l, 1997). Although there is 
a feeling that more retinal tumours may develop in patients treated with chemotherapy 
(Shields CL, personal communication), there is as yet no evidence of an increase in 
chemotherapy induced malignancies in RB patients.
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A small number of studies have investigated in vitro drug resistance in RB, and these 
have mainly used cell lines (in particular the Y79 and WeriRbl cells) (Chan et al., 1989 
& 1991; Giuliano et al., 1998; Di Felice et al., 1998). The isolation of tumour-derived 
cells from RB samples is technically challenging, as these tumours tend to be rather 
small and necrotic or calcified. Until 2003, there were only two reports of 
chemosensitivity testing in human RB tumours (Chan et al., 1989; tnomata et al., 1997). 
Both studies used the clonogenic assay, which measures colony forming capacity and 
has therefore a cell growth endpoint (section 1.3). Chan et al. did not test fresh tumour 
cells; cells were passaged through immunodeficient mice before the assay, probably to 
generate the large number of cells required to perform this type of assay. This study 
found resistance to methotrexate in nearly all samples, while good sensitivity was noted 
for the other cytotoxics tested, which included etoposide, vincristine, 
cyclophosphamide, melphalan, DTIC, cisplatin, doxorubicin and cytarabine. The second 
study by Inomata et al. employed fresh tumour-derived cells, and did not confirm the 
findings from the previous report. All samples in the Inomata series were sensitive to 
melphalan, and a proportion was sensitive to doxorubicin and cisplatin, while 
vincristine, 5-FU, DTIC, methotrexate and cytarabine did not influence cell growth.
In the period 2001-2003 two new studies appeared on the subject (Schouten-van 
Meeteren, et al., 2001; Di Nicolantonio et a l, 2003), both of which employed cell death 
assays, the MTT and ATP assays respectively, to investigate the chemosensitivity 
profile in fresh RB cells. The results of the study based on the ATP assay are reported 
here.
5.2 Materials and Methods
Tumour. Material from ten untreated primary RBs (2M:8F, patient median age 5 
months, range 2-36 months) and one skin metastasis from a primary tumour that was 
not required for diagnosis and further genetics research at St Bartholomew’s hospital 
was obtained. Of these samples only 6 primary tumours and the metastasis contained 
sufficient viable cells.
ATP-TCA. Cells were obtained from the tumours either by mechanical dissociation 
with a Pasteur pipette or by a gentle enzymatic digestion, usually 75 pg/ml collagenase 
for 2 hours. Viable tumour-derived cells were separated from dead cells and debris by
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density centrifugation (Histopaque 1077-1, Sigma), washed, counted and resuspended 
to 100,000 cells/ml. The cells were used to set up ATP-TCA plates as described in 
section 2.1 (Andreotti et a l , 1995). Not all drugs were tested in all samples.
5 3  Results
The ATP-TCA was performed successfully in 7/11 samples giving an assay evaluability 
rate of 64%. In two cases no viable cells were obtained after collagenase digestion, and 
in the remaining two the cells did not survive the incubation period.
The results showed very high sensitivity to single agents, particularly cisplatin, 
doxorubicin and vinca alkaloids (table 5.1). The shape of the inhibition curves is 
interesting. In most cases there was a plateau effect with etoposide and vinblastine, 
which was not present with cisplatin (figure 5.1, panels a,b,e).
Of the anti-metabolites tested, 5-FU was relatively disappointing (though still active), 
and gemcitabine showed considerable activity consistent with a cytotoxic effect (figure 
5.1, panels c-d).
One tumour, indicated as case 3, was much more resistant than the others tested 
particularly to vinblastine, but also to the topoisomerase inhibitors which failed to 
achieve complete kill at any concentration tested. This may represent overexptession of 
MDR1 by a proportion of the cells present, but no further tissue has been available to 
check this using immunohistochemistry.
O f the combinations (VAC and VEC), the VAC regimen looks marginally more active 
in the more resistant of the two cases tested.
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Table 5.1 Median values for AUC, IndexsuM, IC90 and IC50 calculated for the 
cytotoxics tested in 7 RB samples. For the combinations the values marked with (*) are 
expressed as percentage of TDC. Where the inhibition exceeded 50% even at the lowest 
concentration of drug used, the IC50 was extrapolated using the formulas indicated in 
the Appendix.
Abbreviations are VEC = vinblastine + etoposide + cisplatin; VAC = vinblastine + 
doxorubicin + cisplatin.
Drug IndexAUC IC90 pM IC50 pM IndexsuM
Cisplatin 18409 1.8 0.40 55
(n=7) (17626-19021) (0.60-7.2) (0.30-0.70) (21-135)
Etoposide 17939 38 3.2 51
(n=5) (17312-18399) (4.1-77) (2.4-4.1) (29-99)
Doxorubicin 16963 0.22 0.052 77
(n=4) (16697-17621) (0.086-0.81) (0.034-0.14) (4-127)
Vinblastine 18769 0.061 0.022 50
(n=5) (11739-19041) (0.033-1.6) (0.016-0.050) (14-256)
5-FU 14153 649 41 218
(n=2) (13915-14931) (623-675) (38-45) (212-223)
Gemcitabine 18386 8.0 1.6 50
(n=3) (15308-19287) (2.3-87) (1.3-2.0) (4-148)
VEC 18806 6* 3* 21
(n=3) (17904-19207) (6-53) (3-4) (9-78)
VAC 19033 6* 3* 17
(n=2) (18841-19225) (-) (-) (7-26)
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Figure 5.1 Concentration - inhibition curves in RB samples tested with cisplatin (a) and
etoposide (b). Data are represented as mean±SD of triplicate values.
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Figure 5.1 (continued). Concentration - inhibition curves in RB samples tested with 5-
FU (c) and gemcitabine (d). Data are represented as mean±SD of triplicate values.
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mean±SD of triplicate values.
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5.4 Discussion
In this study the ATP-TCA has been used to investigate the chemosensitivity profile of 
RB samples, despite the small numbers of cells available. This is the first report of using 
this assay for such tumour, and one of the very few studies available on the subject. The 
evaluability rate of the ATP-TCA in our series was 64%, which is lower than that 
achievable with other tumours (see table 1.9). However, this is comparable to the 70% 
success rate obtained by Schouten-van Meeteren (2003) with the M IT assay. In both 
studies an extremely low concentration of collagenase during the digestion step was 
found to be a critical factor to obtain viable cells. In two successful cases in our series 
that presented as solid tiny fragments, the enzymatic digestion was omitted and replaced 
by mechanical disruption by simply pipetting the suspension several times. Another 
factor that could have affected our low evaluability rate is the size of the tumour 
samples received, as part of the spare tissue not required for diagnosis was shared for 
genetic studies with Dr Zerrin Onadim’s group at St Bartholomew’s hospital.
The results confirm that this is a very chemosensitive tumour, in keeping with its high 
growth fraction and the observed clinical efficacy of the drugs tested. Similar data has 
been produced by Gertjan Kaspers’ group in Amsterdam using the MTT assay 
(Schouten-van Meeteren et al., 2003).
Based on other tumour types, all these results show significant activity of at least one of 
the cytotoxic drugs tested, although in one case none produce complete ATP inhibition 
consistent with 100% cell kill. The best dose response effect was seen with cisplatin, 
which probably indicates that platinum is the most effective drug in this tumour. The 
combination with doxorubicin is likely to be as active as the three-drug combination 
VAC and the availability of liposomal preparations (Doxil/Caelyx) should allow high 
concentrations to be achieved with a lower risk from MDR positive tumours. Addition 
of an MDR inhibitor in such patients may be more rational that the use of the current 
three drug regimen incorporating vincristine (Chan et a l , 1996).
The major risk to survival in these patients is second malignancy. Etoposide use is 
associated with haematogenous malignancy (Felix, 1998) and could probably be 
avoided. The evidence of this study suggests that doxorubicin is equally effective and it 
does carry lower risk.
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Drug resistance can occur, and may arise in several different ways. There is relatively 
little information on the relative importance of these mechanisms in RB, although as a 
tumour with a relatively simple molecular pathogenesis, it may have much to teach 
oncology in general. The MDRl/PgP mechanism has been studied in some detail by the 
Toronto group. Up to 15% of RBs express the MDR1 drug efflux protein and there is 
evidence that resistant cases express MRP (Chan et a l , 1997). Cyclosporin, an inhibitor 
of MDR1, can augment the control of RB (Chan et a l, 1996) and new inhibitors are in 
development. Other mechanisms are less well studied: BCRP and MVP are alternative 
drug efflux pump molecules similar to P-gp in their function, resistance to DNA 
damaging agents could be influenced anti-apoptotic mechanisms. In RB, p53 
inactivation and p21Wafl expression have recently been implicated in resistance to 
apoptosis, as could BCL-2 expression, which also occurs in RB (Divan et a l, 2001).
Although chemotherapy for RB is already very successful, several newer cytotoxic 
drugs are available with improved side effect profiles and anti-neoplastic activity, 
including different mechanisms of action. While it would be difficult to justify clinical 
trials of the large number of different options in RB, it would be sensible to explore 
these options pre-clinically and then conduct a trial against existing practice.
In conclusion the results show that RB is highly chemosensitive, in keeping with the 
highly proliferative nature of this tumour and the observed clinical efficacy of the drugs 
tested. Chemosensitivity testing of RB is feasible and can be used to improve 
understanding of the sensitivity/resistance of RB to chemotherapy, and to develop new 
drug combinations.
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Chapter 6 - The ex vivo activity of XR11576, a 
novel dual topoisomerase inhibitor
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6.1 Introduction
It has been proposed that the ATP-TCA can be used in the development of new agents 
and combinations for use in cancer patients (Cree & Kurbacher, 1999). As an example, 
this method has been previously employed to assess the ex vivo activity of a novel dual 
topoisomerase I and II inhibitor, XR5000 (Neale et a l , 2000b): the assay showed that 
this new drug was active against melanoma as well as ovarian cancer, but at 
concentrations which were unlikely to be achieved in patients (Cree et a l, 2003).
Several dual inhibitors of topoisomerase I and II have been described in addition to 
XR5000/DACA (Finlay et a l, 1996; Neale et a l, 2000b). These are intoplicine (Riou et 
a l,  1993), F 11782 (Perrin et a l, 2000), XR5944 (Stewart et a l, 2001), XR11576 
(Mistry et a l, 2002), XR11612 (Mistry et a l, 2001), TAS-103 (Utsugi et a l, 1997; 
figure 6.1), although the latter predominantly inhibits topoisomerase Ila (Byl et a l, 
1999). Most of these compounds are currently undergoing clinical trials (Denny & 
Baguley 2003). During the course of my PhD I have had access to a number of such 
experimental agents, as a part of collaboration with Xenova pic (Slough, Berkshire, 
UK). These compounds were XR11576 (MLN576; Millennium Pharmaceuticals) and 
its isomer XR11612. XR5000/DACA and TAS-103 were also supplied to enable 
comparative testing.
XR11576 demonstrated potent cytotoxic activity against a panel of human and murine 
tumour cell lines (IC50 = 6-47nM). This activity was unaffected by multidrug resistance 
(MDR) mediated by overexpression of either P-glycoprotein or MDR-associated protein 
(MRP), or by down regulation of topoisomerase II ((Mistry et a l, 2002). Importantly, 
XR11576 also showed marked efficacy against a number of human tumours including 
sensitive (H69/P) and multidrug-resistant (H69/LX4) small cell lung cancer and HT29 
colon carcinoma xenografts (Mistry et a l, 2002). XR11576 was proposed as a dual 
inhibitor of topoisomerase I and II based on its ability to stabilise cleavable complexes 
for both topoisomerase I and II in vitro in a dose dependent fashion (Mistry et a l,
2002). Cleavable complex formation by XR11576 was also analysed in human 
leukaemic K562 cells using the ‘Trapped in Agarose DNA Immunostaining’ (TARDIS) 
assay (Jobson et a l, 2002 & 2003). In this assay equal volumes of drug-exposed cells 
and an agarose solution in PBS are mixed together and spread evenly across a 
microscope slide. The slides are cooled to 0°C to allow for agarose gelification and
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lysed with a buffer containing sodium dodecyl sulfate. This traps DNA with covalently 
bound TOPO molecules. The slides are then exposed to a primary Ab directed towards a 
specific isoform of TOPO and a fluorescein isothiocyanate (FITC)-conjugated secondary 
Ab, which binds to the primary Ab. Areas occupied by DNA are defined using Hoechst 
dye blue fluorescence, and FITC green immunofluorescence within each defined DNA 
area is quantified using an imaging analysis software (Willmore et a l , 1998). Using this 
technique, Jobson et al. (2002,2003) demonstrated XR11576-induced cleavable 
complex formation for topoisomerase I, Ila and 11(3 in a dose and time dependent 
manner. These observations, however, do not exclude additional or alternative 
mechanisms of action for the cytotoxic activity of XR11576. XR11612 is an isomer of 
XR11576, which has shown promising cytotoxic activity in tumour cell lines (Mistry et 
a/., 2001).
As XR11576 has recently entered clinical trials, it is important to demonstrate that the 
compound is effective against cells derived from clinical tumour samples. A broad ex 
vivo activity profile would strengthen further clinical development and generate 
information to help design Phase II trials.
In the present study we aimed to determine the ex vivo activity of XR11576 in a variety 
of solid tumours and compare its activity with other dual topoisomerase I/II inhibitors, 
including XR5000 and TAS-103, as well as other cytotoxics currently in clinical use.
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6.2 Materials and Methods
Patients and Samples. A total of 89 tumours (44 solid tumours, 37 ascites, 8 pleural 
effusion) were tested with XR11576 (table 6.1). The ovarian cancer patients sub-group 
were all previously treated with carboplatin alone, or carboplatin plus taxane first line, 
followed in 5 cases by an anthracycline-containing regimen, in 4 cases by the 
combination treosulfan plus gemcitabine, in 3 cases by carboplatin plus gemcitabine 
and in 3 cases by etoposide.
ATP-TCA. The ATP-TCA was performed as detailed in chapter 2. XR11576 
hydrochloride salt, XR11612, XR5000 and TAS-103 were supplied by Xenova Ltd 
(Slough, Berkshire, UK) as powder. They were dissolved in DMSO to give a stock 
solution of 1 mg/ml and aliquots were stored at -20 °C. TDCs were 145nM for 
XR11576,290nM for XR11612,1.45 pM for TAS-103 and 2.9 pM for XR5000. The 
TDCs for the experimental compounds were determined on the basis of cell lines data 
provided by Xenova Ltd. The other cytotoxics were tested at the concentrations listed in 
table 2.2. XR11576 was tested in every case, while the other compounds were tested 
only when number of cells allowed. We evaluated the activity of XR11576 in 
combination with paclitaxel or vinorelbine in a subgroup of tumours (n = 43). These 
samples consisted of 22 ovarian carcinomas (of which 12 had previous taxane 
exposure), 7 unknown primaries, 5 skin melanomas, 4 colorectal carcinomas, 3 breast 
carcinomas, 1 oesophageal carcinoma, and 1 sarcoma.
Combinations were made up by adding both drugs concurrently at their 200% TDC to 
the wells at the beginning of the assay and diluted in a constant ratio: sequential studies 
were not performed.
IHC. Of the 89 tumour samples studied, material for IHC was available for 40 tumours 
(12 skin melanomas, 10 ovarian carcinomas, 9 colorectal carcinomas, 3 oesophageal 
carcinomas, 3 unknown primaries, 2 breast carcinoma and 1 sarcoma). These were 
stained for MDR1, TOPO I and TOPO Ila as described in Chapter 2.4.
Data analysis. Non-parametric statistical analysis was performed, the Wilcoxon two- 
tailed rank sum test for paired observations or the Mann-Whitney U test for unpaired 
data, as appropriate (Statsdirect). IC50 and IC90 values for XR11576 were compared to
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those for other drugs using Spearman’s rank correlation coefficient, with a Bonferroni 
correction: statistical significance was taken as p < 0.005.
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Figure 6.1 Chemical structures o f  the proposed dual topoisomerase inhibitors TAS-103, 
XR5000, XR5944, X R 11576 and X R 11612.
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Table 6.1 Tumours tested with XR11576, showing the average age (range), sex ratio, and previous treatment.
Tumour type n Age Sex Previous treatment
Ovarian Carcinoma 42 58
(38-78)
0M:42F Primary: platinum + taxane (n=25), platinum (n=17) 
Second-line: anthracycline (n=5), treosulfan+gemcitabine (n=4), 
etoposide (n=3), carboplatin+gemcitabine (n=3), 
mitoxantrone+paclitaxel (n=l)
Cutaneous Melanoma 14 58
(35-78)
7M:7F Primary: melphalan (n=3), vindesine (n=2), cyclophosphamide (n=l)
Unknown primary 10 63
(45-78)
3M:7F Primary: carboplatin (n=l)
Colorectal Carcinoma 9 71
(39-88)
4M:5F Primary: irinotecan (n=l)
Breast Carcinoma 5 57
(39-61)
0M:5F Primary: cyclophosphamide + anthracycline (n=3), antihormonal 
agent (n=2)
Oesophageal Carcinoma 3 55
(52-72)
3M:0F Primary: Epirubicin + Cisplatin + 5-FU (n=2)
Endometrial Carcinoma 2 60
(55-66)
0M:2F Primary: carboplatin (n=2) 
Second-line: paclitaxel (n=l)
Sarcoma 2 70
(57-82)
0M:2F None
Lung (NSCLC) 1 58 0M:1F Primary: cisplatin+vinorelbine (n=l)
Uveal Melanoma 1 67 0M:1F None
TOTAL 89 60
(35-88)
17M:72F
63  Results
63.1 Activity of XR11576 against tumour-derived cells
XR11576 showed a steep concentration response curve in most tumours. The effect of 
XR11576 varied both between tumour types and markedly between patients within the 
same tumour type (figure 6.2). Overall, XR11576 had median IC50 and IC90 values of 
1 lOnM and 242nM, respectively. The median IC50 and IC90 values calculated for each 
tumour type are shown in table 6.2. The IC90 values well correlated with the IC50 
values (r=0.893, p<0.0001, non parametric Spearman correlation). In all samples 
XR11576 was more potent than other experimental or clinical chemotherapeutic agents, 
such as XR5000, TAS-103, paclitaxel, doxorubicin and topotecan (table 6.3).
XR11576 showed activity against a wide variety of different tumours. Unknown 
primaries, breast and gynaecological malignancies proved highly sensitive to this new 
agent, though GI tumours were less sensitive (figure 6.2). In particular, 37/42 (88%) 
ovarian cancer samples had an IC50 value below 200nM and an IC90 below 300nM. 
When compared to other agents used in second-line for ovarian cancer, XR11576 was at 
least 10-fold more potent than doxorubicin or topotecan (figure 6.1, table 6.3). The 
median IC90 value for XR11576 in those samples from ovarian cancer patients who had 
received a taxane-based regimen (n=26) was 242nM compared to 155nM of samples 
from the small number of patients who had not been pre-exposed to taxanes (n=16), but 
this difference was not statistical significant (p=0.108, Mann-Whitney U-test).
The best activity (e.g. the lowest median IC90 value) was observed in the small group 
of breast tumours tested (n=5). In these tumours, XR11576 had an IC90 of 173nM, 
which was 170-fold more potent than the test results for paclitaxel. XR11576 showed 
remarkable activity against skin melanoma, a tumour type that is usually poorly 
sensitive to chemotherapy. In 11/14 (79%) melanoma samples XR11576 had an IC50 
value below 200nM and an IC90 value below 300nM.
XR11576 showed decreased potency in colorectal and oesophageal samples. When all 
12 GI tumours were analysed together, the median IC90 and IC50 were 308nM and 
212nM (figure 6.2), and these values were significantly higher than the corresponding 
values in ovarian samples (p<0.0005, Mann-Whitney test). 5/9 (56%) colorectal 
samples had IC50 values below 200nM, while all three oesophageal specimens had an
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IC50 slightly over 200nM. However, GI samples were also very resistant to other drugs: 
in this tumour type we recorded the highest median IC50 and IC90 values for most 
drugs.
Table 6.2 Median IC90 and IC50 values (range) for XR11576 tested in the ATP-TCA 
in n=number of samples for each tumour type.
Tumour type n IC50nM IC90 nM
Ovarian carcinoma 42 97.0 (7.20-675) 212 (63.5-1215)
Skin melanoma 14 125 (5.80-229) 215 (42.0-400)
Unknown primary 1 0 111 (46.4-252) 244(122-410)
Colorectal carcinoma 9 200 (33.4-338) 306 (242-608)
Breast carcinoma 5 109(42.1-184) 173 (137-356)
Oesophageal carcinoma 3 213(212-231) 310 (299-380)
Sarcoma 2 118(14.8-222) 176 (65.2-287)
Endometrial carcinoma 2 125 (83.0-167) 237 (175-300)
Lung (NSCLC) 1 97.3 137
Uveal Melanoma 1 181 325
TOTAL 89 110(5.80-675) 242 (42.0-1215)
Table 6.3 Median IC90 and IC50 values (range) for the cytotoxics tested in the ATP- 
TCA in n=number of samples of all tumour types.
Drug n IC50 pM IC90 pM
XR11576 (MLN576) 89 0.110(0.00580-0.675) 0.242 (0.0420-1.215)
XR11612 30 0.250 (0.0145-0.499) 0.505(0.113-0.911)
XR5000 73 1.94(0.174-5.13) 5.05 (0.870-7.26)
TAS-103 27 0.991 (0.0590-5.54) 2.79 (1.38-9.98)
Cisplatin 79 13.3 (0.430-80.4) 25.9 (7.57-145)
Treosulfan 76 39.4 (2.88-391) 116(23.9-703)
Etoposide 47 74.2 (3.27-933) 177(16.8-1679)
Topotecan 51 1.02 (0.0656-10.0) 3.60 (0.293-18.0)
Doxorubicin 73 1.10(0.103-45.7) 2.47 (0.296-82.3)
Paclitaxel 82 8.78 (0.554-32.8) 25.4 (3.50-59.0)
Vinorelbine 58 2.17(0.371-34.5) 16.8 (0.668-62.1)
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Figure 6.2 Heterogeneity o f  X R 11576 sensitivity in ovarian samples (n=42), skin 
melanomas (n=14), breast samples (n=5), gastro-intestinal tumours (n=12) and tumours 
o f  unknown origin (n=10). Each symbol represents the 1C50 (a) or IC90 (b) value for an 
individual patient. The horizontal lines represent median values.
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6J.2  Cross-resistance of XR11576 with other anticancer agents
When IC50 values were analysed using Spearman's rank correlation coefficient (non- 
parametric method for paired data), cross-resistance was seen between XR11576 and 
the other experimental agents XR5000 (f =0.609, p<0.0001), XR11612 (r=0.484, 
p<0.005) and TAS-103 (r=0.724, p<0.0001). A significant correlation was also found 
with the other topoisomerase II inhibitors doxorubicin (r=0.407, p<0.0005) and 
etoposide (r=0.428, p<0.005). Some cross-resistance was seen with paclitaxel (r=0.330, 
p<0.005), while no correlation was observed between the IC50 values for XR11576 and 
vinorelbine (r=0.285, NS), treosulfan (r=0.258, NS) and topotecan (r=0.250, NS) and 
cisplatin (r=0.148, NS).
The IC90 values confirmed the cross-resistance pattern described above. A significant 
correlation was found between XR11576 and the topoisomerase inhibitors XR5000 
(r=0.582, p<0.0001), XR11612 (r=0.588, p<0.005), TAS-103 (r=0.556, p<0.005), 
doxorubicin (r=0.441, p<0.0001) and etoposide (r=0.389, p<0.005). Some cross­
resistance was still seen with paclitaxel (r=0.325, p<0.005), while no correlation was 
observed between the IC90 values for XR11576 and vinorelbine (r=0.240, NS), 
cisplatin (r=0.135, NS), treosulfan (r=0.106, NS) or topotecan (r=0.100, NS).
63 3  Activity of XR11576 in combination with other anticancer agents
The effect of XR11576 in combination with other cytotoxics was studied by the method 
of Poch et al., 1995 in which the observed effect at each concentration tested is 
compared with the expected effect. A median-effect analysis was also performed (Chou 
& Talalay 1984) and combination indices calculated for each sample tested with 
XR11576 combinations at 90% cell death (CI90) and at 50% cell death (CI50). 
Combination indices were also calculated for the median concentration-inhibition curve 
produced by each combination.
6.3.3.1XR11576 and doxorubicin
The combination of XR11576 with doxorubicin showed a median CI50 value of 1.03, 
therefore suggesting an additive effect (figure 6.3). Considerable heterogeneity was 
found among samples as shown in tables 4a and 4b. Synergism (CI<0.8) was identified 
in 6/38 (16%) and in 12/38 (32%) samples when CI90 and CI50 values were considered, 
respectively; while antagonism (CIso>1.2) was found in 13/38 (34%) samples tested
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with this combination, although this percentage increased to 47% when CI90 values 
were calculated. Additivity was identified in 13/38 (34%) samples on the basis of the 
CI50 and in 14/38 (37%) samples on the basis on the CI90.
6.3.3.2 XR11576 and DNA damaging agents
The median CI50 values for the combinations of XR11576 with cisplatin or treosulfan 
were 1.19 and 1.37, while the median CI90 values were 1 .2 2  and 1.38, respectively. As 
suggested by these high median Cl values, antagonism between XR11576 and these two 
DNA damaging agents was identified in a large proportion of cases: CI50 values >1.2 
were calculated in 28/40 (70%) and in 20/42 (48%) samples for the combinations with 
treosulfan or cisplatin, respectively. Synergism was found only in a minority of cases. 
When CI90 values for each individual tumour were considered, the combination of 
XR11576 with treosulfan showed synergism in only 1/41 (2%) samples (Cl9o=0.76), 
while the addition of cisplatin to XR11576 did not produce any synergistic effect. On 
the basis of the CI50 values, the combinations of XR11576 with treosulfan or cisplatin 
showed synergism in 3/40 (8%) and in 5/42 (12%) samples, respectively.
6.3.3.3 XR11576 and microtubule-interfering agents
The median CI50 values for the combinations of XR11576 with vinorelbine or paclitaxel 
were 1.11 and 2.12, while the median CI90 values were 1.11 and 1.51, respectively. The 
best effect was obtained with the combination of XR11576 + vinorelbine, which was 
better than XR11576 alone in 30/31 paired observations (p<0.0001 on IC50 or IC90, 
Wilcoxon matched-pairs signed-ranks test). Figure 6.4a shows the advantage of the 
combination XR11576 and vinorelbine over the individual agents in terms of inhibition; 
when analysed by the method of Poch et al., 1995, some synergism was seen at the 
lower concentrations, while additivity was observed at the highest dose (figure 6.4b). 
This is reflected by the combination indices calculated by the Chou and Talalay method 
on the median dose-response curve, which were 0.45 (synergy) and 0.86 (additivity) for 
an effect of 50% and 90% inhibition, respectively. CI50 and CI90 values >1.2 
(antagonism) were found, respectively, in 38/42 (90%) and in 31/43 (72%) samples 
tested with the combination of XR11576 with paclitaxel. According to Poch, a median 
antagonistic effect at the lower concentrations between these 2 drugs was also found 
(figure 6.5). Some additivity was found at the higher concentrations as shown by the 
Poch method (figure 6.5) and by the analysis of the CI90 values (table 6.4b).
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Table 6.4 Effect of combining XR11576 with other cytotoxics using the Chou and 
Talalay Combination Index (a) for 50% cell death (CI50) and (b) for 90% cell death 
(CI90) calculated in n= number of cases.
42____________________^ ^ ^ ____________________________________________________
Tumour type XR11576
and
Number of 
samples tested
Combination Index 1W CI50
<0.8 0.8-1.2 >1.2
All tumours paclitaxel 42 3 1 38
All tumours vinorelbine 30 9 9 12
All tumours treosulfan 40 3 9 28
All tumours cisplatin 42 5 17 20
All tumours doxorubicin 38 12 13 13
Ovarian paclitaxel 22 0 1 21
Ovarian vinorelbine 17 4 5 7
Ovarian treosulfan 21 1 2 18
Ovarian cisplatin 22 2 6 14
Ovarian doxorubicin 22 7 8 7
Non-ovarian paclitaxel 20 3 0 17
Non-ovarian vinorelbine 14 5 4 5
Non-ovarian treosulfan 19 2 7 10
Non-ovarian cisplatin 20 3 11 6
Non-ovarian doxorubicin 16 5 5 6
M
Tumour type XR11576
and
Number of 
samples tested
Combination Index 1:«) cioo
<0.8 0.8-1.2 > 1 .2
All tumours paclitaxel 43 2 10 31
All tumours vinorelbine 31 7 15 9
All tumours treosulfan 41 1 17 23
All tumours cisplatin 42 0 19 23
All tumours doxorubicin 38 6 14 18
Ovarian paclitaxel 22 1 4 17
Ovarian vinorelbine 17 5 9 3
Ovarian treosulfan 22 0 7 15
Ovarian cisplatin 22 0 8 14
Ovarian doxorubicin 22 5 6 11
Non-ovarian paclitaxel 21 1 6 14
Non-ovarian vinorelbine 14 2 6 6
Non-ovarian treosulfan 19 1 10 8
Non-ovarian cisplatin 20 0 11 9
Non-ovarian doxorubicin 16 1 8 7
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Figure 6.3 Summary o f  the combination indices values calculated for (a) 50% (CI50) and 
(b) 90% cytotoxicity (CI90) in tumour derived cells treated with the combinations 
shown. For each combinations the interquartile range (grey histograms), the median and 
the range are shown. In graph a) the figures to the right indicate off-scale values.
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Figure 6.4 (a) Median activity (±interquartile range) o f  X R 11576 in combination with 
vinorelbine in n=31 samples, (b) Combination analysis (Poch et al. , 1995) showing a 
greater than additive effect. When analysed by the Chou and Talalay method (1984) a 
Cl5o=0.45 (synergy) and a Cl9o=0.86 (additivity) were calculated.
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Figure 6.5 (a) Median activity (± interquartile range) o f  X R 11576 in combination with 
paclitaxel in n=43 samples, (b) Combination analysis (Poch et al., 1995) showing a 
slightly antagonistic effect. When analysed by the Chou and Talalay method (1984) a 
0 5 0 =2 .2 6  (antagonism) and a Cl9o=1.09 (additivity) were found.
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6.3.3.4 Correlation ofX R l1576 activity with immunohistochemistry 
Immunostaining for P-gp was positive in 14/40 (35%) samples tested with XR11576. 
The P-gp expressing samples consisted of 4 ovarian tumours, 3 skin melanomas, 3 
oesophageal cancers, 2 colorectal tumours and 2 unknown primary carcinomas. The 
median XR11576IC50 values for P-gp negative and positive samples were 140nM and 
209nM, respectively (p=0.0488, Mann-Whitney U test), while the median IC90 values 
were 263 and 308 nM, respectively (p=0.098, ns, Mann-Whitney U test). No correlation 
by linear regression analysis was found between the IC50 of XR11576 or the IC90 and 
the intensity of P-gp staining.
Immunostaining for topoisomerase I and Ila was positive in 35/40 (87%) and 9/40 
(22%) samples tested with XR11576, respectively. Those samples that were positive for 
topoisomerase I included 13 ovarian tumours, 8 skin melanomas, 6 colorectal tumours,
3 unknown primary carcinomas, 2 oesophageal cancers, 2 breast tumours and 1 
sarcoma. The topoisomerase Ila expressing samples consisted of 6 colorectal tumours, 2 
ovarian tumours and 1 skin melanoma. The median XR11576IC50 values for 
topoisomerase I negative and positive samples were 162nM and 135nM, respectively 
(p=0.7185, NS, Mann-Whitney U test), while the median IC90 values were 274 and 262 
nM, respectively (p=0.8368, NS, Mann-Whitney U test). The median XR11576IC50 
values for topoisomerase Ila negative and positive samples were 133nM and 191nM, 
respectively (p=0.154, NS, Mann-Whitney U test), while the median IC90 values were 
261nM and 283nM, respectively (p=0.3226, NS, Mann-Whitney U test). No correlation 
by linear regression analysis was found between the IC50 or IC90 values for XR11576 
and either the topoisomerase I or the topoisomerase Ila immunohistochemistry indices 
(P=NS).
6.4 Discussion
The ex vivo profile of XR11576 in human solid tumours has confirmed it to be an 
exceptionally potent cytotoxic agent. In all samples tested, XR11576 was more active 
than all other compounds tested, including topotecan, doxorubicin, paclitaxel and the 
experimental agents XR5000 and TAS-103. As expected, the potency of XR11576 was 
less in tumour-derived cells compared with cell lines, which probably reflects the 
homogeneity and the fast-growing status of the cell lines used in previous studies
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(Mistry et a l, 2002). This is true of most cytotoxic drugs (Andreotti et al., 1994; see 
chapter 4). The effect of XR11576 varied considerably between tumour types as well as 
against samples from the same tumour type derived from different patients. This is 
consistent with both the situation found in the clinic and also other previous findings 
involving the testing of conventional cytotoxics (Cree et al., 1999; Whitehouse et a l, 
2003; Mercer et al., 2003).
XR11576 showed considerable activity in the subset of ovarian cancer samples. The 
fact that a large proportion of samples obtained from heavily pre-treated ovarian cancer 
patients do not appear resistant to XR11576 augurs well for its use as second-line 
therapy in this clinical condition.
Furthermore, XR11576 activity is only slightly reduced in GI tumours that are well 
known to overexpress MDR1 and other pump proteins (Cordon-Cardo et a l, 1990), and 
are generally refractory to chemotherapy (Gottesman et al., 2002). This is in accordance 
with previous studies that have shown XR11576 is not a substrate for either P-gp or 
MRP efflux pumps (Mistry et a l, 2002). Data from this study suggest that P-gp plays 
little, if any, role in resistance to XR11576.
Previous chemosensitivity studies have reported reduced levels of Topoisomerase Ila to 
correlate with in vitro resistance to topoisomerase inhibitors such as doxorubicin and 
etoposide (Matsumoto et al., 1997; Koshiyama et a l, 2001). However our data showed 
that XR11576 activity does not correlate with the expression of either topoisomerase I 
or Ila. On the other hand, there is cross-resistance with topoisomerase inhibitors, 
including doxorubicin, TAS-103, and XR5000. These findings are therefore consistent 
with inhibition of both enzymes, though we cannot exclude an alternative mechanism of 
action, as recently suggested (Fleming et a l, 2003).
Previous in vitro and ex vivo studies have reported enhanced cell kill when 
topoisomerase inhibitors were combined with vinca alkaloids (Bahadori et al., 2001; 
Barret et a l, 2002; Di Nicolantonio et a l, 2002; see chapter 8). While an increased 
effect was not found for all samples tested, individual cases that displayed true 
synergism between XR11576 and vinorelbine were apparent in our series. Despite some 
cross-resistance between XR11576 and doxorubicin, we found synergism between these
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two drugs in a proportion of samples, suggesting that non-topoisomerase mediated 
effects of the anthracycline may be important for cytotoxicity. Antagonism was found 
between XR11576 and cisplatin or treosulfan; this is in contrast with other ex vivo 
studies that reported some synergism between cisplatin and topoisomerase inhibitors 
(Jonsson et al., 1998; Neale et a l , 2000; Sargent et a l , 2003). Substantial antagonism 
was noted between XR11576 and paclitaxel. These results are consistent with several in 
vitro studies that have shown an antagonistic effect when paclitaxel is combined with 
certain non-anthracycline topoisomerase inhibitors, such as etoposide, topotecan, SN38 
and tafluposide (Kaufmann et a l , 1996; de Jonge et a l , 1998; Kano et a l , 1998; Ma et 
a l , 1998; Perez et a l , 1998; Barret et a l , 2002), although others reported additive or 
synergistic effects in different cell lines (Chou et a l , 1994; Jonsson et a l , 1998; 
Bahadori et al., 2001).
Chemosensitivity testing using fresh tumour cells taken directly from patients is not 
commonly used for pre-clinical studies at present. It has been proposed, nevertheless, 
that it provides useful information on the cellular sensitivity of novel compounds before 
they reach more expensive phase I/II trials (Cree, 2003). The results of this study may 
assist the further clinical development of XR11576. If phase I studies prove the safety 
of this compound, then these results suggest that phase II trials should target those 
clinical conditions (breast, ovarian cancer, and cutaneous melanoma) where this new 
agent is likely to produce the greatest benefit.
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Chapter 7 - The ex vivo characterisation of 
XR5944 (MLN944) against a panel of human 
clinical tumour samples
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7.1 Introduction
The novel bis-phenazine XR5944 (MLN944) is an extremely potent cytotoxic agent 
both in vitro and in vivo (Stewart et a l, 2001). Against a panel of human cell lines in 
vitro the IC50 of XR5944 was 0.04-0.4 nM and this potency translated well to human 
xenograft models in vivo where XR5944 induced complete tumour regression in the 
H69 SCLC model (Stewart et a l, 2001). Although XR5944 originated from a 
programme to generate dual topoisomerase (TOPO) I and II inhibitors (Gamage et a l, 
2001) recent data suggest that cell death is not mediated via TOPO inhibition, but the 
precise mechanism of action is still being elucidated. XR5944 has been reported to bind 
strongly and intercalate into DNA (Gamage et a l, 2001) and can stabilise TOPO- 
dependent cleavage complexes as visualised by electrophoresis using linearised labelled 
plasmid DNA and purified TOPO I and II. XR5944 also induced cleavage complex 
formation for TOPO I and II (a  and P) in human leukaemic K562 cells visualised using 
the TARDIS assay (Jobson et a l, 2002). Although these observations suggested a 
TOPO-mediated mechanism for XR5944, the increase in enzyme-mediated DNA 
cleavage required relatively high concentrations of XR5944 and, in the K562 cells, long 
incubation times. Furthermore, data have been presented recently demonstrating a 
TOPO-independent mechanism of action for XR5944. In yeast models, the cytotoxicity 
of XR5944 was not dependent on the presence of either TOPO I or II and the potency 
was not attenuated in mutant strains unable to repair double strand DNA breaks 
(Fleming et a l, 2003). Cell cycle analysis also differentiated XR5944 from both TOPO 
I and II inhibitors as XR5944 treatment induced a G1 and G2 arrest in contrast to the 
G2/M arrest noted with either doxorubicin (a TOPO II inhibitor) or camptothecin (a 
TOPO I inhibitor) (Freathy et a l, 2003). Finally, functional genomic data has also 
differentiated XR5944 from known TOPO inhibitors. Transcript profiling of XR5944 in 
yeast cells indicated up-regulated expression of RNA polymerase subunits, as well as 
genes involved in rRNA processing, but importantly, DNA damage response genes 
appeared to be unaffected (Fleming et a l, 2003; Sappal et a l, 2004).
Previous in vitro studies showed that XR5944 is probably a substrate for both the 
multidrug resistance-associated protein (MRP) and P-glycoprotein (P-gp) (Stewart et 
a l, 2001), the product of the multidrug resistance gene (MDR1). Although the potency 
of XR5944 is somewhat attenuated in cell lines overexpressing these drug efflux
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proteins, XR5944 remains a very active cytotoxic with IC50 values similar to or better 
than other chemotherapeutic agents such as topotecan and paclitaxel in drug resistant 
cells.
As part of ongoing collaboration with Xenova pic (Slough, Berkshire, UK), during the 
course of my PhD studies, I had access to XR5944. As this compound has very recently 
entered clinical trials, it is important to demonstrate that the compound is effective 
against cells derived from clinical tumour samples. Therefore in the present study I 
aimed to determine the ex vivo activity of XR5944 in a variety of solid tumours tested in 
the ATP-TCA.
7.2 Materials and Methods
Patients and Samples. A total of 90 tumours (44 ovarian, 9 colorectal, 5 breast, 3 
oesophageal and 2 endometrial carcinomas, 14 cutaneous melanomas, 1 sarcoma, 1 
NSCLC and 10 carcinomas of unknown primary origin) were tested with XR5944, with 
local ethics committee approval for the use of tissue or cells not required for diagnosis. 
The median age of the patients was 59 years (range 35-88; 17M:73F). The ovarian 
cancer subgroup patients were all previously treated with carboplatin alone, or 
carboplatin plus taxanes first line, followed in 4 cases by an anthracycline-containing 
regimen and in 2 cases by etoposide. A drug resistant CCRF-CEM sub-line was 
obtained by step-wise treatment with XR5944 up to 10 nM (for details see section 
2.3.4), and was also tested.
ATP-TCA. The ATP-TCA was performed as described in chapter 2. XR5944 bis- 
mesylate salt was supplied by Xenova Ltd (Slough, Berkshire, UK) as powder. It was 
dissolved in DMSO to give a stock solution of 1 mg/ml and aliquots were stored at -20 
°C. The TDC for XR5944 was 72.5nM, while all other cytotoxics were tested at the 
concentrations listed in chapter 2. XR5944 was tested in every case, while npt all the 
other compounds were tested for all samples, as preference to clinically relevant drugs 
for each tumour type was given.
Immunohistochemistry (IHC1. Of the 90 tumour samples studied, material for IHC was 
available for 32 tumours (12 skin melanomas, 10 ovarian carcinomas, 3 colorectal 
carcinomas, 3 oesophageal carcinomas, 2 unknown primaries, 1 breast carcinoma and 1
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sarcoma). These were stained for MDR1, TOPO I and TOPO Ila as described in 
Chapter 2.4.
qRT-PCR. Total RNA was extracted from at least 107 CCRF-CEM cells and reverse- 
transcribed as described in chapter 2.5. The expression levels of BCRP, MDR1, MRP1, 
MRP2, MVP, TOPO I, TOPO Ila and TOPO lip were measured in reference to HPRT1, 
PBGD and TBP in both the parental and the drug selected sub-line. The following 
formula was used to calculate the relative amount of the transcript in the sample: 2'MCt, 
where ACt is the difference in Ct between the gene of interest and the mean of the 3 
reference genes, and AACt = ACt of the parental CCRFCEM line -ACt of XR5944- 
resistant subline.
Data analysis. IC50 and IC90 values for XR5944 were compared to those for other 
drugs using Spearman’s rank correlation coefficient, with a Bonferroni correction: 
statistical significance was taken as p < 0.005.
73 Results
73.1 Activity of XR5944 against tumour-derived cells
The concentration response curve of XR5944 was steep in most tumours, as displayed 
in the ovarian cancer sample shown in figure 7.1. XR5944 exhibited potent cytotoxic 
activity in the nanomolar range for the vast majority of samples tested (table 7.1). 
Overall, XR5944 had median IC50 and IC90 values of 26 nM and 68 nM, respectively 
(table 7.1). Notably, in all samples XR5944 was more potent than other common 
chemotherapeutic agents currently used in the clinic (table 7.1 and figure 7.1). The IC90 
of XR5944 was above the l.OpM threshold in only 1/90 sample (table 7.1): this ovarian 
tumour was relatively refractory to chemotherapy, as shown also by the extremely high 
IC90 and IC50 values for doxorubicin (53.8pM and 29.9jiM, respectively, table 7.1).
XR5944 demonstrated its activity on a wide variety of different tumours. Unknown 
primaries, breast and gynaecological malignancies proved highly sensitive to this new 
agent. In particular, an IC50 value below 50nM was calculated in 37/44 (84%) ovarian 
cancer samples and an IC90 below lOOnM in 33/44 (75%) specimens. When compared 
to other agents used in second-line therapy for ovarian cancer, XR5944 was at least 40- 
fold more potent than doxorubicin or topotecan.
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The best median activity was observed in the small group of breast tumours tested 
(n=5), in which XR5944 had an IC50 of 23 nM and an IC90 of 55 nM. In this tumour 
type XR5944 had an IC50 value 340-fold better than paclitaxel.
XR5944 retained excellent activity in skin melanoma, a tumour that is usually poorly 
sensitive to chemotherapy. In 11/14 (79%) melanoma samples we found an IC50 value 
below 50nM and in 10/14 (71%) an IC90 value below lOOnM.
XR5944 had slightly decreased potency in colorectal and oesophageal samples, in 
which the median IC50 values were, respectively, 126 nM and 66 nM. Only 2/9 (22%) 
colorectal samples had an IC50 value below 50nM, and, none had IC9Q values below 
100 nM. However, in colorectal samples we recorded the highest median IC50 and IC90 
yalues of most of the tested drugs (table 7.1).
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Table 7.1(a). Median IC90 and IC50 values (range) for XR5944 tested in the ATP-TCA 
in n=number of samples for each tumour type.
Tumour type n IC50 nM IC90 nM
Ovarian carcinoma 44 22.9 (2.90-253) 59.6(16.0-1315)
Skin melanoma 14 31.2(2.18-64.3) 71.0(15.2-157)
Unknown primary 10 29.0(7.25-54.3) 65.7(29.0-125)
Colorectal carcinoma 9 126 (8.70-221) 249 (160-399)
Breast carcinoma 5 23.3 (3.97-76.0) 55.5 (35.5-164)
Oesophageal carcinoma 3 65.9 (16.7-97.2) 178 (69.6-197)
Sarcoma 2 34.4(11.6-57.3) 115(110-120)
Endometrial carcinoma 2 25.1 (24.2-25.9) 97.0 (43.6-150)
Lung (NSCLC) 1 17.1 33.1
TOTAL 90 26.5 (2.18-253) 68.2 (15.2-1315)
Table 7.1 (b). Median IC90 and IC50 values (range) for XR5944 and other cytotoxics 
tested in the ATP-TCA in n=number of samples of all tumour types.
Drug n IC50 pM IC9Q pM
XR5944 (MLN944) 90 0.0265 (0.00218-0.253) 0.0682(0,0152-1.32)
Cisplatin 81 13.4 (0.430-80.4) 25.9 (7.57-145)
Treosulfan 77 39.6 (2.9-390.8) 116.4(23,9-703.4)
Etoposide 49 74.2 (3.27-932) 177 (16.8-1678)
Topotecan 53 1.00(0.0656-10.0) 3.62 (0.293-18,0)
Doxorubicin 74 1.20(0.103-45.7) 2.49 (0.296-82,3)
Paclitaxel 84 8.99 (0.554-32.8) 25.4 (3.50-59.0)
Vinorelbine 58 2.17(0.371-34.5) 16.8 (0.668-62.1)
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Figure 7.1 Representative example o f  ATP-TCA results in an ovarian tumour. XR5944 
shows a steep concentration-inhibition curve and is at least 10-fold more potent than the 
other conventional cytotoxics tested.
213
73.2 Cross-resistance of XR5944 with other anticancer agents
When IC50 and IC90 values were analysed using Spearman’s rank correlation 
coefficient (table 7.2) cross-resistance was clearly seen only between XR5944 and 
doxorubicin (r=0.426 and r=0.468, respectively, both p<0.0001). A modest correlation 
was also found between the IC90 values of XR5944 and those of vinorelbine (r=0.352, 
p<0.0034), although not between the IC50 values (table 7.2). No statistically significant 
correlation was seen between XR5944 and cisplatin, treosulfan, paclitaxel, etoposide or 
topotecan (table 7.2).
Table 7.2 Cross-resistance patterns between XR5944 and other cytotoxics. The IC90 
and IC50 values for XR5944 were compared to those for other drugs using 
Spearman’s rank correlation coefficient (non-parametric method for paired data) with 
a Bonferroni’s correction for the number of correlations (n=14). Statistical 
significance was taken at p<0.0036.
Drugs 
XR5944 vs
Samples
tested
(n)
IC90 values IC50 values
Spearman’s 
correlation 
coefficient R
P
Spearman’s
correlation
coefficient
R
P
Cisplatin 81 0.1022 ns (0.1819) 0.1524 ns (0.0914)
Treosulfan 77 0.1816 ns (0.0570) 0.2518 ns (0.0136)
Doxorubicin 74 0.4676 <0.0001 0.4256 <0.0001
Etoposide 49 0.1070 ns (0.2322) 0.08017 ns (0.2920)
Topotecan 53 0.2500 ns (0.0355) 0.2469 ns (0.0388)
Paclitaxel 84 0.2068 ns (0.0296) 0.1211 ns (0.1392)
Vinorelbine 58 03515 <0.0034 0.2802 ns (0.0182)
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7 3 3  Correlation of XR5944 activity and immunohistochemical data
Immunostaining for P-gp was positive in 14/32 (44%) samples tested with XR5944. The 
P-gp expressing samples consisted of 5 ovarian tumours, 3 skin melanomas, 3 
oesophageal cancers, 2 colorectal tumours and 1 unknown primary carcinoma. The 
median XR5944IC50 values for P-gp negative and positive samples were 23 and 58 
nM, respectively (p<0.05, Mann-Whitney U test, p=0.0143), while the median IC90 
values were 68 and 142 nM, respectively (p<0.05, Mann-Whitney U test, p=0.0113). 
The expression of P-gp shifted to the right the drug-response curve of XR5944 (figure 
7.2-a). A positive correlation by linear regression analysis was found between P-gp 
staining and the IC50 (i=0.65, p<0.0001) and the IC90 (r=0.54, p<0.005) for XR5944 
(figure 7.2-b), but not with either the TOPO I or Ila IHC indices (p=NS; data not 
shown). It must be pointed that the highly statistically significant correlation in Fig.
7.2b (p<0.0001) might have been biased by the presence of three P-gp strongly positive 
tumours which showed high IC90 and IC50 values for XR5944.
73.4 Activity of XR5944 against CCRF-CEM cell lines
In the ATP-TCA the IC50 values for XR5944 were 0.27±0.05 nM and 4.24 ±0.25 nM in 
the CCRFCEM parental and XR5944-resistant sub-lines, respectively. The changes in 
gene expression profile of various MDR transporters and the TOPO enzymes between 
the parental and the resistant sub-line were investigated by qRT-PCR in three 
experiments. The qRT-PCR technique produced extremely reproducible results with an 
intra- and inter-assay coefficient of variation of <1.5% and <5%, respectively. The 
XR5944-line showed a 10-fold and a greater than 100-fold increase in mRNA levels of 
MVP and MDR1, respectively, when compared to the parental line (Figure 7.3). qRT- 
PCR also showed a modest increase in the expression of MRP-1 (2-AACt= 2.0) in the 
resistant line. The levels of BCRP, MRP2 and the TOPO isoforms were essentially 
unchanged in the resistant sub-line.
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Figure 7.2 (a) Influence o f  P-gp status on XR5944 activity (median ±  interquartile 
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immunostaining.
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Figure 7.3 Difference in gene expression between CCRFCEM parental and XR5944-
selected subline determined by qRT-PCR. Results are represented as mean o f  3 replicate 
observations. Standard deviation error bars are not shown as they were smaller than the 
marks on the graph, in keeping with the minimal intra- (<1.5%) and inter-assay (<5%) 
coefficient o f  variation showed by the qRT-PCR technique.
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7.4 Discussion
The ex-vivo profile of XR5944 in human solid tumours showed it to be an exceptionally 
potent cytotoxic agent. In all samples tested, XR5944 was several-fold more active than 
all other compounds tested, including topotecan, doxorubicin and paclitaxel. In keeping 
with the results of many other drugs, the potency of XR5944 is attenuated in tumour- 
derived cells compared to cell lines (chapter 4, vide infra), but this probably reflects the 
homogeneity and the fast-growing status of the CCRF-CEM cells used here and the cell 
lines used in previous studies (Stewart et al., 2001).
Although the expression levels of MDR1 were increased at least 100-fold after 
prolonged and gradual XR5944 selection of the CCRF-CEM cells, the IC50 value in the 
resistant line showed a modest 15-fold increase when compared to the IC50 of the 
parental line. The relevance of this resistance model in the clinical setting may be 
questionable. In fact, it should be pointed that resistant lines generated in vitro after 
prolonged treatment might not reflect the in vivo situation, as factors that allow cell 
survival following acute cytotoxic drug exposure in vivo may differ from mechanisms 
selected by chronic drug exposure in vitro. Furthermore, a recent study (Yague et a l, 
2003) has shown that in K562 myelogenous leukaemic cells, only long-term, and not 
short-term- drug exposure, was able to overcome a translational block so that MDR1 
mRNA was translated and P-gp overexpressed.
It is remarkable that XR5944 showed its greatest activity in the subset of ovarian cancer 
samples, as all of the ovarian patients had relapsed after receiving a platinum-based 
regimen, which might have resulted in a gradual enrichment of resistant cells in those 
samples. Platinum treatment may cause upregulation of drug detoxifying enzymes, such 
as the glutathione-S-transferases (GST) (Cheng et al., 1997), and loss of mismatch 
repair mechanisms (MMR) in a proportion of patients (Samimi et al., 2000), therefore 
rendering the cells more resistant to several chemotherapeutic agents (Irving & Hall, 
2001). Our data therefore suggest that XR5944 may not be sensitive to the common 
resistance mechanisms affecting cisplatin in ovarian cancer patients.
The median IC90 and IC50 values of XR5944 in colon carcinoma samples were 4-fold 
greater than the median for all tumour samples. All but 1 of these patients were 
chemotherapy-naive, excluding the possibility that previous treatment could have
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altered tumour response in these cases. On the other hand, colorectal carcinoma is well 
known to overexpress MDR1 and other pump proteins (Cordon-Cardo et al., 1990) and 
is generally refractory to chemotherapy. However, it should be noted that even in those 
samples overexpressing P-gp, XR5944 showed better activity than the other cytotoxic 
agents tested.
Although the expression of P-gp could play a role in conferring resistance to XR5944, 
resistance is very often multifactorial and other mechanisms may be important, too. Our 
data on the CCRF-CEM and other cell lines (Stewart et a l, 2001) suggest that other 
MDR transporters, such as MVP and MRP-1, may mediate chemoresistance to this new 
agent. No immunostaining for these proteins was performed in this study, and further 
investigation is needed to evaluate the importance of these newly recognised pumps to 
XR5944 resistance in the clinical setting.
Previous experiments of sub-lines selected using TOPO inhibitors reported alteration in 
the expression levels of the targeted enzyme (reviewed in Larsen & Skladanowski 
1998). The data in this chapter showed that XR5944 activity does not correlate with the 
expression of either TOPO I or Ila, and that the levels of these enzymes are unaltered in 
drug-selected leukaemic CCRF-CEM cells. Although these findings could be explained 
by inhibition of both enzymes, it is probable that XR5944 acts through an alternative 
mechanism of action, distinct from TOPO inhibition, as has recently been suggested 
(Fleming et a l, 2003; Sappal et a l, 2004).
Multiple resistance mechanisms (including those not mentioned here or as yet 
undiscovered) may explain the heterogeneity of chemosensitivity between tumour types 
and individual tumours within the same tumour type observed in our series. However, in 
this study, the cell line data, the decreased potency in gastrointestinal tumours, and the 
better correlation of P-gp with the IC50 of XR5944 than with the IC90, all suggest that 
P-gp may be a mechanism of resistance relevant to very low concentrations of XR5944, 
and that higher levels of the drug may overcome such resistance. The results of this 
study may help further clinical development of XR5944. If phase I studies prove the 
safety of this compound, then our results suggest that phase II trials should target those 
clinical conditions (breast, ovarian cancer, and possibly metastatic skin melanomas) 
where the new agent is likely to produce the greatest benefit.
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Chapter 8 - The ex vivo effect of high dose 
doxorubicin combinations in ovarian cancer
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8.1 Introduction
Anthracyclines are active against a wide variety of human cancers, but their toxicities, such 
as bone marrow suppression and cardiac damage, have largely prevented dose 
intensification. Cardiovascular damage may represent a potentially life-threatening and 
dose-limiting toxicity. In the last decade, several efforts have been made to improve the 
therapeutic index of doxorubicin. The doxorubicin 4’-epimer, epirubicin, has a more 
favourable toxicity profile than doxorubicin since at equimolar doses is associated with 
identical clinical activity and less cardiotoxicity and myelosuppression (Bonadonna et a l , 
1993; Plosker & Faulds 1993). More recently doxorubicin has been encapsulated in 
polyethylene-glycol (PEG) coated ‘stealth’ liposomes that confer to the drug a significantly 
longer half-life and an altered tissue distribution, with a high concentration of the active 
agent in the tumour (Gabizon et al., 1994; Vaage et a l , 1994; Lasic, 1996; Gabizon & 
Martin 1997; Gabizon et a l , 1998; Symon et a l , 1999; Gabizon 2001). Pegylated 
liposomal doxorubicin (PEG-DOX; Caelyx/Doxil; Schering Plough/Sequus) has been 
demonstrated to be active against Kaposi’s sarcoma, and ovarian, breast, and head/neck 
carcinomas (Muggia 1997; Stewart et a l , 1998; Caponigro et a l , 2000; Safra et a l, 2001; 
Muggia & Hamilton 2001). In clinical trials PEG-DOX has been reported to induce less 
cardiac toxicity and myelosuppression than free doxorubicin (Alberts & Garcia 1997;
Berry et a l, 1998; Lyass et a l, 2000; Safra et a l, 2001), but its use has been associated 
with mucositis and the development of a peculiar side-effect, palmar-plantar 
erythrodysesthesia (hand-foot syndrome), which may represent a dose-limiting toxicity 
(Vail et a l, 1998; Amantea et a l, 1999).
Doxorubicin is not a new drug and has been widely used in combination with alkylating 
agents, antimetabolites and spindle-active agents. There is less data on the combination of 
liposomal preparations with other drugs, but current results indicate that similar 
combinations are likely to be effective (Sparano et a l, 2001; Gebbia et a l, 2002).
The ATP-TCA has been previously employed to assess the chemosensitivity of 21 ovarian 
carcinoma samples to the high concentrations of doxorubicin achievable with PEG-DOX 
(Neale et a l, 2000). During the course of this PhD it has been possible to use excess cells 
from many of the ovarian adenocarcinomas that were sent for the Phase III trial (chapters 
1 -2) to extend the original study by Neale et a l (2000). The ATP-TCA has again been used 
to determine the responsiveness of tumour-derived cells to concentrations of doxorubicin
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achievable with liposomal preparations, but also to look at the addition of other drugs in 
combination with doxorubicin (Di Nicolantonio et a l , 2002). Treosulfan, vinorelbine and 
cisplatin were tested in combination with doxorubicin, which was used at five times (x5) or 
three times (x3) the standard TDC (see Chapter 2) to mimic the concentrations that have 
been obtained from in vivo studies with PEG-DOX (Gabizon et a l. 1994, Vaage et a l , 
1994, Gabizon et a l, 1998, Symon et a l, 1999). It is not possible to test PEG-DOX 
directly in the ATP-TCA as serum-free media do not hydrolyse pegylated liposomes, and a 
previous study has shown no effect of PEG-DOX in cell lines maintained in such media 
(Wang et a l, 1999). However, in vivo, the intratumoral concentration of doxorubicin can 
range from 4-16 fold greater than standard preparations of doxorubicin when using PEG- 
DOX (Gabizon et a l, 1994, Vaage et a l, 1994, Gabizon et a l, 1998, Symon et a l, 1999). 
Therefore to achieve similar concentrations of doxorubicin in vitro the TDC of doxorubicin 
was increased x3 or x5, as originally suggested by Neale et a l, 2000.
8.2 Materials and Methods
Tumours. A total o f200 recurrent ovarian tumours were tested. These were all previously 
treated with carboplatin alone, or carboplatin + taxanes first line, followed in 21 cases by 
an anthracycline-containing regimen. The median age of the patients was 59 years (range 
35 -81). Tumour histological type was stated on the submission form in 78 cases: 52 were 
of serous histological type, 9 endometrioid, 4 clear cell, 3 mucinous, and 10 poorly 
differentiated.
ATP-TCA. The ATP-TCA was performed as previously described in Chapter 2.
In the first series of samples studied the TDC of doxorubicin was 4.31 pM, which 
represented x5 the concentration normally employed for free doxorubicin (xl) in the ATP- 
TCA. For the second group of experiments (from October 2001 onwards) the TDC of 
doxorubicin was decreased to 2.59 pM (Doxorubicin x3). Combinations were made up by 
adding both drugs at their 200% TDC to the wells at the beginning of the assay: sequential 
studies were not performed. Not all drugs or combinations were tested in every case, as the 
number of cells available varied and clinical needs took precedence.
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8 3  Results
83.1 Ex vivo activity of single agents
For the purposes of comparison between drugs and tumours, an IndexsuM of <300 was 
taken as ex vivo sensitivity and >350 as resistance, as previously published (Hunter et a l , 
1993; Cree et a l , 1999). Values between these two points were regarded as equivocal. On 
this basis, 76% (90/118) of the ovarian tumours tested showed resistance to cisplatin, with 
only 16% (19/118) showing sensitivity. In contrast, 84% (103/123) showed sensitivity to 
doxorubicin x5, 37% (37/106) to treosulfan, and 77% (41/53) to vinorelbine (table 8.1). 
Only six tumours were tested with 5-FU, though four showed sensitivity.
Doxorubicin x5 achieved >95% inhibition at 100% TDC (4.31 pM) in 102/123 (83%) of 
the ovarian tumours tested (table 8.1); and >99% inhibition was only observed in 61/123 
(49.6%) of the samples tested. Ten ovarian tumours showed complete resistance. Of these, 
only three had previous exposure to anthracyclines.
8 3 3  Ex vivo activity of doxorubicin x5 in combination with other cytotoxics
The combinations tested were only slightly better than doxorubicin x5 alone, as shown in 
table 8.1 and in figures 8.1, 8.2 and 8.3. All produced >90% sensitivity based on an 
IndexsuM of <300 (doxorubicin x5 with cisplatin = 98%, with treosulfan = 98%, with 5-FU 
= 90%, with vinorelbine = 100%). The best effect was obtained with the combination of 
doxorubicin x5 plus vinorelbine (figure 8.3), which was better than doxorubicin x5 alone in 
51/53 paired observations (Wilcoxon matched pairs test: p < 0.0001 on IndexsuM), and 
better than doxorubicin x5 plus treosulfan in 39/41 paired observations (p < 0.0001). When 
analysed by the method of Poch et al (1995), in which the observed effect at each 
concentration tested is compared with the expected effect, the combinations of doxorubicin 
x5 with cisplatin, treosulfan and vinorelbine all produced a greater than additive effect at 
the lower concentrations tested (figures 8.1, 8.2, 8.3).
83 3  Ex vivo activity of doxorubicin x3 with vinorelbine
The proportion of tumours apparently sensitive to doxorubicin x5 exceeded the response 
rates obtained in clinical trials of PEG-DOX in recurrent ovarian cancer (Muggia et a l, 
1997; Campos et a l, 2001; Gabizon, 2001; Gordon et a l, 2001; Hensley et a l, 2001; 
Muggia & Hamilton, 2001). The largest of these obtained a 20% response rate (Gordon et
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al., 2001). Therefore during the course of this study, the concentration of doxorubicin was 
decreased to x3 in order to improve the predictive accuracy of the ATP-TCA.
In the second group of 77 ovarian tumours tested, doxorubicin x3 achieved >95% 
inhibition at 100% TDC (2.59 pM) in 31/77 (40%) of the samples (table 8.2); and >99% 
inhibition was observed in 16/77 (21%) cases. On the basis of IndexsuM, 45% (35/77) of 
the ovarian tumours tested showed sensitivity to doxorubicin x3, as opposed to 84% 
samples which were found sensitive to x5 in the first part of the study (tables 8.1 and 8.2), 
in line with the concentration response curves previously obtained.
The second group of tumour biopsies was found to be generally more resistant to 
doxorubicin when the actual IC90 and IC50 values were considered and compared to those 
calculated in the first series of samples. In the first series, tested with x5, the median IC90 
and IC50 values were 1.57 pM and 0.523 pM, while they were respectively 2.66 pM and 
1.57 pM in the second group tested with x3 (tables 8.1 and 8.2). These differences were 
found to be statistically significant for both parameters (p<0.0001, Mann Whitney U test). 
However, it should be noted that the shape of the median concentration-inhibition curve for 
doxorubicin x3 is sigmoidal (figure 8.4), while that for doxorubicin x5 is somewhat flatter 
(figure 8.3), and this may have influenced the extrapolation of parameters such as IC90 and 
IC50.
The second group of samples appeared to be also slightly more resistant to vinorelbine 
when compared to the first series, although no significant differences were found when the 
various sensitivity indices were analysed (NS for IndexsuM, IC90 and IC50, Mann Whitney 
U test).
The combination of doxorubicin x3 and vinorelbine tested at 100% TDC produced >95% 
inhibition in 65/77 (84%) samples (table 8.2). On the basis of IndexsuM, 68/77 samples 
(88%) showed sensitivity to this combination, while only 4/77 (5%) were found to be 
resistant. The combination was better than doxorubicin x3 alone in 72/77 paired 
observations (p < 0.0001 on IndexsuM, Wilcoxon matched pairs test:), and better than 
vinorelbine alone in 73/77 paired observations (p < 0.0001).
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When analysed by the method of Poch et al (1995), in which the observed effect at each 
concentration tested is compared with the expected effect, the combination of doxorubicin 
x3 with vinorelbine produced a median additive effect (figure 8.4).
A median-effect analysis was also performed (Chou & Talalay 1984) and combination 
indices calculated for each sample tested with doxorubicin x3 and vinorelbine at 90% cell 
death (CI90; figure 8.5, panel a) and at 50% cell death (CI50; figure 8.5, panel b). The 
median of all CI90 values was 0.97 (range 0.27-2.95; figure 8.5) and the median of the CI50 
values was 1.08 (range 0.11-7.82; figure 8.5). Considerable heterogeneity was found 
among samples as shown in figure 8.5. Synergism (CI<0.8) was identified in 21/77 (27%) 
and in 13/77 (32%) samples when CI90 and CI50 values were considered, respectively; 
while antagonism (Cl >1 .2 ) was found in 26/77 (34%) samples both for CI90 and CI50 
values. Additivity was identified in 30/77 (39%) samples on the basis of the CI90 although 
this percentage increased to 49% (38/77) when CI50 values were calculated.
Combination indices were also calculated for the median concentration-inhibition curve 
produced by doxorubicin x3 and vinorelbine shown in panel a) of figure 8.4. In this 
instance the CI90 and CI50 values were respectively 0.85 and 0.79, in keeping with the 
additive effect observed with the Poch analysis in panel b) of figure 8.4.
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Table 8.1 Median values and range (in brackets) for AUC, IndexsuM, IC90 and IC50 measured in n samples. For the combination the values 
marked with (*) are expressed as percentage of TDC. An IndexsuM of > 600 represents no activity and < 300 is taken as sensitivity for most 
single agents. An IndexAUC of 19,000 would represent complete inhibition at all doses tested, while zero would equal no effect. The percentage 
of tumours showing >95% inhibition at 100% concentration tested is also shown.
Drug/Combination n Age IndexAUC IC90 uM IC50 pM IndexsuM > 95% Inh
Doxorubicin x5 123 58 
(35 - 80)
18014
(7085-19565)
1.57
(0.259-12.8)
0.523
(0.144-7.10)
139 
(3 - 505)
83%
(102/123)
Cisplatin (CDDP) 118 58 
(35 - 80)
7686 
(266 - 17144)
25.7 
(7.61 -143)
13.5
(0.400-79.4)
445
(113-940)
4%
(5/118)
Treosulfan (TREO) 106 59 
(35 - 80)
12657 
(433-18121)
133 
(23.9 - 703)
44.9 
(3.39 - 391)
343 
(91 - 846)
44%
(47/106)
5-Fluorouracil (5-FU) 6 51
(48 - 64)
16672 
(0- 18936)
294
(62.0-931)
52.6 
(12.7 - 574)
151 
(46- 1338)
67%
(4/6)
Vinorelbine (VinR) 53 61 
(40 - 80)
15508 
(6145 - 19158)
16.2
(0.660-26.9)
0.639
(0.367-15.5)
183
(15-502)
72%
(38/53)
Doxorubicin x5 + CDDP 52 60 
(36 - 80)
18615 
(12267- 19488)
2 1 *
( 6  - 246)
9 *
(3 - 52)
92
(8-314)
8 8 %
(46/52)
Doxorubicin x5 + TREO 41 61 
(44 - 80)
18725 
(12857- 19491)
2 1 *
( 6  - 205)
8 *
(4 - 72)
92 
( 8  - 346)
98%
(40/41)
Doxorubicin x5 + 5-FU 11 58 
(48 - 69)
17455 
(10696 - 19234)
40*
(10-292)
9 *
(4 - 46)
119
(21-361)
55%
(6 / 1 1 )
Doxorubicin x5 + VinR 53 61 
(36 - 80)
19013 
(16746 - 19488)
1 2 *
( 6  - 8 6 )
4 *
(3 - 28)
37 
(0 - 209)
98%
(52/53)
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Table 8.2 Median values and range (in brackets) for AUC, IndexsuM, IC90 and IC50 measured in n samples. For the combination the values 
marked with (*) are expressed as percentage of TDC. An IndexsuM of > 600 represents no activity and < 300 is taken as sensitivity for most 
single agents. An IndexAUC of 19,000 would represent complete inhibition at all doses tested, while zero would equal no effect. The percentage 
of tumours showing >95% and >99% inhibition at 100% concentration tested is also shown.
Drug/Combination n Age IndexAUC IC90 nM IC50 nM IndexsuM > 95% Inh > 99% Inh
Doxorubicin x3 77 61
(38-81)
14084
(600-18788)
2 . 6 6
(0.543-31.9)
1.215
(0.129-17.7)
319 
(101 -684)
40%
(31/77)
2 1 %
(16/77)
Vinorelbine (VinR) 77 61
(38-81)
15712 
(2391 - 18883)
13.0
(1.56-56.4)
1.67
(0.429-31.3)
199 
(35 - 643)
31%
(24/77)
16%
(12/77)
Doxorubicin x3 + VinR 77 61
(38-81)
17947 
(5581 - 19300)
48*
(6-381)
9 *
(3-211)
131
(13-469)
84%
(65/77)
66%
(51/77)
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Figure 8.1 (a) Median (± interquartile range) activity o f  doxorubicin x5 in combination 
with cisplatin (CDDP) in n=52 ovarian cancer samples, (b) Combination analysis (Poch 
et al. , 1995) showing at least an additive effect o f  the two drugs in this series o f  
samples.
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Figure 8.2 (a) Median (± interquartile range) activity o f  doxorubicin x5 in combination 
with treosulfan (Treo) in n=41 ovarian cancer samples, (b) Combination analysis (Poch 
et a l 1995) showing at least an additive effect o f  the two drugs in this series o f  
samples.
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Figure 8.3 (a) Median (± interquartile range) activity o f  doxorubicin x5 in combination 
with vinorelbine (VinR) in n=53 ovarian cancer samples, (b) Combination analysis 
(Poch et a l 1995) confirming at least an additive effect o f  the two drugs in this series 
o f  samples.
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Figure 8.4 (a) Median (± interquartile range) activity o f  doxorubicin x3 in combination 
with vinorelbine (VinR) in n=77 ovarian cancer samples, (b) Combination analysis 
(Poch et al. , 1995) showing an additive effect o f  the two drugs in this series o f  samples.
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Figure 8.5 Combination indices calculated for each sample tested with doxorubicin x3 
and vinorelbine at 90% cell death (CI90; panel a) and at 50% cell death (CI50; panel b). 
Cl values <0.8 suggest synergy; Cl values >1.2 indicate antagonism; and values 
between 0.8 and 1.2 indicate additivity (Chou & Talalay 1984, Greco et al., 1995).
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8.4 Discussion
PEG-DOX has proved somewhat useful as a single agent in recurrent ovarian cancer 
(Muggia et al., 1997; Campos et a l , 2001; Gabizon, 2001; Gordon et a l, 2001; Hensley 
et a l, 2001; Muggia & Hamilton, 2001). Therefore it was decided to investigate its 
activity in this tumour type using the ATP-TCA. As it was not possible to test PEG- 
DOX directly in the assay (Wang et a l, 1999), high concentrations of free doxorubicin 
(x5) (Neale et a l, 2000a) were used to take into account the enhanced intratumoral 
concentrations apparently achievable with PEG-DOX (Gabizon et a l, 1994; Vaage et 
a l, 1994; Lasic, 1996; Gabizon et a l, 1998; Symon et al., 1999; Gabizon, 2001). The 
proportion of tumours apparently sensitive to doxorubicin x5 exceeded the response 
rates obtained in clinical trials of PEG-DOX in recurrent ovarian cancer (Muggia et a l, 
1997; Campos e ta l, 2001; Gabizon, 2001; Gordon et al., 2001; Hensley etal., 2001; 
Muggia & Hamilton, 2001). The largest of these obtained a 20% response rate (Gordon 
et a l, 2001). The reason for this discrepancy may be overestimation of the likely 
concentration of free doxorubicin to which tumour cells are actually exposed. Some of 
the doxorubicin measured in the previous pharmacokinetics studies of PEG-DOX may 
have been sequestered within liposomes. Gabizon et al (1994) measured the 
pharmacokinetics of doxorubicin and/or liposome-associated doxorubicin in seven 
patients after injections of equivalent doses (50 mg / m2) of free doxorubicin and PEG- 
DOX. The plasma elimination of PEG-DOX followed a biexponential curve with 
median half-lives of 2 and 45 hours, and nearly 100% of the drug detected in plasma 
after PEG-DOX injection was in liposome-encapsulated form (Gabizon et a l, 1994). In 
the ATP assay free doxorubicin is incubated directly with the tumour cells for 144 
hours, bypassing the distribution phase, and also excluding renal and hepatic clearance; 
therefore in light of the differences in pharmacokinetics, the results presented in this 
chapter are a very vague approximation of the activity of PEG-DOX.
The initial use of x5 the standard TDC for doxorubicin was based on available data 
from animal studies (Vaage et a l, 1994; reviewed in Gabizon et a l, 2003). Forty hours 
after treatment with PEG-DOX the levels of doxorubicin in mice prostate carcinoma 
xenografts were greater than 7.0 pg / mg tumour tissue; the intratumour concentration 
then decreased following a biphasic pharmacokinetics, with a remarkable level of 1.5 pg 
drug / mg tissue still present 160 hours after treatment (Vaage et a l, 1994). Northfelt et 
al (1996) reported localisation in Kaposi’s sarcoma lesions of 5.2- to 11.4-fold higher
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concentrations of doxorubicin after treatment with PEG-DOX compared to treatment 
with an equivalent dose of free doxorubicin. Seventy-two hours after 10 mg/m2 PEG- 
DOX was administered, the levels of doxorubicin in sarcoma biopsies were 2.06 ± 0.42 
pg / mg tissue. This concentration is in the range tested in the ATP-TCA (1.5 pg/ml for 
Doxo x3 and 2.5 ug/ml for Doxo x5), although in the assay the cells were incubated for 
a longer period, 144 hours, with a likely increase of AUC. Another report measured 
doxorubicin concentration in bone tumour metastases from two breast carcinoma 
patients (Symon et a l , 1999): in the first case, 6 days after administration of 50 mg/m 
PEG-DOX the levels were 6.5 pg/g of tissue; the intratumour doxorubicin concentration 
was 1.4 pg/g of tissue in the second patient who had received 35 mg/m PEG-DOX 
twelve days prior obtaining the biopsy. Another study of human subjects presented at 
the 2001 San Antonio Breast Cancer Symposium also suggested a higher and more 
sustained enhancement of doxorubicin levels in tumours from breast cancer patients 
treated with PEG-DOX (Schueller et a l, 2001), however these observations have not 
been fully published.
On the basis of the data above described, the concentration tested in the ATP-TCA for 
liposomal doxorubicin was lowered to x3 the normal TDC for free doxorubicin. The 
reduced concentration was tested in a group of 77 ovarian cancer specimens, and, as 
expected, the proportion of samples sensitive to the drug was decreased when compared 
to that observed in the series tested with x5. However, the second group of samples was 
found to be in general more resistant to doxorubicin, as demonstrated by the increased 
median IC50 and IC90 values. While this can be attributed to heterogeneity of 
chemosensitivity in different human cancers, other technical factors may be important. 
The shape of the median concentration-inhibition curve for doxorubicin x3 was 
sigmoid, while that for x5 was somewhat flatter. This could have produced inaccurate 
calculations of the IC90 and IC50 parameters, which are extrapolated with a 
mathematical algorithm from the dose-inhibition curve. In addition, the high 
concentrations employed when testing doxorubicin at the x5 concentration could have 
produced a general increase in chemosensitivity due to the volatility of the drug itself. 
Although cross-talk between wells in the plate does not generally represent a problem in 
the ATP-TCA, occasional cases of enhanced cytotoxicity due to drug volatility of 
certain compounds have been observed (Andreotti et a l, 1995). Thus it is possible that 
the levels of doxorubicin present in the wells containing the 100% TDC and 200%
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TDC, by evaporation, have increased the actual levels of drug exposure also in those 
wells containing the lower concentrations. While these are only speculations, correlation 
data comparing ATP-TCA results with clinical outcome from follow-up of those 
patients in this series treated with PEG-DOX are awaited.
The previous study that tested high concentrations of doxorubicin in the ATP-TCA did 
not explore combinations in any detail, though it was noted that the addition of 
gemcitabine was unable to augment the response to any great extent (Neale et a l, 
2000a), a finding that has now been explored clinically in a small phase I study (Rivera 
et al., 2001). While this study did show 9/27 responses, it should be noted that 6 
patients had not received prior chemotherapy. Equally, I did not try to combine TOPO I 
and II inhibitors, as topotecan and PEG-DOX was found to be toxic (Ryan et a l, 2000).
As most of the patients had had previous exposure to taxanes, I did not test this in 
combination with doxorubicin x5, though it should be noted that recent results 
combining liposomal doxorubicin with docetaxel are encouraging (Sparano et a l,
2001). I chose instead to examine the effect of doxorubicin on cisplatin resistance and in 
combination with another alkylating agent to which resistance is less common in this 
setting, treosulfan. The results for the combination of doxorubicin x5 with treosulfan, 5- 
FU and cisplatin are relatively disappointing, with little improvement in efficacy 
compared with single agent doxorubicin x5, though these combinations are still active 
(table 8.1).
The combination of vinorelbine and doxorubicin x5 or x3 showed consistently additive 
effects in both group of samples studied. In a few cases strong antagonism was found, 
while at the same time in a number of cases true synergism was identified. This 
combination was tried in the clinic in metastatic breast cancer and was found to be safe, 
with acceptable toxicity (Burstein et a l, 1999; Gebbia et a l, 2002). It also showed a 
good response rate (68%) in the small number of patients (n = 18) treated (Gebbia et a l,
2002). Recently a phase I trial conducted in refractory or resistant ovarian cancer 
recorded a response in 6/29 patients (Tambaro et a l, 2003), which is somewhat lower 
than expected from the data presented above, but still suggests that this combination is 
worthy of further clinical consideration.
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There are a number of other combinations that need to be studied. Some of these are 
already being tested in the clinic on an empirical basis, for example the combination of 
PEG-DOX with Herceptin (Winer & Burstein 2001). It would be particularly interesting 
to examine the role of Caelyx/Doxil in combination with taxanes in ovarian cancer 
samples from previously untreated patients, as combinations of anthracyclines with 
taxanes have previously been shown to be very active in this tumour type (Kurbacher et 
a l , 1997 & 1998; Konecny et a l , 2000). It is clear from this and previous studies that 
the use of ATP-based chemosensitivity testing can assist the development of new 
regimens and has the potential to speed up their introduction to the clinic (Cree & 
Kurbacher 1999). The combination vinorelbine and PEG-DOX is clearly of 
considerable interest and further clinical data are awaited.
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Chapter 9 - Molecular determinants of sensitivity 
to doxorubicin
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9.1 Introduction
Resistance to doxorubicin is thought to be mediated via a number of different 
mechanisms (see chapter 2), which include mutation or alteration of its target enzyme, 
TOPO Ila; up-regulation of drug export proteins, such as BCRP, MRP1, MVP and 
MDR-1; and other complex mechanisms, which are related to the multiple pathways 
leading to cell death, including apoptosis, cell cycle regulation and checkpoints, and 
DNA repair (Larsen & Skladanowski, 1998; Beck et a l , 1999; Gottesman et a l , 2002). 
Most of these mechanisms have been identified in cell lines studies, while their clinical 
relevance in relation to doxorubicin chemotherapy has been less investigated.
A number of recent studies have tried to correlate the molecular phenotype with ex vivo 
chemosensitivity of tumour-derived cells to anthracyclines (Satherley et a l, 2000; 
Koshiyama et a l, 2001a & 2001b; Coley et a l, 2002; Lewandowicz et a l, 2002). 
Koshiyama et al (2001) used the MTT assay to assess the ex vivo chemosensitivity of 
24 endometrial and 19 ovarian carcinoma samples; this study found that the 
immunohistochemical detection of TOPO Ila well correlated with sensitivity to 
topoisomerase Ila inhibitors, including doxorubicin. Another study by Coley et al 
(2002) also employed the MTT assay to study doxorubicin resistance in ovarian tumour 
derived cells; but they did not find any significant relationship between P-gp expression 
determined by immunocytochemistry and sensitivity to doxorubicin or the ability of P- 
gp inhibitor PSC-833 to modulate such sensitivity. Similarly another study from the 
same group (Lewandowicz et a l, 2002) failed to correlate MRP1 expression with 
doxorubicin sensitivity in a group of 20 ovarian cancer samples tested with the MTT 
assay. Satherley et al (2000) correlated the ATP-TCA chemosensitivity data of 29 
choroidal melanoma samples with the immunohistochemical expression of MDR1, 
MRP, MVP, TOPO Ila and TOPO lip. Again, this study did not find any significant 
difference in sensitivity to anthracyclines with any of the molecular markers examined. 
However of the 13 tumours found to show some anthracycline sensitivity ex vivo, six 
expressed TOPO Ila; while at least one of the classical drug resistance molecules LRP, 
MDR1 or MRP was expressed in all but one of the tumours showing weak 
anthracycline sensitivity.
While studies exist on the relationship between drug resistance gene expression in 
ovarian cancer and sensitivity to doxorubicin in the MTT assay, no such data has been
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published for the ATP-TCA in any cancers other than choroidal melanoma (Satherley et 
a l , 2000). Therefore I decided to determine the immunohistochemical expression of 
MDR1, TOPO I and TOPO Ila in a series of ovarian cancer tumours for which 
chemosensitivity testing results were available. In addition I also investigated the 
relevance of P-gp and other putative chemoresistance genes by measuring the mRNA 
levels in breast and ovarian tumour derived cells using qRT-PCR. I also aimed to test 
the hypothesis that the lack of correlation between gene expression and doxorubicin 
resistance is due to rapid up- or down-regulation of genes involved in sensitivity to this 
drug.
9.2 Materials and Methods
IHC. IHC for P-gp, TOPO I and TOPO Ila was performed on 39 ovarian cancer 
specimens as detailed in Chapter 2 The median age of the patients was 58 years (range 
38 -76). These were all previously treated with carboplatin alone, or carboplatin + 
taxane first line, followed in 9 cases by an anthracycline-containing regimen.
qRT-PCR samples. Tumour derived cells were obtained from 14 breast cancer patients 
(median age 58; range 37-94; previous treatment included paclitaxel plus mitoxantrone 
for one patient; epirubicin plus cyclophosphamide for another patient; anti-hormonal 
treatment for a third patient) and 12 ovarian cancer patients (median age 58; range 42- 
72; 3 primaries, and 9 from recurrent ovarian cancer patients who had been previous 
treated with platinum alone (n=4) or platinum plus taxane (n=5), followed by treosulfan 
and gemcitabine in 2 cases). Cells were grown for 6 days in CAM with or without 
doxorubicin, before RNA extraction and further PCR analysis (chapters 2 & 3).
9.3 Results
9.3.1 IHC expression of P-gp, TOPO I / Ila and sensitivity to doxorubicin
Immunostaining for P-gp was positive in 11/39 (28%) samples tested with doxorubicin. 
The median doxorubicin IC90 values for P-gp negative and positive samples were 2.37 
and 3.71 pM, respectively (p<0.041, Mann-Whitney U test), while the median IC50 
values were respectively l.lOjiM and 1.54pM (p=NS, Mann-Whitney). A modest 
correlation was observed by linear regression analysis (figure 9.1) between the IC90 
values of doxorubicin and P-gp (R=0.357; p<0.0257), while there was no correlation 
with the IC50 values. A modest correlation was found when the data was analysed using
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non-parametric Spearman’s correlation (table 9.1). P-gp positivity shifted the 
concentration-inhibition curve of doxorubicin to the right (figure 9.2).
Immunostaining for TOPO I and Ila was positive in 32/39 (82%) and 8/39 (20%) 
samples tested with doxorubicin respectively. No correlation by linear regression 
analysis or Spearman rank test was found between the IC50 or IC90 values for 
doxorubicin and either the TOPO I or the TOPO Ila IHC indices (table 9.1).
Table 9.1 Spearman rank correlation analysis for comparison between the IC90 and 
IC50 values of doxorubicin in the ATP-TCA and the IHC expression of P-gp, TOPO I 
and TOPO Ila.
Protein
IC9Ci pM IC50 pM
R P R P
P-gp 0.348 <0.0301 0.343 <0.0325
TOPO I -0.016 0.9245 0.074 0.6547
TOPO Ila 0.178 0.2794 0.218 0.1825
93.2 Effect of in vivo chemotherapy on doxorubicin sensitivity
I was able to compare the activity of doxorubicin x3 in 18 paired ovarian samples that 
were obtained from 9 patients before and after administration of an anthracycline-based 
regimen (mitoxantrone and paclitaxel, n=7; liposomal doxorubicin, n=2). An increase in 
resistance was seen in 7/9 cases (figure 9.3a). The mean IC50 values (±SD) of 
doxorubicin in the pre- and post-treatment samples were 0.65±0.46 and 1.44±1.03, 
respectively (p<0.0243; paired t test), confirming that resistance developed following 
treatment. No material from patients was available for PCR analysis both before and 
after treatment with PEG-DOX. However, I was able to compare the molecular profile 
of one pair of ovarian tumours obtained from another patient who received 6 cycles of 
mitoxantrone plus paclitaxel, rather than doxorubicin. The mRNA expression of 7 
chemosensitivity genes implicated in resistance to anthracyclines was measured by 
qRT-PCR as described previously (chapters 2 and 3) in two different experiments which 
produced similar results. The mean values of the calculated differences in gene 
expression are presented in figure 9.3 (b). A remarkable 114-fold increase of MDR1 
mRNA was found in the post-chemotherapy specimen when compared to the pre- 
chemotherapy sample. Among the other MDR genes studied, no changes were observed
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for BCRP and MVP, while a marginal decrease of MRP 1 expression was noted in both 
experiments. The expression of TOPO Ila appeared essentially similar between the two 
biopsies. A significant up-regulation of TOPO I mRNA levels (>3-fold) was detected, 
while TOPO lip expression was markedly decreased in the post-chemotherapy 
specimen.
9.3.3 Correlation between gene expression in control cells and chemosensitivity
Univariate analysis was performed to correlate the results obtained in the ATP-TCA 
with the gene expression profile measured in tumour derived cells (cultured for six days 
in CAM only) by qRT-PCR. The results indicated a correlation (R=0.7204, p<0.0124) 
between the expression of ERCC1 and the IC50 values determined for doxorubicin in 
11 breast samples obtained from chemotherapy naive patients (figure 9.4). No other 
statistically significant correlations were identified for the other genes tested.
93.4 Doxorubicin effects in short-term cell culture
To pursue the changes in gene expression after doxorubicin exposure further, we used 
RT-PCR for the genes as the endpoint in plates set up alongside the ATP-TCA using 
both breast and ovarian tumour derived cells. This allowed us to examine the changes in 
gene expression after 6 days of drug exposure.
An example of an ovarian tumour is shown in figure 9.5 (a); in this case doxorubicin 
exposure induced at least a 4-fold up-regulation of both MDR1 and BCRP genes, while 
at the same time markedly reducing the expression levels of Topo Ila. The ATP-TCA 
results (figure 9.5 b) for this sample showed resistance to doxorubicin (IC90 = 4.92pM; 
IC50 = 2.20 pM; IndexsuM = 472), which was partly reversed in the assay by the 
addition of tariquidar, a P-gp specific inhibitor. Notably, IHC staining for P-gp in this 
sample (cytoclot) was negative, as shown in figure 9.5 (c).
When the results of the qRT-PCR experiments were grouped together for each target 
gene in each tumour type, a significant up-regulation of MRP-1 (p<0.0001, Wilcoxon 
matched pairs test; table 9.2) and of MVP (p<0.0023, Wilcoxon matched pairs test) was 
observed, but this was limited to the breast cancer subgroup. In the ovarian cancer group 
the levels of MRP-1 and MVP increased over 0.5 fold in only 4/12 and 3/12 samples, 
respectively. No significant changes were found in the median expression of MDR-1
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and BCRP, although it should be noted that there was substantial heterogeneity among 
individual tumours (figure 9.6- a,d). For example, I measured a greater than 2-fold 
increase of MDR-1 levels in 2/12 ovarian samples (none of whom had previously 
received a MDR-1 pumped chemotherapeutic agent), and a significant up-regulation of 
BCRP in 3/12 ovarian samples.
Doxorubicin exposure also induced significant down-regulation of TOPO Ila (table 
9.2); its median levels decreased from 0.546 to 0.017 relative units in a group of 14 
breast samples (p<0.0001, Wilcoxon matched pairs test) and from 1.491 to 0.089 
relative units in the ovarian cancer subgroup (p<0.0015, Wilcoxon). The down- 
regulation of TOPO Ila levels was greater than 2-fold in 13/14 breast samples and in 
9/12 ovarian samples (figure 9.6-h). We observed a slight increase of TOPO I only in 1 
breast tumour, while we noted a general trend of diminished levels in the remaining 
samples, particularly in the ovarian subgroup.
No significant changes were found in the median expression of ERCC1 (table 9.2; 
figure 9.6-c). However it must be noted that the expression levels of this gene increased 
more than 0.5 fold in 3/11 ovarian and 3/14 breast samples.
Doxorubicin exposure decreased the expression of COX-2 in ovarian cells from 0.445 
to 0.144 units (table 9.2). Although this difference was not statistically significant, a 
moderate down-regulation was noted in 11/12 ovarian samples. The level of COX-2 in 
breast cancer cells, instead, increased after doxorubicin exposure in 6/14 samples.
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Table 9.2 Relative expression of mRNA levels in tumour samples after ex vivo exposure 
to doxorubicin (Doxo). The p values have been calculated using non parametric 
statistics, i.e. the Wilcoxon matched pairs test for paired samples with a Bonferroni’s 
correction (statistical significance was taken at p<0.005).
Target
gene
Number
of
samples
Breast tumour 
samples
P
Number
of
samples
Ovarian
sam
tumour
pies
P
Control Doxo Control Doxo
BCRP 14 0.039 0.044 0.8077 12 0.010 0.027 0.042
COX-2 14 7.72 12.5 0.2958 12 0.445 0.144 0.0269
ERCC1 14 0.711 0.826 0.2412 11 0.440 0.506 0.4922
MDR1 14 0.0698 0.0567 0.0494 12 0.00550 0.00493 0.2036
MRP1 14 3.89 5.69 0.0001 12 1.89 2.32 0.083
MVP 14 4.99 6.92 0.0023 12 2.25 2.69 0.042
TOPO I 14 5.46 5.13 0.0419 12 6.11 3.36 0.001
TOPO Ila 14 0.546 0.017 0.0001 12 1.49 0.089 0.0015
TOPO Up 14 6.62 6.46 0.0785 12 5.91 5.25 0.0322
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Figure 9.1 Correlation between sensitivity to doxorubicin (expressed as IC90 and IC50) 
and P-gp expression determined by immunohistochemistry in 39 ovarian cancer 
samples.
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Figure 9.2 Concentration-inhibition curves for doxorubicin in P-gp negative (n=28) and 
P-gp positive (n=l 1) samples. The error bars show the interquartile range.
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Figure 9.3 (a) Doxorubicin activity (IC50) in the ATP-TCA in paired samples obtained 
from 9 ovarian cancer patients before and after they were treated with an anthracycline 
containing regimen (paclitaxel+mitoxantrone n=7; liposomal doxorubicin n=2). Gene 
expression changes in one o f  these pairs o f  samples were analysed by qRT-PCR (b).
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Figure 9.4 Correlation between the sensitivity to doxorubicin (expressed as IC50pM) 
and the relative ERCC1 mRNA levels measured by qRT-PCR in breast tumour derived 
cells not exposed to previous chemotherapy (n=l 1).
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(mean±SD) for the same sample; in this case doxorubicin resistance is partly reversed in 
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Figure 9.6 Changes in (a) BCRP, (b) COX-2, (c) ERCC1, (d) MDR1, (e) MRP1, (f) 
MVP gene expression after doxorubicin exposure in the ATP-TCA in tumour 
derived cells from 12 ovarian (in red) and 14 breast (in black) cancer patients.
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expression after doxorubicin exposure in the ATP-TCA in tumour derived cells from 12 
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9.4 Discussion
The heterogeneity of chemosensitivity to doxorubicin observed in chapter 8 has been 
investigated further in this chapter and correlated with gene expression profiling for P- 
gp and TOPO I/IIa determined by both IHC and qRT-PCR. This study failed to 
correlate strongly any of the investigated genes with doxorubicin resistance, although 
evidence was found supporting a role of P-gp, especially in a sub-group of the ovarian 
cancer patients. These findings are consistent with previous reports from various groups 
that were not able to correlate molecular expression with chemosensitivity data 
(Satherley et al., 2000; Coley et al., 2002; Lewandowicz et a l , 2002).
In this chapter it was also showed that ovarian patients who relapse after being treated 
with an anthracycline based regimen are usually more resistant to doxorubicin in the 
ATP-TCA when the results of the assay are compared with the results of the test before 
chemotherapy. In the only case in which material was available, the expression levels of 
MDR1 mRNA were increased over 100-fold in the biopsy obtained after anthracycline 
plus taxane treatment. This is no surprise as the acquisition of a multidrug resistance 
phenotype in relapsed ovarian cancer is well documented (Baekelandt et al., 2000). 
According to the model proposed by Goldie and Coldman (1979) drug resistance in a 
cancer cell population arises from spontaneous mutations which confer a selective 
survival advantage. The growth of selected clones requires several cell divisions and the 
development of drug resistance becomes apparent after several cycles of chemotherapy 
(Duhem et al., 1996). However, a number of recent studies have shown that the 
expression of P-gp may be rapidly up-regulated shortly (i.e. within hours) after the 
patients are administered chemotherapeutic agents such as anthracyclines (Abolhoda et 
al., 1999; Hu et a l , 1999; Stein et a l , 2002; Tada et a l , 2002). The short timeframe 
does not support a role for mutations driven resistance. On the other hand, if this was a 
general pattern in cancer behaviour, then it could explain, at least in part, the 
inconsistent results obtained when gene expression measured at diagnosis is compared 
with the in vivo or ex vivo response to chemotherapy.
To test this hypothesis I measured the changes in gene expression induced by 
doxorubicin exposure for 6 days in primary breast and ovarian cells. The length of 
exposure was chosen so that tumour derived cells from the ATP-TCA could be used for 
qRT-PCR studies. While a period of 6 days is longer in relation to the half life of free
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doxorubicin (Northfelt et a l , 1996), it is considerably shorter when compared to the 
several months employed by other groups to select doxorubicin resistant sublines 
(Kudoh et a l , 2000; Watts et a l , 2001; Kang et a l, 2004).
A marked and consistent decrease in the expression levels of TOPO Ila was observed 
after doxorubicin exposure. This was expected, as TOPO Ila inhibitors preferentially 
kill cells with high levels of this enzyme (Hande 1998).
A significant up-regulation of drug transporter genes, in particular of MRP 1 and MVP 
in breast cancer cells, was also noted. However, not all tumours up-regulated these 
genes, and considerable variation was found for all transporters studied.
This is the first study that has coupled a well standardised ex vivo chemosensitivity 
assay to qRT-PCR technology to measure gene expression changes induced by drug 
exposure. The only comparable data existing in literature are provided by cDNA 
microarray studies. Kudoh et al. (2000) used cDNA microarrays to monitor the 
expression profiles of MCF-7 cells that were either transiently treated with doxorubicin 
or selected for resistance to doxorubicin. These researchers identified a set of genes with 
altered expression that overlap between doxorubicin-induced and -selected cells, and 
among them XRCC1. In our experiments, another enzyme involved in similar NER 
processes, ERCC1 was found to correlate with doxorubicin sensitivity in tumour 
derived cells from untreated breast cancer patients, but not in ovarian cancer cells. Up- 
regulation of ERCC1 in response to doxorubicin treatment was noted in approximately 
25% samples, suggesting a role of for NER in repairing the DNA damage indirectly 
induced by topoisomerase inhibitors (Champoux 2001).
Another study used cDNA microarrays to search for differentially expressed genes 
between a human multiple myeloma cell line and doxorubicin-selected sub-clones that 
express ABCB1 and are multidrug resistant (Watts et a l, 2001); these authors found 
that sensitivity to doxorubicin was correlated with the expression of a number of 
apoptotic genes, most of which have never been associated with anthracycline 
resistance.
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While cDNA microarray studies offer the potential advantage of assessing thousands of 
target genes, the poor reproducibility of the data produced and the background noise 
(Macgregor & Squire 2002) suggests the need for a cautious approach when interpreting 
their predictive value, particularly when assessing small differences in gene expression. 
Moreover microarrays are inherently less sensitive than real time RT-PCR, so, as 
suggested by Macgregor & Squire (2002), less abundant transcripts (such as MDR1 or 
BCRP in breast and ovarian cancer cells) may be and almost certainly will be missed.
In conclusion this study has confirmed that the resistance to doxorubicin observed in the 
ATP-TCA is multifactorial and cannot be predicted by the expression of a single gene 
such as MDRl/P-gp or TOPO Ila. The results have also shown that the substantial 
heterogeneity of chemosensitivity among samples of the same tumour type is reflected 
by heterogeneity of resistance/sensitivity molecular determinants induced by 
doxorubicin at the mRNA level. The clinical relevance of these findings are partly 
corroborated by the observed rapid up-regulation of MDRl/P-gp in patients undergoing 
anthracycline-based chemotherapy (Abolhoda et al., 1999; Hu et al., 1999; Stein et a l , 
2002; Tada et a l , 2002). More clinical studies are needed to confirm the importance of 
such rapid changes in the molecular phenotype in conferring resistance to 
anthracyclines.
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Chapter 10 -  The effect of tariquidar on 
sensitivity to doxorubicin, vinorelbine and 
paclitaxel
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10.1 Introduction
New specific P-gp inhibitors are currently being developed to overcome MDR-1 
mediated resistance (see Chapter 1.2.1), among them tariquidar (XR9576; figure 10.1). 
This is a highly potent anthranilic acid derivative that has been demonstrated to reverse 
P-gp dependent multidrug resistance in various preclinical models. Tariquidar is a non­
competitive P-gp inhibitor, it has a high affinity for P-gp (Xd=2.5±0.7nM; Martin et a l , 
1999) and, importantly, has no effect on the related transporter multidrug-resistance- 
associated protein (Stewart et a l , 1998). The binding site of tariquidar on P-gp has not 
clearly been defined, but it inhibits the ATPase activity of P-gp (Martin et a l , 1999).
The inhibitory effects of tariquidar on the P-gp transporter pump greatly exceed those of 
first- and second-generation P-gp modulators with respect to potency and duration of 
action. In an in vitro study, P-gp pump transport remained blocked for more than 22 
hours after tariquidar had been removed from the culture medium; in the same assay, 
the clearance time for cyclosporin was 60 minutes (Mistry et a l, 2001). Tariquidar was 
found to potentiate the activity of a number of MDR-associated cytotoxics in cell lines 
overexpressing P-gp with a typical IC50 of approximately 30 nM (Mistry et a l, 2001). 
This in vitro activity translates to tumour bearing animals where tariquidar has been 
shown to reverse the resistance of multidrug-resistant human xenografts at well- 
tolerated doses (Mistry et a l, 2001).
Phase I clinical trials of tariquidar commenced in May 1998 in healthy volunteers and 
were single dose, dose escalation studies to establish its safety and tolerance and to 
evaluate the plasma concentrations. In these studies, doses of tariquidar up to 2mg/Kg
i.v. and up to 750mg/volunteer p.o. were very well tolerated. These trials also included 
the use of a surrogate marker of efficacy to establish inhibition of P-gp as a 
pharmacological end point. As reported by Witherspoon et a l (1996), CD56+ 
lymphocytes constitutively express significant levels of P-gp. Thus the measurement of 
inhibition of P-gp in CD56+ lymphocytes is a surrogate for the inhibition of P-gp in 
tumours. In healthy volunteers tariquidar effectively inhibited P-gp in CD56+ 
lymphocytes, and 100% blockade was seen at tariquidar plasma concentration around 
240 nM (Stewart et a l, 2000). In phase Ila trials, the pharmacokinetic behaviour of 
tariquidar was studied in combination therapy with a range of P-gp pumped cytotoxic 
agents, namely vinorelbine, doxorubicin and paclitaxel. The primary purpose of these 
trials was to assess the degree of interaction, if any, between tariquidar and the cytotoxic
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agent. The successful conclusion of the first phase Ila trial involving tariquidar and 
paclitaxel in ovarian cancer patients was announced in March 2000. Although not 
designed as an efficacy study, a significant response was observed in 6 (3CR+3PR) of 
the 12 cases in this cohort of patients who had recurred more than six months after first 
(n=l 1) or second-line (n=l) treatment (Thomas et al., 2001). Further positive data was 
also announced for the second of the Phase Ila trials, in which tariquidar was 
administered in combination with doxorubicin (Ferry et al., 2001). In the third and final 
Phase Ila trial tariquidar was given in combination therapy with vinorelbine and one 
patient each with breast cancer and renal cancer responded to chemotherapy. In the last 
study administration of tariquidar resulted in a 15% increase in vinorelbine AUC and 
reduced clearance, but these differences were not statistically significant (Abraham et 
al., 2001). The results of these three studies demonstrated that tariquidar is a potent P- 
gp inhibitor, without significant side effects and with less pharmacokinetic interaction 
than other inhibitors used previously (Boniface et al., 2002). This allowed the use of 
standard doses of these chemotherapeutic agents without the need for dose reduction. A 
randomised placebo-controlled phase III clinical trial in patients with non-small-cell 
lung cancer (NSCLC) started in 2002, using tariquidar as an adjunctive treatment in 
combination with first-line chemotherapy. After enrolling 304 patients this trial was 
stopped in May 2003 following a recommendation from the independent Data Safety 
Monitoring Committee (DSMC). The review of the data arising from the Phase III 
NSCLC trial has recently been completed. This review has shown that the levels of 
toxicities associated with the cytotoxic drugs administered to patients in the trial were 
increased in those individuals receiving tariquidar and cytotoxic compared with those 
receiving placebo and cytotoxic.
The aim of this study was to determine the ability of tariquidar to alter the 
chemosensitivity of various solid tumours to commonly used chemotherapeutic agents. 
It was chosen to study doxorubicin, paclitaxel, and vinorelbine as examples of 
anthracyclines, taxanes and vinca alkaloids, and have related the results to the 
expression of P-gp by the tumours studied, though this was limited by the nature of the 
material available.
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Figure 10.1 Chemical structure of tariquidar bis mesylate salt that was used in the ex- 
vivo studies.
10.2 Materials and methods
Tissue Samples. Of the 37 solid tumour samples studied, 21 were ovarian carcinomas, 5 
were unknown primaries, 5 were skin melanomas, 2 were breast carcinomas, 2 were 
oesophageal, 1 colon and 1 lung (NSCLC) carcinomas. Patients consisted of 32 females 
and 5 males, having a median age of 58 (range 36-76). Several patients received one or 
more chemotherapy regimens, while 10/37 had no previous treatment (table 10.1).
Drugs. Tariquidar was provided by Xenova pic (Slough, Berkshire) as powder. A stock 
solution of tariquidar (XR9576.14 bis-mesylate salt; figure 10.1) was prepared in 
DMSO at a concentration of 1 mg/ml and stored as aliquots at -20°C. For cell 
treatments, the stock solution was further diluted in culture medium to give a tariquidar 
TDC lpM with the final DMSO concentration less than 0.1%. The other drugs used in 
the assay were prepared as described in chapter 2.2.9. Only one plate was prepared with 
the combinations of tariquidar with vinorelbine, paclitaxel and doxorubicin. 
Combinations were made up by adding both drugs at their 200% TDC to the wells at the 
beginning of the assay: sequential studies were not performed. Not all drugs or 
combinations were tested in every case.
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IHC. When solid tissue or cytoclots were available (n=23), MDRl/P-gp monoclonal 
antibody (NCL-JSB1) from Novacastra Laboratories Ltd was visualised using the 
Vectastain® Universal Alkaline Phosphatase kit (Vector Laboratories Ltd., 
Peterborough, UK), as detailed in chapter 2.4. All of the IHC shown here was carried 
out by the biomedical scientists working with Prof Cree’s research team in Portsmouth 
and London.
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Table 10.1 Patient and sample characteristics.
Tumour
Type
No of 
samples
Patient age 
(median) Sex Sample type Previous Treatment (1)
Ovarian
carcinoma
21 58 (38-76) 21F 5 solid, 2 pleural fluid, 14 
ascites
Carboplatin (n=13), Platinum+Taxane (n=10), Liposomal 
Doxorubicin (n=3), Treosulfan+Gemcitabine (n=2), 
Carboplatin+Gemcitabine (n=l), Mitoxantrone+Paclitaxel 
(n=l), Topotecan (n=l), Etoposide (n=l)
Skin
Melanoma
5 48 (36-66) 3M:2F 5 solid Melphalan (n=l), Cyclophosphamide (n=l)
Unknown
Primary
5 61 (45-68) 5F 3 solid, 2 pleural fluid Carboplatin (n=l)
Breast
carcinoma
2 49 (39-59) 2F 1 solid, 1 pleural fluid Anastrozole (n=l)
Oesophageal
carcinoma
2 62 (52-72) 2M 2 solid Epirubicin+Cisplatin+5-Fluorouracil (n= 1)
Colon
carcinoma
1 39 IF solid Irinotecan (n=l)
Lung
(NSCLC)
1 58 IF pleural fluid Cisplatin+Vinorelbine (n=l)
Total 37 58 (36-76) 5M:32F 17 solid, 20 fluid
(1) The numbers in brackets indicates the number of patients who received the previously listed treatment. In the ovarian carcinoma subset 
several patients received more than one chemotherapeutic treatment.
10.3 Results
10.3.1 Anti-tumour activity of single agents
As expected, tariquidar alone showed no activity over a wide range o f  concentrations up 
to and including 2 pM (n=14) (figure 10.2). Each o f  the cytotoxics tested produced a 
wide range o f  tumour inhibition, as can be seen in table 10.2. This is consistent with 
considerable heterogeneity o f  chemosensitivity, as previously published (Cree et a l ,  
1999; Whitehouse et a l ,  2003; Mercer et a l ,  2003).
The calculated IC90 values were used to assess the activity o f  each cytotoxic. Values o f  
IC90 > 100 %TDC were considered to suggest resistance, while values <100 %TDC 
were interpreted to suggest probable clinical sensitivity to the agent tested. When the 
addition o f  tariquidar decreased the cytotoxic IC90 to <50 % TDC, this was interpreted 
as a complete reversal o f  resistance.
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Figure 10.2. Tumour cell growth inhibition by tariquidar as a single agent (n=14). The 
results are expressed as mean mean±SEM o f  the values calculated for each tumour for 
each drug concentration.
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Table 10.2. Summary of ATP-TCA results (median and range) of tariquidar activity in combination with vinorelbine, doxorubicin and paclitaxel. 
Statistical analysis was peformed using the two-tailed Wilcoxon paired signed rank test; n indicates the number of samples tested for each drug 
combination.
Patients n= 31 
(4M:27F) Age
Vinorelbine 
IC90 pM
Vinorelbine + 
tariquidar 
IC90 pM
P
Vinorelbine 
IC50 pM
Vinorelbine + 
tariquidar 
IC50 pM
P
Median 59 15.51 9.51 0.0003 2.27 0.77 0.0739
Range (36-76) (0.66-61.41) (0.67-20.01) (0.37-34.11) (0.37-11.96)
Patients n=37 
(5M:32F) Age
Doxorubicin 
IC90 pM
Doxorubicin + 
tariquidar 
IC90 pM
P
Doxorubicin 
IC50 pM
Doxorubicin + 
tariquidar 
IC50 pM
P
Median 58 2.57 1.67 <0.0001 1.57 0.92 0.0028
Range (36-76) (0.39-21.49) (0.05-16.16) (0.10-11.95) (0.03-8.98)
Patients n=34 
(4M:30F) Age
Paclitaxel 
IC90 pM
Paclitaxel + 
tariquidar 
IC90 pM
P
Paclitaxel 
IC50 pM
Paclitaxel + 
tariquidar 
IC50 pM
P
Median 58 27.42 20.65 0.0201 9.72 7.73 0.0425
Range (36-76) (5.73-59.02) (6.53-38.17) (0.80-32.81) (0.80-25.89)
103.2 Effect of tariquidar on doxorubicin activity
The median doxorubicin IC90 and IC50 were 2.57 pM and 1.57pM, respectively. The 
IC90 of doxorubicin was >100%TDC (2.5 pM) in 20/37 (54%) samples. For the ovarian 
cancer subset, in vitro resistance, according to IC90, was seen in 12/21 (57%) samples.
Immunostaining for P-gp was positive in 9/22 (41%) samples tested with doxorubicin. It 
is notable that 5/13 P-gp negative samples were obtained from chemotherapy naive 
patients, while 8/9 P-gp positive samples were from patients who had received previous 
treatment. The median doxorubicin IC50 values for P-gp negative and positive samples 
were 0.90 and 2.00pM, respectively, and this difference was statistical significant 
(p=0.0065, Mann-Whitney U test). The median doxorubicin IC90 values for P-gp 
negative and positive samples were 2.05 and 5.08 pM, respectively (p=0.0071, Mann- 
Whitney U test). A correlation was also observed by linear regression analysis between 
the IC90 of doxorubicin and P-gp staining (R=0.705; p=0.0002), and between the IC50 
and P-gp expression (R=0.815; p < 0.0001; Figure 10.3). It should be noted that this 
statistically significant correlation might be biased by the presence of three P-gp 
strongly positive tumours which showed high IC90 and IC50 values for doxorubicin. 
Indeed, on the basis of IC90, only 22 % (2/9) of the P-gp positive samples showed 
sensitivity to doxorubicin, while 85% (11/13) of the P-gp negative samples showed 
sensitivity.
The addition of tariquidar to doxorubicin decreased the median IC90 of doxorubicin 
from 2.57 to 1.67pM (p<0.0001) and the IC50 from 1.57 to 0.92pM (p=0.0028, 
Wilcoxon). An example of ATP-TCA results in which tariquidar modulates sensitivity 
to doxorubicin is shown in figure 10.4. Overall, tariquidar showed some reversal of 
resistance to doxorubicin in 14/20 (70%) samples classified as in vitro resistant, and in 2 
cases (10%) converted the sensitivity to an IC90 below 1.25 pM, which represents 50% 
TDC. Both these patients had recurrent ovarian carcinoma and none had previous 
anthracycline exposure. In the ovarian cancer subset, tariquidar showed some reversal 
of resistance to doxorubicin in 11/12 (92%) samples classified as in vitro resistant 
(figure 10.5). However, in one case that was considered sensitive to doxorubicin as a 
single agent, the addition of tariquidar increased the IC90 of doxorubicin from 1.24 to 
3.37pM. In all 9 P-gp positive cases the addition of tariquidar improved the activity of
261
doxorubicin in the ATP-TCA. In 4/9 cases (44%), the IC90 o f  doxorubicin decreased 
below 2.5 pM, and in 1/9 below 1.25 pM (figure 10.4).
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Figure 10.3 Linear regression analyses showing a correlation between P-gp staining in 
tumour samples (n=22) and sensitivity to doxorubicin in the ATP-TCA.
262
-20
0.05 0.11 0.22 0.43 0.86 1.67
Test Drug Concentration pM
(b)
doxorubicin doxorubicin + tariquidar
Figure 10.4 An example o f  the ATP-TCA results for an ovarian adenocarcinoma (a). 
Results are shown as mean (±SD) o f  triplicate values for each drug concentration. Error 
bars are not shown for some data points, as they are smaller than the symbols on the 
graph, (b) P-gp IHC for this sample.
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Figure 10.5 Effect o f  the addition o f  tariquidar on the activity o f  doxorubicin expressed 
as IC90pM in ovarian (a) and non-ovarian tumour samples (b). The samples labelled 
with a ‘plus’ in a black square are P-gp positive tumours, while the samples labelled 
with a triangle and a dashed line are P-gp negative tumours; P-gp staining was not 
performed in samples labelled with the other symbols. A line has been drawn in each 
graph to indicate 100% TDC o f  doxorubicin.
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1033  Effect of tariquidar on vinorelbine activity
The median IC90 and IC50 for vinorelbine were 15.5pM and 2.3pM. The IC90 of 
vinorelbine was >100% TDC (1 lpM) in 17/31 samples, indicating probable in vitro 
resistance in 55% of the tumours tested. For the ovarian cancer subset, in vitro 
resistance according to IC90 was seen in 8/17 (47%) tumours. Immunohistochemical 
staining for P-gp was positive in 7/22 (32%) samples tested with vinorelbine. The 
median IC90 values for P-gp negative and positive samples were 12.5 and 20.8pM, 
respectively, but this difference did not reach statistical significance (p=0.0556, Mann- 
Whitney U test). Semiquantitative visual assessment of the degree of staining showed 
no correlation with sensitivity to vinorelbine (IC90 and IC50) by linear regression 
analysis (data not shown). However, it should be noted that only 1/7 (14%) of the P-gp 
positive samples showed sensitivity to vinorelbine on the basis of IC90, while 8/15 
(53%) of the P-gp negative samples showed sensitivity to vinorelbine.
The addition of tariquidar decreased the median IC90 of vinorelbine from 15.5 pM to
9.5 pM (pO.OOl, Wilcoxon). Tariquidar showed some reversal of resistance to 
vinorelbine in 6/17 (35%) samples classified as resistant and in 1 case (6%) converted 
the sensitivity to an IC90 below 5.5 pM, which represents 50% TDC (figure 10.6). In 
the ovarian cancer subset, tariquidar showed some reversal of resistance to vinorelbine 
in 3/8 (37%) samples classified as resistant (figure 10.6). Examples of tariquidar effects 
on individual tumours tested with vinorelbine are shown in figure 10.7.
Tariquidar produced little or no effect on vinorelbine activity in P-gp negative samples 
(Figure 10.8). In all 7 P-gp positive cases the addition of tariquidar improved the 
activity of the vinca alkaloid in the ATP-TCA. In 4/7 P-gp positive cases (57%) the 
IC90 of vinorelbine decreased below 11 pM and in 1/7 below 5.5 pM.
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Figure 10.6 Effect o f  the addition o f  tariquidar on the activity o f  vinorelbine expressed 
as IC90pM in ovarian (a) and non-ovarian tumour samples (b). The samples labelled 
with a ‘plus’ in a black square are P-gp positive tumours, while the samples labelled 
with a triangle and a dashed line are P-gp negative tumours; P-gp staining was not 
performed in samples labelled with the other symbols. A line has been drawn in each 
graph to indicate 100% TDC o f  vinorelbine.
Effect o f tariquidar on vinorelbine activity in ovarian tumours
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Figure 10.7 Examples o f  the ATP-TCA results for (a) a cutaneous melanoma and (b) a 
colorectal adenocarcinoma. Results are shown as mean (±SD) o f  triplicate values for 
each drug concentration. Error bars are not shown for some data points, as they are 
smaller than the symbols on the graph. P-gp immunostaining for each sample is shown 
in panels (c) and (d).
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Figure 10.8 Effect o f  tariquidar on vinorelbine activity (mean±SEM) in (a) P-gp 
positive (n=7) and (b) P-gp negative (n=15) tumours.
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10.3.4 Effect of tariquidar on paclitaxel activity
The median IC90 and IC50 for paclitaxel were 27.4 fiM and 9.7jiM respectively. In 
vitro resistance to paclitaxel according to IC90 was seen in 27/34 (79%) samples. In 
9/27 cases classified as resistant in vitro, the patients had been previously exposed to a 
taxane-based regimen. In this particular subset the median IC90 for paclitaxel was 38.4 
pM, while in the remaining 18/27 in vitro resistant cases the median IC90 decreased to
29.0 pM (p<0.05, Mann-Whitney). For the ovarian cancer subset, in vitro resistance to 
paclitaxel according to IC90 was seen in 17/21 (81%) samples
Immunohistochemical staining for P-gp was positive in 9/21 (43%) samples. 
Semiquantitative visual assessment of the degree of staining in this relatively small 
number of cases showed no correlation with sensitivity (IC90 and IC50) by linear 
regression analysis (data not shown). It should be noted that only 1/9 (11%) of the P-gp 
positive samples showed sensitivity to paclitaxel on the basis of IC90, and only 2/12 
(17%) of the P-gp negative samples showed sensitivity to paclitaxel. Of those patients 
with P-gp positive samples, 8/9 had received previous chemotherapy, and 3 had been 
treated with a paclitaxel based regimen. Of those patients with P-gp negative samples, 
5/12 were chemotherapy naive and 4/12 had previously received a taxane-based 
regimen.
The addition of tariquidar decreased the median IC90 of paclitaxel from 27.4pM to 
20.6pM (p<0.05, Wilcoxon). Tariquidar showed some reversal of in vitro resistance to 
paclitaxel in 6/27 (22%) samples classified as resistant, of which 2/17 (12%) were 
ovarian cancer samples (figure 10.9). An example of tariquidar effects on paclitaxel 
activity in a P-gp positive ovarian carcinoma is shown in figure 10.10.
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Figure 10.9 Effect o f  the addition o f  tariquidar on the activity o f  paclitaxel expressed as 
IC90pM in (a) ovarian and (b) non-ovarian tumour samples. The samples labelled with 
a ‘plus’ in a black square are P-gp positive tumours, while the samples labelled with a 
triangle and a dashed line are P-gp negative tumours; P-gp staining was not performed 
in samples labelled with the other symbols. A line has been drawn in each graph to 
indicate 100% TDC o f  paclitaxel.
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Figure 10.10 (a) Example o f  the ATP-TCA results for a P-gp positive ovarian 
adenocarcinoma. Results are shown as mean (±SD) o f  triplicate values for each drug 
concentration. Error bars are not shown for some data points, as they are smaller than 
the symbols on the graph. The bottom panel (b) shows the results o f  the P-gp IHC for 
this sample.
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10.4 Discussion
The results of this study show that in the ATP-TCA, tariquidar is able to modulate the 
chemosensitivity in a number of solid tumours that are in vitro resistant to cytotoxic 
drugs known to be P-gp substrates. However, not all tumours showed such potentially 
beneficial effects, nor all drugs, and these results suggest that patients must be carefully 
selected.
Most tumours that showed some increased sensitivity after the addition of tariquidar 
were P-gp positive by immunohistochemistry, but an effect was also seen in a 
proportion of P-gp negative samples. Thus, there was a distinct lack of correlation with 
estimates of the degree of expression present. This may simply reflect the subjective and 
at best semi-quantitative nature of immunohistochemistry. Further, it is possible that P- 
gp negative samples up-regulated P-gp in the presence of the cytotoxic, and tariquidar 
was able to reverse P-gp mediated resistance. It has been clearly shown that expression 
of P-gp may be rapidly up-regulated in response to chemotherapeutic agents both in 
vitro and in vivo (Chaudhary & Roninson, 1993; Abolhoda et a l , 1999; Hu et a l , 1999; 
Stein et a l , 2002; Tada et a l , 2002), so it might be possible that up-regulation of 
MDRl/P-gp occurred within the six days of the assay.
In three cases, two ovarian samples tested with doxorubicin, and one unknown primary 
tested with paclitaxel, the addition of tariquidar caused a marked increase in the IC90 of 
the cytotoxic. It should be noted that at least two of these samples were P-gp negative, 
and the hypothesis that tariquidar prevented the development of classic MDR, and 
therefore favoured the onset of other alternative and more effective mechanisms of 
resistance, might be considered. In a previous in vitro study (Cocker et a l , 2001) the 
investigators failed in several attempts to obtain cell lines resistant to vincristine when 
the cells were grown in the presence of tariquidar; while classic MDR developed when 
the cells were grown in the presence of the cytotoxic alone. In early clinical trials testing 
P-gp modulation in acute leukaemia, cells that survived chemotherapy in the presence 
of modulators, resulting in clinical relapse, had reduced expression of P-gp (List et a l , 
1993; Marie et a l , 1993). The hypothesis that the development of MDR may be 
preventable using Pg-p modulators therefore warrants further in vitro and clinical 
studies.
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The data suggest that while P-gp expressing tumours are nearly always resistant to 
pumped drugs, those that do not express P-gp are not always sensitive. Although the 
MDR phenotype mediated by P-gp appears to be an important mechanism of resistance 
to anthracyclines, taxanes and vinca alkaloids, other mechanisms may be of greater 
importance in many patients. It should be noted that many of our patients had been 
previously exposed to paclitaxel and there may have been induction of non-MDR 
mechanisms of resistance in these cases. Other ATP-dependent pumps such as MRP1 
and BCRP have been shown to confer resistance to doxorubicin (Grant et a l , 1994; 
Doyle et al., 1998), though it should be noted that the role of MRP in paclitaxel and 
vinorelbine resistance is controversial and probably marginal (Vanhoefer et al., 1997; 
Dantzig et a l , 2002; Shepard et a l , 2003; Thomas &Coley, 2003). Non-classical 
mechanisms of resistance are also likely to be involved. For microtubule-interfering 
agents, altered microtubule dynamics, alterations in a- and P-tubulins, and/or altered 
binding sites may confer resistance. Altered metabolism and/or subcellular distribution, 
altered interaction of antitubulin agents with microtubules and inadequate induction of 
apoptotic signals are among the possible non-MDR mechanisms of resistance to 
tubulin-binding agents (Dumontet & Sikic, 1999). For anthracyclines such as 
doxorubicin, decreased levels of topoisomerase Ila  have been associated with 
resistance, and changes in DNA repair may also be important (Fedier et a l , 2001).
In this study, immunohistochemical detection of P-gp alone was not sufficient to predict 
an ex vivo response to tariquidar. Pluralities of techniques have been used for diagnosis 
of P-gp expression in clinical samples, such as immunocytochemistry, flow cytometry, 
functional test, RT-PCR (see section 1.2.1). Imperfections exist in all methods, and the 
lack of standardisation renders it virtually impossible to compare studies from different 
laboratories. Whether the assay parameter should be MDR1 mRNA, protein, or P-gp 
substrate transport ability remains unresolved.
The ATP-TCA is a well-standardised assay capable of determining the activity of 
cytotoxic drugs ex vivo in tumour-derived cells and shows excellent correlation with 
outcome in breast and ovarian cancer (Cree et a l, 1996; Konecny et a l, 2000; Sharma 
et a l, 2003). It could be used to select patients for tariquidar therapy, and has the 
distinct advantage that it measures the effect of P-gp blocking agents in the context of
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other resistance mechanisms that may be present, but it is only applicable to those from 
whom sufficient tumour tissue can be obtained for testing.
In summary, the results of this study show that tariquidar is able to significantly reduce 
the median IC90s for doxorubicin, paclitaxel and vinorelbine in a panel of human 
tumours. Considerable translational research will be required to determine which are the 
most cost-effective predictive methods to employ, but it seems unlikely that 
immunohistochemistry alone will be sufficient and the use of functional assays showing 
ex vivo efficacy of tariquidar should be considered.
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Chapter 11-Cellular adaptation to chemotherapy
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11.1 Introduction
In chapter 9 it was noted a general increase in resistance to doxorubicin in the ATP- 
TC A in tumour-derived cells from paired biopsies collected from ovarian cancer 
patients before and after administration of anthracycline-based regimens. Another study 
had previously shown a similar effect in tumour derived cells from paired biopsies 
collected from breast cancer patients before and after administration of doxorubicin- 
containing chemotherapy (Cree et a l , 1996). In the study by Cree et a l (1996) the loss 
of ATP was measured as a marker of chemosensitivity in tumour-derived cells, and the 
authors were able to show that tumour cells adapt pre- and post-chemotherapy to the 
drugs that they are given, but show variable or no change in cytotoxicity in response to 
drugs with unrelated mechanisms of resistance.
In chapter 9 the same endpoint, i.e. loss of ATP, was used, but I was also able to 
correlate chemosensitivity with changes in gene expression caused by doxorubicin 
exposure in tumour-derived cells from ovarian and breast cancer patients.
1 have extended the initial observations to other tumour types such as GI carcinomas 
and other classes of cytotoxic agents, including the TOPO I inhibitors topotecan and 
irinotecan, and the anti-metabolite 5-FU. In this chapter the first data of these 
experiments are reported and in the case of oesophageal cancer specimens the results 
are correlated with the changes in gene expression observed in biopsies taken before 
and after in vivo chemotherapy.
11.2 Materials and Methods
Patients and tissue samples for ex vivo studies. Tumour derived cells were obtained 
from 13 breast cancer patients (12 primaries; 1 pre-treated with mitoxantrone and 
paclitaxel), 10 ovarian cancer patients (all pre-treated with a cisplatin-based regimen),
10 colorectal cancer patients (all primaries) and 7 oesophageal cancer patients (3 
untreated; 4 treated with ECF). Cells were grown for 6 days in CAM with or without 
camptothecins, 5-FU or ECF, before RNA extraction and further PCR analysis (chapters
2 & 3).
Patients and tissue samples for in vivo study. Twelve paired oesophageal 
adenocarcinoma biopsies were obtained from 6 patients before and after administration
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of 2 cycles of ECF chemotherapy. The median age of the patients was 60 years old 
(range 42-77; 6M:0F). After enzymatic digestion, tumour derived cells were centrifuged 
over Ficoll -Hypaque (Sigma 1077-1) to remove blood contaminating cells, washed in 
PBS, and stored in RNA later (Ambion) at -80°C until further molecular analysis was 
performed (chapters 2 and 3). Tissue sections from these samples were stained for P-gp 
and COX-2 as detailed in chapter 2.
ATP-TCA and qRT-PCR methods. These were performed as detailed in chapters 2-3. 
113 Results
113.1 Gene expression changes induced by camptothecins in short-term cell 
culture
The effects of ex vivo exposure to two camptothecin derivatives, irinotecan and 
topotecan, were studied on colorectal and ovarian tumour cells, respectively. As both 
compounds act via TOPOI inhibition, we firstly measured the levels of the mRNA 
encoding their target enzyme. We noted a trend towards down-regulation of TOPO I in 
treated cells (table 11.1): exposure to irinotecan decreased TOPO I levels >2-fold in 3/7 
colorectal tumours, while topotecan caused down-regulation in 4/10 ovarian samples 
(figures 11.1 g and 11.2f). The decrease of TOPO I was accompanied by a concomitant 
reduction of TOPO Ila expression, which was particularly pronounced (>4-fold) in 6/7 
colorectal tumours and 8/10 ovarian tumours.
No significant changes were observed in the expression of the drug efflux molecules, 
MDR1, BCRP and MRP1 (table 11.1), though, considerable heterogeneity was noted. 
For example, we observed an increase of BCRP levels after irinotecan or topotecan 
exposure in 2/7 colorectal samples and 3/9 ovarian samples (figures 11.1a and 11.2a).
Among the genes implicated in DNA repair, the modest down-regulation of MLH1 by 
topotecan exposure was not found statistically significant, although it was noted in 7/10 
ovarian samples. Up-regulation of ERCC1 expression was found in all 10 ovarian 
cancer samples exposed to topotecan (p<0.002, Wilcoxon matched pairs test), and in all 
7 colorectal specimens treated with irinotecan, although in this group the increase was 
modest and the median difference did not reach a statistically significant value (p=0.016, 
Wilcoxon) when a Bonferroni’s correction was applied.
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Finally, I examined COX-2 and EGFR as markers of tumour growth and progression. 
Following treatment of ovarian-tumour derived cells with topotecan, the levels of COX- 
2 increased in 4/10 samples, decreased in 4/10 and remained essentially unaltered in the 
remaining 2/10 tumours analysed. After irinotecan treatment, it was observed a down- 
regulation of COX-2 in all 7 colorectal samples analysed (figure 11.2b), with the 
median level decreasing from 105 to 38.5 units (p=0.0156, Wilcoxon matched pairs test; 
NS, with Bonferroni). Changes in the expression of EGFR were only studied after 
topotecan exposure: we found a decrease (more than 2-fold) in the expression of this 
growth factor in 9/10 ovarian samples (figure 11.1c), with the median levels decreasing 
from 0.470 to 0.163 units (p<0.0039, Wilcoxon matched pairs test).
Table 11.1 Relative expression of mRNA levels (2' ) in tumour samples after ex-vivo 
exposure to camptothecins. The p values have been calculated using non parametric 
statistics (Wilcoxon matched pairs test for paired samples with a Bonferroni’s 
correction; statistical significance was taken at p<0.006).
Target
gene n
Ovarian samples
P n
Colorectal samples
P
Control Topotecan Control Irinotecan
BCRP 9 0.0156 0.0125 >0.999 7 0.0354 0.0515 0.688
COX-2 10 0.253 0.475 0.770 7 105 38.5 0.016
EGFR 10 0.470 0.163 0.004 - - - -
ERCC1 10 0.252 0.399 0.002 7 1.40 2.47 0.016
MDR1 9 0.00897 0.00340 0.570 7 0.225 0.294 >0.999
MLH1 10 0.263 0.227 0.037 - - - -
MRP1 - - - - 7 5.13 3.78 0.016
TOPOI 10 4.49 2.45 0.037 7 1.47 1.12 0.109
TOPO Ila 10 1.09 0.0670 0.002 6 0.285 0.0733 0.219
TOPO lip - - - - 7 0.740 0.506 0.031
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Figure 11.1 Changes in BCRP (a), COX-2 (b), ERCC1 (c) and EGFR (d) gene
expression after topotecan exposure in the ATP-TCA in tumour derived cells from 10
ovarian cancer patients.
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Figure 11.1 (continued). Changes in MDR1 (e), MLH1 (f), TOPO I (g) and TOPO Ila
(h) gene expression after topotecan exposure in the ATP-TCA in tumour derived cells
from 10 ovarian cancer patients.
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Figure 11.2 Changes in BCRP (a), COX-2 (b), ERCC1 (c) and MDR1 (d) gene
expression after irinotecan exposure in the ATP-TCA in tumour derived cells from 7
colorectal cancer patients.
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Figure 11.2 (continued). Changes in MRP1 (e), TOPO I (f), TOPO Ila (g) and TOPO 
lip  (h) gene expression after irinotecan exposure in the ATP-TCA in tumour derived 
cells from 7 colorectal cancer patients.
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113.2 Gene expression changes induced by 5-FU in short-term cell culture
The effects of ex vivo exposure to 5-FU were studied on material derived from 10 
colorectal tumour samples and 13 breast tumour samples. Among the genes known to 
be involved in 5-FU metabolism, we found an increase of TS levels in 12/13 breast 
samples and in all colorectal specimens (figures 113d and 11.4d). The results also 
indicated a general trend towards DPD down-regulation in the cells that had been 
exposed to 5-FU ex vivo (table 11.2; figures 11.3b and 11.4b), this effect being more 
pronounced in breast (10/13 samples) than in colorectal cells (6/10). It should also be 
noted that in 3/10 colorectal samples 5-FU treatment caused >2-fold up-regulation 
(figure 11.4b). Heterogeneity was found in the expression of TP levels; after 5-FU 
exposure TP levels increased in 6/10 colorectal samples, decreased in 2/10 and 
remained unaltered in other 2 cases (figure 11.4c). Similarly, in breast no changes were 
seen in 9/13 samples (figure 11.3c).
The results showed a significant up-regulation of the median mRNA levels of COX-2, 
which increased from 7.91 to 171 units in the breast subgroup (p<0.0002, Wilcoxon 
matched pairs test) and from 122 to 392 units in colorectal samples (p<0.004, Wilcoxon 
matched pairs test). Notably, there was a COX-2 increase greater than 2-fold in 11/13 
breast samples (figure 11.3a) and 9/10 colorectal samples (figure 11.4a).
Table 11.2 Relative expression of mRNA levels (2'ACt) in n tumour samples after ex- 
vivo exposure to 5-FU. The p values have been calculated using non parametric 
statistics (Wilcoxon matched pairs test for paired samples with a Bonferroni’s 
correction; statistical significance was taken at p<0.0125).
Target
gene n
Breast samples
P n
Colorectal samples
P
Control 5-FU Control 5-FU
COX-2 13 7.91 171 0.0002 10 122 392 0.0039
DPD 13 1.29 0.494 0.0012 10 0.503 0.448 0.4922
TP 13 8.88 10.9 0.6848 10 4.62 5.96 0.0840
TS 13 1.14 3.82 0.0005 10 2.16 7.95 0.002
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Figure 11.3 Changes in COX-2 (a), DPD (b), TP (c) and TS (d) gene expression after 5- 
FU exposure in the ATP-TCA in tumour derived cells from 13 breast cancer patients.
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Figure 11.4 Changes in COX-2 (a), DPD (b), TP (c) and TS (d) gene expression after 5- 
FU exposure in the ATP-TCA in tumour derived cells from 10 colorectal cancer 
patients.
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1133  Gene expression changes induced by ECF in short-term cell culture
I was able to study the ex vivo effect of the combination of epirubicin, cisplatin and 5-
FU (ECF) in tumour-derived cells from 7 oesophageal cancer patients, 4 of which had 
already been previously treated with ECF. Few genes could be tested in 2 cases due to 
limited amounts of RNA.
No statistically significant differences were observed in any of the genes studied when a 
Bonferroni’s correction was applied to the Wilcoxon test performed in such a small 
number of cases (table 11.3). However, a marked increased expression of TS was found 
in all 6 samples after ECF exposure (figure 11.5 h). A general trend of increased 
expression of COX-2 was also noted, being more pronounced (>4-fold) in 3 cases. 
Among the pump proteins, up-regulation of MDR1 was detected in 3/7 samples, while 
the levels of MRP 1 and MVP were unchanged or slightly decreased (figure 11.5 c,d,f).
When genes possibly implicated in cisplatin resistance were considered, there was 
marked up-regulation of Metallothionein IIA (MTII) in 1 sample, while in all the others 
a decrease in expression was noted.
Table 11.3 Relative expression of mRNA levels (2' ) in n oesophageal tumour 
samples after ex vivo exposure to ECF. The p values have been calculated using 
non parametric statistics (Wilcoxon matched pairs test for paired samples with a 
Bonferroni’s correction; statistical significance was taken at p<0.006).
Target gene n
Oesophageal samples
P
Control ECF
COX-2 7 106 197 0.0313
GST-jc 7 0.769 0.686 0.1563
MDR1 7 0.171 0.195 > 0.999
MRPl 6 9.37 5.61 0.0313
MTII 6 24.5 13.5 0.4375
MVP 5 9.55 8.21 0.625
TP 6 5.56 2.46 0.0313
TS 6 3.50 16.4 0.0313
286
0.01
Control ECF C ontrol ->  ECF
Control
Control
Figure 11.5 Changes in COX-2 (a), GST-tc (b), MDR1 (c) and MRP1 (d) gene 
expression after ECF exposure in the ATP-TCA in tumour derived cells from 7 
oesophageal cancer patients.
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Figure 11.5 (continued). Changes in MTII (e), MVP (f), TP (g) and TS (h) gene 
expression after ECF exposure in the ATP-TCA in tumour derived cells from 6 
oesophageal cancer patients.
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113.4 Gene expression changes induced by in vivo ECF chemotherapy
Twelve oesophageal adenocarcinoma biopsies were collected from 6 patients before and 
after treatment with 2 courses of ECF. The median values of expression for each target 
gene are shown in table 11.4. Due to the limited number of samples, no statistically 
significant differences were found. However, a trend of variation in certain genes was 
noted (figure 11.6 a-h). For example ECF chemotherapy induced up-regulation of the 
mRNA levels of COX-2 and TS in 5/6 samples.
Among the drug transporters, there was an increase of the mRNA levels of MDR1 in 
5/6 paired samples following ECF chemotherapy (figure 11.6 c). We also noted a trend 
towards increased expression of MRP 1 and MVP (table 11.4). Notably, three tumours 
showed concomitant up-regulation of MVP and MRP1 (figure 11.4 d,f). Futhermore, 
the increased expression of MRP1 paralleled that of GST-7t in 2 samples (figure 11.4 b), 
which is consistent with the mechanism of detoxification of MRP 1 involving transport 
of glutathione-conjugated molecules.
It should be noted that these results were all obtained from tumour samples that 
included normal cells present in the tumour as well as neoplastic cells, and could be 
affected by stress responses in normal cells as well as neoplastic cells. We therefore 
examined the immunohistochemical expression of those genes that were found to 
produce the same effect in at least 5/6 samples, namely COX-2 and MDR1, to try to 
confirm these data from changes in protein levels.
113.5 Chemotherapy-induced changes in protein levels in biopsy material
Immunohistochemistry (IHC) was performed on all 12 oesophageal biopsies for which 
molecular biology data had been obtained and paraffin embedded material was available. 
However one sample was considered by a consultant histopathologist too small to be 
assessed. Overall, we were able to confirm an increased expression of the MDR-1 
encoded protein, P-gp, in 2 tumour samples obtained from patients who had been 
exposed to ECF chemotherapy (figure 11.7a). In one case P-gp positivity was already 
present in the pre-chemotherapy sample, and was found also in the post-chemotherapy 
specimen. The remaining two cases were P-gp negative at diagnosis and remained such 
after treatment. COX-2 positivity was found in all samples but one post-chemotherapy
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specimen (figure 11.7b); in this instance the decrease in protein level was paralleled by 
a decrease in the mRNA levels. Overall, this data showed that there was little 
correlation between the mRNA and the degree of expression of protein levels 
determined by IHC. Confounding factors may be the presence of non-cancerous cells as 
mentioned above, but also the nature of IHC, which is at best a semiquantitative 
technique.
Table 11.4 Relative expression of mRNA levels (2'ACt) in tumour samples after 
in vivo treatment with ECF. The p values have been calculated using non 
parametric statistics (Wilcoxon matched pairs test for paired samples with a 
Bonferroni’s correction; statistical significance was taken at p<0.006).
Target gene Paired oesophageal samples (n=12) P
Pre-chemo Post-chemo
COX-2 30.2 88.8 0.219
GST-jt 1.61 1.85 0.844
MDR1 0.114 0.426 0.0313
MRP1 4.58 10.8 0.438
MTII 12.5 24.1 0.844
MVP 6.39 9.11 0.562
TP 3.56 3.01 >0.999
TS 1.27 2.27 0.438
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Figure 11.6 Changes in COX-2 (a), GST-71 (b), MDR1 (c) and MRP1 (d) gene 
expression in paired oesophageal biopsies obtained before and after in vivo treatment 
with ECF.
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with ECF.
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Figure 11.7 Changes in MDR1 (a) and COX-2 (b) protein levels determined by IHC in 
paired oesophageal biopsies obtained before and after in vivo treatment with ECF.
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11.4 Discussion
The results shown in this chapter confirmed those previously obtained in chapter 9, and 
suggest that there is rapid adaptation to chemotherapy in tumour-derived cells. This 
adaptation is mediated by down- or up-regulation of genes that are sometimes correlated 
to the mechanism of action of the individual chemotherapeutic agent, but are often 
implicated in general survival or resistance pathways. The data presented in this chapter 
suggest that short-term cell culture methods with exposure to chemotherapy of patients’ 
cells could provide a suitable model for studying resistance mechanisms, and ultimately 
predicting response in the clinic.
A large proportion of the published studies on resistance to chemotherapy have 
investigated the development of resistance using cell lines generated in the laboratory 
after prolonged and step-wise exposure to anti-cancer drugs. These in vitro models are 
not necessarily representative of the in vivo situation, when patients are usually 
administered one cycle of chemotherapy every 3-4 weeks. There are few studies in 
clinical samples. The approach presented in this thesis allows exposing the tumour cells 
to single drugs under carefully controlled conditions, even if this would be an 
inappropriate drug for that particular patient. In this cytotoxicity and molecular markers 
of resistance can be studied concomitantly in the same experiment. I have begun to 
explore less obvious forms of resistance using this technology, and show here that in 
some tumours, loss of MLH1 contributes to resistance to camptothecins, as previously 
shown in cell lines (Fedier et a l, 2001). In addition, our results are consistent with 
previous studies that found low levels of EGFR to correlate with topotecan resistance in 
cervical cancer cell lines (Ling et a l, 2001), and could provide an explanation for the 
synergy demonstrated by the combination of topotecan and gefitinib, an EGFR tyrosine 
kinase inhibitor (Ciardiello et a l, 2000).
One intriguing finding from our work is the marked up-regulation of COX-2 mRNA 
levels after 5-FU exposure in three different tumour types, while treatment with 
irinotecan tended to decrease the expression of this enzyme in primary colon cells. The 
only comparable data are from cell line studies. Recently, Yamaguchi et a l (2003) 
showed that SN-38 was able to inhibit phorbol ester (PMA)-mediated induction of 
COX-2 in human gastrointestinal cancer cell lines. Although the authors did not report a
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direct effect of camptothecin derivatives on constitutive COX-2 levels, they suggested a 
link between TOPO I and COX-2. On the other hand, other studies suggest that the up- 
regulation of COX-2 by 5-FU may be part of a general anti-apoptotic response; Sun et 
al (2002) have demonstrated that forced COX-2 expression attenuated apoptosis 
induction by 5-FU predominantly through inhibition of the cytochrome c-dependent 
apoptotic pathway; Grosch et a l (2001) have also shown that the selective COX-2 
inhibitor celecoxib is able to induce cell cycle arrest and apoptosis in cultured colon 
cancer cells. It must be noted, however, that these studies all used cell lines, and that 
both in the case of Sun et a l , and Yamaguchi et a l, the authors stimulated or forced the 
expression of COX-2. Interestingly another study showed that in colorectal cell lines 
pretreated with 5-FU, re-growth was slowed by administration of Interferon-y combined 
with indomethacin and phenylbutyrate (Huang et a l, 2000). As yet, I am uncertain 
whether the marked change in COX-2 expression following exposure to 5-FU 
represents part of a re-growth phenomenon, or whether it simply gives the cells a 
survival advantage (and may therefore render them resistant to 5-FU chemotherapy). 
Further studies are needed on this point, and it would valuable to build measurements of 
COX-2 into clinical trials involving 5-FU. Our data also raise the possibility that 
combination of COX-2 inhibitors with chemotherapy might be useful and provide a 
molecular rationale for the observed efficacy of combinations of topoisomerase I 
inhibitors with 5-FU in gastro-intestinal cancers.
The potential fo r  positive selection: molecular chess
It is common to show a cross-over with clinical trials of treatments with differing 
mechanisms of action, in which patients with treated with one type of chemotherapy 
show sensitivity to the alternative regimen following failure of the one to which they 
were allocated. The recognition that selection of a molecular phenotype by exposure to 
some anti-cancer agents leads to the expression of molecular targets for other drugs 
raises the possibility that it might be possible to enhance sensitivity to second-line or 
maintenance therapy by careful selection of patients for first-line therapy. It might 
therefore be possible to use tumour derived cells to guide such therapy to overcome the 
inherent heterogeneity of such changes between tumour cells which may underlie the 
variable results obtained from sequential chemotherapy to date.
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Chapter 12 - General Discussion and Future 
Perspectives
296
12.1 General discussion
The work presented in this thesis has shown that considerable heterogeneity of 
chemosensitivity exists between different tumours corroborating some previous findings 
(Andreotti et a l , 1995; Myatt et a l, 1997; Cree et a l , 1999). Even a highly 
chemosensitive tumour such as retinoblastoma occasionally shows reduced sensitivity 
to anticancer agents (chapter 5). Drug resistance can be intrinsic or acquired following 
treatment with chemotherapy. Often exposure to one drug results in the acquisition of a 
resistance to a broad range of chemically unrelated compounds, a phenomenon that is 
called classical ‘multidrug resistance’ or MDR. Therefore cross-resistance patterns can 
be identified in the data obtained from chemosensitivity testing of fresh tumour cells 
even for unrelated drugs.
The data presented in this thesis has shown that drug resistance rapidly develops in 
tumour-derived cells exposed to cytotoxics ex vivo in short-term culture (chapters 9 and 
11). The high reproducibility and accuracy of qRT-PCR -coupled with the use of 
multiple reference genes and rigorous data analysis (chapter 3) - allows the detection of 
even very small changes in gene expression that could be missed with less sensitive 
techniques such as cDNA microarray or traditional PCR with gel-based analysis. Using 
qRT-PCR, we were able to show up-regulation of MDR1 mRNA in a number of 
samples that had been exposed to anthracyclines in the ATP-TCA (chapter 9). In 
addition, all samples tested with doxorubicin showed decreased levels of TOPO Ila 
expression after drug exposure. While some changes in gene expression can be 
predicted on the basis of the mode of action of the drug in question, as in the case of 
TOPO Ila and doxorubicin, others appear not to be so strictly related to the drug- 
specific cytotoxicity. During the course of this thesis, evidence has been presented that 
5-FU, an antimetabolite, consistently induces COX-2 expression (a gene which has 
recently been show implicated in tumour cell growth) in tumour derived cells from 
breast and gastrointestinal carcinomas (chapter 11). Importantly, a similar increase of 
COX-2 expression induced by 5-FU based chemotherapy was also found in the cells of 
twelve oesophageal cancer patients when we compared the gene expression profile of 
pre- and post-chemotherapy biopsies. This change was not confirmed at the protein 
level by immunohistochemistry, which is at its best a semiquantitative technique, 
although a high proportion of oesophageal cancer biopsies showed COX-2 positivity.
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The relevance of these findings in the clinical setting has not been fully investigated yet, 
but the pilot study on the oesophageal tumour-derived cells suggest that cancer cells can 
adapt in vivo to chemotherapy by rapidly altering their molecular phenotype. Indeed, 
some studies have shown that the expression of MDRl/P-gp is up-regulated within 
hours of anti-cancer drug treatment in vivo in patient samples (Abolhoda et a l , 1999;
Hu et al., 1999; Stein et a l , 2002; Tada et a l , 2002), although this effect was not 
observed in all patients. This may be an important factor when specific inhibitors of P- 
gp are used in clinical trials. So far clinical studies that have employed such inhibitors 
have been disappointing. This is probably due to the limited specificity and selectivity 
for P-gp of the inhibitors used in the early studies (causing unacceptable toxicities), but 
also to the lack of activity of these compounds when administered to an unselected 
cancer patient population, disregarding the expression of P-gp. It is notable that in some 
recent trials of P-gp inhibitors a benefit was only achieved in those patients with P-gp 
positive tumours (Baer et a l , 2002; Solaiy et a l, 2003).
In the course of this thesis we were able to test the ex vivo activity of a third-generation 
P-gp inhibitor, tariquidar, in the ATP-TCA (chapter 10). This inhibitor showed some 
reversal of resistance to doxorubicin, paclitaxel and vinorelbine in a small proportion of 
the samples tested. Notably, we failed to correlate the activity observed in the TCA with 
the degree of P-gp immunostaining, as not all P-gp positive tumours benefited from 
tariquidar. Other mechanisms, including some other MDR transporters, can also 
mediate resistance to doxorubicin, paclitaxel and vinorelbine. The clinical significance 
of these other transporters is less well established, but there was little correlation 
between the expression of P-gp and the ex vivo activity shown in the ATP-TCA by 
some MDR sensitive drugs, suggesting that these other mechanisms may be important. 
However, both doxorubicin (chapter 9) and the experimental agent XR5944 (chapter 7) 
failed to produce >95% inhibition in most P-gp positive tumours (particularly GI 
tumours, which often express multiple transporters).
In the case of XR5944, this finding might influence the choice of the clinical conditions 
chosen for trials of this new drug. However, while this compound has now been 
recognised as a MDR substrate by our and other studies (Mistry et a l, 2001), our 
attempt to generate a drug resistant leukaemia sub-line produced only a modest 10- to 
15-fold increase of the IC50 values of XR5944. Moreover, we found a stronger
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correlation between P-gp positivity and IC50 values rather than with the IC90s of 
XR5944, suggesting that higher concentrations of this compound can probably 
overcome MDR-mediated resistance. It should be noted that the concentration of 
XR5944 required to produce >95% inhibition was often in the 100-200 nanomolar 
range, showing the exceptional potency of this cytotoxic when compared with many 
currently available drugs (chapter 7).
Current anticancer drug screening is carried out using a panel of cell lines grown as 
monolayers in serum-rich medium. While this method has undeniable advantages (cost, 
rapidity, reproducibility), there are some drawbacks. As shown in chapter 3 the 
chemosensitivity of cell lines differ substantially from that of tumour-derived cells. 
Primary cultures can be up to 10-fold more chemoresistant than established cell lines. 
This is true for virtually all cytotoxics (Andreotti et a l, 1994, chapter 4), including the 
experimental agents XR5000, XR11576 and XR5944 that were employed in this study. 
Possible explanations for this phenomenon include the homogeneity of cell lines versus 
the heterogeneity observed in tumour-derived cells; the highly-proliferative status of 
cell lines compared with the relatively quiescent cell population usually found in solid 
tumours; and the fact that cell lines are usually grown as single cells, while the 
dissociation of solid tumours often yields small clumps of cells. The work presented in 
chapter 3 has also shown that altering cell culture conditions can partly affect 
chemosensitivity. Cell lines grown in low-serum media or even in serum-free appear 
more resistant than cells cultured in standard or high-serum concentrations. This is 
especially true for drugs that kill cells in the S-phase of the cellular cycle, further 
suggesting that chemosensitivity is somewhat also determined by the highly 
proliferative nature of cell lines.
The studies described in chapters 6,7 and 10 have shown the usefulness of tumour 
chemosensitivity assays with primary cells for new drug development. For example, 
XR5000 was shown to be active ex vivo only at concentrations that exceeded 5 pM, 
which represents about twice the plasma levels achievable in patients (Caponigro et a l, 
2002; Dittrich et a l, 2003a). Therefore the ATP-TCA was able to predict the lack of 
activity of this compound well before the results of the phase II clinical trials were 
available (Neale et a l, 2000; Caponigro et a l, 2002; Dittrich et a l, 2003 a & b). The 
results in chapter 6 demonstrated that XR11576, a compound originated from the same
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medicinal chemistry programme as XR5000, is about 20-fold more potent than 
XR5000, while its isomer, XR11612, is only 10-fold more potent. XR11576 was found 
to be active in a great variety of solid tumours, including gastrointestinal cancers that 
are usually refractory to chemotherapy. In keeping with previous studies in cell lines, 
the activity of XR11576 was not particularly affected by MDR mechanisms or 
topoisomerase levels, consistently with the proposed role of dual topoisomerase 
inhibitor of this compound. XR11576 has also been tested in combination with some 
standard cytotoxics, and some cases of synergy were identified with vinorelbine and 
doxorubicin.
Chemosensitivity tests are not only a tool to assess new drugs, but they have the 
potential to identify new regimens that might be clinically useful. In the past the ATP- 
TCA has been used to develop two combinations, mitoxantrone plus paclitaxel, and 
treosulfan plus gemcitabine. Both have been successfully evaluated in second-line 
ovarian cancer patients. In this thesis the ATP-TCA, in two series of ovarian tumour 
samples, has identified at least additive activity between vinorelbine and doxorubicin 
tested at concentrations which approximate those achievable with liposomal 
preparations (chapter 8). This combination is currently being assessed in the clinic: the 
early results in advanced breast and ovarian cancer are encouraging.
In conclusion, it is clear that the mechanisms which affect the chemosensitivity of 
individual patients to chemotherapy are complex. However, this thesis shows that 
application of a combination of molecular methods such as qRT-PCR, 
immunohistochemistry, and cellular assays such as the ATP-TCA can determine sub­
sets of patients who might benefit from particular drugs, and that such methods can also 
assist the development of new drugs and combinations.
300
12.2 Future work
There are several directions in which the work presented here could be continued.
First of all, the work presented in chapter 4 is currently being extended by Dr Augusta 
Fernando at the Translational Oncology Research Centre in Portsmouth using other cell 
lines derived from tumour types other than skin melanoma. If successful this would lead 
to the generation of a panel of human tumour cell lines that - grown under selected 
conditions - would mimic the chemosensitivity profile of primary cultures. This panel 
could then be used to aid in the development of new anti-cancer agents, thereby 
overcoming the need for fresh tumour-derived cells.
The pilot study on the chemosensitivity of retinoblastoma described in chapter 5 formed 
the basis of a successful grant application awarded jointly to St Bartholomew’s hospital 
in London and to Prof Ian Cree in Portsmouth to extend the initial findings. This study 
is attempting to correlate retinoblastoma chemosensitivity to the expression of drug 
resistance proteins such as MDRl/P-gp and MRP1 in the hope that inhibitors of these 
molecules could help some patients.
The mRNA data shown in chapters 9 and 11 awaits confirmation at the protein level 
with more sensitive techniques than immunohistochemistry. It is envisaged that ELISA- 
based assays could be useful for this purpose.
The studies in gene expression changes induced by chemotherapeutic agents are 
currently being continued by Ms Louise Knight and Mr Sanjay Sharma at the 
Translational Oncology Research centre in Portsmouth. We aim to extend these 
observations to other cytotoxic drugs, and to different molecular mechanisms.
Finally the “Molecular Chess” hypothesis that giving one drug to a patient would alter 
the patient’s response to another unrelated drug at relapse needs to be proven in the 
clinical setting with clear evidence in accompanying translational studies that the 
expected changes have occurred in the patients treated.
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Formulas and macros used to analyse the ATP-TCA data presented in this thesis. The equations employed to calculate IndexSUM, 
IndexAUC, IC50 and IC90 are listed below. The percentage of inhibition at each drug concentration tested (Inh%) was calculated 
according to the equation shown in Chapter 2.2.19.
IndexAUC = 50*(Inh2oo+Inh1oo)+25*(Inh1oo+Inh5o)+12.5,,t(Inh5o+Inh25)+6.25>,,(Inh25+Inhi2.5)+3.125*(Inhi2.5+Inh6.25)
IndexSUM = 600 -  (Inh6.25+Inhi2.5+Inh25+Inh50+Inhioo+Inh2oo)
IC50 =  ((50-y4)/(y2-y4)*(yi-y3))+y3; where the values yi, y2, y3 and y4 are calculated using the following macros:
If Inh6.25 < 49.99 and Inh^.s > 50 and Inh25 > 50 is true, then xi = 6.25; if  false, xi = 0
If Inh .^25 < 49.99 and Inh^s < 49.99 and Inh25 > 50 and Inhso > 50 is true, then xi = 12.5; if  false, xi = 0
If Inhi2.5 < 49.99 and Inh25 <49.99 and Inhso > 50 and Inhioo > 50 is true, then xi = 25; if  false, xi = 0
If Inh25 < 49.99 and Inhso <49.99 and Inhioo > 50 and Inh2oo > 50 is true, then xi = 50; if  false, xi = 0
If Inhso <49.99 and Inhioo < 49.99 and Inh2oo > 50 is true, then xi = 1 0 0 ; if  false, xi = 0
If  Inhioo < 49.99 and Inh2oo > 50 is true, then xi = 2 0 0 ; if  false, xi = 0
yi = S(xi)
If Inh6.25 < 49.99 and Inh^.s > 50 and Inli25 > 50 is true, then X2 = Inh^s; if  false, X2 = 0
If Inh6.25 < 49.99 and Inh^.s < 49.99 and Inh25 > 50 and Inhso > 50 is true, then X2 = Inhns; if  false, X2 = 0
If Inhi2.5 < 49.99 and Inh25 <49.99 and Inhso > 50 and Inhioo > 50 is true, then X2 = Inh2s; if  false, X2 = 0
If I11I125 < 49.99 and Inhso <49.99 and Inhioo > 50 and Inh2oo > 50 is true, then X2 = Inhso; if  false, x2 = 0
If Inhso <49.99 and Inhioo < 49.99 and Inh2oo > 50 is true, then X2 = Inhioo; if  false, X2 = 0
If Inhioo < 49.99 and Inh2oo > 50 is true, then X2 = Inh2oo; if  false, X2 = 0
y2 = S(x2)
If Inh6.25 > 50 and Inh^.s > 50 is true, then X3 = 6.25; if  false, X3 = 0
If Inh .^25 < 50 and Inh^.s > 50 and Inh25 > 50 is true, then X3 = 12.5; if  false, X3 = 0
If Inli6.25 < 50 and Inhns < 50 and Inh2s > 50 and Inhso > 50 is true, then X3 = 25; if  false, X3 = 0
If Inh6.25 < 50 and Inh^.s < 50 and Inh2s < 50 and Inhso > 50 and Inhioo > 50 is true, then X3 = 50; if  false, X3 = 0
If Inh^.s < 50 and Inh25 < 50 and Inhso < 50 and Inhioo > 50 and Inh2oo > 50 is true, then X3 = 1 0 0 ; if  false, X3 = 0
If Inh^.s < 50 and Inh2s < 50 and Inhso < 50 and Inhioo < 50 and Inh2oo > 50 is true, then X3 = 2 0 0 ; if  false, X3 = 0
y3 = £(x3)
If Inh6.25 > 50 and Inh^.s > 50 is true, then x4 = Inh6.25; if  false, x4 = 0
If  Inh6.25 < 50 and Inh^.s > 50 and Inh2s > 50 is true, then x4 = Inh^.s; if  false, x4 = 0
If  Inli6. 5 < 50 and Inhn.s < 50 and Inh25 > 50 and Inhso > 50 is true, then x4 — Inh2s; if  false, X 4 — 0
If Inh6.25 < 50 and Inh^.s < 50 and Inh2s < 50 and Inhso > 50 and Inhioo > 50 is true, then x4 = Inhso; if  false, x4 = 0
If  Inh^.s < 50 and Inh2s < 50 and Inhso < 50 and Inhioo > 50 and Inh2oo > 50 is true, then x4 = Inhioo; if  false, x4 = 0
If Inhi2.5 < 50 and M 125 < 50 and Inhso < 50 and Inhioo < 50 and Inh2oo > 50 is true, then x4 = Inh2oo; if  false, x4 = 0
y4 = I(x 4)
IC 9 0  =  ((90^4)/(y2-y4)* (y ry3))+ y3 ; Where the values y1.y2.y3 andy4 are calculated using the following macros:
If Inh6.25 < 89.99 and Inh^.s > 90 and Inh25 > 90 is true, then xi = 6.25; if  false, xi = 0
If Inh6.25 < 89.99 and Inh^.s < 89.99 and Inh25 > 90 and Inhso > 90 is true, then xj = 12.5; if  false, xi = 0
If Inh^.s < 89.99 and I11I125 <89.99 and Inhso > 90 and Inhioo > 90 is true, then xi = 25; if  false, xi = 0
If Inh25 < 89.99 and Inhso <89.99 and Inhioo > 90 and Inh2oo > 50 is true, then xi = 50; if  false, xi = 0
If Inhso <89.99 and Inhioo < 89.99 and Inli2oo > 90 is true, then xi = 100; if  false, xi = 0
If Inhioo < 89.99 and Inh2oo > 90 is true, then xi = 200; if  false, xi = 0
yi = S(xi)
If Inh6.25 < 89.99 and Inh^.s > 90 and Inh25 > 90 is true, then X2 = I11I16.25; if  false, X2 = 0
If Inh6.25 < 89.99 and Inh^.s < 89.99 and Inh25 > 90 and Inhso > 90 is true, then X2 = Inh^.s; if  false, X2 = 0
If Inh^.s < 89.99 and Inh25 <89.99 and Inhso > 90 and Inhioo > 90 is true, then X2 = Inh2s; if  false, X2 = 0
If Inh25 < 89.99 and Inhso <89.99 and Inhioo > 90 and Inh2oo > 90 is true, then X2 = Inhso; if  false, X2 = 0
If Inhso <89.99 and Inhioo < 89.99 and Inh2oo > 90 is true, then X2 = Inhioo; if false, X2 = 0
If  Inhioo < 89.99 and Inh2oo > 90 is true, then X2 = Inh2oo; if  false, X2 = 0
y2 = S(x2)
If Inh6.25 > 90 and Inh^.s > 90 is true, then X3 = 6.25; if  false, X3 = 0
If Inh6.25 < 90 and Inh^.s > 90 and Inh25 > 90 is true, then X3 =12.5; if  false, X3 = 0
If Inh6.25 < 90 and Inh^.s < 90 and Inh25 > 90 and Inhso > 90 is true, then X3 = 25; if  false, X3 = 0
If  Inh6.25 < 90 and Inh^.s < 90 and Inh25 < 90 and Inhso > 90 and Inhioo > 90 is true, then X3 = 50; if  false, X3 = 0
If  Inh^.s < 90 and Inh2s < 90 and Inhso < 90 and Inhioo > 90 and Inh2oo > 90 is true, then X3 = 100; if  false, X3 = 0
If Inh^.s < 90 and Inh25 < 90 and Inhso < 90 and Inhioo < 90 and Inh2oo > 90 is true, then X3 = 200; if  false, X3 = 0
y3 = s (x 3)
If Inh^ 5 > 90 and Inh^.s> 90 is true, then X4 -  Inh6.25i if  false, X4 -  0
If  Inh6.25 < 90 and Inh^.s > 90 and Inli25 > 90 is true, then X4 = Inh^ s; if  false, X4 = 0
If Inh6.25 < 90 and Inh^.s < 90 and Inh2s > 90 and Inhso > 90 is true, then X4 = Inh2s; if  false, X4 = 0
If Inh6.25 < 90 and Inh^.s < 90 and Inh25 < 90 and Inhso > 90 and Inhioo > 90 is true, then X4 = Inhso; if  false, X4 = 0
If Inh^.s < 90 and Inh25 < 90 and Inhso < 90 and Inhioo > 90 and Inh2oo > 90 is true, then X4 = Inhioo; if  false, X4 = 0
If Inh^.s < 90 and Inh25 < 90 and Inhso < 90 and Inhioo < 90 and Inh2oo > 90 is true, then X4 = Inh2oo; if  false, X4 = 0
y4 = I(x 4>
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Use of an ATP-based chemosensitivity assay to design 
new combinations of high-concentration doxorubicin 
with other drugs for recurrent ovarian cancer
Federica Di Nicolantonio,12 Michael H Neale,2 Louise A Knight,1 Alan Lamont,3 
Geraldine E Skailes,4 Richard J Osborne,5 Rosanne Alierton,6 Christian M Kurbacher7 
and Ian A Cree1,2
1Translational Oncology Research Centre, Michael Darmady Laboratory, Department of 
Histopathology, Queen Alexandra Hospital, Portsmouth P 06  3LY, UK. departm ent of Pathology, 
Institute of Ophthalmology, University College London, Bath Street, London EC1V 9EL, UK. 
d ep a rtm en t of Radiotherapy and Oncology, Southend Hospital, Westcliff-on-Sea SSO ORY, UK 
4Rosem ere Cancer Centre, Royal Preston Hospital, Preston PR2 9HT, UK. 5Dorset Cancer Centre, 
Poole BH15 2JB, UK. 6Deansley Centre, New Cross Hospital, Wolverhampton WV10 OOP, UK. 7Labor 
fur Chemosensitivitatestungen, Universitats-Frauenklinik, University of Cologne Medical Center, 
50931 Cologne, Germany.
Liposomal doxorubicin (Caelyx/Doxil) has been shown lo be active 
in around 20*/* of recurrent ovarian cancers. As yet, there is little 
clinical data on combinations of existing agents with liposomal 
doxorubicin, despite considerable clinical experience with soluble 
doxorubicin In combination. In this study, we have used an ATP- 
based tumor chemosensitivity assay to determine the relative ef­
ficacy of high concentrations of doxorubicin tested in combination 
with cispiatin, treosulfan, 5-fluorouracil (5-FU) or vinorelbine 
against cells obtained from recurrent ovarian tumor tissue. The re­
sults show little enhancement of the efficacy of high concentra­
tions of doxorubicin by 5-FU, cispiatin, or treosulfan. However, 
vinorelbine + liposomal doxorubicin showed additive inhibition, 
and this combination is worthy of further testing in clinical 
trials. [ i 2002 Lippincott Williams & Wilkins.]
Key words: Caelyx, chemotherapy, combination, Doxil, 
liposomal doxorubicin, ovarian cancer.
Introduction
A n th r a c y c l in e s  a r e  a c tiv e  a g a in s t  a  w id e  v a r ie ty  o f  
h u m a n  c a n c e r s ,  b u t  t h e i r  c a rd io to x ic i ty  h a s  la rg e ly
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p r e v e n t e d  d o s e  in te n s i f ic a t io n .  L ip o s o m a l p r e p a r a ­
t i o n s  (C a e ly x /D o x il ; S c h e r in g  P lo u g h /S e q u u s )  a l lo w  
m u c h  h ig h e r  in t r a - tu m o r a l  c o n c e n t r a t i o n s  t o  b e  
a c h ie v e d  w i th o u t  a n y  in c r e a s e  in  to x ic i ty . 1-6 W e h a v e  
p r e v io u s ly  u s e d  a n  A T P -b a se d  t u m o r  c h e m o s e n s i t i v ­
ity  a s s a y  (A TP-TCA ) to  s h o w  th a t  th e  d o x o r u b ic in  
d o s e - r e s p o n s e  in  m a n y  p a t i e n t s  p la te a u s  b e lo w  
100% c e ll  in h ib i t i o n ,  s u g g e s t in g  th a t  t h e r e  m ig h t  b e  
a  s u b s e t  o f  a n th r a c y c l in e - r e s i s t a n t  c e l ls  w h ic h  e v e n  
th e  h ig h e r  c o n c e n t r a t i o n s  p r o d u c e d  b y  l ip o s o m a l  
e n c a p s u l a t i o n  d o e s  n o t  a ffec t.
D o x o r u b ic in  is  n o t  a  n e w  d r u g  a n d  h a s  b e e n  
w id e ly  u s e d  in  c o m b in a t io n  w i th  a lk y la t in g  
a g e n ts ,  a n t im e ta b o l i t e s  a n d  s p in d le - a c t iv e  a g e n ts .  
T h e r e  is  le s s  d a t a  o n  th e  c o m b in a t io n  o f  l i p o s o m a l  
p r e p a r a t i o n s  w i th  o t h e r  d r u g s ,  b u t  c u r r e n t  r e s u l t s  
in d i c a t e  th a t  s im i la r  c o m b in a t io n s  a r e  l ik e ly  t o  b e  
e f f e c t iv e .8
I n  th i s  s tu d y  w e  h a v e  a g a in  u s e d  th e  A TP-TCA  to  
d e t e r m i n e  th e  c o n c e n t r a t i o n  r e s p o n s iv e n e s s  o f  t u ­
m o r - d e r iv e d  c e lls  t o  c o n c e n t r a t i o n s  o f  d o x o r u b ic in  
a c h ie v a b le  w i th  l ip o s o m a l  p r e p a r a t i o n s ,  b u t  h a v e  
lo o k e d  a t  th e  a d d i t i o n  o f  o t h e r  d r u g s  in  c o m b in a t io n  
w i th  d o x o r u b ic in .  T h e  A TP-TCA  is  b a s e d  o n  th e  
m e a s u r e m e n t  o f  A TP b y  th e  fire fly  lu c i f e r in - lu c i f e r a s e  
r e a c t io n .  A TP is  t h e  m a jo r  in t r a c e l lu la r  s o u r c e  o f  
e n e rg y  f o r  m e ta b o l is m .  W h e n  c e l ls  d ie  t h e i r  A TP is 
ra p id ly  d e g r a d e d  b y  A T P ases , s o  th a t  lo s s  o f  A TP c a n  
b e  u s e d  a s  a  s e n s i t iv e  i n d i c a t o r  o f  c y to to x ic i ty .9 T h e  
ATP-TCA  r e s u l t s  s h o w  g o o d  c o r r e l a t i o n  w i th  c l in ic a l
ISSN 0959-4973 < 2002 Lippincott Williams & Wilkins Anti-Cancer Drugs Vol 13 2002 625
F Di Nicolantonio et al.
o u t c o m e ,10'11 a n d  th e r e  is  e v id e n c e  th a t  th i s  w ill 
t r a n s l a te  in t o  c l in ic a l  b e n e f i t  f o r  a s s a y -d ir e c te d  
t h e r a p y .12 T h e  a s s a y  h a s  b e e n  u s e d  t o  a s s e s s  n e w  
a g e n ts  a n d  to  d e s ig n  n e w  c o m b in a t io n s  a s  a n  a id  t o  
t h e  p l a n n in g  o f  c l in ic a l t r i a ls .7'13-15
L ip o s o m a l d o x o r u b ic in  h a s  p r o v e d  p a r t ic u la r ly  
u s e fu l  a s  a  s in g le  a g e n t  in  r e c u r r e n t  o v a r ia n  
c a n c e r6'16-20 a n d  w e  th e r e f o r e  c h o s e  t o  l o o k  a t  th i s  
t u m o r  ty p e .  T r e o s u l f a n ,  v in o r e lb in e  a n d  c i s p i a t i n  
w e r e  t e s t e d  in  c o m b in a t io n  w i th  d o x o r u b ic in ,  w h ic h  
w a s  u s e d  a t  5 t im e s  t h e  t e s t  d r u g  c o n c e n t r a t i o n  
(T D C ) u s e d  f o r  th e  s ta n d a r d  d r u g  f o r m u la t io n  to  
a c c o u n t  f o r  t h e  in c r e a s e d  in t r a - tu m o r a l  c o n c e n t r a ­
t i o n  a c h ie v a b le  w i th  l i p o s o m a l  p r e p a r a t io n s .  I t is  n o t  
p o s s ib le  t o  t e s t  l i p o s o m a l  d o x o r u b ic in  d i r e c t ly  in  o u r  
a s s a y  a s  s c ru m -f ire c  m e d ia  d o  n o t  h y d ro ly z e  p e g y -  
l a te d  l i p o s o m e s  a n d  a  p r e v io u s  s tu d y  h a s  s h o w n  n o  
e f fe c t o f  l i p o s o m a l  d o x o r u b ic in  in  c e l l  l i n e s  m a in ­
t a in e d  in  s u c h  m e d ia .21
Materials and methods
Tumors
A to t a l  o f  1 2 3  r e c u r r e n t  o v a r ia n  t u m o r s  w e r e  t e s t e d ,  
w i th  lo c a l  e th ic s  c o m m i t t e e  a p p r o v a l  f o r  t h e  u s e  o f  
t i s s u e  o r  c e l ls  n o t  r e q u i r e d  fo r  d ia g n o s i s .  T h e s e  w e r e  
a ll p r e v io u s ly  t r e a t e d  w ith  c a r b o p la t i n  a l o n e  o r  
c a r b o p l a t i n  4- ta x a n e s  f ir s t  l in e ,  f o l lo w e d  in  n in e  
c a s e s  b y  a n  a n t h r a c y c l in e - c o n ta in in g  r e g im e n .  T h e  
m e d ia n  a g e  o f  t h e  p a t ie n t s  w a s  5 8  y e a r s  ( r a n g e  3 5 -  
8 0 ) .  All p a t i e n t s  h a d  F IG O  s ta g e  3 b  o r  4  d is e a s e  a t 
r e c u r r e n c e :  2 9 %  (2 9  o f  101) s h o w e d  c l in ic a l  r e s is ­
t a n c e  t o  p la t in u m  a n d  h a d  r e l a p s e d  d u r in g  o r  w i th in  
6  m o n t h s  o f  p r im a r y  p la t in u m - b a s e d  th e r a p y .  H is to ­
lo g ic a l ty p e  w a s  s ta t e d  o n  th e  s u b m is s io n  fo rm  in  7 6  
c a s e s :  5 0  w e r e  o f  s e r o u s  h is to lo g ic a l  ty p e ,  n in e  w e r e  
e n d o m e t r i o id ,  f o u r  w e r e  c l e a r  c e ll ,  t h r e e  w e r e  
m u c in o u s  a n d  10 w e r e  p o o r ly  d i f f e re n t ia te d .
ATP-TCA
T h e  A TP-TCA  w a s  p e r f o r m e d  a s  p r e v io u s ly  d e ­
s c r ib e d .7'9'15 S a m p le s  w e r e  t r a n s p o r t e d  to  t h e  
l a b o r a to r y  in  t r a n s p o r t  m e d iu m  c o n s i s t i n g  o f  
D u lb e c c o ’s  m o d i f ie d  E a g le ’s  m e d iu m  (S ig m a , P o o le ,  
UK; D 5 6 7 1 )  a s  p r e v io u s ly  d e s c r i b e d .7 B rie fly , th e  
t u m o r  s a m p le s  w e r e  f irs t s u b je c te d  to  g e n t le  e n z y ­
m a tic  d is s o c ia t io n  b y  c o l la g e n a s e  (0 .7 5  m g /m l; S ig ­
m a ; C 8 0 5 1 )  t o  p r o d u c e  a  s in g le -c e ll  s u s p e n s i o n .  T h e  
c e l ls  w e r e  t h e n  c u l tu r e d  in  s e r u m - f r e e  m e d ia
(C o m p le te  A ssay  M e d iu m ; D C S  In n o v a t iv e  D ia g n o s -  
t ik  S y s te m e , H a m b u r g ,  G e r m a n y )  in  9 6 -w e ll  p o ly ­
p r o p y le n e  p la te s  (C o m in g - C o s ta r ,  H ig h  W y c o m b e , 
U K) w i th  o r  w i t h o u t  th e  t e s t  d r u g s  a t  s ix  d i l u t io n s ,  
a l lo w in g  f o u r  d r u g s  t o  b e  t e s t e d  w i th  t r i p l ic a te  w e lls  
f o r  e a c h  d a t a  p o in t .  C o m b in a t io n s  w e r e  m a d e  b y  
d i r e c t  a d d i t i o n  o f  d i e  tw o  d r u g s  a t  th e  s a m e  
c o n c e n t r a t i o n  u s e d  f o r  th e  s in g le  a g e n ts .  T w o  
c o n t r o l s  w e r e  i n c lu d e d  in  12 w e ll s  e a c h :  a  m a x im u m  
in h i b i to r  (M I) w h ic h  k i l le d  a ll t h e  c e l ls  p r e s e n t  g iv in g  
a  z e r o  A TP c o u n t  a n d  a  n o  d r u g  c o n t r o l  (M 0) 
c o n s i s t i n g  o f  m e d iu m  a lo n e .  T h e  c e l ls  w e r e  c u l tu r e d  
f o r  6  d a y s  a t  3 7 ° C  w i th  5%  C 0 2. F o l lo w in g  in c u b a ­
t i o n ,  a  c o m m e r c i a l  d e t e r g e n t - b a s e d  e x t r a c t i o n  r e ­
a g e n t  w a s  u s e d  t o  ly se  th e  c e lls  a n d  in h ib i t  th e  
A T P ases  c o n t a in e d  w i th in  t h e  c e l ls  (D C S  I n n o v a t iv e  
D ia g n o s t ik  S y s te m e ) .  A TP q u a n t i f i c a t io n  t o o k  p la c e  
b y  a d d i n g  th e  lu c i f e r in - lu c i f c r a s e  c o u n t i n g  r e a g e n t  
t o  t h e  c e ll  ly s a te . T h e  a m o u n t  o f  l ig h t  p r o d u c e d  w a s  
m e a s u r e d  in  a  m ic r o p la te  l u m i n o m e t e r  ( B e r th o ld  
M PLX). T h e  r e s u l t s  a r e  e x p r e s s e d  a s  t h e  p e r c e n t  
in h ib i t i o n  a c h ie v e d  a t  e a c h  c o n c e n t r a t i o n  
t e s t e d ,  c a lc u la te d  as: % in h i b i t i o n  =  1 -  ( te s t  -  M I)/ 
(M 0 —M I) x 1 0 0 . S e v e ra l in d i c e s  o f  e ff ic a c y  s u c h  as  
IC S0 a n d  IC 90 c a n  b e  c a lc u la te d  f ro m  th e  d a t a ,  b u t  w e  
h a v e  p r e v io u s ly  f o u n d  th a t  a  n a t u r a l  lo g a r i th m ic  s u m  
in d e x  ( ln d e x stlM) c a lc u la te d  b y  th e  d i r e c t  a d d i t i o n  o f  
th e  p e r c e n t  s u rv iv a l a t  e a c h  c o n c e n t r a t i o n  p r o v id e s  
th e  b e s t  d i s c r im in a t io n  b e t w e e n  d r u g s  a n d  tu m o r s  to  
s h o w  th e  h e t e r o g e n e i ty  o f  th e  a c tiv i ty  o b s e r v e d .9,11,22 
W e h a v e  a l s o  c a lc u la te d  t h e  a r e a  u n d e r  t h e  c o n c e n -  
t r a t i o n - i n h ib i t i o n  c u r v e  ( I n d e x AU<) a n d  th e  p e r ­
c e n ta g e  o f  t u m o r s  a c h ie v in g  9 5 %  in h ib i t i o n .  
C o m b in a t io n  e f fe c ts  w e r e  a s s e s s e d  b y  t h e  m e th o d  
o f  P o c h  et al.,2* a s  p r e v io u s ly  u s e d  w i th  th e  A TP-TCA  
in  o t h e r  s tu d i e s . 13'14
Drugs
T h e  d r u g s  u s e d  in  th e  a s s a y  w e r e  o b t a in e d  a s  v ia ls  f o r  
in je c t io n  a n d  m a d e  u p  a c c o r d in g  to  t h e  m a n u f a c ­
t u r e r ’s  in s t r u c t io n s .  D o x o r u b ic in ,  t r e o s u l f a n  a n d  
v in o r e lb in e  w e r e  s to r e d  in  a l iq u o ts  a t  — 2 0 ° C , w h i le  
c i s p ia t in  w a s  k e p t  a t  r o o m  t e m p e r a t u r e .  T h e  100%  
T D C  u s e d  w e r e  d e r iv e d  f ro m  p h a r m a c o k in e t i c  d a ta ,  
a d ju s t e d  f o r  p r o t e in  b in d i n g  to  a p p r o x i m a t e  th e  
c o n c e n t r a t i o n  c l in ic a lly  a c h ie v a b le  in  th e  p a t i e n t .  F o r  
c i s p ia t in  t h e  100%  T D C  w a s  3 .0  p g /m l,  f o r  t r e o s u l f a n  
2 0 p g /m l ,  f o r  5 - f lu o ro u r a c i l  (5 -F U ) 4 5  p g /m l,  f o r  
d o x o r u b ic in  x 5 2.5  x ( ig /m l a n d  f o r  v in o r e lb in e  
12 p g /m l. C o m b in a t io n s  w e r e  m a d e  u p  b y  a d d i n g  
b o th  d r u g s  a t  t h e i r  2 0 0 %  T D C  t o  t h e  w e l l s  a t  th e
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C om binations o f  doxorubicin  in  ovarian  cancer
b e g i n n in g  o f  t h e  a s say : s e q u e n t ia l  s t u d ie s  w e r e  n o t  
p e r f o r m e d .  N o t  a ll d r u g s  o r  c o m b in a t io n s  w e r e  
t e s t e d  in  e v e ry  c a s e .
Data analysis
D a ta  f r o m  t h e  l u m in o m e te r  w e r e  t r a n s f e r r e d  t o  a  
s p r e a d s h e e t  (E x c e l 9 7 ; M ic ro s o f t)  a n d  c a lc u la t io n s  t o  
d e r i v e  t h e  in d i c e s  p e r f o r m e d  u s in g  a  t e m p la te .  T h e  
c a lc u la te d  a n d  d e s c r ip t iv e  d a t a  w e r e  e n t e r e d  in t o  a n  
A c c e s s  2 0 0 0  d a t a b a s e  (M ic ro s o f t)  f o r  f u r th e r  a n a ly s is  
a n d  a n a ly z e d  u s in g  n o n - p a r a m e t r i c  s ta t is t ic s  
(Q L S T A T ; A d d in s o f t ,  P a ris , F ra n c e ) .
Results
T h e  r e s u l t s  s h o w  th a t  d o x o r u b ic in  x 5  a c h ie v e s  
> 9 9 %  in h i b i t i o n  a t  c l in ic a lly  a c h ie v a b le  c o n c e n t r a ­
t i o n s  in  6 1  o f  1 2 4  (4 9 % ) o f  t h e  o v a r ia n  tu m o r s  t e s t e d  
( T a b le  1). T e n  o v a r ia n  tu m o r s  s h o w e d  c o m p le t e  
r e s i s ta n c e .  O f  th e s e ,  o n ly  t h r e e  h a d  p r e v io u s  e x ­
p o s u r e  to  a n th r a c y c l in e s .  F o r  th e  o t h e r  in d iv id u a l  
a g e n t s  t e s t e d ,  t h e r e  w a s  a  s ig m o id a l  c o n c e n t r a t i o n -  
r e s p o n s e  c u r v e  f o r  b o th  c i s p ia t in  a n d  5-F U , w i th  a  
s o m e w h a t  f la t te r  c u rv e  fo r  v in o r e lb in e  (d a ta  n o t  
s h o w n ) .
F o r  th e  p u r p o s e s  o f  c o m p a r i s o n  b e t w e e n  d r u g s  
a n d  tu m o r s ,  a n  l n d e x S (j M  o f  < 3 0 0  w a s  t a k e n  a s  ex 
vivo  s e n s i t iv i ty  a n d  >  3 5 0  a s  r e s is ta n c e ,  a s  p re v io u s ly  
p u b l i s h e d .22,24 V a lu e s  b e t w e e n  th e s e  tw o  p o in t s  
w e r e  r e g a r d e d  a s  e q u iv o c a l .  O n  th i s  b a s is ,  7 6 %  (9 0  
o f  1 1 8 )  o f  t h e  o v a r i a n  tu m o r s  t e s t e d  s h o w e d  
r e s i s ta n c e  t o  c i s p ia t in ,  w i th  o n ly  16%  (1 9  o f  1 1 8 )
s h o w in g  s e n s it iv ity . In  c o n t r a s t ,  8 4 %  (1 0 3  o f  1 2 3 ) 
s h o w e d  s e n s i t iv i ty  t o  d o x o r u b ic in  x 5 , 3 7 %  ( 3 7  o f  
1 0 6 ) t o  t r e o s u l f a n  a n d  7 7 %  (4 1  o f  5 3 )  t o  v in o r e lb in e  
(T a b le  1). O n ly  s ix  tu m o r s  w e r e  t e s t e d  w i th  5-F U , 
a l th o u g h  f o u r  s h o w e d  s e n s it iv ity .
T h e  c o m b in a t io n s  t e s t e d  a r e  o n ly  s l ig h t ly  b e t t e r  
t h a n  d o x o r u b ic in  x  5  a lo n e ,  a s  s h o w n  in  F ig u re  1 
a n d  T a b le  1 . All p r o d u c e  > 9 0 %  s e n s i t iv i ty  b a s e d  o n  
a n  In d ex su M  o f  < 3 0 0  ( d o x o r u b ic in  x 5  w i th  c i s p i a ­
t i n  =  9 8 % , w i th  t r e o s u l f a n  =  9 8 % , 5 -F U  =  9 0 % , w i th  
v in o r e l in e  =  10 0 % ). T h e  b e s t  e f fe c t is  o b t a i n e d  w i th  
t h e  c o m b in a t io n  o f  d o x o r u b ic in  x  5  +  v in o r e lb in e ,  
w h ic h  is  b e t t e r  th a n  d o x o r u b ic in  x  5  a l o n e  in  51  o f  
5 3  p a i r e d  o b s e r v a t io n s  ( M a n n - W h itn e y  ( /- te s t:  
/> < 0 .0 0 0 1  o n  Index.suM )< a n d  b e t t e r  th a n  d o x o r u b i ­
c in  x 5  +  t r e o s u l f a n  in  3 9  o f  41  p a i r e d  o b s e r v a t io n s  
( p < 0 .0 0 0 1 ) .  T h e  e x a m p le  s h o w n  in  F ig u re  2 s h o w s  
t h e  a d v a n ta g e  o f  th e  c o m b in a t io n  o v e r  t h e  in d iv id u a l  
a g e n ts  in  t e r m s  o f  in h ib i t i o n ,  b u t  th e  e f fe c t is  a d d i t iv e
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Figure 1. Median effect of doxorubicin x 5  against 
ovarian cancer compared with the combinations tested.
Table 1. Results for single-agent doxorubicin tested at 5 times the standard concentration to reflect the increased intra- 
tumoral concentration achievable with the liposomal preparation
Drug/
combination
n Age lndexAUC IC90 IC50 IndexsuM >95%
Inhibition
Doxorubicin
V
123 58 (35-80) 18014 (7085-19565) 35 (6-297) 12 (3-165) 139 (3-505) 83 (102/123)
A \J
Cispiatin 118 58 (35-80) 7686 (266-17144) 257 (76-1429) 135 (4-794) 445 (113-940) 4 (5/118)
Treosulfan 106 59 (35-80) 12657 (433-18121) 185 (33-978) 62 (4-544) 343 (91-846) 44 (47/106)
5-FU 6 51 (48-64) 16672(0-18936) 85 (18-269) 15 (4-166) 151 (46-1338) 67 (4/6)
Vinorelbine 53 61 (40-80) 15508 (6145-19158) 146 (6-242) 6 (3-140) 183 (15-502) 72 (38/53)
Doxorubicin 52 60 (36-80) 18615 (12267-19488) 21 (6-246) 9 (3-52) 92 (8-314) 88 (46/52)
x 5 +  cispiatin
Doxorubicin 41 61 (44-80) 18725 (12857-19491) 21 (6-205) 8 (4-72) 92 (8-346) 98 (40/41)
x 5 -1- treosulfan
Doxorubicin 11 58 (48-69) 17455 (10696-19234) 40 (10-292) 9 (4-46) 119 (21-361) 55 (6/11)
x 5 + 5-FU
Doxorubicin 53 61 (36-80) 19013 (16746-19488) 12 (6-86) 4 (3-28) 37 (0-209) 98 (52/53)
x 5 +  vinorelbine
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— ■— Combination o - ■ Independent action
Figure 2. (a) Comparison of the activity of doxorubicin alone and in combination with vinorelbine in a tumor showing 
resistance to doxorubicin and vinorelbine. (b) Combination analysis23 conf i rming an additive effect of the two drugs in 
this instance.
r a t h e r  th a n  s y n e r g is t ic  w h e n  a n a ly z e d  b y  t h e  m e th o d  
o f  P o c h  et al. ,2i in  w h ic h  th e  o b s e r v e d  e f fe c t a t e a c h  
c o n c e n t r a t i o n  te s t e d  is  c o m p a r e d  w i th  t h e  e x p e c t e d  
e f f e c t  (F ig u r e  2 ) .
Discussion
T h e  p r o p o r t i o n  o f  tu m o r s  a p p a r e n t ly  s e n s i t iv e  t o  
d o x o r u b ic in  x 5  e x c e e d s  th e  r e s p o n s e  r a t e s  o b t a in e d  
in  c l in ic a l  t r i a ls  o f  l i p o s o m a l  d o x o r u b ic in  in  r e c u r ­
r e n t  o v a r i a n  c a n c e r .6 ,16-20 T h e  la rg e s t  o f  th e s e  
o b t a in e d  a  2 0 %  r e s p o n s e  r a t e . 18 T h e  r e a s o n  fo r  th i s  
d is c r e p a n c y  m a y  b e  o v e r e s t im a t io n  o f  th e  lik e ly
c o n c e n t r a t i o n  t o  w h ic h  tu m o r  c e l ls  a r e  e x p o s e d .  
O u r  u s e  o f  5  t im e s  t h e  s ta n d a r d  T D C  f o r  d o x o r u b ic in  
w a s  b a s e d  o n  a v a ila b le  d a t a  f ro m  a n im a l  s tu d i e s .2 I t is  
w o r th  n o t i n g  th a t  a  r e c e n t  s tu d y  o f  h u m a n  s u b je c ts  
p r e s e n t e d  a t  th e  2 0 0 1  S a n  A n to n io  B re a s t  C a n c e r  
S y m p o s iu m  a l s o  s u g g e s ts  a  h ig h e r  a n d  m o r e  
s u s t a in e d  e n h a n c e m e n t  o f  d o x o r u b ic in  le v e ls  in  
t u m o r s  f ro m  b r e a s t  c a n c e r  p a t i e n t s  t r e a t e d  w ith  
l i p o s o m a l  d o x o r u b ic in .25 H o w e v e r ,  in  a d d i t i o n  to  
th e  p h a r m a c o k in e t ic  c o n s id e r a t io n s ,  r a p i d  a c q u is i ­
t i o n  o f  r e s is ta n c e  b y  a  s m a l l  s u b s e t  o f  t u m o r  c e lls  
d u r in g  t r e a tm e n t  c o u l d  a l s o  e x p la in  o u r  r e s u l t s .  W e 
a r e  p u r s u in g  a n  e x p la n a t io n ,  b u t  o n  th e  b a s is  o f  
th e s e  d a ta ,  w e  h a v e  n o w  r e d u c e d  t h e  c o n c e n t r a t i o n  
te s t e d  in  th e  A TP-TCA  f o r  l i p o s o m a l  d o x o r u b ic in  t o  3
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t im e s  t h e  n o r m a l  T D C . C o r r e l a t i o n  d a t a  c o m p a r in g  
A TP-TC A  r e s u l t s  w i th  c l in ic a l o u t c o m e  f ro m  fo llo w -  
u p  o f  th o s e  p a t i e n t s  in  th i s  s e r ie s  t r e a t e d  w i th  
l i p o s o m a l  d o x o r u b ic in  a r e  a w a i te d .
W e d id  n o t  e x p l o r e  c o m b in a t io n s  in  a n y  d e t a i l  in  
o u r  p r e v i o u s  s tu d y ,  t h o u g h  w e  n o te d  th a t  t h e  
a d d i t i o n  o f  g e m c i t a b in e  w a s  u n a b l e  to  a u g m e n t  t h e  
r e s p o n s e  t o  a n y  g r e a t  e x t e n t ,7 a  f in d in g  th a t  h a s  n o w  
b e e n  e x p l o r e d  c l in ic a l ly  in  a  s m a ll  p h a s e  1 s tu d y .26 
W h ile  th i s  s tu d y  d id  s h o w  n in e  o f  2 7  r e s p o n s e s ,  it  
s h o u ld  b e  n o t e d  th a t  s ix  p a t ie n t s  h a d  n o t  r e c e iv e d  
p r i o r  c h e m o th e r a p y .  W e  k n o w  o f  n o  r a t io n a l e  f o r  
a d d i n g  th e s e  tw o  d r u g s  t o g e th e r ,  o t h e r  th a n  e m p i r i ­
c a l e v i d e n c e  o f  a c tiv i ty  o f  b o th  s in g le  a g e n ts  in  
m u l t i p l e  t u m o r  ty p e s .  E q u a lly , w e  d id  n o t  t ry  to  
c o m b in e  to p o i s o m e r a s e  I a n d  II in h ib i to r s ,  a s  
t o p o t e c a n  +  l i p o s o m a l  d o x o r u b ic in  w a s  f o u n d  t o  b e  
to x ic .27
A s m o s t  o f  t h e  p a t i e n t s  h a d  a ll h a d  p r e v io u s  
e x p o s u r e  t o  ta x a n e s ,  w e  d id  n o t  t e s t  th i s  in  
c o m b in a t io n  w i th  d o x o r u b ic in  x 5, th o u g h  it  s h o u ld  
b e  n o t e d  t h a t  r e c e n t  r e s u l t s  c o m b in in g  l i p o s o m a l  
d o x o r u b ic in  w i th  d o c e ta x e l  a r e  e n c o u r a g in g .8 W e 
c h o s e  i n s te a d  t o  e x a m in e  th e  e f fe c t o f  d o x o r u b ic in  
o n  c i s p i a t i n  r e s i s ta n c e  a n d  in  c o m b in a t io n  w ith  
a n o t h e r  a lk y la t in g  a g e n t  t o  w h ic h  r e s is ta n c e  is  le s s  
c o m m o n  in  th i s  s e t t in g ,  t r e o s u l f a n .  T h e  r e s u l t s  f o r  
th e  c o m b in a t io n  o f  d o x o r u b ic in  x  5  w i th  t r e o s u l f a n ,  
5-F U  a n d  c i s p i a t i n  a r e  d i s a p p o in t in g ,  w i th  l i td e  
i m p r o v e m e n t  in  e ff ic a c y  c o m p a r e d  w i th  s in g le  a g e n t  
d o x o r u b ic in  x 5  ( T a b le  1 a n d  F ig u re  1). T h e  la c k  o f  
e f fe c t  w i th  c i s p i a t i n  s u g g e s ts  th a t  a n th r a c y c l in e s  d o  
n o t  g r e a t ly  i n f l u e n c e  r e s i s ta n c e  t o  c i s p ia t in .
I n  c o n t r a s t ,  t h e  c o m b in a t io n  o f  v in o r e lb in e  a n d  
l i p o s o m a l  d o x o r u b ic in  s h o w e d  a d d i t iv e  e f fe c ts .  T h is  
c o m b in a t io n  h a s  b e e n  t r i e d  in  t h e  c l in ic  in  m e ta s ta t ic  
b r e a s t  c a n c e r  a n d  th e  d a t a  h a s  b e e n  p r e s e n t e d  a t  a n  
i n t e r n a t io n a l  m e e t i n g ,  a l th o u g h  it is  n o t  y e t  p u b ­
l i s h e d .28 T h e  c o m b in a t io n  w a s  f o u n d  to  b e  s a fe , w ith  
a c c e p ta b le  to x ic i ty ,  b u t  s h o w e d  a  d is a p p o in t in g ly  
lo w  r e s p o n s e  r a t e  (1 8 % ) in  t h e  s m a l l  n u m b e r  o f  
p a t i e n t s  (n = 2 2 )  t r e a t e d .  O u r  d a t a  s u g g e s ts  th a t  th i s  
c o m b in a t io n  is  w o r th y  o f  f u r th e r  c o n s id e r a t i o n  a n d  
s h o u l d  b e  t e s t e d  c l in ic a l ly  in  r e c u r r e n t  o v a r ia n  
c a n c e r .
T h e r e  a r e  a  n u m b e r  o f  o t h e r  c o m b in a t io n s  th a t  
n e e d  t o  b e  s tu d i e d .  S o m e  o f  th e  p o s s ib le  c o m b in a ­
t i o n s  a r e  a l r e a d y  b e i n g  t e s t e d  in  t h e  c l in ic  o n  a n  
e m p i r ic a l  b a s is ,  e .g .  t h e  c o m b in a t io n  o f  l i p o s o m a l  
d o x o r u b ic in  w i th  H e r c e p t in .29 I t w o u ld  b e  p a r t i c u ­
la r ly  i n t e r e s t i n g  t o  e x a m in e  th e  r o le  o f  C a e ly x /D o x il  
in  c o m b in a t io n  w i th  ta x a n e s  in  o v a r ia n  c a n c e r  
s a m p l e s  f r o m  p r e v io u s ly  u n t r e a t e d  p a t ie n t s ,  a s  w e  
h a v e  p r e v io u s ly  s h o w n  c o m b in a t io n s  o f  a n th r a c y -
Com binations o f  doxorubicin  in  ovarian  cancer
c l in e s  w i th  ta x a n e s  t o  b e  v e ry  a c tiv e  in  th i s  t u m o r  
t y p e ” - ' 3
Conclusion
I t is  c l e a r  f r o m  th i s  a n d  p r e v io u s  s tu d ie s  th a t  th e  u s e  
o f  A T P -b a se d  c h e m o s e n s i t iv i ty  te s t in g  c a n  a s s is t  th e  
d e v e lo p m e n t  o f  n e w  r e g im e n s  a n d  h a s  th e  p o te n t ia l  
t o  s p e e d  u p  th e i r  i n t r o d u c t i o n  t o  t h e  c l in ic .29 
V in o r e lb in e  +  l i p o s o m a l  d o x o r u b ic in  is  c le a r ly  o f  
c o n s id e r a b le  in t e r e s t  a n d  w e  a w a i t  f u r th e r  c l in ic a l 
d a ta .
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Preclmical report 1
Ex vivo reversal of chemoresistance by tariquidar (XR9576)
Federica Di Nicolantonio3, Louise A. Knight3, Sharon Glaysher3, Pauline A. 
Whitehouse3, Stuart J. Mercer3, Sanjay Sharma3, Lisa Mills3, Alison Prin3, 
Penny Johnson3, Peter A. Charltonb, David Norris6 and Ian A. Cree3
The expression of P-glycoprotein (P-gp) has been de­
monstrated to confer resistance to several anticancer 
drugs, including anthracyclines, taxanes and vinca alka­
loids. Tariquidar is a novel inhibitor of P-gp that has been  
shown to reverse resistance to cytotoxic drugs in tumor 
cell lines and m ouse xenografts. We have used an ATP- 
based chem osensitivity assay (ATP-TCA) to compare the 
activity of cytotoxic drugs in combination with tariquidar 
against a variety of solid tumors (n= 37). The expression of 
P-gp w as determined in a subset of solid tumor sam ples by 
immunohistochemistry (n = 16). Resistance w as seen  in 20 
of 37 (54%) tum ors tested with doxorubicin, in 27 of 34 
(79%) sam ples tested  with paditaxel and 17 of 31 (55%) 
with vinorelbine. Tariquidar alone showed no activity over a 
wide range of concentrations up to 2pM ( n = 14). The 
median ICgoS for doxorubicin, paditaxel and vinorelbine, 
alone w ere 2.57, 27.4 and 15.5 pM. These decreased to 1.67 
( p < 0.0005), 20.6 (p< 0 .05) and 9 .5pM ( p < 0.001), respec­
tively, in combination with tariquidar. Tariquidar also  
significantly decreased  resistance in 14 of 20 (70%), six of 
27 (22%) and six of 17 (35%) sam ples tested with 
doxorubicin, paditaxel and vinorelbine, respectively. Im- 
munohistochemical staining for P-gp was positive in nine 
of 16 (56%) sam ples and in all of these c a ses  addition of
tariquidar improved the activity of the cytotoxic The results 
show that tariquidar is able to decrease resistance in a 
number of solid tumors resistant to cytotoxic drugs known 
to be P-gp substrates. These data support the introduction 
of tariquidar in combination with chemotherapy to dinical 
trials of patients expressing P-gp. Anti-Cancer Drugs 
15:000-000 © 2004 Lippincott Williams & Wilkins.
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Introduction
The success of chemotherapy is ofren severely compro­
mised by the development of resistance. Some tumors 
display resistance not only to the original agents used in 
treatment, but also to agents to which they have not 
previously been exposed, many of which are dissimilar in 
structure or mode of action. This phenomenon is known 
as classical multidrug resistance (MDR). ML)R is strongly 
associated with overexpression of ATP-dependent pump 
molecules such as P-glycoprotein (P-gp). Many different 
chemotherapeutic agents have been shown to be 
susceptible to P-gp, including taxanes, vinca alkaloids, 
and anthracyclines [1J.
P-gp, the product of the multidrug resistance gene 
(MDR1), is a transmembrane efflux pump responsible 
for detoxifying normal cells as well as rendering tumor 
cells resistant to chemotherapy. Its role as a cellular efflux 
pump controlling intracellular concentrations of harmful 
substances is reflected by its cell- and organ-specific 
distribution in kidney bile canaliculi, gut epithelium and
0959-4973 ©  2004 Lippincott Williams A Wilkins
capillary endothelium, as well as its ability to recognize 
and transport a wide range of compounds. In human 
tumors, P-gp expression is most commonly detected in 
colon, hepatic, renal and adrenal carcinomas. It has also 
been observed in human hematological malignancies, 
breast, ovarian, lung and gastric carcinomas, skin cancers, 
and certain germ cell tumors and sarcomas [1,2 ].
Several studies have shown an inverse correlation 
between P-gp expression and chemosensitivity or survival 
in a variety of tumor types, including leukemia [3-5], 
lymphomas [6 ], osteogenic sarcoma [7,8], small cell lung 
cancer [9,10], breast cancer [11-13], advanced ovarian 
cancer [14,15] and pediatric solid tumors [16-18]. 
However, it should be noted that associations with 
chemoresistance have also been reported for other 
transmembrane efflux pump molecules, including MRP, 
LRP/MVP and BCRP [19-21]. There is considerable 
controversy around which of these molecules are of 
greatest clinical importance to chemosensitivity’ or 
resistance, but reversal of such resistance could be of
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considerable benefit, and inhibitors of P-gp have there­
fore been developed.
A broad range of compounds that interact with P-gp and 
block drug efflux have been reported to reverse the MDR 
phenotype. The first generation modulators consisted of 
calcium channel blockers, calmodulin inhibitors, hormo- 
nal/'sreroidal derivatives, antibiotics, cardiovascular drugs 
and the cyclosporins [22). These compounds were 
developed for pharmacological uses other than the 
reversal of MDR and were relatively non-specific and 
weak inhibitors. The requirement for more selective and 
potent agents as resistance modifiers has led to the 
development of several ‘second-generation’ modulators 
such as the non immunosuppressive cyclosporin D analog, 
PSC 833 (valdospar) and VX-710 (biricodar); however, 
these compounds have shown significant enhancement of 
pharmacokinetics and toxicity of various cytotoxics (23]. 
This effect has required the reduction of the cytotoxic 
drug dose when administered with these modulators. 
Furrher studies led to the development of third-genera­
tion molecules such as XR9576 (tariquidar; Fig. 1), 
LY335979 (zosuquidar), R101933 (laniquidar) and ONT- 
093 [24]. These agents have high potency and specificity 
for P-gp.
Tariquidar is a highly potent anthranilic acid derivative 
that has been demonstrated to reverse P-gp dependent 
multidrug resistance in tumor cell lines and animal 
models (25,26]. In healthy volunteers administration of 
tariquidar demonstrated P-gp inhibition in GD56+ 
lymphocytes (27]. Tariquidar selectively binds to P-gp 
with high affinity and its long duration of action helps in 
the restoration of sensitivity of MDR + tumors to a range 
of chemotherapeutic agents. A series of phase Ila trials 
have been carried out to study the pharmacokinetic 
behavior of tariquidar when given with certain cytotoxic
agents known to be affected by P-gp, i.e. vinorelbine, 
doxorubicin and paditaxel. The results of these three 
studies demonstrated that tariquidar is a potent P-gp 
inhibitor, without significant side-effects and w'ith less 
pharmacokinetic interaction than other inhibitors used 
previously [28]. MDRI mechanisms may reduce the 
toxicity of some drugs such as anthracyclines and their 
inhibition may therefore change the side-effect profile of 
some drugs [23].
The ATP-Tumor Chemosensitivity Assay (ATP-TCA) is 
capable of determining drug sensitivity and drug resis­
tance in individual tumor samples by measuring cell 
viability. This assay has a high evaluability rate (93% in 
ovarian cancer) [29] and measures the effect of multiple 
drugs or drug combinations at different concentrations.
The aim of this study was to determine the ability of 
tariquidar to alter the chemosensitivity of various solid 
tumors to commonly used chemotherapeutic agents. We 
chose to study doxorubicin, paditaxel and vinorelbine as 
examples of anthracyclines, taxanes and vinca alkaloids.
Materials and methods 
T issue sam ples
Of the 37 solid tumor samples studied, 21 were ovarian 
carcinomas, five were unknown primaries, five were skin 
melanomas, two were breast carcinomas, two were 
esophageal, one colon and one lung (non-small cell lung 
cancer) carcinomas. Patients consisted of 32 females and 
five males, having a median age of 58 (range 36-76). 
Several patients received one or more chemotherapy 
regimens, while 10 of 37 had no previous treatment 
(Table 1). All tumor samples were removed as part of 
patient treatment, with consent for rissue donation and 
Local Research Ethics Committee approval for use of the
Hq.1
CHO
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.2CH SO H.XH20
Tariquidar (XR9576)
Chemical structure of tariquidar.
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Table 1 Patient and sam ple characteristics
Tumor type No. samples Patient age (median) Sex Sample type Previous treatment*
Ovarian carcinoma 21 58 (38-76) 21F 5 solid. 2 pleural fluid. 14 
ascites
Carboplatin (n—13), plati­
num + taxane (n— 10), li­
posomal doxorubicin 
(n=3), treosulfan + - 
gemcitabine (n-2), car­
boplatin + gemcitabine 
(/t“1), mitoxantrane-t - 
paditaxel (r>—1), topo­
tecan (n— 1), etoposide 
ln-1)
Skin melanoma 5 48 (36-66) 3M:2F 5 sofcd Melphalan (n— 1), cyclo­
phosphamide t'/i —1)
Unknown pnmary 5 61 (45-68) 5F 3 solid, 2 pleural fluid Carboplatin (r>=1)
Breast carcinoma 2 49 (39-59) 2F 1 solid, 1 pleural fluid Anastrozole (n— 1)
Esophageal carcinoma 2 62 (52-72) 2M 2 sofcd Eptrubicin + cispiatin + 5- 
fluorouradl (n = 1)
Colon carcinoma 1 39 IF Solid Irinotecan (n = 1)
Lung (non-small cell lung 
cancer)
1 58 IF Pleural fluid Cispiatin + vinorelbine
(n-1)
Total 37 58 (36-76) 5M:32F 17 solid. 20 fluid
“The numbers in brackets indicates the number of patients who received the previously listed treatment. In the ovarian carcinoma subset several patients received more 
than one chemotherapeutic treatment.
tissue surplus to diagnostic requirements for chemosen­
sitivity testing and further molecular studies.
Drugs
Tariquidar was provided by Xcnova. A stock solution of 
tariquidar (XR9576 mesylate salt) was prepared in 
DMSO at a concentration of 1 mg/ml and stored as 
aliquots at -20°C. For cell treatments the stock solution 
was further diluted in culture medium with the final 
DMSO concentration less than 0.1%. The other drugs 
used in the assay were obtained as vials for injection from 
the pharmacy at Queen Alexandra Hospital. Doxorubicin 
was stored in aliquots at -20°C, vinorelbine was stored in 
the refrigerator at 4°C, while paditaxel was kept at room 
temperature. The 100% test drug concentrations (TDC) 
used were derived from pharmacokinetic data, adjusted 
for protein binding to approximate the concentration 
clinically achievable in the patient and to provide good 
discrimination between tumors. The TDC for drugs 
included in the study were as follows, doxorubicin
2.5 pM, vinorelbine 11 pM, paditaxel 15.9 pM and 
tariquidar 1 pM. Combinations were made up by adding 
both drugs at their 200% TDC to the wells at the 
beginning of the assay: sequential studies were not 
performed. Not all drugs or combinations were tested in 
every case.
Chem osensitivity a ssa y
The ATP-TCA was performed as previously described 
[30,31]. Samples were transported to the laboratory in 
transport medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma, Poole, UK; cat. no. 
D5671). Briefly, the tumor samples were first subjected 
to gentle enzymatic dissociation by collagenase (0.75 mg/ 
ml; Sigma; cat. no. C8051) to produce a single-cell
suspension. The cells were then cultured in serum-free 
media (Complete Assay Medium; DCS Innovative 
Diagnostik Systeme, Hamburg, Germany) in 96-well 
polypropylene plates (Corning-Costar, High Wycombe, 
UK) with or without the test drugs at six dilutions, 
allowing four drugs to be tested with triplicate wells for 
each data [>oint. Combinations were made by direct 
addition of the two drugs at the same concentration used 
for the single agents. Two controls were included in 12 
wells each: a maximum inhibitor (MI) which killed all the 
cells present giving a zero ATP count and a no drug 
control (MO) consisting of medium alone. The cells were 
cultured for 6 days at 37°C with 5% CO2. Following 
incubation, a commercial detergent based extraction 
reagent was used to lyse the cells and inhibit the 
ATPases contained within the cells (DCS Innovative 
Diagnostik Systeme). ATP quantification took place by 
adding the luciferin—luciferasc counting reagent to the 
cell lysate. The amount of light produced was measured 
in a microplate luminometer (MPLX; Berthold, Ham­
burg, Germany). The results arc expressed as the percent 
inhibition achieved at each concentration tested, calcu­
lated as: % inhibition = 1 - f(Test-M I)/(M O-M I)] x 
100.
Immunohistochemistry
MDR1 (P-glycoprotein) monoclonal antibody (NCL- 
JSB1) from Novacastra (supplied by Vector, Peterbor­
ough, UK) was visualized using the Vecrastain Universal 
Alkaline Phosphatase kit (Vector). Sections were cut on 
to positively charged slides (Surgipath Europe, Peterbor­
ough, UK) and dried at 60°C for 40min. Prior to staining 
sections were de-waxed via immersion in solvent and 
alcohol before being rinsed in water. Antigen-presenting 
sites blocked by formalin fixation [32] were revealed by
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high-tcmperaturc antigen retrieval (pressure cooking) 
using sodium citrate buffer, pH 6.0, for 2min. After 
cooling in water sections were incubated in normal horse 
serum for 20min to block non-specific staining. Endo­
genous avidin-binding activity was blocked by a further 
2 0 min of incubation in avidin and 2 0 min with biotin. 
Following this samples were incubated overnight in the 
primary antibody in a humid incubation chamber at 4:’C. 
Concentration of antibody was determined by titration on 
positive control tissue (renal proximal tubules). The 
antibody was diluted in Tris-buffercd saline (TBS), pH 
7.6, to its optimum dilution. Positive and negative 
controls were included with each batch of staining. The 
negative control consisted of duplicate of the test section 
with the primary antibody omitted.
The following day, slides were allowed to acclimatize to 
room temperature before rinsing in TBS. These were 
then incubated for 30min with diluted biotinylated 
universal secondary solution, rinsed and incubated for a 
further 30min with Vectastain ABC-AP reagent. In order 
to visualize the reaction, slides were incubated for 2 0 min 
in Vector Red alkaline phosphate substrate kit (plus 
levamisole to inhibit endogenous alkaline phosphatase 
activity). The slides were counterstained with Gill’s 
Hematoxylin, dehydrated and cleared using the Lcica XL 
slide staining machine. The sections were thus mounted 
in Vector Mount producing a permanently mounted 
section with an optimal refractive index to retain the 
color intensity of Vector Red substrate reaction product.
Immunohistochemisrry could only be performed in a 
proportion of samples, as some cytological specimens did 
not provide sufficient material for staining before 
treatment began.
Data analysis
Luminometer readings were entered into an Excel 
spreadsheet (Microsoft Office 2000), which automatically 
calculated IC90 and IC50 values for each drug and 
combination. The IC90 was used to correlate drug efficacy 
with immunostaining. Values of IC*, >  100% TDC were 
considered to suggest resistance, while values 
IC90 < 100% TDC were interpreted to suggest probable 
clinical sensitivity to the agent tested. When the addition 
of tariquidar decreased the cytotoxic IC90 to < 50% 
TDC, this was interpreted as a complete reversal of 
resistance. Assessment of slides was done using the H- 
score. Staining intensity (none = 0 points; weak = 1 
point; moderate =  2 points; strong = 3 points) and 
percentage of positive tumor cells were multiplied to 
achieve a score between 0 and 300. A H-score of 100 or 
more was regarded as positive. The calculated and 
descriptive data were entered into an Access 2000 
database (Microsoft) and analyzed using a Wilcoxon 
two-railcd paired rank sum test, the Mann-Whitncv U-
test for unpaired data or linear regression as appropriate 
(Statsdirect: Statsdirect, Sale, UK).
Results
Each of the agents rested produced a wide range of rumor 
inhibition consistent with considerable heterogeneity of 
chemosensitivity, as previously published [33-35J. As 
expected, tariquidar alone, rested in a subset of 14 
tumors, showed no activity over a wide range of 
concentrations up to and including 2pM (Fig. 2).
Doxorubicin
The median doxorubicin 1G*) and IC50 values were 2.57 
and 1.61 pM, respectively. The IC90 of doxorubicin was 
greater rhan 100% TDC (2.5 pM) in 20 of 37 (54%) 
samples. For the ovarian cancer subset, resistance 
according to IG*) was seen in 12 of 21 (57%) samples 
(Fig. 3a).
Immunostaining for P-gp was positive in nine of 15 (60%) 
samples tested with doxorubicin. The median doxorubi­
cin IGjo values for P-gp-negative and -positive samples 
were 2.44 and 4.40 pM, respectively, but this difference 
did not reach statistical significance (NS, Mann-Whitney 
U-test). It is notable that five of six P-gp negative 
samples were obtained from chemotherapy naive pa­
tients, while eight of nine P-gp-positive samples were 
from patients who had received previous treatment. No 
correlation was observed by linear regression analysis 
between the IC90 of doxorubicin and P-gp, but there was 
a correlation between the IC50 and P-gp expression 
(p < 0.005, Fig. 4). It should also be noted that 57% (four 
of seven) of the P-gp-ncgative samples showed sensitiv­
ity, while only 22% (two of nine) of the P-gp-positivc 
samples showed seasitivity to doxorubicin on the basis of 
JG*>.
The addition of tariquidar to doxorubicin decreased the 
median IC90 of doxorubicin from 2.57 to 1.67 pM 
(p< 0.0001) and the IC50 from 1.61 to 0.92 pM 
(p < 0.002, Wilcoxon).
Tariquidar showed some reversal of resistance to doxor­
ubicin in 14 of 20 (70%) samples classified as resistant 
and in two cases (10%) converted the sensitivity to an 
IC90 below 1.25 pM, which represents 50% TDC. Both 
these patients had recurrent ovarian carcinoma and none 
had previous anthracycline exposure. In the ovarian 
cancer subset, tariquidar showed some reversal of 
resistance to doxorubicin in 10 of 12 (83%) samples 
classified as resistant.
In all nine P-gp-positive cases the addition of tariquidar 
improved the activity of doxorubicin in the ATP-TCA. In 
four of nine cases (44%), the IG>o of doxorubicin
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decreased below 2.5 pM and in one of nine below 
1.25 pM.
Vinorelbine
The median ICqo and IC50 values for vinorelbine were
15.5 and 2.3 pM. The IG>o of vinorelbine was greater than 
100% TDC (11 pM) in 17 of 31 samples, indicating 
probable resistance in 55% of the tumors rested. For the 
ovarian cancer subset, resistance according to ICqo was 
seen in eight of 17 (47%) tumors (Fig. 3b).
Immunohistochemical staining for P-gp was positive in 7 
of 12 (58%) samples tested with vinorelbine. The median 
IC90 values for P-gp-negative and -positive samples were 
9.7 and 20.8 pM, respectively, but this difference did not 
reach statistical significance (NS, Mann-Whitncy U- 
test). Semiquanritative visual assessment of the degree 
of staining in this relatively small number of cases showed 
no correlation with sensitivity' to vinorelbine (ICqo and 
IGso) by linear regression analysis (data not shown). 
However, it should be noted that only one of seven (14%) 
of the P-gp-positive samples showed sensitivity to 
vinorelbine on the basis of ICqo, while three of five 
(60%) of the P-gp-ncgative samples showed sensitivity to 
vinorelbine.
The addition of tariquidar decreased the median IC90 of 
vinorelbine from 15.5 to 9.5 pM </> < 0.0003, Wilcoxon). 
Tariquidar showed some reversal of resistance to vinor­
elbine in six of 17 (35%) samples classified as resistant 
and in one case (6%) converted the sensitivity to an IG*,
below 5.5 pM, which represents 50% TDC (Fig. 3b). In 
the ovarian cancer subset, tariquidar showed some 
reversal of resistance to vinorelbine in three of eight 
(37%) samples classified as resistant. Tariquidar produced 
little or no effect on vinorelbine activity in P-gp-ncgative 
samples (Fig. 5). In ail seven P-gp-positive cases the 
addition of tariquidar improved the activity of the vinca 
alkaloid in the ATP-TCA. In four of seven P-gp-positive 
cases (57%) the ICqo °f vinorelbine decreased below 
11 pM and in one of seven below 5.5 pM.
Paditaxel
The median ICqo and IC50 values for paditaxel were 27.4 
and 9.7 pM respectively. Resistance to paditaxel accord­
ing to IC90 was seen in 27 of 34 (79%) samples. In nine of 
27 resistant cases, the patients had been previously 
exposed to a taxane-based regimen. In this particular 
subset the median ICqo for paditaxel was 38.4 pM, while 
in the remaining 18 of 27 resistant cases the median IG*) 
decreased to 29.0 pM (p < 0.05, Mann-Whitney (/-test). 
For the ovarian cancer subset, resistance according to ICqo 
was seen in 17 of 21 (81%) samples to paditaxel (Fig. 3c).
Immunohistochemical staining for P-gp was positive in 
nine of 14 (64%) samples. Semiquantitative visual 
assessment of the degree of staining in this relatively 
small number of cases showed no correlation with 
sensitivity (IG» and IC50) by linear regression analysis 
(data not shown). It should be noted that only one of nine 
(11%) of the P-gp-positive samples showed sensitivity to 
paditaxel on the basis of ICqo, while one of five (20%) of
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the P-gp-negative samples showed sensitivity to paclitax- 
cl. Of those patients with P-gp-posirive samples, eight of 
nine had received previous chemotherapy and three had 
been treated with a paclitaxel-based regimen. Of those 
parients with P-gp-negative, three of five were che­
motherapy naive and one of five had previously received a 
taxane-based regimen.
The addition of tariquidar decreased the median IQx) of 
paditaxel from 27.4 to 20.6 pM (p <  0.05, Wilcoxon). 
Tariquidar showed some reversal of resistance to pacli- 
taxel in six of 27 (22%) samples classified as resistant.
Discussion
The results of this study show that in the ATP-TCA, 
tariquidar is able to reverse resistance to cytotoxic drugs 
known to be P-gp substrates. These data support the 
potential clinical benefit of tariquidar in combination 
with chemotherapy. However, not all tumors showed such 
potentially beneficial effects nor all drugs and it is clear 
from these results that patients must l>e carefully 
selected.
Almost all of those tumors that showed some increased 
sensitivity were P-gp positive by immunohistochemistry, 
though there was a distinct lack of correlation with 
estimates of the degree of expression present. This may 
simply reflect the subjective and at best scmi-quantita- 
tive nature of immunohisrochemisrry. Further, expression 
of P-gp may be rapidly up-regulated in response to 
chemotherapeutic agents both in vitro and in vivo [36-40). 
These observations may explain the lack of correlation 
between P-gp expression at the time of diagnosis (before 
treatment) and eventual outcome in a number of studies 
[41—43J.
Our data suggest that while P-gp-expressing tumors are 
nearly always resistant to pumped drugs, those that do 
not express P-gp are not always sensitive. Although the 
MDR phenotype mediated by P-gp appears to be an 
important mechanism of resistance to anthracyclines, 
taxanes and vinca alkaloids, other mechanisms may be of 
greater importance in many patients. It should be noted 
that many of our patients had been previously exposed to 
paditaxel and there may have been induction of non- 
MDR mechanisms of resistance in these cases. Other 
ATP-dependent pumps such as MRP1 and BCRP have 
been shown to confer resistance to doxorubicin [44,45], 
although it should be noted that the role of MRP in 
paditaxel and vinorelbine resistance is controversial and 
probably marginal [24,46-48). Non-classical mechanisms 
of resistance are also likely to be involved. For 
microrubules interfering agents, altered microtubule 
dynamics, alterations in a- and ^-tubulins, and/or altered 
binding sites may confer resistance. Altered metabolism 
and/or subcellular distribution, altered interaction of anti­
tubulin agents with microtubules and inadequate induc­
tion of apoptotic signals are among the possible non- 
MDR mechanisms of resistance to tubulin-binding agents 
[49). For anthracyclines such as doxorubicin, decreased 
levels of topoisomerase Ha have been associated with
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resistance, and changes in DNA repair may also be 
important |50J.
The ATP-TCA is a well-standardized assay capable of 
determining the activity of cytotoxic drugs ex vivo in 
cumor-dcrivcd cells and shows excellent correlation with 
outcome in breast and ovarian cancer [51-53]. It could be 
used to select patients for tariquidar therapy and has the 
distinct advantage that it measures the effect of P-gp 
blocking agents in the context of other resistance 
mechanisms that may be present, but it is only applicable 
to those from whom sufficient tumor tissue can be 
obtained for testing. Other functional assays of P-gp have 
been widely employed to study cell lines and hematolo­
gical malignancies, but only occasionally in cells derived 
from solid tumors [54]. For these, in vivo radioimaging 
techniques have been developed [55,56]. The use of 
[99mTc]MIBI and analogous " ’Hr'c-labeled agents (which 
have been shown to be P-gp substrates) allows the clinical 
assessment of P-gp function in cancer patients [57], but 
so far no large prospective clinical trials have been 
performed to investigate their potential as predictive 
tests [58].
Most studies of P-gp have used immunohistochemistry. A 
comparison of several studies reveals that there are inter­
laboratory differences due to differing tissue fixation, 
processing and staining rechniquc, experience of rhe 
observer in selecting hot spots, and the technique of 
counting positive cells [59].
In summary, the results of this study show that tariquidar 
is able to significantly reduce the median IC90S for 
doxorubicin, paditaxel and vinorelbine in a panel of 
human tumors. Furthermore, tariquidar is able to reverse 
resistance in a small percentage of solid tumors resistant 
to doxorubicin, paditaxel and vinorelbine. The ideal 
patient for tariquidar treatment would express functional 
P-gp, but few if any of the other possible resistance 
mechanisms. Considerable translational research will be 
required to determine which are the most cost-effective 
predictive methods to employ, but it seems unlikely that 
immunohistochemistry alone will be sufficient and the 
use of functional assay's showing ex vivo efficacy of 
tariquidar should be considered.
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Ex vivo characterization of XR11576 (MLN576) against 
ovarian cancer and other solid tumors
Federica Di Nicolantonio3, Louise A. Knight3, Silvana Di Palma3, Sanjay 
Sharma3, Pauline A. Whitehouse3, Stuart J. Mercer3, Peter A. Charlton5, David 
Norris5 and Ian A. Cree3
XR11576 (MLN576) is a novel monophenazine with a 
mechanism of action that indudes interaction with both 
topoisom erase (Topo) I and II. The aim of this study was to 
evaluate its cytotoxicity against fresh tumor cells taken 
from patients with a variety of solid tumors. Cells were 
obtained from 89 patients and exposed for 6 days to 
XR11576 alone, or in combination with doxorubicin, 
cisplatin, treosutfan, paclitaxel or vinorelbine. Cell survival 
was measured using the ATP-Tumor Chemosensitivity 
Assay (ATP-TCA). Immunohistochemical staining of Topo I, 
Topo lla and MDR1 w as performed on paraffin em bedded  
blocks in those  tumors for which tissue w as available 
(n= 4 9 ). Overall, the median IC*0 and IC5 0  values of 
XR11576 in tumor-derived cells were 242 and 110nM, 
respectively. In all sam ples XR11576 was more potent than 
the other cytotoxics tested. Breast and gynecological 
m alignandes were m ost sensitive to XR11576, while the 
potency of this compound was slightly attenuated in 
gastrointestinal tumors, in which the median IC*o and ICso 
values were 308 and 212 nM, respectively. C ases of 
synergism were identified when combining XR11576 with 
vinorelbine (nine of 30 sam ples) and doxorubicin (12 of 38 
sam ples), while the addition of paclitaxel resulted in an 
antagonistic effect (Clso>1-2) in 38 of 42 tumors. A very
m odest correlation by linear regression analysis w as found 
between the intensity of M0R1 staining and the IC50 of 
XR11576 (r=  0.311, p =0.0312), but not with the IC90 
(r=  0.247, NS). These data support the rapid introduction of 
XR11576 to clinical trials and su ggest that it may be 
effective against a broad spectrum of tumor types. Anti- 
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Introduction
Several joint inhibitors of topoisomerase (Topo) I and II 
have been recently described (reviewed in (11): DACA/ 
XR5000 [2], intoplicine [3], F 11782 [4], XR5944 [51, 
XR11576 [61, XR11612 [71 and TAS-103 [8 ], although 
the latter predominantly inhibits Topo Ha [9]. XR11576 
(MLN576) is a monophenazine that recently entered 
clinical evaluation. XR11576 demonstrated potent cyto­
toxic activity against a panel of human and murine rumor 
cell lines (IC50= *>-47 and this activity was un­
affected by multidrug resistance (MDR) mediated by 
overexpression of either P-glycoprotein or MDR-asso- 
ciated protein (MRP), or by downregulation of Topo II. 
Importantly, XR11576 also showed marked efficacy 
against a number of human tumors including sensitive 
(H69/P) and multidrug-resistant (H69/LX4) small cell 
lung cancer and IIT29 colon carcinoma xenografts [61. 
XR11576 w’as proposed as a dual inhibitor of Topo I and II 
based on its ability to stabilize cleavable complexes for
both Topo I and II in vitro in a dose dependent fashion 
[6 ]. Cleavable complex formation by XR11576 w'as also 
analyzed in human leukemic K562 cells using the 
TARDIS assay [10,11], which demonstrated drug-in­
duced cleavable complex formation for Topo I, lla  and lla 
in a dose- and time-dependent manner. These observa­
tions, however, do not exclude additional or alternative 
mechanisms of action for the cytotoxic activity of 
XR11576. In a very recent study, XR11576 was has 
recently been shown to bind to DNA [12].
XR11576 has been selected for further development and 
thus it is important to demonstrate that the compound is 
effective against cells derived from clinical tumor 
samples. A broad ex vivo activity profile would strengthen 
further clinical development and generate information to 
help design phase II trials. It has been proposed that the 
ATP-Tumor Chemosensitivity Assay (ATP-TCA) can be 
used in the development of new agents and combinations
0959-4973 ©  2004 Uppincott Williams A Wilkins
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for use in cancer patients [13]. As an example, this 
method has been previously employed to assess the ex 
vivo activity of a novel dual inhibitor of Topo I and II 
inhibitor, XR5000 [14]: the assay showed that this new 
drug was effective against melanoma as well as ovarian 
cancer, but at concentrations which were unlikely to lie 
achieved in patients [15].
In the present study we aimed to determine the ex vkv  
activity of XR11576 in a variety of solid tumors and 
compare its activity with other dual Topo I/ll inhibitors as 
well as other cytotoxics currently in clinical use.
Materials and methods
P atien ts and sam ples
A total of 89 tumors (44 solid tumors, 37 ascites and eight 
pleural effusions) were tested with XRl 1576, with local 
ethics committee approval for the use of tissue or cells 
not required for diagnosis. The median age of the 
patients was 60 years (range 35-88; 17M:72F; Table 1). 
1 'he ovarian cancer patienrs sub-group were all previously 
treated with carboplatin alone or carboplatin plus taxanes 
first line, followed in four cases by an anthracycline- 
containing regimen, in four cases by the combination 
treosulfan plus gemcitabine, in three cases by carboplatin 
plus gemcitabine and in three cases by etoposide. Briefly, 
tumor tissue that was not required for diagnosis was taken 
by a histopathologist or surgeon under sterile conditions, 
with patient consent, and transported to the laboratory in 
cell culture medium of Dulbecco’s modified Eagle’s 
medium (l)MEM; Sigma, Poole, UK; cat. no. D5671) 
with antibiotics (lOOU/ml penicillin and lOOpg/ml 
streptomycin; Sigma; cat. no. P0781) at 4°C.
Drugs
XRl 1576 hydrochloride salt, XR5000 and TAS-103 were 
supplied by Xenova Ltd (Slough, UK) as powder. They 
were dissolved in DMSO to give a stock solution of 1 mg/ 
ml and aliquots were stored at -20°C. Cisplatin,
treosulfan, vinorelbine (Navelbine), paclitaxel (Taxol), 
doxorubicin, etoposide (Vepesid) and topotecan (Hy- 
camptin) were obtained from the pharmacy at Queen 
Alexandra Hospital. Cisplatin and paclitaxel were stored 
at room temperature, vinorelbine was kept in the 
refrigerator, and all other drugs were stored at - 20°G, 
as previously reported [16]. XRl 1576 was tested in every 
case and six or more other cytotoxics were tested 
concurrently for each sample. We evaluated the activity 
of XRl 1576 in combination w ith paclitaxel or vinorelbine 
in a subgroup of tumors (a = 43). These samples 
consisted of 22 ovarian carcinomas (of which 12 had 
previous raxane exposure), seven unknown primaries, five 
skin melanomas, four colorectal carcinomas, three breast 
carcinomas, one esophageal carcinoma and one sarcoma.
ATP-TCA
Cells were obtained from solid tumors by gentle 
enzymatic dissociation, usually 0.75 mg/ml. collagenase 
(Sigma; cat. no. C8051) overnight. Viable tumor-derived 
cells were separated from dead cells and debris by density 
centrifugation (Histopaque 1077-1; Sigma), washed, 
counted and resuspended to 100000  cells/ml in case of 
ascitic specimens or 200000  cells/ml for solid biopsies. 
The cells were used to set up ATP-TCA plates according 
to the protocol previously described [17].
Briefly, cells were seeded in 96 well polypropylene 
microplates (Coming-Costar, High Wycombe, UK; cat. 
no. 3790) at 10000-20000 cells/well with each drug/ 
combination at six doubling dilutions in triplicate from 
200% test drug concentration (TDC) to 6.25% TDC. 
TDCs were 150nM for XRl 1576, 2.9 pM for XR5000, 
1.45pM for TAS-103, lO.OpM for cisplatin, 71.9pM for 
treosulfan, 11.1 pM for vinorelbine, 15.9 pM for paclitax­
el, 2.5 pM for doxorubicin, 81.6 pM for etoposide and 
1.64 pM for topotecan, respectively. Combinations were 
made up by adding both drugs concurrently at their 200% 
TDC to the wells at the beginning of the assay and
Table 1 Tumors tested with XR11576, showing the average age (range), sex ratio and previous treatment
Tumor type n Age Sex Previous treatment
Ovarian carcinoma 42 58 (38-78) 0M:42F Primary: platinum + taxane (n«25), platinum (n= 17)
Second-line: anthracycline (n=5), treosulfan + gemcitabine (n=4), etopo­
side (n—3), carboplatin + gemcitabine (n—3). mitoxantrone + paclitaxel 
(n-1)
Cutaneous melanoma 14 58 (35-78) 7M:7F Primary: melphalan (n=3), vindesine (n=2), cyclophosphamide (n= 1)
Unknown primary 10 63 (45-78) 3M:7F Primary: carboplatin (n=1)
Colorectal carcinoma 9 71 (39-88) 4M:5F Primary: irinotecan (n— 1)
Breast carcinoma 5 57 (39-61) 0M:5F Pnmary: cyclophosphamide + anthracycline (n—3), antihormonal agent 
(n-2)
Esophageal carcinoma 3 55 (52-72) 3M.-OF Pnmary: Epirubicin + Cisplatin + 5-FU (n=2)
Endometrial carcinoma 2 60 (55-66) 0M.2F Primary: carboplatin (n = 2) 
Second-line: paclitaxel (r»=1)
Sarcoma 2 70 (57-82) 0M:2F None
Lung (non-small cell lung can­
cer)
1 58 0M:1F Primary: cisplatin + vinorelbine (n=1)
Uveal melanoma 1 67 0M:1F None
Total 69 60 (35-88) 17M:72F
v
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diluted in a constant ratio: sequential studies were not 
performed.
The plates were then incubated at 37°C in 5% CO2 for 6 
days. The degree of cell inhibition at the end of this 
period was assessed by measurement of the remaining 
ATF in comparison with negative control (no drug, MO) 
and positive control (maximum inhibitor, MI) rows of 12 
wells each. ATP was extracted from the cells and 
measured by light output in a microplate luminometer 
(Berthold Diagnostic Systems, Hamburg, Germany) 
following addition of luciferin-luciferase.
Im m unohistochem istry
Of the 89 tumor samples studied, material for immuno­
histochemistry was available for 40 tumors (12 skin 
melanomas, 10 ovarian carcinomas, nine colorectal 
carcinomas, three esophageal carcinomas, three unknown 
primaries, two breast carcinoma and one sarcoma). The 
monoclonal antibodies P-gp (NCL-JSB1), Topo 1, clone 
1D6, (NCL-TOPOl) and Topo Hot, clone 3F6 (NCL- 
Topo IIA) from Novacastra (Newcastle upon Tyne, UK) 
were detected using the Vectastain Universal Alkaline 
phosphatase kit (Vector laboratories, Peterborough. UK). 
Sections were cut on to Surgipath positively charged 
slides (Surgipath Europe, Peterborough, UK) and dried at 
60°C for 40 min. Wax was removed from the sections prior 
to staining by immersion in several changes of solvent 
followed by several changes of alcohol and rinsed in 
running tap water.
High-temperature antigen retrieval (pressure cooking), 
using sodium citrate buffer pH 6.0 for 2 min was used to 
reveal the antigen-presenting sites blocked by formalin 
fixation [18]. The sections were rapidly cooled and 
washed in running tap water.
The sections were then incubated for 20 min in normal 
blocking serum (in the universal kit used this was horse 
serum). This was followed by incubation in the primary 
antibody at room temperature for 30 min for the Topo I 
and II.
To block endogenous avidin-binding sections for the 
MDR-1 antibody were treated with separate blocking 
stages of 20 min in avidin and 20 min in biotin, prior to 
overnight incubation in the primary antibody at 4:’C in a 
humid incubation chamber.
Following incubation in the primary antibody and rinsing 
in Tris-buffered saline (TBS), the slides were incubated 
for 30min with diluted biotinylated universal secondary 
solution, rinsed and then incubated for 30 min with 
Vectastain ABC-AP reagent. To visualize the reaction the 
slides were incubated for 20 min in Vector Red alkaline
phosphate substrate kit (plus levamisole to inhibit 
endogenous alkaline phosphatase activity).
The slides were counterstained with Gills Hematoxylin 
dehydrated and cleared using the Leica X L  slide staining 
machine. The sections were mounted in Vector Mount, 
which produces a permanently mounted section and has 
an optimal refractive index to retain the color intensity of 
Vector Red substrate reaction product.
The concentration of the antibody was determined by 
titration on positive control material and was made up to 
its optimal dilution in TBS, pH 7.6. A positive control 
section was run with each batch of staining (renal 
proximal tubules for P-gp, tonsil or appendix for Topos). 
A  duplicate of each test section was included as a 
negative control by omitting the antibody and replacing 
with TBS.
Data analysis
The percentage inhibition for each drug concentration 
was calculated as 1 - [(Test-MI)/(MO-MI)] x 100 
using an Excel 2000 spreadsheet (Microsoft). For each 
drug concentration curve, the 50% inhibitory concentra­
tion (IC5 0) and the 90% inhibitory concentration (IC«#)) 
were calculated as previously described [19]. Non- 
parametrical statistical methods were used. The calcu­
lated and descriptive data were entered into an Access 
2000 database (Microsoft) and analyzed using a Wilcoxon 
two-tailed paired rank sum test or the Mann-Whitney U  
test for unpaired data, as appropriate (Statsdirect). IC5 0  
and IC90 values for XRl 1576 were compared to those for 
other drugs using Spearman’s rank correlation coefficient, 
with a Bonfcrroni correction: statistical significance was 
taken as p < 0.005. Combination effects were assessed by 
the method of Foch etal. [2 0 ], as previously used with the 
ATP-TCA in other studies [21-23]. We also performed a 
Chou and Talalay analysis [24] where the combination 
indices (Cl) were determined at 50 and 90% cell death, 
and were defined as follows:
CIa+b =[(A\/a+b)/A\] + K^b/a+b) /^ b]
+ [«(Ava+bx/>b/a+b)/A\/>b]
where CIa + b = Cl for a fixed effect (F = 50 or 90%) for 
the combination of cytotoxic A and cytotoxic B; />a/ 
a  +  b  = concentration of cytotoxic A in the combination 
A + B giving an effect F, DW\  + b = concentration of 
cytotoxic B in the combination A + B giving an effect F  
Z)A = concentration of cytotoxic A alone giving an effect 
F; Z)B = concentration of cytotoxic B alone giving an 
effect F. a  = parameter with value 0 when A and B arc 
mutually exclusive and 1 when A and B are mutually non­
exclusive.
The combination index Cl indicated: synergism < 0.8, 
additivity 0 .8- 1 .2 and antagonism > 1 .2 ; slight syncrgis-
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tic and additive cytotoxic activity for values of 0.8  and 1.2, 
respectively 125).
Immunohistochemistry assessment was performed using 
the //-score. Staining intensity (none = 0 points: 
weak = 1 point; moderate =  2 points; strong = 3 points) 
and percentage of positive tumor cells were multiplied to 
achieve a score between 0 and 300. A H-score of 100 or 
more was regarded as positive. The correlation coeffi­
cients were calculated by rhe method of the least squares, 
and the correlation between the IC90 and IC50 values and 
immunohistochemistry indices was assessed using uni­
variate linear regression (Statsdirect).
Results
Activity o f XRl 1576 against tumor-derived cells
XRl 1576 showed a steep concentration response curve in 
most tumors as exemplified in Fig. t.
The effect of XRl 1576 varied both between tumor types 
and markedly between patients within the same tumor 
type (Fig. 2). Overall, XRl 1576 had median IC50 and IC90 
values of llOnM and 242 nM, respectively. The median 
IC'50 and IG90 values calculated for each tumor type are 
shown in Table 2 . The IG» values well correlated with 
the IC50 values (r = 0.893, ^ < 0 .0001 , non-parametric 
Spearman correlation). In all samples XRl 1576 was more 
potent than other experimental or clinical chemother­
apeutic agents, such as XR5000, TAS-103, paclitaxel, 
doxorubicin and topotecan (Table 3).
XRl 1576 demonstrated its activity on a wide variety of 
different tumors. Unknown primaries, breast and gyne­
cological malignancies proved highly sensitive to this new 
agenr, though gastrointestinal tumors were less sensitive 
(Fig. 2). In particular, 37 of 42 (88%) ovarian cancer 
samples had an IC50 value below 200 nM and an IC90 
below 300 nM. When compared to other agents used in 
second-line for ovarian cancer, XRl 1576 was at least 10- 
fold more potent than doxorubicin or topotecan (Fig. 1 
and Table 3). The median IC^ o value for XRl 1576 in 
those samples from ovarian cancer patients who had 
received a taxane-based regimen («=  26) was 242 nM 
compared to 155 nM of samples from rhe small number of 
patients who had not been pre-exposed to taxanes 
(» = 16), but this difference was not statistical significant 
(/> =  0.108, Mann-Whitney U-test).
The best activity (e.g. the lowest median IC*) value) was 
observed in the small group of breast tumors rested 
(« = 5). In these tumors, XRl 1576 had an IC90 of 173 nM, 
which was 170-fold more potent than the test results for 
paclitaxel. XRl 1576 showed remarkable activity against 
skin melanoma, a tumor type that is usually poorly 
sensitive to chemotherapy. In 11 of 14 (79%) melanoma 
samples XRl 1576 had an ICso value below 200 nM and an 
IGW value below 300 nM.
XRl 1576 showed decreased potency in colorectal and 
esophageal samples. When all 12 gastrointestinal tumors 
were analyzed together, the median IC90 and IC50 values 
were 308 and 212 nM (Fig. 2), and these values were
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significantly higher than the corresponding values in 
ovarian samples (p < 0.0005, Mann-Whitney test). Five 
of nine (56%) colorectal samples had IC50 values below 
200 nM, while all three esophageal specimens had an IC50 
slightly over 200 nM. However, gastrointestinal samples 
were also very resistant to other drugs: in this tumor type 
we recorded rhe highest median IC50 and IC90 values for 
most drugs.
Comparison o f XR11576 with other anticancer agen ts
When IC50 values were analyzed using Spearman’s rank 
correlation coefficient (non-parametric method for paired 
data), cross-resistance was seen between XRl 1576 and 
the other experimental agents XR5000 (r = 0.609, 
p <  0.0001) and TAS-103 (r=  0.724, p <  0.0001). A 
significant correlation was also found with the other 
Topo II inhibitors doxorubicin (r = 0.407, p  < 0.0005) and
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Table 2 Median IC*, and ICso values (range) for XR11576 tested in the ATP-TCA In n = number of samples for each tumor type
Tumor type n ICsopM KWM
Ovarian carcinoma 42 0.097 (0.007-0.675) 0.212 (0.064-1.215)
Skin melanoma 14 0.125 (0.006-0.229) 0.215 (0.042-0.400)
Unknown primary 10 0.111 (0.046-0.252) 0.244 (0.122-0.410)
Colorectal carcinoma 9 0.200 (0.033-0.338) 0.306 (0.242-0.608)
Breast carcinoma 5 0.109 (0.042-0.184) 0.173 (0.137-0.356)
Esophageal carcinoma 3 0.213 (0.212-0.231) 0.310 (0.299-0.380)
Sarcoma 2 0.118(0.015-0.222) 0.176 (0.065-0.287)
Endometrial carcinoma 2 0.125 (0.083-0.167) 0.237 (0.175-0.300)
Lung (non-small cell lung cancer) 1 0.097 0.137
Uveal melanoma 1 0.181 0.325
Total 89 0.110 (0.006-0.675) 0.242 (0.042-1.215)
Table 3 Median ICao and ICso values (range) for the cytotoxics tested in the ATP-TCA in n =  number of samples
Drug n IC50 pM
XRl 1576 (MLN578) 89 0.110 (0.006-0.675) 0.242 (0.042-1.215)
XR5000 73 1.94 (0.17-6.13) 5.05 (0.87-7.26)
TAS-103 27 0.99 (0.06-5.54) 2.79 (1.38-9.98)
Cisplatin 79 13.3 (0.4-80.4) 25.9 (7.6-144.8)
TreosuHan 76 39.4 (2.9-390.8) 116.3 (23.9-703.4)
Etoposide 47 74.2 (3.3-932.7) 177.2 (16.8-1679.3)
Topotecan 51 1.02 (0.07-10.02) 3.60 (0.29-18.04)
Doxorubicin 73 1.10 (0.10-45.74) 2.47 (0.30-82.32)
Paclitaxel 82 8.78 (0.55-32.79) 25.35 (3.50-59.03)
Vinorelbine 58 2.17 (0.37-34.49) 16.85 (0.67-62.08)
etoposide (r = 0.428, p  < 0.005). Some cross-resistance 
was seen with paclitaxel (r = 0.330, p  < 0.005), while no 
correlation was observed between the IC90 values for 
XRl 1576 and vinorelbine (r = 0.285, NS), treosulfan 
(r = 0.258, NS) and topotecan (r =  0.250, NS) and 
cisplatin (r = 0.148, NS).
The IC90 values confirmed the cross-resistance pattern 
described above. A significant correlation was found 
between XRl 1576 and the Topo inhibitors XR5000 
(r = 0.582, p  < 0.0001), TAS-103 (r = 0.556, p  < 0.005), 
doxorubicin (r=  0.441, p <  0.0001) and etoposide 
(r =  0.389, p <  0.005). Some cross-resistance was still 
seen with paclitaxel ( r  =  0.325, ^<0.005), while no 
correlation was observed between the IC^ o values for 
XRl 1576 and vinorelbine (r = 0.240, NS), cisplatin 
(r = 0.135, NS), treosulfan (r = 0.106, NS) or topotecan 
(r = 0.100, NS).
Activity o f XRl 1576 in com bination with other antic­
ancer agen ts
X R l 1576 plus doxorubicin
The combination of XRl 1576 with doxorubicin showed a 
median CI50 value of 1.03,. therefore suggesting an 
additive effect (fig. 3). Considerable heterogeneity was 
found among samples as shown in Table 4. Synergism 
(Cl < 0.8) was identified in six of 38 (16%) and in 12 of 
38 (32%) samples when Cl values were calculated for 
90% (CIqo) and 50% (CI50) cytotoxicity’, respectively; 
while antagonism (Cl5o>1.2) was found in 13 of 38 
(34%) samples tested with the combination of XRl 1576 
with doxorubicin, although this percentage increased to
47% when CI90 values were calculated. Additivity was 
identified in 13 of 38 (34%) samples on the basis of the 
CI50 and in 14 of 38 (37%) samples on the basis on the 
CIqo-
X R l 1576 plus DNA-damaging agents
The median CI50 values for the combinations of XRl 1576 
with cisplatin or treosulfan were 1.19 and 1.37, while the 
median CIqo values were 1.22 and 1.38, respectively. As 
suggested by these high median C l values, antagonism 
between XRl 1576 and these two DNA damaging agents 
was identified in a large proportion of cases: CI50 values 
> 1.2 were calculated in 28 of 40 ( 70%) and in 20 of 42 
(48%) samples for the combinations with treosulfan or 
cisplatin, respectively. Synergism was found only in a 
minority of cases. When CIqo values for each individual 
tumor were considered, the combination of XRl 1576 
with treosulfan showed synergism in only one of 41 (2%) 
samples (CIqo = 0.76), while rhe addition of cisplatin to 
XRl 1576 did not produce any synergistic effect. On the 
basis of the CI50 values, the combinations of XRl 1576 
with treosulfan or cisplatin showed synergism in three of 
40 (8%) and in five of 42 (12%) samples, respectively.
X R l 1576 plus microtubule-interfering agents
The median CI50 values for the combinations of XRl 1576 
with vinorelbine or paclitaxel were 1.11 and 2.12,. while 
the median CIqo values were 1.11 and 1.51, respectively. 
The best effect was obtained with the combination of 
XRl 1576 + vinorelbine, which was better than XRl 1576 
alone in 30 of 31 paired observations (/> < 0.0001 on IC50 
or ICqo, Wilcoxon marched-pairs signcd-ranks test).
Ex vivo activity of XR11576 Di Nicolantonio et al. 7
Fig. 3
(a) Synergy Antagonism
XRl 1576+vinorelbine
XR11578+treosulfan
XR11576+doicorubicin
XR11576+cisplatin
XR11576+paclitaxel
Synergy Antagonism
XR11576+vinorelbine
XRl 1576+paclitaxel
Summary of the Cl values calculated for 50% (a) and 90% (b) cytotoxicity in tumor derived cells treated with the combinations shown. For each 
combinations the interquartile range (grey histograms), the median and the range are shown.
XR11576+cisplatin
XRl 1576+treosulfan 
XR11576+doxorubicin
Figure 4(a) shows the advantage of the combination 
XRl 1576 + vinorelbine over the individual agents in 
terms of inhibition; when analyzed by the Foch method 
(201, in which the observed effect at each concentration 
tested is compared with the expected effect, some 
synergism was seen at the lower concentrations, while 
additivity was observed at rhe highest dose (Fig. 4b). 
This is reflected by the combination indices calculated by 
the Chou and Talalay method (24) on the median dose- 
response curve, which were 0.45 (synergy) and 0.86 
(additivity) for an effect of 50 and 90% inhibition, 
respectively.
CI50 and Clgo values > 1 . 2  (antagonism) were found, 
respectively, in 38 of 42 (90%) and in 31 of 43 (72%) 
samples tested with the combination of XRl 1576 with 
paclitaxel.
According to Foch, a median antagonistic effect at rhe 
lower concentrations between these two drugs was also 
found (Fig. 5). Some additivity was found at the higher 
concentrations as shown by the Foch method (Fig. 5) and 
by the analysis of the CI90 values (Table 4b).
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Table 4  Effect of combining XRl 1576 with other cytotoxics for 
n=number of samples tested using the Chou and Tala lay Cl 
calculated on the ICso (*) and on the IC90 (b)
Tumor type XR11576
and
No. sam­
ples tested
Cl(n)
<0.8 0.8-1.2 <1.2
(a) ICso
all tumors paclitaxel 42 3 1 38
vinorelbine 30 9 9 12
treosulfan 40 3 9 28
cisplatin 42 5 17 20
doxorubicin 38 12 13 13
ovarian paclitaxel 22 0 1 21
vinorelbine 17 4 5 7
treosulfan 21 1 2 18
cisplatin 22 2 6 14
doxorubicin 22 7 8 7
non-ovanan paclitaxel 20 3 0 17
vinorelbine 14 5 4 5
treosulfan 19 2 7 10
cisplatin 20 3 11 6
doxorubicin 16 5 5 6
(b) ICso
all tumors paclitaxel 43 2 10 31
vinorelbine 31 7 15 9
treosulfan 41 1 17 23
cisplatin 42 0 19 23
doxorubicin 38 6 14 18
ovarian paclitaxel 22 1 4 17
vinorelbine 17 5 9 3
treosulfan 22 0 7 15
cisplatin 22 0 8 14
doxorubicin 22 5 6 11
non-ovanan paclitaxel 21 1 6 14
vinorelbine 14 2 6 6
treosulfan 19 1 10 8
cisplatin 20 0 11 9
doxorubicin 16 1 8 7
Correlation of XR11576 activity with immunohistochem­
istry
Immunostaining for P-gp was positive in 14 of 48 (29%) 
samples tested with XRl 1576. The P-gp expressing 
samples consisted of four ovarian tumors, three skin 
melanomas, three esophageal cancers, two colorectal 
tumors and two unknown primary carcinomas. The 
median XRl 1576 IC50 values for P-gp-negative and - 
positive samples were 131 and 210 nM, respectively 
(p =  0.0178, Mann-Whitney (/-test), while the median 
IC90 values were 262 and 309 nM, respectively 
(p = 0.038, Mann-Whitney (/-test). A very modest 
correlation by linear regression analysis was found 
between the IC50 of XRl 1576 and the intensity of P-gp 
staining (r =  0.311, p = 0.0312), but not with the ICqo 
(r = 0.247, N S,p =  0.091).
Immunostaining for 'Topo 1 and lla was positive in 35 of 
46 (76%) and nine of 44 (20%) samples tested with 
XRl 1576, respectively. Those samples that were positive 
for Topo I included 13 ovarian tumors, eight skin 
melanomas, six colorectal tumors, three unknown primary 
carcinomas, two esophageal cancers, two breast tumors 
and one sarcoma. The Topo lla expressing samples 
consisted of six colorectal tumors, two ovarian tumors and
one skin melanoma. The median XRl 1576 IC50 values for 
Topo I negative and positive samples were 162 and 
135 nM, respectively (/> =  0.7185, NS, Mann-Whitney (/- 
test), while the median IC90 values were 274 and 262 nM, 
respectively (p =  0.8368, NS, Mann-Whitney (7-test).
The median XRl 1576 IC50 values for Topo lla  negative 
and positive samples were 133 and 191 nM. respectively 
(/> = 0.154, NS. Mann-Whitney (7-test), while the 
median IC<*, values were 261 and 283 nM, respectively 
(p =  0.3226, NS, Mann-Whitney (/-test). No correlation 
by linear regression analysis was found between the ICso 
or ICqo values for XRl 1576 and either the Topo I or the 
Topo lla  immunohistochemistry indices (p =  NS).
Discussion
The rx vivo profile of XRl 1576 in human solid tumors has 
confirmed it to be an exceptionally potent cytotoxic 
agent. In all samples tested, XRl 1576 was more active 
than all other compounds tested, including topotecan, 
doxorubicin, paclitaxel, and the experimental agents 
XR5000 and TAS-103. As expected, the potency of 
XRl 1576 is less in rumor-derived cells compared to cell 
lines, which probably reflects the homogeneity and the 
fast-growing status of the cell lines used in previous 
studies [6 ]. This is true of most cytotoxic drugs [26]. The 
effect of XRl 1576 varied considerably between tumor 
types as well as against samples from the same tumor type 
derived from different patients. This is consistent with 
both the situation found in the clinic and also our 
previous findings testing conventional cytotoxics [27—29].
XRl 1576 showed great considerable activity in the subset 
of ovarian cancer samples. As all the ovarian patients had 
relapsed after receiving a platinum-based regimen and 
were resistant in the ATP-TCA, enhancement of drug 
resistance mechanisms to DNA damaging agents is 
expected. Platinum treatment may cause uprcgulation 
of drug detoxifying enzymes, such as the glutathione-S- 
transferases (GST) [301, and loss of mismatch repair 
mechanisms (MMR) in a proportion of patients [31], 
therefore rendering the cells more resistant to several 
chemotherapeutic agents [32]. Our data may therefore 
suggest that XRl 1576 activity is not susceptible to these 
resistance mechanisms, although this should be tested in 
further studies. The fact that a large proportion of | 
samples obtained from heavily pre-treated ovarian cancer 
patients do not appear resistant to XRl 1576 augurs well 
for its use as second-line therapy in this clinical condition.
It should be noted that even in those samples over- 
expressing P-gp, XRl 1576 showed better greater activity 
than the other cytotoxic agents tested. Furthermore, 
XRl 1576 activity is only slightly reduced in gastrointest­
inal tumors that are well known to overexpress MDR1 
and other pump proteins, and arc generally refractory to
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chemotherapy. This is in accordance with previous 
studies that have shown XRl 1576 is not a substrate for 
either P-gp or MRP efflux pumps [6]. Data from this 
study and our marginal data from this study suggest that 
P-gp plays little, if any, role in resistance to XRl 1576.
Although some in vitro and in vivo reports have reported 
reduced levels of Topo lla to correlate with resistance to 
Topo inhibitors such as doxorubicin and eroposide [33— 
35], our data showed that XRl 1576 activity does not 
correlate with the expression of either Topo I or lla. On
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the other hand, there is cross-resistance with Topo 
inhibitors, including doxorubicin, TAS-103 and XR5000. 
These findings are therefore consistent with inhibition of 
both enzymes, although we cannot exclude an alternative 
mechanism of action, as recently suggested [36].
Previous in vi/ro and ex vivo studies have reported 
enhanced cell kill when Topo inhibitors are combined 
with vinca alkaloids [23,37,38]. While an increased effect 
was not found for all samples tested, individual cases that 
displayed true synergism between XRl 1576 and vinor-
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elbine were apparent in our series. Despite some cross 
cross-resisrance between XRl 1576 and doxorubicin, we 
found synergism between these two drugs in a proportion 
of samples, suggesting that non-Topo mediated effects of 
the anthracycline may be important for cytotoxicity. We 
found, unexpectedly, no synergism between XRl 1576 and 
cisplatin or treosulfan; this is in contrast with other rxvioo 
studies that reported some synergism between cisplatin 
and Topo inhibitors [14,39,40]. Some antagonism was 
noted between XRl 1576 and paclitaxel. These results are 
consistent with previous m vitro studies that have shown 
an antagonistic effect when paclitaxel is combined with 
certain non-anthracycline Topo inhibitors, such as etopo­
side, topotecan, SN38 and tafluposide [38,41-45], 
although others reported additive or synergistic effects 
in different cell lines [37,39,46].
Chemosensitivity testing using fresh tumor cells taken 
directly from patients is not used conventionally com­
monly used for pre-clinical studies at present. We believe, 
nevertheless, that it provides useful information on rhe 
cellular sensitivity' of novel compounds before they reach 
more expensive phase 1/11 trials [15]. The results of this 
study may assist the further clinical development of 
XRl 1576. If phase I studies prove the safety of this 
compound, then our results suggest that phase II trials 
should target those clinical conditions (breast, ovarian 
cancer and cutaneous melanoma) where this new agent is 
likely to produce the greatest benefit.
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Chemosensitization strategies use the administration of one drug 
or agent to render cancer cells more susceptible to a second agent. 
Usually this involves enhanced drug metabolism, improvement of 
drug uptake or blockage of resistance mechanisms. Alteration of 
the susceptibility of cancer cells to apoptosis, the process of 
individual cell death by which many chemotherapeutic drugs act. 
shows particular promise for therapy in the future, and is the focus 
of this review. The dependence of cancer cells on non-neoplastic 
cells to form solid tumors allows anti-angiogenic therapy to be 
used in conjunction with chemotherapy to increase the therapeutic 
index. Chemosensitization strategies are set to become increasingly 
important in cancer therapy, allowing rational design of 
synergistic drug combinations at an earlier stage in drug 
development.
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Introduction
A p o p to s is  is  to  cell d e a th  w h a t  m ito s is  is to  ce ll g ro w th  [1.2]. It 
is  th e  p ro c e s s  b y  w h ic h  u n w a n te d  ce lls  a re  e l im in a te d  fro m  
t is s u e s  p h y s io lo g ica lly ; in  p a th o lo g y , in a p p ro p r ia te  a p o p to s is  
le a d s  to  t is s u e  a t ro p h y , w h ile  lack  o f  a p p ro p r ia te  a p o p to s is  is 
in te g ra l  to  o n c o g e n e s is  [3»*]. In te rfe ren ce  w ith  su c h  
m e c h a n is m s  is  th e re fo re  u n lik e ly  to  be  free  o f  s id e  effects. 
H o w e v e r , th e re  a re  o p p o r tu n i tie s  to  ex p lo it th e  d iffe re n ces  
b e tw e e n  n o rm a l a n d  c a n c e r  ce lls  in  th is  a re a  a n d  to  e n h a n c e  
th e  a b i li ty  o f  o ld - fa sh io n e d  cy to to x ic  d ru g s  to  k ill tu m o r  ce lls  
b y  w o rk in g  w ith  th e  n e w  a g e n ts  r e s u lt in g  fro m  a  m o re  
t h o r o u g h  u n d e r s ta n d in g  o f  ca n c e r  b io logy . M a n y  an ti-  
a p o p to t ic  g e n e s  fu n c t io n  as  s u rv iv a l fac to rs  fo r n eo p la s tic  cells, 
p r e v e n t in g  th e m  fro m  e n te r in g  a p o p to s is  w h e n  th is  w o u ld  be 
th e  r e s p o n s e  o f  a  n o n -n e o p la s tic  ce ll w ith  D N A  d a m a g e . 
G ro w in g  ce lls  a r e  u s u a lly  m o re  su sc e p tib le  to  a p o p to s is  [4,5] 
a n d  a re  d e p e n d e n t  o n  e x o g e n o u s  su rv iv a l fac to rs, u s u a lly  
c y to k in e s  o r  cell a d h e s io n  m o lecu les , to  p re v e n t a p o p to s is . 
N e o p la s t ic  ce lls  a lso  s u b v e r t  th e se  m e ch an ism s, b u t  a s  ag e n ts
a re  d is c o v e re d  w h ic h  ta rg e t th e se  m o le c u la r  p a th w a y s , th e  
p o ss ib ili ty  o f  re s to r in g  c o n tro l a n d  d r iv in g  c a n c e r  ce lls  to w a rd s  
a p o p to s is  is  r a p id ly  b e c o m in g  a  rea lity .
Endogenous inhibitors of apoptosis
T h e  b e s t-k n o w n  a n t i- a p o p to t ic  g e n e  is  Bcl-2, w h ic h  is 
c o n s t i tu t iv e ly  e x p r e s s e d  by  m a n y  ly m p h o c y tic  ly m p h o m a  
c e lls  a s  th e  r e s u l t  o f  a  tra n s lo c a t io n  [6]. T h is  o n c o g e n e , 
h o w e v e r , is  a ls o  e x p re s s e d  b y  m a n y  s o l id  tu m o r s .  A n tis e n s e  
o lig o n u c le o tid e s  to  a n t i- a p o p to t ic  m o le c u le s  s u c h  a s  Bcl-2 
h a v e  th e  a b i li ty  to  e n h a n c e  th e  a c t iv i ty  o f  s e v e ra l  d r u g s  
[7* ,8 ,9 |. Bcl-xL is  a  s im i la r  ta r g e t  a n d  a g a in  a n t is e n s e  a g e n ts  
s h o w  s im ila r  e n h a n c e m e n t  o f  a p o p to is  (10*J. E x a m in a t io n  o f  
o th e r  g e n e s  s u c h  a s  e n d o g e n o u s  c a s p a s e  in h ib i to r s  is a t  e a r ly  
s ta g e  o f  d e v e lo p m e n t .  R e p la c e m e n t o f  m is s in g  g e n e  fu n c t io n  
is  d e a l t  w ith  b e lo w , b u t in d u c t io n  o f  a p o p to s i s  b y  p53 g e n e  
t r a n s f e r  h a s  p r o d u c e d  In c re a se d  a p o p to t ic  a c t iv i ty  in  ce ll 
lin e s  a n d  a n im a l  m o d e ls  [11,12).
Bcl-2 m a y  b e  r e g a rd e d  a s  a n  e n d o g e n o u s  s u rv iv a l  fa c to r , b u t  
c e lls  c a n  b e  r e s c u e d  fro m  a p o p to s i s  b y  e x o g e n o u s  c y to k in e s , 
a s  s h o w n  in  a  s e r ie s  o f  e le g a n t e x p e r im e n ts  b y  G e ra rd  E v a n  
u s in g  n o n - tr a n s fo rm e d  f ib ro b la s ts  [4,5]. T h e ra p e u tic  a g e n ts  
ta rg e t in g  n o n -c y to k in e  m e c h a n is m s  a n d  e n h a n c in g  th e  
a c tiv i ty  o f  c y to to x ic  d r u g s  c a n  in h ib i t  r e s c u e  f ro m  a p o p to s is ;  
e x a m p le s  in c lu d e  C D 20  [13], a n d  h y a lu r o n id a s e  [14]. T h e  
C D 2 0  in d u c e d  d o w n - m o d u la t io n  o f  a n t i- a p o p to t ic  p r o te in s  
s u c h  a s  X IA P  a n d  M cl-1 m a y  e x p la in  h o w  r i tu x im a b  (an ti-  
C D 2 0  m o n o c lo n a l a n t ib o d y ;  1DEC P h a rm a c e u tic a ls  C o rp )  
s e n s it iz e s  c h ro n ic  ly m p h o c y tic  le u k e m ia  ce lls  to  th e  
cy to to x ic  effec t o f  c h e m o th e ra p y  in vivo [13], H y a lu ro n id a s e  
a ffe c ts  m a n y  p a th w a y s ,  b u t r e d u c t io n  o f  a d h e s io n  le a d in g  to  
a p o p to s is  a p p e a r s  to  b e  im p o r ta n t  [14]. M a n y  s u rv iv a l  
f a c to rs  a re  c y to k in e s  a n d  th e  a d v e n t  o f  ty r o s in e  k in a se  
in h ib i to r s  s h o u ld  im p ro v e  th e  a b i l i ty  o f  o n c o lo g is ts  to  
in t e r r u p t  th i s  re s is ta n c e  m e c h a n is m .
Inhibition of growth factor receptors 
HER2
T h e  a d d i t io n  o f  a n t i -H E R -2 /n e u  a n t ib o d y  e n h a n c e s  
p la t in u m  a c tiv i ty  in  o v a r ia n  c a n c e r  c e lls  [15]. C o m b in a t io n  
o f  a n ti-H E R 2  ( tr a s tu z u m a b ; h e rc e p tin ; G e n e n te c h  Inc) w ith  
th e  C O X -2 in h ib ito r , c e leco x ib  (P h a rm a c ia  C o rp ) , le a d s  to  
in c re a s e d  a c t iv i ty  a g a in s t  c o lo n ic  c a n c e r  x e n o g ra f ts  [16,17]. 
C o m b in a t io n  c h e m o th e ra p y  w i th  t r a s tu z u m a b  in  p a t ie n t s  
s h o w in g  a m p lif ic a tio n  o f  H E R 2  s h o w s  a  g r e a te r  e ffec t th a n  
e x p e c te d  f ro m  p h a s e  II tr ia ls  o f  t r a s tu z u m a b  a lo n e  [18»]. 
T h e se  e ffec ts  a r e  e x p lic a b le  o n  th e  b a s is  o f  in te r fe re n c e  w ith  
a  s u rv iv a l  m e c h a n is m , a s  h a s  b e e n  r e p o r t e d  fo r  a n t is e n s e  
ta rg e t in g  o f  HER2 in vitro, w h ic h  r e s u l t s  in  in h ib i t io n  o f  ce ll 
cy c le  p ro g re s s io n  in  G O /G la n d  in c re a s e d  a p o p to s i s  [19].
EGFR/HER1
H E R 2 is  b u t  o n e  o f  f iv e  r e la te d  r e c e p to r s , th e  m o s t  w e ll 
k n o w n  o f  w h ic h  is  th e  e p id e r m a l  g r o w th  fa c to r  (EGF) 
re c e p to r , k n o w n  a s  H ER1 o r  E G F R  [20,21], A n  a n t ib o d y
in h ib i to r  o f  th i s  m o le c u le , c e tu x im a b  (C225; Im C lo n e  
S y s te m s  I n c /B r is to l - M y e r s  S q u ib b  C o), is  in  c l in ic a l tr ia ls  in  
c o m b in a t io n  w i th  e x is t in g  c h e m o th e r a p y  re g im e n s , in  th e  
h o p e  th a t  s im i la r  e n h a n c e m e n t  o f  a c tiv i ty  (as s e e n  w i th  a n t i-  
H E R 2  th e r a p y )  w ill  b e  a c h ie v e d . O th e r  re s e a rc h e rs  h a v e  
ta k e n  a  s m a l l  m o le c u le  a p p ro a c h  b a s e d  o n  ty ro s in e  k in a se  
in h ib i t io n ,  e g . O S I-774  (e r lo to n ib ; O SI P h a rm a c e u tic a ls  
I n c / G e n e n te c h  I n c /R o c h e  H o ld in g  A G ) a n d  I re s sa  
(g e f itin ib ; A s t r a Z e n e c a  p ic ; F ig u re  1). T h e se  m o le c u le s  h a v e  
th e  p o te n t ia l  to  a c t a s  c h e m o s e n s itiz in g  a g e n ts  s in c e  th is  
r e c e p to r  m e d ia te s  a  s u r v iv a l  s ig n a l in  s o m e  cell ty p e s  a n d  
h a s  b e e n  d e m o n s t r a te d  to  s h o w  s y n e rg y  in vitro w i th  
in c r e a s e d  a p o p to s i s  [22*,23]. E x p e r im e n ts  in  x e n o g ra f t  
m o d e ls  w i th  p a c lita x e l h a v e  b e e n  e n c o u ra g in g  [22»J. L ik e  a
Figure 1. Structures of OSI-774 and Iressa.
n u m b e r  o f  o th e r  c y to k in e  r e c e p to r s , E G F R  a c t iv a t io n  le a d s  
to  in t ra c e l lu la r  s ig n a l in g  v ia  th re e  p a th w a y s ;  (i) th e  
p h o s p h a tid y l in o s i to l  3 -k in a se  (P I3 K ) /A k t p a th w a y ;  (ii) th e  
J a n u s  k in a se  a n d  s ig n a l t r a n s d u c e r s  a n d  a c t iv a to r s  o f  
tr a n s c r ip t io n  (Jak /S T A T ) p a th w a y ;  a n d  (iii) th e  R a s /R a f  
p a th w a y  (F ig u re  2). T h e re  a r e  in h ib i to r s  u n d e r  d e v e lo p m e n t  
fo r  a ll th r e e  p a th w a y s ,  a n d  s e v e ra l  o f  th e s e  h a v e  n o w  
re a c h e d  c l in ic a l tr ia ls , th e  p o in t  a t  w h ic h  it b e c o m e s  
im p o r ta n t  to  c o n s id e r  p o s s ib le  c o m b in a t io n s . I f  in d iv id u a l  
p a th w a y s  m e d ia te  s u rv iv a l  s ig n a l in g  v ia  E G F R  a n d  o th e r  
c y to k in e  re c e p to r s  e x p re s s e d  b y  a  p a r t ic u la r  c a n c e r  ce ll, i t  is  
th e o re tic a lly  p o s s ib le  th a t  m o d u la t io n  o f  th e s e  in d iv id u a l  
p a th w a y s  m a y  p ro d u c e  g r e a te r  c h e m o s e n s i t iz a t io n  th a n  
a g e n ts  th a t  t a r g e t  o n e  re c e p to r  a lo n e .
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(legend) A simplified diagram of the EGF (epidermal growth factor) pathway showing the three main intracellular pathways activated by 
stimulation of the EGF receptor (EGFR). EGFR activation leads to intracellular signalling via three pathways: the PI3K/Akt pathway, the 
Jak/STAT pathway, and the ras/raf pathway [69].
PI3K phosphatidylinositol 3-kinase, mTOR mammalian target of rapamycin, PTEN Phosphatase and tensin homolog deleted on chromosone 
ten, Jak/STAT Janus kinase/Signal transducers and activators of transcription, MEK Mitogen/extracellular-signal regulated kinase, MAPK 
Mitogen activated protein kinase, FTI Farnesyl protein transferase inhibitors
The PI3K/Akt pathway
T h e  m a m m a lia n  ta rg e t o f  r a p a m y d n  (m TO R), a  m e m b e r  o f  th e  
P I3K  s e r in e -th re o n in e  k in a se  fam ily  is in v o lv ed  in  th e  c o n tro l o f 
ce ll g ro w th  a n d  th e  cell cyc le  [24,25]. m T O R  is a c tiv a te d  by  A kt, 
a  s e c o n d  m e sse n g e r  in  th e  PI3K  p a th w a y  a c tiv a te d  b y  cell 
s u r fa c e  re c e p to rs  su ch  a s  EG FR to  p ro m o te  th e  tra n s la tio n  o f  
m R N A s  in v o lv e d  in  ce ll-cycle reg u la tio n . In vitro, in h ib ito rs  o f  
m T O R  in c rease  th e  tu rn o v e r  o f  cyc lin  D I, a n d  d e c re a se  th e  
tu r n o v e r  o f  th e  c y c lin -d e p e n d e n t k in a se  inh ib ito r. p 2 7 (k ip l) , 
le a d in g  to  ce ll cycle a r re s t  in  G l / S  p h a s e  [24,25]. In h ib ito rs  o f  
m T O R  ca n  in d u c e  p 5 3 -d e p e n d e n t ap o p to s is  [25], CC I-779 
(W y e th  R esearch ; F ig u re  3), a n  a n tican c e r d r u g  in  d in ic a l 
d e v e lo p m e n t , exe rts  an tip ro life ra tiv e  effec ts  in  vitro a n d  in  
a n im a l  m o d e ls , p a r tic u la r ly  th o se  s tim u la te d  b y  c y to k in es  (such  
a s  EG F) s tim u la t in g  th e  P I3 K /A k t p a th w a y . It s h o w s  a d d itiv e  
e ffec ts  w ith  c isp la tin  a n d  C P T -1 1 in  so m e  m o d e ls  [25]. In  p h a se  
I s tu d ie s  it d e m o n s t ra te d  a  m ild - to -m o d e ra te  tox ic ity  p ro file , 
w ith  s o m e  m in o r  re s p o n s e s  o b se rv ed . C o m b in a tio n  s tu d ie s  
w i th  g e m c ita b in e  a n d  5 -fluo rou rac il a re  in  p ro g re ss . S ince CCI- 
779  ta rg e ts  a  g ro w th  p a th w a y  th a t is d y s re g u la te d  in  m a n y  
tu m o r s  by  m u ta tio n  o f  th e  PTEN tu m o r  s u p p re s s o r  g en e  
[26,27], it m a y  h av e  th e  p o te n tia l to  a u g m e n t th e  ac tiv ity  o f  
ty ro s in e  k in a se  in h ib ito rs  th a t ta rg e t u p s tre a m  cy to k in e  
re c e p to rs . It m a y  be  p o ss ib le  to  g u id e  su c h  th e ra p y  by  
im m u n o h is to c h e m ic a l an a ly s is  o f  P T E N  a n d  p h o s p h o ry la te d  
A k t in  tu m o rs . In te rac tio n s  w ith  s ta n d a rd  cy to tox ic  d ru g s  a re  
l ik e ly  b ec au se  P TEN  is  re g u la te d  in  ce lls ex p o se d  to  c isp la tin . 
d o x o ru b ic in  a n d  pac litax e l [28]. T h is  req u ire s  in ten s iv e  
tra n s la tio n a l re sea rc h  a lo n g s id e  clin ical tr ia ls  o f  C CI-779 a n d  
o th e r  s u c h  a g e n ts .
Figure 3. Structure of CCI-779.
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The Jak/STA T pathway
J a k  a n d  S T A T  a r e  c y to p la s m ic  p ro te in s  th a t  c o m b in e  ro le s  a s  
s ig n a l  m e s s e n g e rs  a n d  tr a n s c r ip t io n  fa c to rs  fo r  m a n y  
d i f f e r e n t  c y to k in e s , in c lu d in g  in te r fe ro n s  [29]. S T A T 3 a n d  
S T A T 5  le a d  to  u p r e g u la t i o n  o f  c y c lin  D I a n d  c -M y c  in  
c a n c e r  ce lls , a n d  a r e  n o v e l  ta rg e ts  fo r  a n t ic a n c e r  d ru g s .  
C h a n g e s  in  th e  s u s c e p tib i l i ty  o f  h e a d  a n d  n e c k  c a n c e r  ce ll 
l in e s  to  a p o p to s i s  h a v e  b e e n  a t t r ib u te d  to  c h a n g e s  in  th e  Jak - 
S T A T  p ro f ile , p o s s ib ly  v ia  u p re g u la t io n  o f  Bcl-xL b y  S TA T3 
a s  a  r e s u l t  o f  E G F R  o r  o th e r  r e c e p to r  s t im u la t io n  [30], T h is
p ro v id e s  a  f u r th e r  e x p la n a t io n  fo r  th e  e ffec t o f  EG FR  
b lo c k a d e  o n  c h e m o s e n s itiv ity .
The ras/raf pathway
R as a n d  R a f a re  in t r a c e l lu la r  s ig n a l in g  p r o te in s  th a t  a re  o f te n  
m u ta te d  in  c a n c e r , a n d  fu n c t io n  to  p ro m o te  ce ll g ro w th . 
T h e re  a r e  se v e ra l d if f e re n t is o fo rm s  o f  R as, o f  w h ic h  th e  Ki­
ras o n c o g e n e  is  th e  m o s t im p o r ta n t  [31]. V a r io u s  a p p ro a c h e s  
h a v e  b e e n  ta k e n  to w a r d s  th e  in h ib i t io n  o f  R as, in c lu d in g  
a n t is e n s e  m o le c u le s  [32,33], a n d  in h ib i t io n  o f  f a rn e s y la tio n , a  
k e y  s te p  in  R a s  a c tiv a t io n . F a rn e s y i p r o te in  tra n s fe ra s e  
in h ib ito r s  r e d u c e  g r o w th  r a te s  o f  s e v e ra l tu m o r  ty p e s  a n d  
c a n  b e  s y n e rg is tic  w ith  e x is t in g  d r u g s  in  s o m e  m o d e ls  [33], 
Raf-1 h a s  b e e n  ta rg e te d  u s in g  a n  a n t is e n s e  o lig o n u c le o t id e  
a p p r o a c h  w ith  s o m e  s u c c e s s  [34,35], w h ile  e n z y m e s  in  th e  
m i to g e n -a c tiv a te d  p ro te in  k in a se  p a th w a y  h a v e  b e e n  
in h ib ite d  b y  s m a ll  m o le c u le  d r u g s  (eg. P D -098059  (P fize r 
Inc) a n d  U -0126  (D u P o n t P h a rm a c e u tic a ls  C o)) w ith  
e v id e n c e  o f  in vitro a c tiv i ty  [36,37], C o m b in a t io n s  o f  th e se  
a g e n ts  w ith  e x is t in g  c y to to x ic  d r u g s  in vitro h a v e  p r o d u c e d  
e n c o u ra g in g  r e s u l ts  [38].
It is  in te re s tin g  to  s p e c u la te  o n  h o w  a n t l - R a s /R a f  d r u g s  
c o u ld  be  in te g ra te d  w ith  s ta n d a r d  c h e m o th e ra p y . M o st 
w o u ld  be  e x p e c te d  to  s lo w  th e  g ro w th  o f  tu m o r  ce lls , a n d  
m a y  b e  u s e fu l in  p r e v e n t in g  r e g r o w th  b e tw e e n  c y c le s  o f  
c h e m o th e ra p y . I f  a d m in is te r e d  a s  p a r t  o f  a  c o m b in a t io n  
th e r a p y  re g im e , th e ir  m e c h a n is m  o f  a c tio n  w o u ld  te n d  to  
im p e d e  ce ll-cy c le  a c tiv e  d ru g s .  H o w e v e r , i f  R a s -d e p e n d e n t  
m e c h a n is m s  in  in d iv id u a l  tu m o r s  p r o v id e  a  s u r v iv a l  s ig n a l, 
th e n  c o n c o m ita n t t r e a tm e n t  m a y  b e  h e lp fu l a n d  e v e n  
s y n e rg is tic  [39,40]. In d iv id u a l iz e d  th e r a p y  m a y  w e ll  be  
n e e d e d  to  o p t im iz e  th e i r  u se .
STI-571 and other tyrosine kinase inhibitors
O n e  o f  th e  m o s t ex c itin g  d e v e lo p m e n ts  in  c a n c e r  h a s  b ee n  th e  
in tro d u c tio n  o f  a  ty ro s in e  k in a se  in h ib ito r  fo r  th e  tr e a tm e n t  o f  
ch ro n ic  m y e lo g e n o u s  le u k e m ia  (CM L). STI-571 (im atin ib ; 
N o v a r tis  A G ; F ig u re  4) w a s  d e v e lo p e d  to  in h ib it th e  BCR-ABL 
t r a n s g e n e  c o m m o n  to  n e a rly  a ll c a se s  o f  C M L  [41,42]. 
H o w e v e r , STI-571 a lso  in h ib its  tw o  o th e r  re c e p to r  ty ro s in e  
k in a se s , c-K IT a n d  p la te le t-d e r iv e d  g r o w th  fa c to r  re c e p to r , c- 
K IT is  im p o r ta n t in  th e  o n c o g e n e s is  o f  g a s tro in te s tin a l s tro m a l 
tu m o r  (GIST), a  r a re  b u t r a p id ly  fa ta l s o f t t is s u e  tu m o r  o f  th e  
g u t, w h ic h  n o w  s h o w s  lo n g - la s tin g  re g re s s io n  in  a  h ig h  
p ro p o r tio n  o f  tre a te d  p a t ie n ts  [43,44], th o u g h  th e r e  is e v id e n c e  
th a t  s o m e  p a t ie n ts  w ith  C M L  o r  G IST s ca n  b e c o m e  re s is ta n t to  
s in g le  a g e n t t r e a tm e n t [42-44], T h e  c o n c e p t th a t  STI-571 m ig h t 
c h e m o s e n s ttiz e  tu m o r s  h a s  o n ly  re c e n tly  b e g u n  to  be  
e x p lo re d  in  C M L . T h e re  is  a  g ro w in g  b o d y  o f  e v id e n c e  fro m  
s tu d ie s  o f  STI-571. E G F R  in h ib i to r s  a n d  s im i la r  d r u g s  th a t  
th e s e  a g e n ts  w ill p ro v e  u s e fu l a s  c h e m o s e n s i t iz in g  a g e n ts , in  
c a re fu lly  s e le c te d  p a t ie n ts ,  in  c o m b in a t io n  w i th  n e w  a n d  o ld  
a n t ic a n c e r  d ru g s .
Figure 4. Structure of STI-571.
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T h e  p ro te a s o m e  p a th w a y  m e d ia te s  th e  d e s tru c tio n  a n d  
tu r n o v e r  o f  m a n y  ce ll-cyc le  r e g u la to ry  p ro te in s . R ecen tly , 
p r o te a s o m e  in h ib ito rs , s u c h  a s  PS-341 (M illen n iu m  
P h a rm a c e u tic a ls  I n c /N a t io n a l  C a n c e r  In s titu te ; F ig u re  5), 
h a v e  s h o w n  p ro m is e  a s  a n t ic a n c e r  ag e n ts , in d u c in g  a p o p to s is  
w i th in  t r a n s fo rm e d  ce lls . T h e  ex ac t m e c h a n is m  o f  a c tio n  m a y  
d if fe r  a c c o rd in g  to  ce ll ty p e ; in  s o m e  in s ta n c e s  in h ib itio n  o f  
N F k B a c tiv i ty  h a s  b e e n  im p lic a te d , w h ile  in  o th e r  m o d e ls , 
s ta b i l iz a t io n  o f  th e  p 5 3  tu m o r  s u p p re s s o r  p ro te in  se e m s  to  be  
im p o r ta n t  (45»«,46|. H o w e v e r , th is  is  a  m u ltifu n c tio n a l 
p a th w a y  a n d  th e re  is  e v id e n c e  th a t  p ro te a s o m e  in h ib itio n  
m a y  a ffec t D N A  re p a i r  le a d in g  to  e n h a n c e d  k illin g  b y  
c is p la t in  in  ce ll l in e s  [47]. T h is  m a y  in d ica te  a  b ro a d e r  
c h e m o s e n s itlz in g  effec t in  c o m b in a t io n  w ith  e x is tin g  ag e n ts . 
T h e  im p lic a tio n s  fo r  to x ic ity  a re  n o t y e t  k n o w n .
Figure 5. Structure of PS-341.
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Protein kinase C inhibition
O th e r  s e c o n d  m e s s e n g e rs  o f  c y to k in e s  in c lu d in g  EG F th a t  
a p p e a r  to  b e  o f  p a r t ic u la r  im p o r ta n c e  to  tu m o r  ce ll b io lo g y  
in c lu d e  p ro te in  k in a s e  C  (PK C ) [48]. P K C a  is  a  c y to so lic  
e n z y m e  th a t  t r a n s lo c a te s  to  th e  p e r in u c le a r  m e m b r a n e  o n  
a c t iv a t io n .  T h e re  a r e  a t  le a s t 12 re la te d  m o le c u le s  a n d  
d if f e re n c e s  in  th e i r  fu n c t io n  a r e  g e n e ra l ly  p o o r ly  
u n d e r s to o d ,  th o u g h  th e y  a r e  c e r ta in ly  c e ll- ty p e  sp ec if ic  [48], 
P K C a  is  a c t iv a te d  b y  th e  s e c o n d  m e s s e n g e r  d ia c y lg ly c e ro l in  
a  c a lc iu m - d e p e n d e n t  r e a c tio n  [48]. In vitro, U C N -01  (K y o w a  
H a k k o  K o g y o  C o  L t d /N a t i o n a l  C a n c e r  In s titu te ; F ig u re  6), a  
s ta u r o s p o r in e -d e r iv e d  in h ib i to r  o f  P K C  c a n  a b ro g a te  
c h e c k p o in ts  a n d  p o te n t ia te  to p o is o m e ra s e  1 in h ib ito r  
m e d ia t e d  c y to to x ic ity  [49]. O th e r  s ta u r o s p o r in e  a n a lo g s  (eg, 
C G P -4 1 2 5 1 ; m id o s ta u r in ;  N o v a r t i s  A G ; F ig u re  6) a r e  a lso  
u n d e r  d e v e lo p m e n t .  A lso , a  p h o s p h o ro th io a te  a n t is e n s e  
o l ig o n u c le o t id e  in h ib i to r  o f  P K C a  (ISIS-3521; Isis 
P h a rm a c e u t ic a l s  I n c /E l i  L illy  & C o) h a s  b e e n  te s te d  in  
o v a r i a n  c a n c e r  a n d  ly m p h o m a  p a t ie n ts , e x h ib itin g  s o m e  
s in g le  a g e n t  a c t iv i ty  [50,51]. E a rly  c o m b in a t io n  s tu d ie s  a re  
e n c o u ra g in g ,  th o u g h  p o te n t ia l  c h e m o s e n s itiz a tio n  h a s  y e t  to  
b e  d e m o n s t r a te d  [52].
Figure 6. Structure of UCN-01 and CGP-41251.
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DNA and cell biology
G e n e  m u ta t io n  is  c e n tra l  to  th e  p a th o g e n e s is  o f  m a n y  
tu m o r s .  A c tiv a tio n  o f  o n c o g e n e s  a n d  lo s s  o f  tu m o r  
s u p p r e s s o r  g e n e s  fT S G )  a re  fo u n d  in  m o s t tu m o rs .  
R e p la c e m e n t o f  T S G  fu n c t io n  b y  s m a l l  m o le c u le s  is  n o w  
p o s s ib le  a n d  th e  d e s ig n  o f  s u c h  a g e n ts  in silico is p ro d u c in g  
a  la rg e  n u m b e r  o f  p o te n t ia l  d r u g s  [53]. T h e s e  a g e n ts  h a v e  
th e  c a p a c ity  to  r e p la c e  th e  f u n c t io n  o f  tu m o r  s u p p re s s o r  
g e n e s  in  c a n c e r  ce lls . P o te n t ia l  fo r  c h e m o s e n s i t iz a t io n  b y  
th e s e  a g e n ts  e x is ts , b u t  is  c u r r e n t ly  th e o re tic a l.
T h e  c o n c e p t th a t  n e o p la s tic  t r a n s f o r m a t io n  r e q u i r e s  a  s e r ie s  
o f  m u ta t io n s  h a s  r e c e n tly  b e e n  e n la rg e d  to  In c lu d e  o th e r  
g e n e tic  a l te ra t io n s . M a n y  c a n c e r  ce lls  s h o w  e p ig e n e tic  
c h a n g e s , in c lu d in g  m e th y la t io n  o f  D N A  a n d  h is to n e s , 
a c e ty la tio n  o f  h is to n e s , a n d  lo s s  o f  im p r in t in g  [54-56]. T h e se  
c h a n g e s  a re  s u s c e p tib le  to  th e r a p e u tic  in te rv e n t io n ,  a n d  
th e re  is e v id e n c e  th a t  th e s e  in te rv e n t io n s  c o u ld  
c h e m o s e n s itiz e  ce lls  b y  in te r fe re n c e  w i th  D N A  r e p a i r  o r  
o th e r  c h e m o th e ra p e u tic  ta rg e ts . H o w e v e r ,  i t  is  d if f ic u lt  to  
p r e d ic t  w h ic h  g e n e s  w ill b e  u p  o r  d o w n r e g u la t e d  b y  s u c h  
a g e n ts , le a d in g  to  s o m e  u n c e r ta in ty  r e g a r d in g  effec t.
C a n c e r  ce lls  s h o w  n u m e r o u s  m e ta b o lic  a l te r a t io n s ,  w i th  
in c re a s e d  tu r n o v e r  o f  m a n y  m o le c u le s , in c lu d in g  s o m e  
o n c o g e n e s . W h ile  p53 is  m u ta te d  in  m a n y  c e lls , in  o th e r s  it is 
in a c tiv a te d  b y  in c re a s e d  e x p re s s io n  o f  r e g u la to r y  m o le c u le s  
s u c h  a s  m d m 2  w h ic h  u b iq u in a te s  p 5 3  p r o te in  a n d  ta r g e ts  it 
fo r  d e s tr u c t io n  b y  p ro te o s o m e s  [57]. P ro te a s o m e  in h ib itio n  
m a y  re s to re  p53  f u n c t io n  a n d  m a y  b e  p a r t ic u la r ly  u s e fu l in  
c o m b in a t io n  w ith  a lk y la t in g  a g e n ts  [58]. H e a t  s h o c k  p ro te in s  
(h sp s) a c t a s  m o le c u la r  c h a p e ro n e s ,  m a in ta in in g  th e  
c o n fo rm a tio n  o f  m a n y  p ro te in s .  R e c e n tly , I n h ib i to r s  o f  o n e  
s u c h  m o le c u le . h sp 9 0 , h a v e  s h o w n  s o m e  p ro m is e  as  
a n t ic a n c e r  a g e n ts  a n d  a re  l ik e ly  to  a c t a s  in d i re c t 
c h e m o s e n s i t iz e r s  b y  In te r fe r in g  w i th  th e  a b i l i ty  o f  tu m o r  
c e lls  to  m a in ta in  m o le c u la r  h o m e o s ta s is  s e c o n d a r y  to  d ru g -  
in d u c e d  s tr e s s  r e s p o n s e s  [59].
Gene therapy
G e n e  th e r a p y  fo r  c a n c e r  h a s  a s  y e t  f a i le d  to  fu lf i l its  p ro m is e  
a n d  a  r e tu r n  fo r th e  v a s t  s u m s  s p e n t  o n  it. T h e  id e a  th a t  
r e p la c e m e n t  o f  th e  g e n e s  in a c t iv a te d  d u r in g  c a rc in o g e n e s is  
c o u ld  re s to re  c o n tro l to  c a n c e r  ce lls  is  a t t r a c t iv e ,  b u t  
u n p ro v e n  in  m a n , a n d  it  w ill  b e  s o m e  t im e  b e fo re  s u c h  
a p p ro a c h e s  a r r iv e  in  th e  c lin ic . R e p la c in g  s u f f ic ie n t fu n c t io n  
o r  in t r o d u c in g  a  n e w  e n z y m e  to  c h e m o s e n s i t iz e  ce lls  to  
c y to to x ic  a g e n ts  o r  p r o d r u g s  is a  m o re  re a l is tic  p o s s ib ili ty  a t  
p r e s e n t  [60,61], T h e  m a jo r  p r o b le m  fo r  g e n e  th e r a p y  is th e  
s a m e  a s  a n y  o th e r  c a n c e r  th e ra p y ;  to  b e  e ffec tiv e , it m u s t  
ta rg e t  (d ire c tly  o r  in d ire c t ly )  e v e ry  n e o p la s tic  c e ll in  th e  
b o d y . T h is  is  d iff ic u lt , p a r t ic u la r ly  in  th e  p a t ie n t s  w ith  
a d v a n c e d  d is e a s e  w h o  a r e  o f te n  e n te r e d  in to  c lin ic a l s tu d ie s  
o f  g e n e  th e r a p y . W h ile  lo c a liz e d  r a th e r  th a n  d is s e m in a te d  
tu m o r s  m a y  b e  m o re  a p p r o p r i a te  ta r g e ts ,  th e y  a r e  o f te n  
a m e n a b le  to  e x is t in g  th e r a p e u tic  s tr a te g ie s  s u c h  a s  s u rg ic a l 
re m o v a l o r  r a d io th e r a p y . M o re o v e r , r e p la c e m e n t  o f  a  g e n e  
u n d e r  n o rm a l c o n tro l is  d if f ic u lt ,  a n d  th e  v e c to r s  u s e d  te n d  
to  b e  im m u n o g e n ic  le a d in g  to  th e ir  r a p id  e l im in a t io n  fro m  
th e  b o d y  o r  to x ic  e ffec ts .
D e sp ite  th e  p ro b le m s  th e re  h a v e  b e e n  s o m e  su ccesse s , a n d  
c h e m o s e n s itiz a tio n  h a s  b ee n  a c h ie v e d  b y  ta rg e tin g  p53 
m u ta n t  ce lls  fo r  d e s tru c t io n  u s in g  a n  a d e n o v iru s  la c k in g  th e  
EIB g e n e  (O NY X -015; O n y x  P h a rm a c e u tic a ls  Inc). T h is  su b jec t
w a s  re c e n tly  r e v ie w e d  b y  K im  [62). C h e m o se n s i tiz a tio n  u s in g  
a d e n o v ir u s e s  s u c h  a s  O N Y X -015 a n d  o th e rs  is  feas ib le  [62-65]. 
R e p la c e m e n t  o f  p53 itse lf  is  le ss  ea sy , h o w e v e r , th o u g h  so m e  
p r o g r e s s  is  b e in g  m a d e . C o m b in a tio n  o f  p53 re p la c e m e n t w ith  
c i s p la t in  a p p e a r s  to  e n h a n c e  a p o p to s is  in  cell lin e s  a n d  
x e n o g ra f t  m o d e ls  [11],
Future developments
Th«e a im  o f  c h e m o th e ra p y  is  to  k il l c a n c e r  ce lls . T h e  
r e a l i z a t io n  th a t  th i s  u s u a l ly  in v o lv e s  a p o p to s i s  p r o v id e s  n e w  
o p p o r tu n i t i e s  f o r  c h e m o s e n s i t iz a t io n , th o u g h  it s h o u ld  be 
n o te d  th a t  a p o p to s i s  is  n o t  a lw a y s  th e  m o d e  o f  ce ll d e a th  
i n d u c e d  b y  c h e m o th e r a p y  a n d  th a t  th e  ro le  o f  p53  in  th is  
c o n te x t  r e m a in s  c o n tro v e rs ia l  [66-68]. T h e  p o s s ib ili ty  th a t  
a n y  s p e c if ic  a l te r a t io n  o f  th e  a p o p to t ic  r e s p o n s e  c o u ld  
I n c r e a s e  s e n s i t iv i ty  to  c h e m o th e r a p y  c a n  b e  ra p id ly  te s te d  in  
t h e  la b o r a to r y  a n d  t r a n s la te d  to  th e  c lin ic . T h e  s e a rc h  fo r 
m o r e  s p e c if ic  a g e n ts  fo r  c h e m o th e ra p y  w i th  sp e c if ic  
m o le c u la r  ta r g e ts  h a s  r e s u l te d  in  a n  e m b a r r a s s m e n t  o f  r ic h e s  
f o r  th o s e  in te r e s te d  in  d e s ig n in g  m o re  e ffe c tiv e  
c h e m o th e r a p y  re g im e n s  b a s e d  o n  m o d u la t io n  o f  a p o p to s is . 
H o w e v e r ,  m e th o d s  th a t  e x p lo i t  m o le c u la r  a l te ra t io n s  in  
t u m o r  c e lls  r e q u i r e  in d iv id u a l iz e d  th e ra p y , a s  th e r e  is  
c o n s id e r a b le  h e te ro g e n e i ty  b e tw e e n  tu m o r s  o f  th e  s a m e  
ty p e .  T a r g e t  v a l id a t io n  fo r  in d iv id u a l  p a t ie n ts  m a y  be  
h e lp f u l ,  b u t  it is  r a re ly  e a s y  a s  th e  c u r re n t  a rg u m e n ts  o v e r  
m e th o d s  fo r  H E R 2  a s s a y s  te s t ify  [69]. F u n c tio n a l a s s a y s  m a y  
h a v e  m u c h  to  o ffe r, w h e th e r  th e s e  a re  b a s e d  o n  
im m u n o h is to c h e m ic a l  d e m o n s t r a t io n  o f  p r o te in  (eg, 
p h o s p h o r y la t e d  A k t), c h a n g e s  in  m R N A  o n  re p e a te d  n e e d le  
b lto p sy  [70] o r  ex vivo c e l lu la r  r e s p o n s e  [71].
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Short Communication
Absence of BRAF gene mutations in uveal melanomas in contrast 
to cutaneous melanomas
SC Edmunds1'2, IA Cree*'2*1. F Di Nicolantonio2 3, JL Hungerford4, JS Hurren5 and DP Kelsell1
'Centre for Cutaneous Research, Batts and the London School of Medicine and Dentistry, Queen Mary. University o f London, 2 Newark Street, 
Whitechapel El 2AT, UK 'Translational Oncology Research Centre. Queen Alexandra Hospital, Portsmouth P06 3LY, UK 'Department of Pathology. 
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The recent discovery of activating mutations in the BRAE gene in many cutaneous melanomas led us to screen the genomic sequence 
of BRAF exons 11 and 15 in a series of 48 intraocular (uveal) melanomas, together with control samples from three cutaneous 
melanomas and the SK-Mel-28 cell line, which has a BRAF mutation. The same mutation was detected in two-thirds of our cutaneous 
melanoma samples, but was not present in any uveal melanomas. This finding further underlines the distinction between uveal and 
cutaneous melanomas, and suggests that BRAF inhibitors are unlikely to benefit patients with uveal melanoma.
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Uveal melanoma is the most frequent primary intraocular tumour 
in Caucasian adults, having an annual incidence rate of 0.7 per 
100000 people (Prescher et al, 19%). The eye is the most common 
site for noncutaneous melanomas, accounting for approximately 
80% of such lesions (Sisley et al, 2000) and accounting for 13% of 
all deaths from melanoma because of its very high mortality rate 
(Albert et al, 1992). Both uveal and cutaneous melanomas 
originate from the melanocyte, but little is known about the 
underlying molecular pathogenesis of uveal melanoma. This is in 
contrast to cutaneous melanoma where there have been more 
substantial advances in detecting mutations (Chin et al, 1998). 
Both tumours differ significantly in their aetiology, with UV light 
appearing to play little or no part in the causation of uveal 
melanoma, unlike skin melanoma (Dolin et al, 1994). Uveal 
melanomas spread haematogenously leading to liver metastasis, 
whereas cutaneous melanoma spreads mainly via the lymphatics 
(Seftor et al, 1999) with skin metastases a more common problem. 
Unlike cutaneous melanoma, no genes or tumour-suppressor 
pathways have so far been convincingly linked to uveal melanoma 
(Edmunds et al, 2002).
It has recently been reported that a large proportion of 
cutaneous melanoma tumours contain activating oncogenic 
mutations in the BRAF gene (Davies el al, 2002). This is an 
oncogene in the RAS-RAF-MEK-ERK-MAP kinase pathway 
that mediates cellular response to growth signals. Genetic 
alterations to key components of this pathway are known to 
contribute to the development of many cancers (Pollock and 
Meltzer, 2002). Activating RAS point mutations are known to be
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found in more than 30% of human tumours, predominantly 
pancreatic, colonic, and in up to 36% of cutaneous melanomas 
(Demunter et al, 2001). BRAF is a gene that is regulated by RAS 
binding, and was shown to have missense mutations in 66% of 
primary melanoma tumours, 59% of melanoma cell lines, and 80% 
of melanoma short-term cultures (Brose et al, 2002; Davies et al, 
2002). Mutations have also been detected in up to 82% of 
cutaneous melanocytic nevi (Pollock et al, 2003). Activation of this 
pathway has been noted in uveal melanoma tumours although 
mutations have not been detected in any of the RAS genes (H-, K, 
and N-RAS) (Mooy et al, 1991; Soparker ef al, 1993). This makes 
BRAF an interesting candidate gene to screen in uveal melanoma 
tumours because of BRAF mutation being a potential mechanism 
for the activation of this pathway, and the fact that BRAF 
mutations are not thought to be related to the effects of UV light 
(Davies et al, 2002).
BRAF mutations were predominantly found in two small regions 
of the kinase domain of the BRAF molecule. The majority of the 
mutations were a single T -* A base substitution at nucleotide 17% 
in exon 15 of the BRAF gene, and in some of the adjacent codons. 
A smaller number of mutations were also found in a region of exon 
11, and other lower levels of mutations have been reported in these 
codons in cancers including ovarian, sarcomas, lung (Brose et al, 
2002), and colorectal tumours (Rajagopalan et al, 2002).
MATERIALS AND METHODS
We screened the genomic sequence of BRAF exons 11 and 15 in a 
series of 48 uveal melanoma tumours, using primers taken from 
Davies et al (2002). DNA was extracted from tumours removed 
from enucleated eyes from Moorfields Eye Hospital as described 
previously and used in a previous study (Edmunds et al, 2002). All 
tumour samples were removed as part of patient treatment and
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with local ethical committee approval for use of the tissue in this 
study, and the study protocol adhered to the tenets of the 
Declaration of Helsinki. The median age of the patients was 61 
years old, with a small bias towards male subjects (56%). These 
tumours were predominantly choroidal (74% of tumours), with 
smaller numbers of ciliary body (14%), and mixed choroidal- 
ciliary body (12%) type. We also tested DNA from three cutaneous 
melanoma metastases.
Polymerase chain reaction (PCR) products were amplified using 
Bioline Taq (Bioline, London, UK) in the following conditions: 
5 min 96 C initial denaturation, 96'C 30s, 55'C 1 min, 72 C 30s for 
30 cycles, followed by a final extension cycle for 5 min at 72°C 
(Hybaid, Ashford, UK). Polymerase chain reaction products were 
purified using a QIAquick PCR purification kit (QIAGEN, Crawley, 
UK). Purified PCR products are then directly sequenced using Big- 
Dye terminator chemistry and analysed on an AB Biosystems 377 
automated sequencer (AB, Warrington, UK). As a positive control, 
the cutaneous melanoma cell-line SK-MEL-28 DNA was used, that 
was known to contain the exon 15 T1796A (V599E) mutation 
(Davies et al, 2002). As a negative control, blood DNA from several 
unaffected individuals was used.
Sequences were compared to the assumed wild-type sequence 
from the nontumour DNA, and to the human BRAF sequence 
(Genbank accession number: GI:179532). Sequences were aligned 
with wild-type sequence traces and compared by eye. Particular 
attention was given to the sequence around the two small regions 
of the kinase domain of the BRAF molecule located in exons 11 and 
15 that contain all of the published mutations.
RESULTS
The SK-MEL-28 cell-line exon 15 T1796A (V599E) mutation was 
detected by sequencing, and the same mutation was also detected 
in two-thirds of the skin melanoma tumours studied. This result 
was expected as Davies et al (2002) had shown that 66% of the 
malignant melanoma tumours screened had BRAF mutations, and 
predominantly the T1796A mutation. In contrast to this finding, 
we could not detect exon 11 or 15 BRAF mutations in any of the 
uveal melanoma tumours screened. We were able to produce high- 
quality sequencing to screen for mutations in 35 samples for exon 
15 and 23 samples for exon 11 (Figure 1).
DISCUSSION
It is possible that, with direct sequencing, low levels of mutation 
could have been missed, as it is not as sensitive a technique as 
SSCP or DHPLC. Our tumour DNA samples were very pure 
though, and there was unlikely to be any contamination from 
normal tissues. Sequencing would not be able to detect mutant 
alleles present at low frequency because of somatic mosaicism, but 
the significance of very low levels of mutant tumour cells would be 
questionable. It is also possible that there were mutations in other 
areas of the BRAF gene, as we only screened exons 11 and 15, and 
predominantly concentrated on the mutated hotspots. All pre­
viously reported mutations have been concentrated to these two
Figure I Sequencing trace showing the BRAF exon 15 T1796A (V599E) 
mutation in cutaneous melanoma DNA and wild-type sequence in a uveal 
melanoma tumour.
hotspot regions in the BRAF kinase domain, hence, mutations in 
different regions of the molecule are unlikely to be able to activate 
the oncogene in such a strong manner.
Here, we show another potentially important cancer-associated 
gene that is not mutated in sporadic uveal melanoma. Many other 
studies have found significant genetic (Naus ef al, 2000; Soufir et al, 
2000; Edmunds et al, 2002) and cytogenetic differences (Sisley et al, 
2000) between the tumour types, despite both cells originating 
from the same cell type. Uveal melanoma is less studied in 
comparison to cutaneous melanoma, but to date no significant 
levels of mutated tumour-suppressor genes have so far been 
convincingly linked to it (Edmunds et al, 2002). Epigenetic 
mechanisms of gene inactivation may play a more important role 
in this tumour. If the RAS/RAF pathway is activated in uveal 
melanoma, then it is unlikely to be because of activating mutations 
in RAS or B-RAF, but other members of this pathway have yet to be 
studied, including A-RAF, C-RAF (RAF1), and GAPl.
Our findings further highlight the fact that cutaneous and uveal 
melanomas are very different tumours, and that the oncogenesis of 
uveal melanoma uses very different mechanisms and genes to 
cutaneous melanoma. This has implications for treatment, as 
BRAF inhibitors are now undergoing clinical trials from which 
uveal melanoma patients are unlikely to benefit. (Chow et al, 2001; 
Coudert et al, 2001; Rudin et al, 2001; Cripps et al, 2002).
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Heterogeneity of chemosensitivity of esophageal and 
gastric carcinoma
Stuart J. Mercer3,6, Shaw S. Somers6, Louise A. Knight3, Pauline A. 
Whitehouse3, Sanjay Sharma3, Federica Di Nicolantonio3, Sharon Glaysher3, 
Simon Tohb and Ian A. Cree3 for the Portsmouth Upper Gl Cancer 
Multi-Disciplinary Team
Esophageal and gastric cancer have a poor prognosis, and 
chemotherapy is rarely of long-term benefit This may be 
related in part to heterogeneity of chemosensitivity and to 
constitutive resistance to individual cytotoxic drugs. This 
study aimed to demonstrate the degree of heterogeneity of 
chemosensitivity between tumors. We have examined the 
heterogeneity of chemosensitivity in esophageal and 
gastric cancer specimens (n=85) using an ex vivo 
ATP-based chemosensitivity assay (ATP-TCA). A variety 
of chemotherapeutic agents were tested. Sixty-four 
specimens were endoscopic biopsy samples; the 
remainder were from resection specimens. Cells were 
obtained from 62 specimens (73%). Eight assays were 
infected due to contamination/infection of the biopsy 
material, giving an evaluability rate of 87%. Analysis 
of the data showed considerable heterogeneity of 
chemosensitivity. The most active single agents identified 
by the assay were mitomycin C (56% sensitivity) and 
5-fluorouracil (5-FU; 42% sensitivity). Exposure of tumor 
cells to combinations of drugs showed ECF (epirubicin, 
cisplatin, 5-FU) and mitomycin C + 5-FU to be moderately 
active regimens. Other experimental drug combinations 
showed greater activity. There is a marked heterogeneity
of chemosensitivity in esophageal and gastric cancers. 
The degree of heterogeneity observed suggests that the 
ATP-TCA could be used to individualize chemotherapy by 
selecting agents for particular patients. This approach 
provides the rationale for a trial of ATP-TCA-directed 
therapy to determine whether individualization of 
chemotherapy might improve patient response and 
survival. Anti-Cancer Drugs 14:397-403 CO 2003 Lippincott 
Williams & Wilkins.
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Introduction
Chemotherapy for cancer of the esophago-gastric junction 
(EGJ) remains relatively disappointing. Although com­
bined chemotherapy regimens are able to provide up to a 
61% response rate [1,2], these responses are often short­
lived and are attended by varying degrees of toxicity. As a 
result of controlled trials, there is a trend towards treating 
operable EGJ tumors with neoadjuvant chemotherapy 
[3]. This is based on the belief that neoadjuvant 
chemotherapy may both downstage loco-regional disease 
and reduce or eliminate any subclinical metastatic 
disease. Inoperable disease is routinely treated with 
palliative chemotherapy [4,5],
It is clear from clinical trials that there is a wide range of 
sensitivity of EGJ tumors to chemotherapy. Despite their 
different etiology and histology, both adenocarcinoma and 
squamous cell carcinoma appear to have similarly poor 
overall sensitivities to the most popular chemotherapy
0959-4973 ® 2003 Lippincott Williams & Wilkins
regimens [6], Up to 11% of cases of EGJ cancer show a 
complete pathological response (pCR) to ECF combina­
tion chemotherapy [1,2], while other EGJ tumors treated 
with the same regimen are found to progress [7]. This 
heterogeneity of chemosensitivity is currently unpredict­
able and probably leads to many patients being treated 
with potentially toxic chemotherapy regimens that are 
ineffective against their particular tumor [81.
Over the last 30 years, a number of chemosensitivity 
assays have been developed to try to predict the 
responsiveness of tumors to chemotherapy [9,10]. Early 
assays proved difficult to use for human tumors, but are 
widely used with cell lines for drug development. This 
situation has changed with the introduction of newer 
technology; the ATP-tumor chemosensitivity assay (ATP- 
TCA) has been shown to have a high evaluability rate for 
solid tumors and provides interpretable results in greater 
than 90% of tumors tested [11,12]. A case-control
DOI: 10.1097/01 cad.0000080106.72417.1 b
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intervention study of ATP-TCA directed chemotherapy in 
recurrent ovarian cancer has shown a dramatic improve­
ment in response rate and survival [13,14], and a 
randomized phase III trial for platinum-refractory ovarian 
cancer is currently under way.
This study was undertaken to investigate whether the 
chemosensitivity of tumors of the EGJ can be assessed by 
the ATP-TCA, to see if the technique is applicable to 
endoscopic biopsies, and to determine the degree of 
heterogeneity of chemosensitivity of carcinoma of the 
EGJ.
Methods
Patients
A total of 59 patients (median age 56) with cancer of the 
esophagus or stomach were included in the study. There 
were 53 males and six females. The histology in 53 
patients was adenocarcinoma and in six was squamous 
cell carcinoma. A total of 85 samples were tested: 47 
tumor samples were assayed before any chemotherapy 
had been given and 38 afterwards. Endoscopic biopsies 
were taken using 3.7-mm Jumbo forceps, with a median 
of 6 biopsies per patient (range 4-10). All patients 
included in the study gave informed consent for the 
samples to be taken and for ATP-TCA to be performed on 
the samples and the study was approved by the Local 
Regional Ethics Committee.
ATP-TCA
All tumor samples were removed as part of patient 
treatment, with consent for tissue donation and local 
research ethics committee approval for use of the tissue 
surplus to diagnostic requirements for chemosensitivity 
testing. Sixty-four were endoscopic biopsies taken at 
diagnostic or therapeutic endoscopy, while 21 samples 
were taken from the resection specimen after surgery. 
Tumor samples were sent to the laboratory in labeled 
specimen bottles containing culture medium (DMEM; 
Sigma, Poole, UK) with antibiotics and an anti-fungal 
(penicillin-streptomycin, gentamicin, amphotericin B; 
Sigma-Aldrich, Irvine, UK). Each sample was tested 
using a standardized protocol [12] within 24 h of surgery.
Tumor material was minced under aseptic conditions 
prior to enzymatic tumor cell dissociation according to 
the assay protocol [12]. Cells were washed twice and 
resuspended in a serum-free complete assay medium 
(GAM; DCS, Innovative Diagnostik Systeme, Hamburg, 
Germany). Debris was removed by density centrugation 
over Lymphoprep (Nycomed, Birmingham, UK), accord­
ing to the manufacturer’s instructions, and the cells were 
washed twice in CAM before resuspension to 200000 
cells/ml. Test drugs were added to polypropylene 96-well 
plates (Costar, High Wycombe, UK) at six dilutions 
(6.25-200%) of the test drug concentrations (TDC)
shown in Table 1. Dilutions were prepared in the plate 
(lOOpl/well) from an 800% TDC solution made up 
freshly from frozen aliquots of each drug in CAM [14], 
The TDC of each drug was determined by reference to 
known pharmacokinetic data as previously described 
[12]. Two rows of the plate were reserved for controls— 
a medium only ‘M0’ row containing lOOpl/well of CAM 
and a ‘MI’ row containing lOOpl/well of maximum 
inhibitor of cell survival. Aliquots of 100 pi of ceils were 
added to each well giving a final plating density of 20000 
cells/well in 200 pi total volume. Plates were incubated at 
37°C at 100% humidity and 5% CO2 for 6 days, at the end 
of which cells were lysed by addition of 50 pi Tumor Cell 
Extraction Reagent (DCS) to each well. The ATP 
content of each well was measured by adding 50 pi of 
lysis buffer to each well and transferring 50 pi aliquots to 
a white polystyrene plate. Then 50 pi luciferin—luciferase 
was added to each well of the white plate and 
luminescence measurements were made in a Berthold 
MPLX luminometer (Berthold Diagnostic Systems, 
Hamburg, Germany). The results were entered into a 
spreadsheet (Excel) and calculations of the percent 
inhibition at each drug concentration were used to 
directly plot the results.
Data analysis
The ICqo for each drug was defined as that concentration 
of drug that produced 90% cell death in the assay and is 
expressed as a percentage of the test drug concentration. 
A TCA index, or index of sensitivity, was calculated as 
[600-sum(inhibition 6.25-200%)]. Thresholds for sensi­
tivity and resistance were arbitrarily defined to allow 
inter-sample comparison, as previously described [11,12].
Results
In total. 85 tumor samples from 59 patients were 
submitted to ATP-TCA testing. Of these, 62 (73%) 
samples produced sufficient cells for assay. Assays were 
successfully performed on 54 samples, with infection 
requiring the results to be discarded in eight samples. 
The assay evaluability rate was 54/62 (87%). Of the most 
recent 20 samples tested, 17 (85%) have produced 
sufficient cells for assay with evaluable results.
Of the 23 tumor samples that did not provide sufficient 
cells for assay, 20 were endoscopic biopsies and three 
were from resection specimens (Table 1). Twelve of these 
23 samples (52%) were post-chemotherapy specimens.
Table 1 Twenty-three biopsy specimens yielded too few cells for 
assay by ATP-TCA
Total specimens Endoscopic Resection
biopsies specimens
Pre-chemotherapy 47 10 1
Post-chemotherapy 38 10 2
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Frequency histograms showing heterogeneity of the sensitivity index (y-axis) for each single agent and combination.
The number of chemotherapeutic agents tested on each 
sample varied. Endoscopic biopsies rarely yielded more 
than 10-20 mg of tissue, normally producing enough 
cells for one to four drugs to be tested. Resection 
specimens often provided in excess of a gram of tissue, 
allowing for testing of up to 24 single agents and drug 
combinations.
The results show considerable heterogeneity of chemo­
sensitivity between patients to single agents and to drug 
combinations (Fig. 1). Some tumor cells responded well 
to particular drugs or combinations, while other tumor 
cells showed no response to these, but instead responded 
to an alternative regimen. The most active single agents 
identified were 5-fluorouracil (5-FU) and mitomycin C;
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15 of 36 samples (42%) showed sensitivity to 5-FU 
(IndexsiiM <  250) and 10 of 18 (56%) showed sensitivity 
to mitomycin C.
Figure 2 shows the IC90 for different agents on different 
tumors. Again, the most active single agents are 5-FU and 
mitomycin; 5-FU alone showed an ICqo of less than 100%
TDC in five of 36 (14%) tumor samples tested and the 
corresponding figure for mitomycin C was four of 18 
(22%).
Combinations of drugs demonstrated greater activity. The 
combination of epirubicin, cisplatin and 5-FU (ECF, a 
regimen used commonly for both neoadjuvant therapy
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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and palliative therapy) had an IndexsuM <250 in 24 of 
54 cases (44%), while combinations of cisplatin + 5- 
FU + gemcitabine and mitomycin C + 5-FU showed 
similar high activity in all tumors on which they were 
tested (10 and 17, respectively).
Figure 3 shows the results of testing ECF and its 
constituents individually on tumor cells from an esopha­
geal adenocarcinoma. The cells were sensitive to ECF, 
with much of the activity due to the 5-FU. This pattern 
was seen in many of the tumors tested—much of the 
activity of the ECF combination came from the 5-FU, 
while the cisplatin added a small but variable amount of 
activity; the epirubicin rarely improved the observed 
inhibition.
Combinations of agents also showed lower ICqos. The 
ECF regimen demonstrated an IC90 of less than 100% 
TDC in 29 of 54 (54%) of samples and mitomycin C + 5- 
FU in 15 of 18 (83%). Cisplatin + gemcitabine + 5-FU 
was equally effective, with an IC90 of less than 100% 
TDC in eight of 10 cases tested (80%).
When tumor cell numbers allowed, a number of experi­
mental drug combinations were tested. Among those 
showing good results were the combination of treosulfan 
and gemcitabine (all tested samples were sensitive, with 
nine of 10 showing an ICqo less than 100% TDC) and 
mitomycin C +  gemcitabine (all 10 samples sensitive and 
showing an IC90 less than 100% TDC').
Figure 4 shows the results of testing treosulfan and 
gemcitabine, alone and in combination, on esophageal
Fig. s
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adenocarcinoma cells. Treosulfan demonstrates moderate 
activity on its own, but when combined with the 
relatively inactive gemcitabine the degree of inhibition 
is much improved. Similar results were obtained for the 
combination of mitomycin C with gemcitabine (Fig. 5).
Discussion
The ATP-TCA was used to investigate the chemosensi­
tivity of esophageal and gastric tumors, and was found to
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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produce evaluable results in a high proportion of cases— 
87% of those from which cells could be obtained. This is 
the first study in which endoscopic biopsy-derived cells 
from EGJ tumors have been successfully tested using a 
chemosensitivity assay. Our data show that, once the 
learning curve of both surgeon and laboratory staff has 
been negotiated, the ATP-TCA is a robust method of 
assessing the ex vivo chemosensitivity of upper GI tumors. 
Since 32% of post-chemotherapy specimens yielded too 
few cells for the assay, compared to 23% of pre­
chemotherapy specimens, it seems likely that prior 
chemotherapy reduces cell retrieval.
It is clear from these results that esophageal and gastric 
cancers show marked heterogeneity in their chemosensi­
tivity to single agents and combination regimens, in 
keeping with reported clinical studies [7]. We have 
shown that different tumors demonstrate a range of 
sensitivity to commonly used chemotherapeutic agents.
One of the commonest chemotherapy regimens used in 
esophageal and gastric tumors in the UK is the 
combination of cisplatin and 5-FU (CF), with or without 
the addition of epirubicin (ECF). Clinical studies 
demonstrate a range of response rates to this regimen, 
most of them between 42 and 61% [2,151- Importantly, 
most investigators have reported a percentage of patients 
who show a complete pathological response to CF or ECF, 
defined as the inability of the pathologist to find any 
residual tumor cells in the resected specimen. This 
occurs in up to 11% of EGJ tumors [1,21 and leads to a 
marked improvement in the prognosis for these patients 
[161. Our study showed five out of 56 (9%) patients with 
a tumor IndexsuM for ECF of less than 150, suggesting a 
very high degree of sensitivity of the tumor to ECF, a 
figure consistent with these reports.
Dose-response curves for ECF and for epirubicin, 
cisplatin and 5-FU as single agents show interesting 
results (Fig. 3). In the vast majority of cases, the dose- 
response curve showed ECF to be more active than any 
single agent alone; however, in most tumors this was seen 
to be due in a large part to the activity of 5-FU, with 
varying degrees of an additive effect from the cisplatin. 
Epirubicin alone only infrequently showed activity, and 
rarely added much to the combination of cisplatin and 5- 
FU. There are no published clinical studies comparing 
the response rates to ECF and CF, but comparison of 
published phase II studies does not point towards a 
significant difference 117]. Of the three drugs that make 
up the standard ECF regimen, epirubicin has by far the 
highest toxicity profile; if clinical studies were to support 
our initial findings that epirubicin is inactive in the 
majority of EGJ tumors, then many elderly cancer 
patients might be spared this relatively expensive and 
cardiotoxic drug.
Some experimental chemotherapy combinations not 
currently used in clinical practice appear to show 
interesting potential. Gemcitabine alone does not appear 
to be particularly active. However, the combination of 
gemcitabine with cisplatin and 5-FU demonstrated a high 
chemosensitivity index in all tumors tested, suggesting 
greater activity than the ECF or CF regimens. This may 
result from the ability of gemcitabine to potentiate the 
activity of DNA-damaging agents by interfering with 
DNA repair (18]. Mitomycin C has been used in a 
number of clinical trials with varying degrees of success; 
as a single agent in the ATP-TCA it showed activity 
comparable with 5-FU. However, in combination with 5- 
FU or with gemcitabine, it consistently demonstrated 
higher levels of activity. These are preliminary data and 
further work on this combination is required before phase 
I/II trials are performed. Treosulfan and gemcitabine is a 
novel drug combination not currently used in the 
treatment of upper GI cancers, but with good activity 
against adenocarcinomas of ovary 114] and breast (Sharma 
et al., unpublished data). In our assay it consistently 
produced a good response.
Particular difficulties encountered in the early stages of 
this study included the small size of most of the biopsy 
specimens, the vulnerability of the tumor cell cultures to 
infection, and the degree of necrosis and cell debris 
found, especially in post-chemotherapy specimens. The 
majority of specimens deemed to be not evaluable were 
small endoscopic biopsies that yielded very few tumor 
cells. The surgeons carrying out the endoscopic biopsies 
were asked to take as much tissue as possible from the 
growing edge of the tumor, using 3.7-mm biopsy forceps, 
and usually provided about 10-20 mg of tissue. Some 
early cultures were found to be infected with fungus; 
addition of an appropriate concentration of an anti-fungal 
to the transport media and the dissociation enzyme 
preparation prevented this problem. It was realized that 
endoscopic biopsies of the post-chemotherapy specimens 
were mostly necrotic and rarely contained enough tumor 
cells to carry out an assay; testing of these samples was 
discontinued and instead the resection specimen was 
tested, usually some 4-6 weeks later, as larger samples 
from beneath the mucosa could be taken.
In this study we used chemotherapeutic agents at levels 
related to their peak plasma concentrations, taking into 
account their degree of protein binding [12]. We accept 
that this approach has inherent flaws, since the 6’max is 
not always a good indicator of clinically achievable intra- 
tumor concentrations. Similarly, the ATP-TCA is an ex 
vivo study of the cells’ chemosensitivity and a tumor cell 
suspension does not necessarily reflect the in vivo 
situation. However, previous studies with the ATP-TCA 
suggest that the assay is a good model for the 
investigation of tumor chemosensitivity and the results
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C onclusion: The results show similar response rates to previous studies using ATP-TCA directed 
therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight 
to the reproducibility of results from different centres.
B a c k g r o u n d
D e s p i te  su rg ic a l r e f in e m e n t s  a n d  th e  i n t r o d u c t io n  o f  la n d ­
m a r k  c h e m o th e r a p y  a g e n ts  s u c h  a s  c i s p la t in  in  th e  1 9 7 0 ’s 
a n d  p a c l i ta x e l  in  t h e  1 9 9 0 's ,  im p r o v e m e n ts  in  th e  o v e ra l l  
s u rv iv a l  o f  e p i th e l ia l  o v a r i a n  c a n c e r  h a v e  o n ly  b e e n  m o d ­
e s t  [ 1). T h e  c u r r e n t ly  a c c e p te d  f ir s t  l in e  t r e a tm e n t  is c is- o r  
c a r b o p l a t i n  w i th  th e  a d d i t i o n  o f  a  ta x a n e  a n d  th i s  is  n o w  
t h e  m o s t  c o m m o n ly  e m p lo y e d  c o n t r o l  a rm  in  r a n ­
d o m i s e d  t r ia ls  12 ,3 ) . T h is  to g e th e r  w ith  s u rg e ry  c a n  re s u l t  
in  r e s p o n s e  ra te s  o f  7 0 - 8 0 % .  H o w e v e r , m o s t  o f  th e s e  
p a t ie n t s  w ill  r e la p s e  b e tw e e n  o n e  to  tw o  y e a rs  a n d  o n ly  
2 0 - 3 0 %  w ill  b e  a l iv e  a f te r  5  y e a rs  w i th  a  m e d ia n  o v e ra l l  
s u rv iv a l o f  3 5  m o n t h s  (2 ,3 ) .
T h e  o p t i m a l  t r e a tm e n t  o f  r e c u r r e n t  d is e a s e  is  u n c le a r  a n d  
a  n u m b e r  o f  d if f e re n t  d ru g s  a r e  u s e d .  T h e  r e s p o n s e  ra te  to  
s e c o n d  l i n e  t r e a tm e n t  d e p e n d s  o n  th e  p r e v a le n c e  o f  p la t i ­
n u m  r e s is ta n c e  a t  t h a t  t im e  ( 4 —7 ). T h e  le n g th  o f  th e  d is ­
e a s e  f re e  in te r v a l  c a te g o r is e s  p a t ie n t s  in t o  p la t in u m -  
s e n s i t iv e  ( th o s e  p ro g r e s s in g  6  m o n t h s  o r  m o r e  a f te r  c o m ­
p le t i o n  o f  f irs t l in e  p l a t i n u m  a g e n ts )  a n d  p la t in u m  re f ra c ­
to r y  ( th o s e  p ro g re s s in g  o n  o r  w i th in  6  m o n t h s  a f te r  
c o m p le t io n  o f  f irs t l in e  p l a t i n u m  a g e n ts ) .  S e v e ra l d if f e re n t  
c h e m o th e r a p y  a g e n ts  h a v e  s h o w n  s o m e  a c tiv i ty  in  
p a t i e n t s  w ith  r e c u r r e n t  d is e a s e  b u t  r e s p o n s e  ra te s  a re  s till 
u n d e r  3 0 %  in  u n s e le c te d  g r o u p s  [8 j. H o w e v e r , th e r e  is 
e v id e n c e  o f  h e te r o g e n e i ty  o f  c h e m o s e n s i t iv i ty  a n d  
p a t ie n t s  m a y  b e n e f i t  f r o m  a  c h a n g e  o f  t r e a tm e n t  i f  th e y  
p ro g re s s  o n  th e  firs t d r u g  s e le c te d . T h e re  a re  n o  p h a s e  111 
r a n d o m iz e d  tr i a l- b a s e d  d a t a  t o  su g g e s t th a t  c o m b in a t io n  
c h e m o th e r a p y  is  a n y  b e t te r  t h a n  s in g le  a g e n t  c h e m o th e r ­
a p y , t h o u g h  re c e n t  p h a s e  II t r i a ls  s u g g e s t th a t  c o m b in a ­
t i o n s  m a y  b e  u s e fu l ,  a t  le a s t  i n  p a t i e n t s  r e la p s in g  a f te r  
m o r e  th a n  s ix  m o n t h s  o f f  f i r s t- l in e  t r e a tm e n t  [ 9 ,1 0 |.
S e le c t io n  o f  t h e  o p t i m a l  s a lv a g e  c h e m o th e r a p y  b y  a  la b o ­
r a to r y  te s t  w o u ld  in  th e o r y  a l lo w  in d iv id u a l i s a t i o n  o f  
t r e a tm e n t .  H o w e v e r , th i s  r e q u i r e s  a  s ta n d a r d is e d ,  e v a lu a ­
b l e  a s s a y  te c h n iq u e .  T h e  A TP tu m o r  c h e m o s e n s i t iv i ty  
a s s a y  (A T P -T C A ) d e s c r ib e d  h e r e  is  a  n e w  g e n e ra t io n  assay . 
P re v io u s  c h e m o s e n s i t i v i ty  a s s a y s  h a v e  b e e n  d o g g e d  b y  
te c h n ic a l  d if f ic u l t ie s  o v e r  t h e  p a s t  2 5  y e a rs  [1 1 ,1 2 ] , 
th o u g h  se v e ra l h a v e  s h o w n  p o te n t ia l  in  c l in ic a l tr ia ls  [1 3 ]. 
T h e  A TP-TC A  c o m p a r e s  f a v o u ra b ly  w i th  a ll p r e v io u s  
m e th o d s  in  te r m s  o f  s t a n d a r d i s a t i o n ,  e v a lu a b il i ty ,  tu m o r  
ce ll n u m b e r  r e q u i r e d ,  r e p r o d u c ib i l i ty  a n d  ac c u ra c y . [ 1 3 -  
15] It is p o s s ib le  to  te s t  c e lls  f r o m  n e e d le  b io p s ie s  a n d  
m a l ig n a n t  e f fu s io n s  as  w e ll a s  s o l id  t u m o r  b io p s ie s .  T h e  
h ig h  s e n s i t iv i ty  o f  th e  A T P-T C A  re q u ire s  o n ly  1 x 1 0 6
tu m o r  ce lls  t o  t e s t  4 - 6  d r u g  r e g im e n s .  E n c o u ra g in g  c o r r e ­
la t io n s  b e tw e e n  a s s a y  re s u l ts  a n d  c l in ic a l o u t c o m e  h a v e  
b e e n  r e p o r te d  [1 6 ] , a n d  u s e  o f  t h e  a s s a y  in  o n e  c e n tr e  
(U n iv e r s i ty  o f  K o ln , K o ln , G e r m a n y )  f o r  p a t ie n t s  w ith  
r e c u r r e n t  o v a r ia n  c a n c e r  p r o d u c e d  a  6 4 %  r e s p o n s e  ra te  
w i th  im p r o v e d  p r o g r e s s io n - f r e e  s u rv iv a l [1 7 ] .
H e re  w e  p r e s e n t  th e  r e s u lts  o f  A TP-TC A  d ir e c te d  th e r a p y  in  
m u l t ip l e  c e n tre s  u s in g  5 6  h u m a n  e p i th e l ia l  o v a r ia n  c a n c e r  
s p e c im e n s  f ro m  4 6  p a t ie n t s  p r e v io u s ly  t r e a te d  w i th  c h e m ­
o th e r a p y , 8  o f  w h o m  re c e iv e d  m u l t ip l e  A TP-TC A  d ire c te d  
th e r a p ie s .  W e  r e p o r t  o n  th e  o b je c t iv e  r e s p o n s e  ra te  (O R R ), 
p r o g re s s io n  free  s u rv iv a l (P F S ) a n d  th e  o v e ra l l  s u rv iv a l 
(O A S ) a n d  d is c u s s  th e  r e s u l ts  in  r e l a t i o n  to  s im i la r  A TP 
a s sa y s  c a r r ie d  o u t  in  d i f f e re n t  c e n tre s .
P a tie n ts  a n d  m e th o d s  
Patients and treatment
F ro m  O c to b e r  1 9 9 8  to  N o v e m b e r  2 0 0 1  fo r ty -s ix  p a t ie n t s  
w i th  h is to lo g ic a l ly  p ro v e n  r e c u r r e n t  o v a r i a n  c a rc in o m a  
w e re  t r e a te d  p ro s p e c t iv e ly  w ith  A TP-TC A  d ir e c te d  c h e m o ­
th e r a p y  re g im e n s . P a t ie n t  c h a ra c te r is t ic s  a re  s u m m a r is e d  
in  T a b le  1. W r i t te n  in f o r m e d  c o n s e n t  w a s  o b t a in e d  f ro m  
a l l  p a t ie n t s ,  t u m o r  s p e c im e n s  w e re  o b t a in e d  e i th e r  a t 
la p a r o to m y ,  l a p a r o s c o p y  o r  p a r a c e n te s i s  o f  a  m a l ig n a n t  
a s c i te s  o r  e f fu s io n .  S p e c im e n s  w e re  p la c e d  in t o  s te r i le  c o n ­
ta in e r s  c o n t a in in g  a  b a s ic  t r a n s p o r t  m e d iu m  (D M E M , 
S ig m a -A ld r ic h , P o o le ,  D o r s e t  U K ) w i th  p e n ic i l l in ,  s t r e p t o ­
m y c in  a n d  g e n ta m ic in  a s  a d d i t iv e s .  A sc ite s  c o n ta in e r s  a ls o  
c o n ta in e d  h e p a r in  s u lp h a t e  5 0 0 0  i .u . T h e s e  w e re  i m m e d i ­
a te ly  p a c k e d  in to  c h i l le d  p o ly s ty r e n e  c o n ta in e r s  a n d  t r a n s ­
p o r te d  b y  c o u r ie r  to  a r r iv e  in  t h e  la b o r a to r y  ( Q u e e n  
A le x a n d ra  H o s p i ta l ,  P o r t s m o u th )  w i th i n  2 4  h o u r s .  A ll 
s p e c im e n s  w e re  c o n f i r m e d  fo r  m a l ig n a n c y  b y  h is to lo g y  o r  
c y to lo g y .
P a t ie n ts  w e re  t r e a te d  w ith  th e  o p t i m a l  p r o to c o l  a s  i n d i ­
c a te d  b y  th e  A TP-TC A  a ssay . T h is  w a s  th e  r e g im e n  w ith  th e  
h ig h e s t  ex -v iv o  a c tiv i ty  th a t  c o u ld  b e  to l e r a t e d  b y  th e  
p a t ie n t  c o n c e rn e d ,  ta k in g  in to  a c c o u n t  th e  lik e ly  to x ic ity  
p r o f i l e  o f  t h e  d ru g s  s e le c te d . C o m b i n a t i o n  th e r a p ie s  h a d  
t o  d e m o n s t r a te  c o n s id e r a b le  a c tiv i ty  o v e r  th e  b e s t  s in g le  
a g e n t  te s te d  i f  th e y  w e re  t o  b e  s e le c te d . A n y  s u p p o r t iv e  
t r e a tm e n t  n e e d e d  w a s  free ly  in s t i tu te d  w h e n  n e e d  a ro s e  
d u r in g  th e ra p y .
T h e  o n ly  e l ig ib i l i ty  c r i te r ia  w e re  r e la p s e d  e p i th e l i a l  o v a r ­
ia n  c a n c e r  p re v io u s ly  t r e a te d  w ith  c h e m o th e r a p y  a n d  f i t ­
n e s s  to  re c e iv e  f u r th e r  c h e m o th e r a p y .  R e la p s e  w a s  d e f in e d
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Table I:
PATIENT CHARACTERISTICS N  = 46
Median age (range) 55 (33-76)
Median performance status (range) 2 (0-4)
Median number of prior chemotherapies (range) 2 (1-5)
Sum m ary o f  prior chem otherapy
Number of treatments prior to ATP-TCA No. Patients
1 13(28%)
2 18(39%)
3 10(22%)
4 4(9%)
5 I (2%)
FIGO stage (No.)
Illc 40 (87%)
IV 6(13%)
Patients with non-serous histology 6 ( 13%)
Platinum-refractory patients* 18(39%)
Patients with a Cisplatin Index >350 on first ATP-TCA 33 (72%)
Patients with ascites 37 (80%)
‘Defined as relapse < 6 months after completion of first course of platinum containing chemotherapy
a s  o c c u r r e n c e  o f  m a l ig n a n t  p le u r a l  e f fu s io n  o r  a s c i te s  
( s u b s t a n t i a te d  b y  p o s i t iv e  c y to lo g y ) , a  C A 1 2 5  o f  o v e r  7 0  
U /m L  w h ic h  h a d  a t  le a s t d o u b le d  f ro m  th e  p r e v io u s  v a lu e  
( s a m p le s  ta k e n  >  2 8  d a y s  a p a r t )  (1 8 ] o r  r a d io g r a p h ic a l ly  
m e a s u r a b le  d is e a s e  w i th  > 2 0 %  in c re a s e  in  th e  s u m  o f  th e  
lo n g e s t  d ia m e te r  o f  ta rg e t  le s io n s . P a t ie n ts  o f  a n y  W H O  
p e r f o r m a n c e  s ta tu s  th o u g h t  fit e n o u g h  b y  th e i r  o n c o lo g is t  
t o  w i th s ta n d  c h e m o th e r a p y  w e re  in c lu d e d  in  th i s  se r ie s , 
i r r e s p e c tiv e  o f  m a r ro w , r e n a l  o r  h e p a t ic  f u n c t io n .
T h e r a p y  w a s  m o n i to r e d  u s in g  c l in ic a l,  b io c h e m ic a l  a n d  
r a d io lo g ic a l  p a r a m e te r s .  W h e re  p o s s ib le  C A 1 2 5  m e a s u r e ­
m e n ts  w e re  ta k e n  b e fo r e  t r e a tm e n t  a n d  m o n th ly  th e r e a f ­
te r  in  o r d e r  to  m o n i to r  r e s p o n s e .  P h y s ic a l e x a m in a t io n  
w a s  c a r r ie d  o u t  m o n th ly ,  t u m o r  im a g in g  w a s  p e r f o r m e d  
r o u t in e ly  a f te r  3  cy c le s  o r  e a r l ie r  t o  e s ta b l is h  p ro g re s s iv e  
d is e a s e . P a t ie n t  r e s p o n s e  to  t r e a tm e n t  w a s  a s s e s se d  b y  
c l in ic a l  a n d  r a d io lo g ic a l  m e a n s  a c c o r d in g  to  R EC IST  c r i te ­
r ia  a s  c o m p le t e  r e s p o n s e  (C R ) , p a r t ia l  r e s p o n s e  (P R ), s ta ­
b le  d is e a s e  (S D )  o r  p ro g re s s iv e  d is e a s e  (P D )  [1 9 ] . T h e  
O R R  w a s  d e f in e d  a s  th e  s u m  o f  C R  a n d  PR. A fa l lin g  
C A 1 2 5  w i th o u t  a  c l in ic a l o r  r a d io lo g ic a l  c o r r e la te  d id  n o t  
q u a l i f y  a  p a t i e n t  f o r  a  C R  o r  PR.
P a t ie n ts  w e re  r e g a r d e d  a s  e v a lu a b le  i f  a  m i n im u m  o f  2 
cy c le s  o f  c h e m o th e r a p y  w e re  a d m in is te r e d .  A ll c h e m o ­
th e r a p y  w a s  c o n t in u e d  fo r  a  m i n im u m  o f  4  cy c le s  in  
r e s p o n d e r s  a n d  in  p a t i e n t s  e x p e r ie n c in g  s ta b le  d is e a se . A ll 
p a t i e n t s  w e re  fo l lo w e d  u p  r o u t in e ly  o n  a  th r e e  m o n t h ly  
b a s is  w i th  c l in ic a l e x a m in a t io n  a n d  C A 1 2 5  le v e ls . A d d i­
t i o n a l  im a g in g  w a s  p e r f o r m e d  as  in d ic a te d .  O n  re la p s e  o f  
d is e a se , i f  f u r th e r  t r e a tm e n t  w a s  o f fe re d , th i s  w a s  e i th e r  
p h y s ic ia n 's  c h o ic e  o r  a f u r th e r  c o u r s e  o f  A TP-TC A  d ir e c te d  
th e r a p y . P a t ie n ts  w e re  d e f in e d  a s  p la t in u m - r e f r a c to r y  i f  
th e y  s h o w e d  p ro g re s s io n  o f  d is e a s e  d u r in g  o r  w i th in  6  
m o n t h s  a f te r  c o m p le t io n  o f  p la t in u m - b a s e d  c h e m o th e r ­
a p y  [6 ,2 0 ,2 1 ]
ATP chemosensitivity testing
T h e  A TP-TC A  m e th o d o lo g y  h a s  b e e n  p r e v io u s ly  d e s c r ib e d  
in  d e ta i l  [1 4 ,2 2 ] . B riefly , s p e c im e n s  w e re  o b t a in e d  a t  s u r ­
g e ry  o r  f ro m  m a l ig n a n t  e f fu s io n s , t u m o r  c e lls  w e re  i s o ­
la te d  b y  e n z y m a tic  d is s o c ia t io n  u s in g  C o l la g e n a s e  T y p e  H 
(S ig m a -A ld r ic h , P o o le , D o rs e t,  U K ) a t  a  c o n c e n t r a t io n  o f  
0 .7 5  m g /m L  f o r  12  h o u r s .  C e ll v ia b i l i ty  w a s  e x p re s s e d  a s  a  
p e r c e n ta g e  u s in g  a  c o u n t in g  c h a m b e r  a n d  th e  to t a l  v ia b le  
c e ll c o u n t  u s e d  to  c a lc u la te  f in a l w o r k in g  v o lu m e s .  T h e  
tu m o r  c e lls  w e re  th e n  s e e d e d  in to  e a c h  w e ll  o f  a  9 6 -w e ll  
p o ly p r o p y le n e  m ic r o p la te  u s in g  2 0 ,0 0 0  c e lls  p e r  w e ll  f o r  
s o l id  tu m o r s  a n d  1 0 ,0 0 0  c e lls  p e r  w e ll f o r  a s c i te s  s a m p le s .  
T h e s e  w e re  te s te d  w ith  a  m a x im u m  o f  14  d i f f e re n t  s in g le  
a g e n t  a n d  c o m b in a t io n  c h e m o th e r a p y  a g e n ts . D ru g s  w e re  
a d d e d  to  th e  w e lls  p r io r  t o  s e e d in g  a n d  th e r e  w a s  n o  p r e ­
in c u b a t io n  p e r io d  f o r  th e  ce lls . T h e s e  in c lu d e d  s ta n d a r d  
a n d  e x p e r im e n ta l  c o m b in a t io n s  (T a b le  2 ) .
E a ch  s in g le  a g e n t  o r  c o m b in a t io n  w a s  t e s te d  a t  s ix  d o u ­
b l in g  d i lu t io n s  ( 6 .2 5 %  t o  2 0 0 % )  o f  te s t  d r u g  
c o n c e n tr a t io n s  (T D C ) d e r iv e d  f ro m  p h a r m a c o k in e t ic  
d a ta ,  in c lu d in g  th e  d e g re e  o f  p r o te in  b in d in g .  T h e  a s s a y  is
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Regimen Number of patient treatments 
(N = 56)
Protocol
Carboplatin 1 5(GFR+25)mg;6 cycles; q3 wk
Mitoxantrone 1 12 mg/m2; q3 wk
Treosulfan 1 7000 mg/m2; q4 wk
Gemcitabine 1 1250 mg/m2; d 1,8; q3 wk
Treosulfan and gemcitabine 23 5000 mg/m2; dl & 1000 mg/m2; dl; q3 wk
Liposomal Doxorubicin (Caelyx®/Doxil®) 8 40 mg/m2; dl; q3 wk
Mitoxantrone and paclitaxel 8 4 mg/m2; d 1,2 & 175 mg/m2; d3; q3 wk
Cisplatin and gemcitabine 5 75 mg/m2; d 1 & 1250 mg/m2; d 1,8; q3 wk
Mitoxantrone and gemcitabine 1 12 mg/m2; d 1.21 & 1000 mg/m2; dl; q3 wk
Liposomal Doxorubicin and gemcitabine 1 45 mg/m2; d 1 & 500 mg/m2; d 1.8; q3 wk
Epirubicin and treosulfan 2 60 mg/m2; d 1 & 5000 mg/m2; d 1. q4 wk
Vinorelbine and Liposomal Doxorubicin 2 15 mg/m2 & 30 mg/m2 ; q3 wk
Epirubicin and paclitaxel 2 25 mg/m2; d l ,2 & 175 mg/m2; d3; q3 wk
c a r r ie d  o u t  in  t r ip l ic a te  w e lls  w i th  p o s i t iv e  a n d  n e g a tiv e  
c o n t r o l s  u s in g  a  s e ru m - f r e e  m e d iu m  (C A M , D C S  I n n o v a ­
tiv e  D ia g n o s t ik  S y s te m e , H a m b u rg ,  G e r m a n y ) .  T h e  A TP 
c o n t e n t  o f  e a c h  w e ll w a s  m e a s u r e d  a f te r  6  d a y s  in c u b a t io n  
( 5 %  C 0 2, 3 7 ° C  a n d  1 0 0 %  h u m id i ty )  b y  th e  a d d i t io n  o f  
lu c ife r in - lu c ife ra s e  t o  a n  a l i q u o t  o f  t h e  ly s e d  ce lls  in  a  
lu m in o m e te r  (M PL X , B e r th o ld  D ia g n o s t ic  S y ste m s , H a m ­
b u rg ,  G e rm a n y )  a n d  a n a ly s e d  w i th  c u s to m  s o f tw a re  to  
p r o v id e  b o th  n u m e r ic a l  a n d  g ra p h ic a l  r e s u lts .  L u m in e s ­
c e n c e  m e a s u r e m e n ts  a r e  d ire c t ly  re la te d  t o  A TP le v e ls  a n d  
a l lo w  m e a s u r e m e n t  o f  t h e  p e r c e n ta g e  in h i b i t i o n  b y  re fe r ­
e n c e  to  u n t r e a te d  c o n t r o l  w e lls  in c lu d e d  w i th  e a c h  p la te  
( 1 4 ,1 5 |.
T h e  re s u l ts  a r e  in t e r p r e te d  a n d  c o m p a r e d  u s in g  f o u r  
p a r a m e te r s .  T h e  d r u g  c o n c e n t r a t io n s  th a t  a c h ie v e  5 0  a n d /  
o r  9 0 %  g ro w th  i n h i b i t i o n  ( IC 5 0  a n d  1C 90  re s p e c t iv e ly )  
a r e  c a lc u la te d  b y  in t e r p o la t io n .  A  s e n s i t iv i ty  in d e x  ( In d e x  
S U M ) is c a lc u la te d  a s  t h e  s u m  o f  t h e  p e r c e n ta g e  in h i b i t i o n  
a t  e a c h  c o n c e n t r a t io n  te s te d  (S I = 6 0 0  - £  % I n h ib i t io n  a t
2 0 0 ,1 0 0 ,5 0 ,2 5 ,1 2 .5  a n d  6 .2 5 %  T D C ). L astly , th e  a re a  
u n d e r  th e  d o s e - r e s p o n s e  c u rv e  ( In d e x  A U C ) is c a lc u la te d  
u s in g  th e  t r a p e z o id a l  ru le . P re v io u s  s tu d ie s  h a v e  s h o w n  
th e  In d e x  S U M  t o  b e  s u p e r io r  t o  th e  In d e x  A U C  a n d  IC 5 0  
fo r  d e t e r m i n a t io n  o f  s e n s i t iv i ty  a n d  re s is ta n c e  a s  th i s  
r e la te s  m o re  c lo se ly  t o  th e  s h a p e  o f  th e  c o n c e n tr a t io n -  
i n h i b i t i o n  c u rv e  [1 6 J . D e f in i t io n s  o f  s e n s i t iv i ty  a n d  re s is t­
a n c e  f o r  I n d e x  S U M  a n d  In d e x  A U C  w e re  c a lc u la te d  b y  
lo g - r a n k  te s ts  r e fe r r in g  t o  PFS a n d  O A S  [1 4 ) . In  th i s  s tu d y  
a n  In d e x  S U M  > 3 5 0  w a s  t a k e n  t o  in d ic a te  p r o b a b le  re s is t­
a n c e .  D ru g s  w e re  c la s s i f ie d  i n t o  th r e e  g r o u p s  ( p r o b a b ly  
s e n s it iv ity , e q u iv o c a l  s e n s i t iv i ty  a n d  p r o b a b le  r e s is ta n c e )  
o n  th e  b a s is  o f  In d e x S U M , a n d  c le a r  e v id e n c e  o f  a  c o n c e n -  
t r a t io n - r e s p o n s e  c u rv e  w i th  a t  le a s t 9 5 %  i n h i b i t i o n  a t  
1 0 0 %  T D C . S y n e rg is m  o r  a d d i t iv e  e ffec ts  f o r  in d iv id u a l  
p a t i e n t s  w e re  n o t  r o u t i n e ly  a s s e s se d . A  r e p o r t  w a s  g e n e r ­
a te d  in c lu d in g  th e  in t e r p r e ta t io n  o f  th e  d a ta ,  th e  c o n c e n -  
t r a t io n - i n h ib i t io n  g ra p h s  a n d  th e  d e r iv e d  p a r a m e te r s  
( In d e x S U M , In d e x A U C , IC 9 0  a n d  IC 5 0 ) .  T h is  r e p o r t  w a s  
s e n t  to  th e  o n c o lo g is t  in  c h a rg e  o f  th e  p a t ie n t  w h o  d e c id e d  
th e  t r e a tm e n t  a c c o rd in g  to  th e  a s s a y  r e s u l t s  a n d  p r e v io u s  
to x ic ity  d a t a  f r o m  th e  p a t ie n t  c o n c e r n e d .  In  a l l ca ses , 
p a t i e n t s  w e re  t r e a te d  w i th  d ru g s  s h o w n  t o  b e  a c tiv e  in  th e  
a ssay .
Statistics
T h e  re s u lts  o f  th is  n o n - c o m p a r a t iv e  s tu d y  a re  p r e s e n te d  
w i th  d e s c r ip t iv e  s ta t is tic s  b a s e d  o n  a n  i n t e n t i o n  to  tr e a t 
a n a ly s is .  A ll d a ta  w as  c o l le c te d  r e t ro s p e c t iv e ly  b y  s c ru t in y  
o f  c a se  n o te s  a n d  in v e s t ig a t io n a l  r e s u lts .  C lin ic a l  d e ta i l s  
w e re  c o l le c te d  b l in d  to  th e  a s s a y  re s u lts .  PFS a n d  O A S  
w e re  m e a s u r e d  f ro m  th e  f ir s t  d a y  o f  A TP-TC A  d ire c te d  
c h e m o th e r a p y .  O A S h a s  n o t  b e e n  c o r r e c te d  fo r  c a u s e  o f  
d e a th ,  w h ic h  h a s  b e e n  c o n s id e r e d  to  b e  d u e  to  o v a r ia n  
c a n c e r . A u to p s ie s  w e re  n o t  p e r f o r m e d  o n  th e s e  p a t ie n t s .  
D e s c r ip t iv e  s ta t is t ic s  a re  u s e d  to  d e s c r ib e  p a t ie n t  d e m o ­
g r a p h ic  a n d  d is e a s e  c h a ra c te r is tic s . K a p la n -M e ie r  su rv iv a l 
m e th o d s  w e re  u s e d  to  s u m m a r iz e  t h e  t im e - to  e v e n t  v a r ia ­
b le s  o f  t im e  to  p r o g r e s s io n  a n d  o v e ra l l  s u rv iv a l .
R esu lts
A to t a l  o f  4 6  p a t ie n t s  u n d e r w e n t  5 6  c o u r s e s  o f  A TP-TC A  
d ir e c te d  c h e m o th e r a p y .  T w o  p a t ie n t s  re c e iv e d  o n ly  o n e  
c y c le  o f  a s s a y  d ire c te d  th e r a p y  a n d  th e n  w i th d r e w  f ro m  
t r e a tm e n t .  S e c o n d  lo o k  la p a r o to m ie s  w e re  n o t  p e r fo rm e d , 
b u t  9  p a t i e n t s  h a d  t i s s u e  s a m p le s  ta k e n  a t  d ia g n o s t ic  
la p a ro s c o p y . N o n e  o f  th e  p a t ie n t s  h a d  f u r th e r  tu m o r  
d e b u lk in g  su rg e ry .
T h e  t r e a tm e n ts  g iv e n  a r e  s u m m a r i s e d  in  T a b le  2 . D ru g  
c o m b in a t io n s  w e re  g iv e n  o n  4 4  ( 7 9 % )  o c c a s io n s  a n d  o f  
th e s e  3 0  ( 5 4 % )  w e re  n o n - s ta n d a r d  p ro to c o ls .
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Table 3: Results of chem otherapy
http://www.biomedcentral.com/1471 -2407/3/19
No. of patients 46
No. ATP-TCA directed courses 56
CR 12 (21%)
PR 21 (38%)
SD 6 (11%)
PD 15 (27%)
No. of patients not evaluable for response 2 (4%)
ORR 33 (59%)
Median PFS (months) 6.6
Median OAS (months) 10.4
Response
O f  th e  5 4  A TP-TCA  d ir e c te d  c h e m o th e r a p ie s  e v a lu a b le  fo r  
r e s p o n s e ,  th e r e  w e re  12  c o m p le te  r e s p o n s e s  (C R ), 21  p a r ­
tia l  r e s p o n s e s  (P R ), 6  s ta b le  d is e a s e  (S D ) a n d  15 w i th  p r o ­
g re s s iv e  d is e a s e  (P D ) . T w o  p a t ie n t s  w e re  n o t  e v a lu a b le  fo r  
r e s p o n s e  (w i th d re w  a f te r  o n e  cy c le  o f  t r e a tm e n t ) .  O f  th e  
4 4  p a t ie n t s  tr e a te d , 15  a re  s til l  a l iv e  a t  th e  d a te  o f  a n a ly s is  
(3  C R , 9  PR, 2 S D  a n d  1 P D ). F o r  e v a lu a b le  p a t ie n t s ,  th e  
O R R  w a s  61 %  p e r  c o u rs e  o f  A TP-TC A  d ir e c te d  c h e m o th e r ­
a p y  ( 1 2  C R  a n d  21 P R ). By in t e n t io n - to - t r e a t  (IT T ) a n a ly ­
sis , t h e  r e s p o n s e  ra te  w a s  5 9 % , in c lu d in g  th e  tw o  p a t ie n t s  
w h o  re c e iv e d  ju s t o n e  cy c le  o f  c h e m o th e r a p y  a n d  w e re  n o t  
e v a lu a b le .  T h e  re s u lts  o f  c h e m o th e r a p y  a re  s u m m a r is e d  in  
T a b le  3 .
E ig h t p a t ie n t s  h a d  m o r e  th a n  o n e  c o u rs e  o f  A TP-TC A  
d ir e c te d  c h e m o th e r a p y  ( r a n g e  2 - 4  c o u rs e s ) .  F o u r  o f  th e s e  
r e s p o n d e d  to  tw o  o r  m o re  c o u rs e s  o f  A TP-TCA  d ir e c te d  
c h e m o th e r a p y .  O n e  p a t ie n t  r e s p o n d e d  to  th r e e  s u c c e ss iv e  
c o u r s e s  a n d  3 o f  th e s e  p a t ie n t s  a re  s til l  a l iv e  a t  t h e  t im e  o f  
a n a ly s is .  T h e  m e d ia n  O A S  fo r  th e s e  p a t ie n t s  w a s  1 3 .7  
m o n t h s  (A n d e r s o n  9 5 %  C l 1 1 .5 - 1 5 .9  m o n t h s )  f r o m  th e  
s ta r t  o f  A TP-TC A  d ir e c te d  th e ra p y .
O f  t h e  c l in ic a l ly  p la t in u m - r e s i s ta n t  p a t ie n t s  ( 1 8 ) ,  th e r e  
w e re  3 C R , 8  PR, 4 S D , 3  P D  w ith  a  6 1 %  O R R . O f  p la t i ­
n u m -s e n s i t iv e  p a t ie n t s  ( 2 6 ) ,  th e r e  w e re  8  C R , 9  PR, 2  S D , 
7 P D  w ith  a  6 5 %  O R R . O f  5 4  A TP-TCA s, 5 2  w e re  e v a lu a ­
b le  f o r  c i s p la t in  s e n s it iv ity . A n a ly s is  o f  p a t ie n t s  g r o u p e d  
b y  In d e x  S U M  f o r  c i s p la t in  s e n s i t iv i ty  s h o w e d  7 2 %  o f  
p a t i e n t s  t o  b e  r e s is ta n t  t o  c i s p la t in  i n  th e  a ssay . T h e  O R R  
o f  p a t ie n t s  w ith  a  c i s p la t in  s e n s i t iv i ty  in d e x  > 3 5 0  a n d  
< 3 5 0  w a s  5 8 %  (N  = 3 8 )  a n d  7 5 %  (N  = 1 2 )  re sp e c tiv e ly .
S u rv iva l
T h e  m e d ia n  PFS f o r  a ll 5 6  p a t ie n t s  w a s  6 .6  m o n t h s  
(A n d e r s o n  9 5 %  C l 3 .6 - 9 .6  m o n t h s )  a n d  th e  m e d ia n  O A S  
1 0 .4  m o n t h s  ( A n d e r s o n  9 5 %  C l 7 .9 - 1 2 .8  m o n t h s ) .  F ig ­
u re  1 i l lu s tr a te s  p ro g re s s io n  free  s u rv iv a l a n d  f ig u re  2 i l lu s ­
t r a te s  o v e ra l l  s u rv iv a l fo r  th e  g r o u p  c a lc u la te d  b y  K a p la n -  
M e ie r  s ta t is tic s .
D isc u ss io n
T h e  5 9 %  r e s p o n s e  ra te  ( 6 1 %  fo r  e v a lu a b le  p a t ie n t s )  s u p ­
p o r ts  d a ta  f ro m  p re v io u s  w o rk  u s in g  th e  A TP-TC A  in  
a n o t h e r  c e n tre  [1 7 ] , A ll p a t i e n t s  h a d  s ta g e  IIIc  o r  IV d i s ­
e a se  a n d  th e  in c lu s iv e  c r i te r ia  f o r  t r e a tm e n t  ( w ith  r e g a rd  to  
p e r f o r m a n c e  s ta tu s ,  l a b o r a to r y  c r i te r ia  a n d  p re v io u s  to x ic ­
ity )  a l lo w e d  th e  in c lu s io n  o f  p a t i e n t s  w h o  w e re  c l in ic a l ly  
u n w e l l  a s  a  re s u l t  o f  th e i r  d is e a s e  o r  o th e r w is e .  I t is  r e a s o n ­
a b le  t o  a s s u m e  t h a t  th e  o u tc o m e s  f o r  th i s  g r o u p  a re  lik e ly  
to  b e  le ss  f a v o u ra b le  th a n  g e n e ra l ly  q u o te d  fig u re s .
T h e  u s e  o f  a n t in e o p la s t i c  a g e n ts  in  th i r d  l i n e  a n d  s u b s e ­
q u e n t  th e r a p y  h a s  b e e n  q u e s t i o n e d  s in c e  th e  o b je c t iv e  
r e s p o n s e  ra te  is  s o  lo w  in  w o m e n  f a i l in g  p re v io u s  th e ra p y . 
In  th e  U K , m o s t  p a t ie n t s  w ith  r e la p s e  a f te r  s e c o n d  l in e  
c h e m o th e r a p y  a re  re fe r re d  f o r  p a l l ia t iv e  c a re  ( 2 3 |.  It h a s  
a l s o  b e e n  s u g g e s te d  th a t  p o te n t ia l ly  u s e fu l  n e w  a g e n ts  
s h o u ld  n o t  b e  e v a lu a te d  in  m u l t ip l e  t r e a te d  p a t ie n t  p o p u ­
la t io n s  as  th e y  r is k  b e in g  la b e l le d  " in a c tiv e "  |2 4 j .  H o w ­
ev e r, w e  k n o w  th a t  w o m e n  m a y  s u rv iv e  f o r  m o n t h s  a n d  
e v e n  y e a rs  a f te r  f a i l in g  in i t ia l  th e r a p y  a n d  th a t  th e y  m a y  
r e s p o n d  se v e ra l m o r e  t im e s  t o  c h e m o th e r a p y  re g im e s , 
p a r t ic u la r ly  in  th e  p la t in u m - s e n s i t iv e  g r o u p  [ 2 5 ,2 6 |.  A 
re c e n t  s tu d y  s h o w e d  th a t  c o m p a r e d  to  n o n - c a n c e r  c o n ­
tro ls ,  w o m e n  w i th  r e c u r r e n t  o v a r i a n  c a n c e r  o v e r w h e lm ­
in g ly  p re fe r re d  s a lv a g e  th e r a p y  to  p a l l i a t io n .  Q u a l i ty  o f  
life  w a s  o f  s e c o n d a ry  im p o r ta n c e  t o  t h e  d e s ir e  to  c o n t in u e  
a g g re s s iv e  t r e a tm e n t  (2 7 ) . H o w e v e r , th e  c h o ic e  o f  th i r d ,  
f o u r th  o r  e v e n  f if th  l in e  th e r a p y  is  d if f ic u l t .  P re v io u s  tr ia ls  
o f  c h e m o th e r a p y  in  r e c u r r e n t  o v a r i a n  c a n c e r  h a v e  d o c u ­
m e n te d  r e s p o n s e  ra te s  b e tw e e n  1 3 - 5 0 %  a n d  th i s  in c lu d e s  
tr ia ls  o f  s e c o n d - l in e  th e r a p y  a n d  p a t ie n t s  w i th  s ta g e  I a n d  
II d is e a s e  [ 2 8 - 3 5 ]  T h e re  a re  few  r a n d o m is e d  tr ia ls  a n d  
n o n e  h a v e  d e m o n s t r a te d  a  c le a r  b e n e f i t  f o r  o n e  re g im e n  
o v e r  a n o th e r .  C lin ic a l a c tiv i ty  h a s  b e e n  d e m o n s t r a te d  
w i th  a g e n ts  s u c h  a s  p e g y la te d  l i p o s o m a l  d o x o r u b ic in  
[2 9 ,3 3 ] ,  to p o te c a n  [ 2 8 ,3 0 ,3 2 ] ,  a l t r e t a m in e  [3 4 ] , g e m c i t ­
a b in e  [3 6 J  a n d  e to p o s id e  [3 7 ] . T h e  h e te r o g e n e i ty  o f  
r e s p o n s e  t o  t r e a tm e n t  in  r e c u r r e n t  o v a r i a n  c a n c e r  m a k e s  
c h o ic e  o f  t r e a tm e n t  d if f ic u lt .
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Figure I
PFS following assay-directed chemotherapy.
T h e re  a re  n o  d a t a  c o n c lu s iv e ly  p r o v in g  c o m b in a t io n  th e r ­
a p y  is  s u p e r io r  t o  s in g le - a g e n t  th e r a p y  in  r e la p s e d  d is e a se .
In c r e a s e d  a c t iv i ty  w ith  s o m e  c o m b in a t io n s  h a s  b e e n  
s h o w n  in  r a n d o m is e d  tr ia ls , b u t  o f te n  in  s e le c te d  g ro u p s  
a n d  it  is  n o t  c e r ta in  t h a t  th e  b e n e f i t  w ill  t r a n s la te  in to  
im p r o v e d  s u rv iv a l  [3 8 ) . T w o  s tu d ie s  h a v e  re c e n tly  s h o w n  
im p re s s iv e  r e s p o n s e  ra te s  u s in g  w e e k ly  c is p la t in  a n d  o ra l  
e to p o s i d e  [ 9 ,1 0 |.  V a n  d e r  B u rg  e t  a l. [1 0 ] u s e d  a  d if f e re n t  
d e f i n i t i o n  o f  p l a t i n u m  s e n s i t iv i ty  t o  M e y e r  e t  a l. (9 ), 
f a v o u r in g  t h e  1 9 9 8  c o n s e n s u s  c la s s i f ic a t io n  [3 9 ] . T h is  
g r o u p e d  p a t ie n t s  in t o  p l a t i n u m  re f ra c to ry , p la t in u m  in t e r ­
m e d ia te - s e n s i t iv e  a n d  p l a t i n u m  s e n s i t iv e  b a s e d  o n  th e i r  
t r e a tm e n t  f r e e  in te rv a l  s in c e  la s t p la t in u m  c o n ta in in g  
th e r a p y  ( i.e . < 4  m o n th s ,  4 - 1 2  m o n t h s  a n d  > 1 2  m o n th s ,  
re s p e c t iv e ly ) . T h e  r e s p o n s e  ra te s  w e re  4 6 % , 9 1 %  a n d  9 2 %  
in  th e  r e f ra c to ry , in t e r m e d ia te  a n d  s e n s i t iv e  g ro u p s  re s p e c ­
tiv e ly . H o w e v e r , th e  p a t ie n t  s a m p le  d if fe re d  c o n s id e r a b ly  
f ro m  o u r s  in  t h a t  9 0 %  o f  th e  p a t ie n t  s a m p le  h a d  a  W H O
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p e r f o r m a n c e  s ta tu s  o f  0  o r  1 a n d  7 4 %  h a d  o n ly  o n e  p r io r  
c h e m o th e r a p y  r e g im e n . S u rv iv a l w a s  n o t  c a lc u la te d  o n  a n  
in t e n t i o n  to  t r e a t  a n a ly s is . W e  b e l ie v e  o u r  g r o u p  o f  
p a t ie n t s  is  m o r e  re p r e s e n ta t iv e  o f  th e  e v e ry d a y  c l in ic  s i t u ­
a t io n ,  w e re  o f  a  p o o r e r  p r o g n o s t ic  g r o u p  ( m e d ia n  W H O  
p e r f o r m a n c e  s ta tu s  o f  2 a n d  8 0 %  o f  p a t i e n t s  w i th  a s c i te s ) , 
a n d  h a v e  s h o w n  b e n e f i t  f ro m  th e  u s e  o f  th e  A TP-TCA .
M e y e r  e t  a l. [ 9 | u s e d  a  r e la p s e  c u t - o f f  o f  s ix  m o n t h s  to  
d e f in e  p la t in u m  s e n s it iv e  p a t ie n t s .  U s in g  C A 1 2 5  c r i te r ia  
t o  a sse ss  r e s p o n s e  th e y  f o u n d  th a t  4 6 %  o f  p l a t i n u m  re s is t ­
a n t  p a t ie n t s  r e s p o n d e d  to  th i s  r e g im e n  ( m e d ia n  su rv iv a l 
6 .3  m o n th s ) .  T h e  r e s p o n s e  r a te  in  th e  p l a t i n u m  s e n s i t iv e  
g r o u p  w a s  s l ig h t ly  le ss  ( 4 3 % ) .  T h is  is  s u r p r is in g  a n d  v e ry  
d i f f e re n t  f r o m  th e  r e s u l t s  p u b l i s h e d  b y  v a n  d e r  B u rg  e t  a l. 
[1 0 ] W e  u s e d  th e  s a m e  d e f in i t i o n  o f  p l a t i n u m  s e n s i t iv i ty  
a s  M e y e r  e t  a l. [ 9 | a n d  h a v e  a l s o  s e e n  a  s im i la r  O R R  (6 1 %  
a n d  6 5 %  f o r  p la t in u m  r e s is ta n t  a n d  p l a t in u m  s e n s i t iv e
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Figure 2
OAS following assay-directed chemotherapy.
p a t i e n t s  r e s p e c t iv e ly )  b e tw e e n  th e  tw o  g ro u p s .  H o w e v e r , 
w h e n  g r o u p e d  b y  In d e x  S U M  fo r  c i s p la t in  th e  d if fe re n c e s  
a r e  m o r e  m a rk e d  ( 5 8 %  a n d  7 5 %  O R R  fo r  I n d e x  S U M  
> 3 5 0  a n d  < 3 5 0  f o r  c i s p la t in  re s p e c tiv e ly ) . T h e  m a jo r i ty  o f  
p a t i e n t s  t r e a te d  b y  M e y e r  e t  a l. [9] h a d  2 o r  m o re  p r io r  
c o u r s e s  o f  c h e m o th e r a p y  w h ic h  is s im i la r  to  o u r  o w n  fig ­
u r e s  ( 7 2 %  tw o  o r  m o r e  p r io r  c h e m o th e r a p y  c o u rs e s ) .
W h e n  a n a ly s e d  o n  a n  ITT b a s is  th e  se r ie s  t r e a te d  b y  M e y e r  
e t  a l. [9 ] h a v e  a n  O R R  o f  3 6 % , a  PFS o f  3 .7  m o n t h s  a n d  a n  
O A S  o f  6 .6  m o n th s .  O u r  g ro u p  h a v e  s h o w n  a  g re a te r  
r e s p o n s e  ra te  a n d  lo n g e r  m e d ia n  su rv iv a l t im e s  (O R R  
5 9 % , PFS 6 .6  m o n th s ,  O A S  1 0 .4  m o n th s ) .
A t f ir s t  s ig h t,  th e  c l in ic a l d e f in i t i o n  o f  p l a t in u m  r e s is ta n c e  
d o e s  n o t  a p p e a r  to  m a tc h  th e  n u m b e r  o f  p a t ie n t s  s h o w in g  
c i s p l a t i n  re s is ta n c e  o n  th e  b a s is  o f  In d e x  S U M  in  th e  ATP- 
TC A . H o w e v e r , m o s t  p a t ie n t s  in  th i s  s tu d y  h a d  b e e n  
r e c h a l le n g e d  w i th  a  s e c o n d  lin e  p la t in u m  a g e n t / c o m b in a ­
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t i o n  a n d  th e  a ssay  ta k e n  b e fo r e  th i r d - l in e  th e r a p y  ( o r  
la te r )  s h o w s  th e  e x p e c te d  in c re a s e  in  th e  c i s p la t in  I n d e x  
S U M  d u e  to  a c q u ir e d  re s is ta n c e . By th e  t i m e  p a t ie n t s  p r e ­
s e n te d  fo r  A TP-TCA  d ir e c te d  th e r a p y  7 2 %  w e re  p la t in u m  
re s is ta n t  a c c o r d in g  to  th e  a s s a y  ( c i s p la t in  I n d e x  
S U M > 3 5 0 ) . P re v io u s  s tu d ie s  h a v e  s h o w n  a  n e g a tiv e  p r e ­
d ic t iv e  v a lu e  o f  th e  o r d e r  o f  9 0 %  f o r  r e s is ta n c e  t o  c i s p la t in  
in  th e  a s s a y  (16 ].
M o s t p a t ie n t s  in  th i s  s tu d y  w e re  t r e a te d  w i th  c o m b in a t io n  
th e ra p y , o f te n  w ith  e x p e r im e n ta l  p r o to c o ls .  T h e s e  c o m b i ­
n a t io n s  w e re  p r e v io u s ly  d e v e lo p e d  o n  th e  b a s is  o f  a s s a y  
r e s u lts  a n d  h a v e  k n o w n  c l in ic a l e ff ic a c y  [4 0 ,4 1  j. T h o s e  
c h o s e n  fo r  in d iv id u a l  p a t ie n t s  o f te n  d if fe re d  d u e  to  th e  
w id e  h e te ro g e n e i ty  o f  c h e m o s e n s i t iv i ty  e x h ib i te d  in  o v a r ­
ia n  e p i th e l ia l  c a n c e r  [ 1 3 ,1 4 ,1 6 ] .  T h e  A TP-TC A  n o t  in f r e ­
q u e n t ly  su g g e s ts  p o te n t ia l  b e n e f i t  f ro m  d r u g  re g im e n s  
t h a t  m a y  b e  far f r o m  th e  p h y s ic ia n 's  f ir s t  c h o ic e . T re o s u l-
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Figure 3
CA-125 profile for a patient with 3 successive courses of assay directed therapy
fa n  + g e m c i t a b in e  is a n ew  re g im e n  w ith  a  g o o d  to x ic ity  
p ro f i le ,  in i t ia l ly  d e v e lo p e d  fo r  m e la n o m a  [4 2 ,4 3 ) ,  w h ic h  
h a s  b e e n  s h o w n  to  h a v e  c o n s id e r a b le  a c tiv i ty  a g a in s t  o v a r ­
ia n  c a n c e r  in  a  r e c e n t  s tu d y  |4 4 ,4 5 ) .  In  th is  se r ie s , t r e o s u l ­
fa n  a n d  g e m c i t a b in e  w as u s e d  2 3  t im e s  ( 4 1 % )  a n d  
a c h ie v e d  a n  O R R  o f  5 5 % . O f  p a t ie n t s  e v a lu a b le  fo r  
r e s p o n s e ,  th i r te e n  p a t ie n ts  re c e iv in g  th i s  c o m b in a t io n  
w e re  r e s is ta n t  t o  c is p la tin  in  th e  a s s a y  ( c i s p la t in  I n d e x  
S U M  >  3 5 0 )  a n d  th e  O R R  in  th i s  g r o u p  w a s  6 2 % . S ix  
p a t ie n t s  w e re  p r e d ic te d  as p la t in u m - s e n s i t iv e  ( c i s p la t in  
In d e x  S U M  < 3 5 0 ) ,  a n d  h a l f  o f  th e s e  r e s p o n d e d  t o  t r e o s u l­
f a n  a n d  g e m c ita b in e .  T h e  r e m a in in g  th r e e  p a t ie n t s  
r e c e iv e d  tr e o s u l f a n  a n d  g e m c ita b in e ,  b u t  c i s p la t in  w a s  n o t  
te s te d  in  th e  a ssay . O th e r  c o m b in a t io n s  u s e d  in  th e  a s s a y  
v a r ie d  w id e ly  in  th e i r  m e c h a n is m  o f  a c t io n :  m a n y  
in v o lv e d  a n th r a c y c l in e s  a n d  s o m e  u s e d  p a c lita x e l (T a b le  
2 ) .  T h e re  w a s  r e lu c ta n c e  a m o n g s t  th e  o n c o lo g is ts  in v o lv e d  
in  th i s  s tu d y  to  r e -u s e  p a c lita x e l, th o u g h  re c e n t  re s u lts
w ith  th e  A TP-TC A  su g g e s t th a t  r e s is ta n c e  t o  th i s  a g e n t  
d e v e lo p s  le ss  c o m m o n ly  th a n  to  p l a t i n u m  [ 4 0 |.  K ae rn  e t 
a l. [ 4 6 | s tu d ie d  ta x a n e  re c h a l le n g e  a f te r  p la t in u m /p a c l i t -  
ax e l th e r a p y  a n d  f o u n d  th a t  th e  l ik e l ih o o d  to  r e s p o n d  to  
s e c o n d - l in e  p a c lita x e l is la rg e ly  u n a f f e c te d  b y  th e  p r io r  
p ro g re s s io n  free  in te rv a l .
F ig u re  3 s h o w s  a  p ro f i l e  o f  th e  C A -1 2 5  le v e ls  o f  a  p a t i e n t  
t r e a te d  w i th  3 s u c c e ss iv e  c o u rs e s  o f  a s s a y  d i r e c te d  th e ra p y . 
T h is  p a t i e n t  w a s  c l in ic a l ly  p l a t in u m  r e s is ta n t  a f te r  h a v in g  
b e e n  t r e a te d  w ith  C A P  ( c y c lo p h o s p h a m id e ,  d o x o r u b ic in  
a n d  c i s p la t in )  f o u r  m o n t h s  p r io r  t o  th e  s ta r t  t im e  p o in t  o f  
th e  g ra p h . S e q u e n t ia l  A TP-TC A  as s a y s  r e c o m m e n d e d  c is ­
p la t in  a n d  g e m c ita b in e ;  L ip o s o m a l d o x o r u b ic in ;  M ito x ­
a n t r o n e  a n d  p a c lita x e l re s p e c t iv e ly . T h e  a r ro w s  s h o w  
w h e n  e a c h  t r e a tm e n t  w a s  s ta r te d .  T h e s e  a c h ie v e d  3 
s e q u e n t ia l  p a r t ia l  r e s p o n s e s  in  th e  p a t ie n t  w i th  s ig n if ic a n t  
d r o p s  in  th e  C A -1 2 5  c o u n ts .  A  f o u r th  a s s a y  r e c o m m e n d e d
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t r e o s u l f a n  a n d  g e m c i ta b in e ,  b u t  th e  p a t ie n t  d e te r io r a te d  
r a p id ly  a f te r  2 cy c le s  a n d  d ie d  s o o n  a f te r . N e v e r th e le s s , 
th i s  p a t i e n t  s u rv iv e d  18  m o n t h s  a f te r  d ia g n o s i s  o f  p la t i ­
n u m - r e s i s t a n t  r e c u r r e n t  o v a r ia n  c a n c e r . T h is  e x a m p le  
s h o w s  h o w  th e  a s s a y  c a n  b e  u s e  to  a s s is t  th e  c h o ic e  o f  
c h e m o th e r a p y  o n  m u l t ip l e  o c c a s io n s  d u r in g  th e  c o u rs e  o f  
a n  in d iv id u a l  p a t i e n t 's  il ln e s s .
T h e  u s e  o f  p r e d ic t iv e  a s s a y s  to  in d iv id u a l iz e  c h e m o th e r ­
a p y  h a s  b e e n  h a m p e r e d  b y  te c h n ic a l  d if f ic u l t ie s  a n d  ( i n i ­
t i a l ly )  b y  th e  a v a i la b i l i ty  o f  d ru g s  w i th  d if fe r in g  
m e c h a n is m s  o f  a c t io n .  T h e  in c re a s in g  n u m b e r  o f  d ru g s  
n o w  a v a i la b le  h a s  w id e n e d  th e  c h o ic e  o f  a g e n ts  a n d  p o s ­
s ib le  c o m b in a t io n s  c o n s id e r a b ly .  T h e  A TP-TC A  is a  w e ll-  
s ta n d a r d i s e d  a s s a y  w i th  e s ta b l is h e d  e x te rn a l  q u a l i ty  c o n ­
t r o l  p r o c e d u r e s  c a p a b le  o f  h a n d l in g  m o s t  e n d o s c o p ic  o r  
n e e d le  b io p s ie s  t h a t  c o m p a r e s  f a v o u ra b ly  w i th  o th e r  d o -  
n o g e n ic  a n d  n o n - c lo n o g e n ic  m e th o d s  ( 1 3 ,1 4 ,4 7 ,4 8 ] .
C onclusions
In  c o n c lu s io n ,  th e  A TP-TC A  a ssa y  s h o w s  f a v o u ra b le  
r e s p o n s e  r a te s  w h e n  u s e d  a s  a  p re d ic t iv e  a s s a y  t o  in d i v id ­
u a l iz e  c h e m o th e r a p y  in  h e a v ily  p r e - t r e a te d  r e c u r r e n t  e p i ­
th e l ia l  o v a r ia n  c a n c e r . T h e s e  re s u lts  c o m p a r e  w e ll w ith  
p u b l i s h e d  s e c o n d - l in e  th e r a p y  re s u lts  a n d  s u p p o r t  p re v i­
o u s  w o rk  u s in g  th e  A TP-TC A  in  a  d i f f e re n t  c o u n try .  A 
m u l t i - c e n tr e ,  r a n d o m is e d  tr i a l  o f  A TP-TCA  d ir e c te d  th e r ­
a p y  v e r s u s  p h y s ic ia n 's  c h o ic e  th e r a p y  is in  p ro g re s s  to  h e lp  
c la r ify  th e  ro le  o f  p r e d ic t iv e  c h e m o s e n s i t iv i ty  t e s t in g  in  
r e c u r r e n t  o v a r ia n  c a n c e r .
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Heterogeneity of chemosensitivity of colorectal 
adenocarcinoma determined by a modified ex vivo ATP-tumor 
chemosensitivity assay (ATP-TCA)
Pauline A. Whitehouse3, Louise A. Knight3, Federica Di Nicolantonio3, 
Stuart J. Mercer3, Sanjay Sharma3 and Ian A. Cree3 on behalf of the 
Portsmouth Colorectal Cancer Multidisciplinary Team
Advanced colorectal cancer (CRC) has a poor prognosis 
with a 5-year survival of only 5% despite treatment with 
chemotherapeutic agents. Response rate and overall 
survival varies little between the commonly used single 
agents, although combinations achieve better outcomes. It 
is well established that considerable heterogeneity exists 
between cancers of the same tissue type, but it has been 
difficult to establish this for CRC. We therefore investigated 
the heterogeneity of chemosensitivity in CRC using a 
modified version of the ex vivo ATP-tumor chemosensitivity 
assay (ATP-TCA) capable of handling infected tumor tissue. 
Fifty-three specimens of primary solid or malignant 
effusions of CRC were tested, of which 46 (87%) were 
evaluable. There were considerable differences in 
sensitivities between individuals. The most active single 
cytotoxic agents in the assay were identified as 
5-fluorouracil, irinotecan and mitomycin C (MMC).
Cells were exposed to combinations of drugs added 
simultaneously at the same concentrations tested 
as single agents. All drug combinations achieved 
greater growth inhibition than drugs used alone.
MMC + gemcitabine was found to be the most effective
combination in 83% of specimens. The ATP-TCA has 
previously been shown to be a good predictor of response 
to chemotherapy in other tissue types. The degree of 
heterogeneity demonstrated from these results suggests 
that the ATP-TCA could be used to identify patients who 
might benefit from specific chemotherapeutic agents alone 
or in combination. Anti-Cancer Drugs 14:369-375 © 2003 
Lippincott Williams & Wilkins.
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Introduction
Colorectal adenocarcinoma (CRC) is the second most 
common cancer in both men and women, and is the 
second leading cause of cancer-related death in the UK 
(1). Although 70% undergo potentially curative surgery, 
half of all patients present with or develop advanced local 
disease or metastases. Advanced CRC has a poor 
prognosis with a median survival of only a few months 
(6-15 months) despite chemotherapy.
5-Fluorouracil (5-FU), as single agent or in combination, 
has been the mainstay of medical treatment for CRC for 
over 40 years. This is due to its relatively low toxicity and 
the inability of newer drugs, used as single agents, to 
achieve significantly better response rates. Attempts have 
been made to ameliorate the effect of 5-FU by 
biochemical modulation and route of administration. 
Modulation with leucovorin is standard treatment even 
though a meta-analysis found it increased response rate,
0959-4973 © 2003 Lippincott Williams & Wilkin*
but not overall survival [2]. Continuous infusion sig­
nificantly increases response rate, but produces only a 
modest increase in overall survival compared to bolus 
administration [3]. As a result, a variety of 5-FU regimens 
are available to the clinician. In the UK, the current 
National Institute for Clinical Excellence guidance on 
the treatment of advanced CRC advocates that 5-FU 
with leucovorin should remain as first-line treatment |4|. 
The response rates and overall survival achievable with 
this combination are 18-22% and 12-15 months, respec­
tively f5,6]. In combination with 5-FU, oxaliplatin and 
irinotecan have produced response rates of up to 50%, but 
this has not translated into better overall survival and, at 
present, 5-FU with leucovorin remains the standard 
against which others are judged [7,8].
Currently, much effort is being spent studying the 
molecular biology of CRC with an aim to determine 
markers useful in the prediction of outcome. New
DOI: 10.1097/01 cad.0000070481.94284.15
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
370 Anti-Cancer Drugs 2003, Vol 14 No 5
molecularly targeted drugs are appearing, but these have 
yet to make a clinical impact. Such drugs require that the 
target is present and functionally abnormal in the tumor, 
and that interference with the target alters the biology of 
the cancer. Tumors show heterogeneity of genotype and 
phenotype, and such heterogeneity in colorectal tumors 
almost certainly affects response to 5-FU and other 
cytotoxic agents [9). Predictive assays based on thymi- 
dylate synthase levels show some promise, but cellular 
assays have largely been ignored due to low evaluability 
rates and technical problems, particularly infection, 
which is common in tumor-derived tissue [10,11]. 
However, recent technical developments have produced 
assays, such as the ATP-tumor chemosensitivity assay 
(ATP-TCA), which has high evaluability rates with solid 
tumors and produces interpretable results in more than 
90% of tumors tested [12,13]. The results correlate well 
with outcome in patients with a sensitivity of 95% for 
predicting those who will respond to primary treatment of 
stage III ovarian cancer [14]. The use of this assay has 
been shown to double progression-free survival and 
overall survival in a case-control intervention study in 
recurrent ovarian carcinoma [15].
We performed this study to determine the degree of 
heterogeneity of chemosensitivity in colorectal adenocar­
cinoma as a prelude to studies of the molecular basis of 
resistance in tumor-derived cells and the potential use of 
this assay to guide therapy. We also wished to counter any 
ATP-TCA technical problems, particularly the use of 
infected tumor material.
Materials and methods
Tumor specimens
A total of 53 specimens were studied and 46 of these 
produced evaluable results (87%). Forty-four were from 
patients undergoing resection of their primary colorectal 
adenocarcinoma (of all pathological stages) and two were 
ascites/pleural aspirates in patients with metastatic 
disease. All seven tumors that failed showed infection 
during short-term cell culture. Due to initial problems of 
plate infection of the colorectal samples, we added 
further antibiotics to our culture medium. In order to 
ensure the antibiotics did not alter the sensitivity of the 
cytotoxic drugs, we performed experiments in parallel 
using medium with and without antibiotics (amphoter­
icin B and metronidazole).
Of the solid tumors, 34 were colonic, nine were rectal and 
two were peritoneal biopsies. The median age of the 
patients was 70 years (range 39-86). Of the rectal 
cancers, two patients had received neoadjuvant chemo- 
radiotherapy. Local ethics committee approval was 
obtained and informed consent gained from all patients. 
Biopsies were taken from the luminal surface of resection
specimens by a pathologist or surgeon, ensuring histo- 
pathological diagnosis and staging were not compromised.
ATP-TCA
The ATP-TCA was performed as previously described 
[121- Solid tumor material was minced and dissociated in
1.5 mg/ml collagenase (Sigma, Poole, UK; C8051) over­
night. The samples were purified using Ficoll-Hypaque 
(Sigma; 1077-1) to remove red blood cells and excess 
debris, and resuspended in serum-free complete assay 
medium (CAM; DCS Innovative Diagnostik Systeme, 
Hamburg, Germany) containing penicillin-streptomycin 
(Sigma), gentamicin (Sigma), and additional amphoter­
icin B (Sigma) and metronidazole (Rhone Poulenc Rorer, 
Eastbourne, UK). The cells were then counted and 
viability assessed by the Trypan blue exclusion method. 
The final cell suspension was made up to a concentration 
of 200 000 cells/ml for solid tumors and KM) 000 cells/ml 
for malignant effusions. Round-bottomed polypropylene 
96-well plates (Coming-Ckistar, High Wycombe, UK) 
were prepared with CAM and cytotoxic drugs at six 
dilutions (6.25-200%) of the test drug concentration 
(TDC) in triplicate. The TDC for each drug has 
previously been calculated from pharmacokinetic and 
response data (Table 1) [121. The drugs were stored 
appropriately and made up according to the manufac­
turer’s instructions [16]. Dilutions were prepared in the 
plates from freshly made up 800% TDC drug solutions. 
Combinations of drugs were made by adding both drugs 
each at their 800% TDC. Each plate contained two rows 
of internal controls: a maximum inhibitor (MI) that kills 
all the cells giving a zero ATP count and a medium only 
(MO) of CAM without any drugs. After 6 days incubation 
at 37°C at 100% humidity in 5% C 02, the cells were lysed 
with a detergent-based Tumor Cell Extraction Reagent 
(DCS Innovative Diagnostik Systeme) and the ATP 
content of each well measured using the luciferin— 
luciferase system in a microplate luminometer (MPLX; 
Berthold, Pforzheim, Germany).
Drugs
Irinotecan (CPT-11) is converted to its inactive metabo­
lites by cytochrome P450, and to its active metabolite, 
SN38, by carboxyesterases in the liver, blood and tumors.
Table 1 Drugs tested and their 1004b TDC as used in the ex vivo ATP-TCA
Drug/combination 100% TDC (jig/ml)
5-FU 45
irinotecan 100
Oxaliplatin 5
MMC 0.7
Gemcitabine 13
SN38 0.06
5-FU + oxaliplatin 45 + 5
5-FU + irinotecan 45+100
5-FU + MMC 45 + 0.7
MMC + gemcitabine 0.7+12
Oxaliplatin + gemcitabine 5+12
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Frequency histograms showing heterogeneity of the sensitivity index (y-axis) for each single agent and combination, (a) 5-FU (n = 46), (b) irinotecan 
(n = 45), (c) oxaliplatin (n = 41), (d) M M C  (n=39), (e) gemcitabine (n = 38), (0 5-FU + oxaliplatin (n=43), (g) 5-FU + irinotecan (n= 17), (h)
M M C  + 5-FU (n=39), (i) M M C  + gemcitabine (n = 35) and (j) oxaliplatin + gemcitabine (n = 37).
Discussion
Heterogeneity
The results show the marked heterogeneity of chemo­
sensitivity of CRC to both single agents and combina­
tions of cytotoxic drugs. The proportion of tumors
that responded strongly to combinations was greater 
than the proportion that responded to single agents. 
The drugs and combinations found effective in this 
assay are similar to those found to be active in clinical 
trials, suggesting that the ATP-TCA is able to predict
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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sensitivity and resistance to chemotherapy in individual 
patients.
The evaluability of colorectal samples using the ATP- 
TCA was 87%, which is similar to evaluability rates 
achieved in other ‘cleaner’ tumor types using this assay 
f  12,18,19]. Other in vitro studies of CRC cells, including 
the use of the MTT assay and histoculture drug response 
assay, have produced similar evaluability rates [20,211. 
The ATP-TCA has been shown to be more sensitive than 
these assays, and to have technical advantages over the 
MTT and clonogenic assays [22,23].
Table 2 Summary of sensitivity data (using an arbitrary threshold 
of sensitivity defined as a TCA index < 300 for six concentrations 
used)
Drug No. No. in Sensitivity
sensitive ATP-TCA assessed (%)
5-FU 27 46 59
Irmotecan 24 45 53
Oxaliplatin 1 41 2
MMC 21 39 54
Gemcitabine 19 38 50
SN38 0 11 0
5-FU + oxaliplatin 36 43 84
5-FU + irinotecan 15 17 88
5-FU + MMC 30 39 77
MMC + gemcitabine 35 35 100
Oxaliplatin + gemcitabine 27 37 73
Infection
The main difficulty in applying primary cell assays in the 
routine pathology department is microhial contamination. 
At the commencement of our study there were several 
plate infections which we overcame by adding additional 
antibiotics to the assay medium. These antibiotics were 
shown to have no effect on cytotoxic sensitivity.
The antifungal amphotericin B was used because the 
mechanism of action of other antifungal agents renders 
them unsuitable for use in the assay. Amphotericin B has 
been shown to reverse resistance and to enhance the 
cytotoxicity of cisplatin and its analogs in vitro |24,25,26]. 
This is due to an increased intracellular accumulation of 
drug and an increase in interstrand cross-link formation 
[27]. Amphotericin B does not seem to have a synergistic 
effect with 5-FU or a number of other drugs [28,29]. We 
did not find the addition of amphotericin B in small 
concentrations (2.5 /ig/ml) to have any significant effect 
on the cytotoxicity of the drugs tested, including cisplatin 
and oxaliplatin.
Metronidazole is a synthetic antiprotozoal and antibac­
terial agent. It is known to interact with several drugs, 
including warfarin, lithium, antiepileptics and cimetidine, 
as well as alcohol and disulfiram. The only documented 
interaction with chemotherapeutic agents is with the
Table 3 Median values (and ranges) for each drug and combination
Drug AUC IC50 IC90 lndexSOM
5-FU
Irinotecan
Oxaliplatin
MMC
Gemcitabine 
Oxaliplatin + 5-FU 
Irinotecan + 5-FU 
MMC -b 5-FU 
MMC + gemcitabine
13999 (9384-17788) 
14714 (-931-17885) 
3257 (-2734-12702) 
14049 (4711-18102) 
11600 (3296-18145) 
15289 (10440-17910) 
17456 (10876-17879) 
16027 (-10437-18099) 
17693 (13762-19277)
35 (4-107)
37 (5-981) 
304 (-8104-41192) 
41 (5-223)
23 (4-345)
23 (5-78)
11 (6-82)
23 (-1223-181)
7 (3-24)
184.5 (45-251) 
99 (42-1765)
546 (-14588-74145) 
173 (45-402)
260.5 (31-2500) 
118 (48-231)
60 (45-201) 
85 (-2201-304) 
48 (6-216)
285.5 (94-628)
294 (106-674) 
508 (272-719)
295 (115-543)
298.5 (78-560) 
238 (92-403)
164 (127-414) 
235 (104-814) 
130 (8-268)
Fig. 3
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Heterogeneity data for three single agents expressed as TCA indices for three tumors. A low index (<300) indicates probable sensitivity.
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Sensitivity indices for individual tumors tested with irinotecan (solid 
bars) and SN38 (shaded bars). A low index (<300) indicates probable 
sensitivity.
alkylating agent melphalan 130]. We did not find low 
concentrations of metronidazole (1/ig/ml) to alter the 
chemosensitivity of the drugs tested.
Quality of sample
In general, the colorectal samples were quite fibrous and 
therefore did not dissociate in the enzymatic solution 
particularly well. It was necessary to increase the 
concentration of collagenase from 1 to 1.5 mg/ml for 
better tumor dissociation. Even so, some tumors did not 
dissociate well and only yielded enough cells to test a 
limited set of drugs. Two patients early in the study had 
undergone preoperative chemoradiotherapy. Irradiation of 
rectal tumors may produce so much shrinkage that little 
or no tumor remains macroscopically. We therefore 
decided not to include any further patients who had 
undergone radiation therapy in our study.
Drugs
The drug concentrations used in this study are based on 
their peak plasma concentration (fn*,*), taking into 
account their degree of protein binding [121. We 
acknowledge that this concentration is not necessarily a 
good indicator of clinically attainable intra-tumor con­
centrations, but it allows good comparison between 
agents of different types.
We tested the topoisomerase I inhibitor irinotecan (CPT- 
11) and its active metabolite SN38 at equivalent doses 
derived from pharmacokinetic data. Single-agent irinote­
can showed activity in 53% of samples tested, but SN38 
produced very little growth inhibition in any. Similar 
results were found by Jonsson et al., who showed 
irinotecan and SN38 had almost identical activity when 
tested on cell lines, but that only irinotecan was active 
when tested ex vivo on CRC cells [31]. The inactivity of
SN38 suggests that this metabolite of irinotecan may not 
be relevant and that SN38 is not a good model to 
demonstrate the activity of irinotecan in tumor-derived 
cells. It also highlights the importance of using primary 
cultures of human cells rather than established cell lines, 
which may show considerable differences in chemosensi­
tivity from tumor-derived cells [32,33].
New regimens
We tested some experimental regimens not currently 
used in clinical practice (e.g. MMC + gemcitabine and 
oxaliplatin + gemcitabine). Both these combinations con­
tain gemcitabine which showed some activity as a single 
agent in 50% of samples. MMC + gemcitabine was the 
most sensitive combination tested overall. All samples 
were sensitive to MMC + gemcitabine using the Index 
< 300 threshold and this was the most sensitive 
combination in 83% of samples tested.
Gemcitabine has the ability to inhibit DNA replication 
and repair making it a suitable agent for combination with 
DNA damaging therapy. The rationale for the combina­
tion with MMC is that gemcitabine may enhance the 
DNA alkylation by MMC or inhibit the repair of its 
adducts [34,35]. The low toxicity profile of gemcitabine 
and its clinical activity against numerous solid malig­
nancies make it an attractive drug for use in combination 
therapy.
The ATP-TCA has been used to assist drug and regimen 
development [19,36,371. In colorectal carcinoma, it can 
be routinely applied to samples obtained from surgical 
specimens and malignant effusions. The results obtained 
mirror the heterogeneity of responses observed in clinical 
studies. Correlation of ex vivo ATP-TCA results with 
clinical response is required to initiate randomized 
controlled trials of ATP-TCA directed chemotherapy in 
patients with metastatic CRC.
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As these enzymes are not necessarily present in our 
culture environment, we tested both irinotecan and SN38 
in 11 samples.
Data analysis
Data was transferred directly from the luminometer to a 
spreadsheet (Excel 2000; Microsoft). The results are 
expressed as a number of indices of efficacy, including the 
IC.so and ICqo. The natural logarithmic sum index 
(IndexsiiM) calculated as:
Index =  Sum[Inhibition625+12S+2S+50+l00+200]
has been shown to allow simple comparison of results 
between drugs and tumors [17]. In addition, the area 
under the concentration-inhibition curve (IndexAuc.) and 
the percentage of tumors achieving 90% inhibition was 
calculated.
Results
The evaluability rate (i.e. the number of tumors with 
interpretable results) of colorectal specimens was 87% 
(46 of 53). The failures were due to infection of the 96- 
well plates and were experienced at the beginning of the 
study. As a result, additional antibiotics were added to the 
medium to cover anaerobic and fungal infections. The 
addition of 2.5//g/ml amphotericin B and 1/rg/ml 
metronidazole did not alter the sensitivity of the 
cytotoxic drugs used (Fig. 1).
For comparison between drugs and tumors, an 
IndexsuM < 300, representing an average 50% inhibition 
across all concentrations tested, was used to indicate 
sensitivity, as previously published [ 18,19]. The results 
show considerable heterogeneity of chemosensitivity to 
single agents and drug combinations between the tumors 
tested (Fig. 2, and Tables 2 and 3). Figure 2 shows the 
distribution of sensitivity of all tumors for all single agents 
and combinations tested.
All single agents tested, except oxaliplatin, were active in 
about 50% of samples (50-59%) on the basis of the 
IndexsuM < 300 threshold (Fig. 3). The most active 
single agent tested was 5-FU, to which 59% of samples 
were sensitive. All drug combinations achieved greater 
growth inhibition than drugs used alone (73-100%). All 
samples were sensitive to mitomycin C (MMC) + gem­
citabine and this was the most effective combination in 
83% of the tumors tested (29 of 35). Eleven samples were 
tested with both SN38 and irinotecan. Of these 11, none 
were sensitive to SN38 at the concentration tested (0%), 
but seven were sensitive to irinotecan (64%) (Fig. 4).
Some tumors responded well to one drug or combina­
tion, while others showed no response to this and 
instead responded to an alternative regimen. For a 
limited panel of drugs and combinations (5-FU, irinote­
can, oxaliplatin, 5-FU + irinotecan, 5-FU + oxaliplatin
Flfl. 1
100
60
6.25 12.5 25 50 100 200
TDC (%)
5-FU -1 — Irinotecan Oxaliplatin — Oxaliplatin + 5-FU
(b) 100
cq
I  60c
c01
a
6.25 25 50 100 20012.5
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—• — 5-FU —F— Irinotecan Oxaliplatin — Oxaliplatin + 5-FU
Results for a colorectal ATP-TCA tested (a) in CAM (without additional 
antibiotics), and (b) with additional amphotericin B (2.5 /<g/ml) and 
metronidazole (1 /ig/ml)
and 5-FU + MMC), five cases were sensitive to only 
one drug/combination and resistant to all the others 
tested. Of these five, two were sensitive only to 5-FU, 
one to 5-FU + irinotecan, one to 5-FU + oxaliplatin and 
one to 5-FU + MMC. Two cases were resistant to all 
drugs/combinations tested (4%).
D esp ite  appearing sen sitive to certain drugs using the  
IndexsiJM threshold o f  < 300, many tumors did not reach 
90% inhibition at 100% TDC. O nly 15% o f  tum ors tested  
w ith 5-FU reached 90% growth inhibition (seven  o f  46), 
compared to 0% tested  with oxaliplatin (none o f  41) and 
51% with irinotecan (23 o f 45); 90% growth inhibition was 
achieved in 42% treated w ith 5-FU + oxaliplatin (18 o f  
43), 69% w ith 5-FU + MMC (27 o f  39) and 88% w ith 5- 
FU + irinotecan (14 o f 16).
Nine samples yielded only enough cells for one plate in 
which we tested the four drugs/combinations most 
commonly used clinically in the UK. This was due to 
the fibrotic nature of the samples which made dissocia­
tion difficult. The two rectal samples that had undergone 
neoadjuvant chemoradiotherapy were also small and very 
fibrotic, resulting in few cells available for testing. Further 
patients who had already undergone neoadjuvant treat­
ment were excluded from entering our study.
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Combination chemotherapy in advanced gastrointestinal cancers: 
ex vivo sensitivity to gemcitabine and mitomycin C
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Advanced or metastatic disease is common in both oesophagogastnc and colorectal cancers, with poor 5-year survival despite 
palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine in combination with 
mitomycin C (GeM), using a modified ex vivo ATP-based tumour chemosensitivity assay (ATP-TCA). Tumour matenal from 41 
colorectal and 22 oesophagogastnc cancers were assessed. The GeM combination showed vanable but definite activity in most of the 
samples tested. The results show that GeM achieves > 95% inhibition at concentrations within the range achievable clinically in 60% 
of colorectal tumours (21 out of 35) and 38% of oesophagogastnc tumours (five out of 13) tested. We did not identify any significant 
difference in sensitivity using concurrent or sequential exposure of tumour-denved cells to these two drugs. The results from this 
study suggest that GeM may be a useful combination in the treatment of advanced gastrointestinal malignancy 
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Colorectal adenocarcinoma (CRC) is the second most common 
cause of cancer death in the western world. Despite potentially 
curable surgical treatment in 70 - 80%, half of all patients will die 
from metastatic disease, often within 5 years of diagnosis. 
Palliative chemotherapy may reduce the symptoms, extend 
survival from 6 to 12 months, and despite treatment-related 
adverse effects, often improve or at least maintain the quality of 
life (Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 
1992). In the UK, the current NICE guidance on chemotherapy in 
advanced colorectal disease (NICE, 2002) advocates the use of 5- 
fluorouracil (5FU) with folinic acid (FA) as first line therapy. This 
combination achieves response rates of 18-22% and overall 
survivals of 12-15 months (de Gramont et al, 2000; Maiello et al, 
2000). Combinations using newer agents such as irinotecan and 
oxaliplatin achieve higher response rates of up to 50% and longer 
median overall survivals (Douillard et al, 2000; Saltz et al, 2000; 
Grothey et al, 2002). However, the newer agents, especially in 
combination with 5FU/FA, are associated with greater toxicity, 
which may be severe and dose-limiting.
Oesophageal and gastric cancers together account for 7% of all 
cancer-related deaths. Palliative treatment may be achieved with 
chemotherapy, radiotherapy or chemoradiation. A number of 
chemotherapy regimens are in use. Most are triple therapies 
incorporating 5FU and cisplatin with either epirubicin or 
paclitaxel. Response rates of 48 - 70% have been achieved (Kim 
et al, 1993; Ilson et al, 1998) with a 2-year survival of 13.5% 
(Findlay et al, 1994); however, in general, the responses are often
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short lived and these treatments are associated with varying 
degrees of toxicity.
Recently, we investigated the chemosensitivity of colorectal and 
oesophagogastnc adenocarcinomas (Mercer et al, 2003; White­
house et al, 2003) using a modified ex vivo ATP-based tumour 
chemosensitivity assay (ATP-TCA) (Andreotti et al, 1995; Cree 
et al, 1996). We demonstrated considerable differences in 
sensitivity between individual tumours of both tumour types. 
Mitomycin C (MMC) has been used in the treatment of 
gastrointestinal tumours for many years, although it is not now 
the most commonly used drug due to serious pulmonary, renal 
and haematological toxicities, which tend to occur with over­
dosage. It remains useful in the treatment of metastatic gastro 
intestinal tumours, usually in combination with 5-FA. Gemcitabine 
is licensed for use in pancreatic and non-small-cell lung cancers. It 
has also shown preclinical and clinical activity in several other 
solid tumours, including ovarian, head and neck and breast 
cancers (Carmichael et al, 1995; Markman, 2002). However, phase 
I/II trials of single-agent gemcitabine have not demonstrated any 
activity in advanced colorectal and gastric cancers (Moore et al, 
1992; Christman et al, 1994; Mani et al, 1998). We therefore wished 
to test this combination on further gastrointestinal tumour 
samples and investigate any schedule dependency.
MATERIALS AND METHODS 
Tum ours
Material from 41 colorectal and 22 oesophagogastric tumours was 
tested. All the colorectal tumours were previously untreated. Six 
of the oesophagogastric tumours had received neoadjuvant
